The	NN	O	O
peri-kappa	NN	O	B-DNA
B	NN	O	I-DNA
site	NN	O	I-DNA
mediates	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
2	NN	O	I-DNA
enhancer	NN	O	I-DNA
activation	NN	O	O
in	NN	O	O
monocytes	NN	O	B-cell_type
but	NN	O	O
not	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

GATA-1	NN	O	B-protein
and	NN	O	O
ER	NN	O	B-protein
bind	NN	O	O
to	NN	O	O
each	NN	O	O
other	NN	O	O
in	NN	O	O
vitro	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
DNA	NN	O	O
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Finally	NN	O	O
,	NN	O	O
the	NN	O	O
status	NN	O	O
of	NN	O	O
our	NN	O	O
current	NN	O	O
knowledge	NN	O	O
concerning	NN	O	O
the	NN	O	O
roles	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
in	NN	O	O
the	NN	O	O
commitment	NN	O	O
to	NN	O	O
erythroid	NN	O	B-cell_type
,	NN	O	I-cell_type
myeloid	NN	O	I-cell_type
and	NN	O	I-cell_type
lymphoid	NN	O	I-cell_type
cell	NN	O	I-cell_type
types	NN	O	I-cell_type
is	NN	O	O
summarized	NN	O	O
.	NN	O	O

We	NN	O	O
and	NN	O	O
others	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
EBV	NN	O	O
can	NN	O	O
also	NN	O	O
infect	NN	O	O
a	NN	O	O
subset	NN	O	O
of	NN	O	O
thymocytes	NN	O	B-cell_type
.	NN	O	O

Rather	NN	O	O
,	NN	O	O
EBV	NN	O	O
remains	NN	O	O
in	NN	O	O
a	NN	O	O
linear	NN	O	O
configuration	NN	O	O
from	NN	O	O
which	NN	O	O
replicative	NN	O	B-DNA
genes	NN	O	I-DNA
are	NN	O	O
transcribed	NN	O	O
.	NN	O	O

We	NN	O	O
demonstrate	NN	O	O
,	NN	O	O
through	NN	O	O
the	NN	O	O
deletion	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
UDG	NN	O	I-DNA
promoter	NN	O	I-DNA
sequences	NN	O	I-DNA
,	NN	O	O
that	NN	O	O
expression	NN	O	O
of	NN	O	O
E2F-1	NN	O	B-protein
activates	NN	O	O
the	NN	O	O
UDG	NN	O	B-DNA
promoter	NN	O	I-DNA
through	NN	O	O
several	NN	O	O
E2F	NN	O	B-DNA
sites	NN	O	I-DNA
.	NN	O	O

Jurkat	NN	O	O
cell	NN	O	O
extract	NN	O	O
contained	NN	O	O
PEBP2	NN	O	B-protein
site-binding	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
s	NN	O	O
)	NN	O	O
that	NN	O	O
cross-reacted	NN	O	O
with	NN	O	O
antimouse	NN	O	B-protein
alpha	NN	O	I-protein
A1	NN	O	I-protein
antibodies	NN	O	I-protein
.	NN	O	O

IFN-gamma	NN	O	B-protein
priming	NN	O	O
of	NN	O	O
monocytes	NN	O	B-cell_type
enhances	NN	O	O
LPS-induced	NN	O	O
TNF	NN	O	B-protein
production	NN	O	O
by	NN	O	O
augmenting	NN	O	O
both	NN	O	O
transcription	NN	O	O
and	NN	O	O
MRNA	NN	O	O
stability	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
Myc-associated	NN	O	B-protein
zinc	NN	O	I-protein
finger	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
MAZ	NN	O	B-protein
)	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
predominant	NN	O	B-protein
factor	NN	O	I-protein
binding	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
sites	NN	O	O
.	NN	O	O

Overexpression	NN	O	O
of	NN	O	O
DR-nm23	NN	O	B-protein
,	NN	O	O
a	NN	O	O
protein	NN	O	O
encoded	NN	O	O
by	NN	O	O
a	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
nm23	NN	O	B-DNA
gene	NN	O	I-DNA
family	NN	O	I-DNA
,	NN	O	O
inhibits	NN	O	O
granulocyte	NN	O	B-cell_type
differentiation	NN	O	O
and	NN	O	O
induces	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
32Dc13	NN	O	B-cell_line
myeloid	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_line
with	NN	O	O
IFN-gamma	NN	O	B-protein
for	NN	O	O
9	NN	O	O
hr	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
cycloheximide	NN	O	O
led	NN	O	O
to	NN	O	O
super-induction	NN	O	O
of	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
RI	NN	O	I-protein
expression	NN	O	O
.	NN	O	O

Nuclear	NN	O	O
run-on	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
RI	NN	O	I-protein
transcription	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
IFN-gamma	NN	O	B-protein
.	NN	O	O

MIP1	NN	O	B-protein
alpha	NN	O	I-protein
nuclear	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
MNP	NN	O	B-protein
)	NN	O	O
,	NN	O	O
a	NN	O	O
novel	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
expressed	NN	O	O
in	NN	O	O
hematopoietic	NN	O	O
cells	NN	O	O
that	NN	O	O
is	NN	O	O
crucial	NN	O	O
for	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
MIP-1	NN	O	I-DNA
alpha	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
overexpression	NN	O	O
in	NN	O	O
various	NN	O	O
tumor	NN	O	B-cell_type
cell	NN	O	I-cell_type
types	NN	O	I-cell_type
and	NN	O	O
its	NN	O	O
biological	NN	O	O
significance	NN	O	O
in	NN	O	O
cutaneous	NN	O	O
carcinogenesis	NN	O	O
remain	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Hypercortisolaemia	NN	O	O
,	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
decreased	NN	O	O
affinity	NN	O	O
and	NN	O	O
a	NN	O	O
decreased	NN	O	O
binding	NN	O	O
capacity	NN	O	O
of	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
decreased	NN	O	O
affinity	NN	O	O
of	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
was	NN	O	O
observed	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
relation	NN	O	O
between	NN	O	O
circulating	NN	O	O
cortisol	NN	O	O
concentrations	NN	O	O
and	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
affinity	NN	O	O
and	NN	O	O
number	NN	O	O
.	NN	O	O

Integrin-mediated	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
cytokine	NN	O	B-protein
message	NN	O	O
induction	NN	O	O
in	NN	O	O
monocytic	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

We	NN	O	O
have	NN	O	O
recently	NN	O	O
found	NN	O	O
a	NN	O	O
novel	NN	O	O
conserved	NN	O	B-DNA
motif	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
promoters	NN	O	B-DNA
of	NN	O	O
several	NN	O	O
T-cell-expressed	NN	O	B-protein
cytokines	NN	O	I-protein
[	NN	O	O
human	NN	O	B-protein
interleukin-2	NN	O	I-protein
,	NN	O	I-protein
-4	NN	O	I-protein
,	NN	O	I-protein
-5	NN	O	I-protein
and	NN	O	I-protein
-13	NN	O	I-protein
and	NN	O	O
human	NN	O	B-protein
and	NN	O	I-protein
mouse	NN	O	I-protein
granulocyte/macrophage-colony	NN	O	I-protein
stimulating	NN	O	I-protein
factor	NN	O	I-protein
(	NN	O	O
GM-CSF	NN	O	B-protein
)	NN	O	O
]	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
of	NN	O	O
aspirin	NN	O	O
were	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cyclooxygenase	NN	O	B-protein
activity	NN	O	O
,	NN	O	O
since	NN	O	O
indomethacin	NN	O	O
was	NN	O	O
ineffective	NN	O	O
.	NN	O	O

The	NN	O	O
CHO-DR/B7/LFA-3	NN	O	B-cell_line
triple	NN	O	I-cell_line
transfectant	NN	O	I-cell_line
induced	NN	O	O
a	NN	O	O
further	NN	O	O
increase	NN	O	O
in	NN	O	O
AP-1	NN	O	B-protein
and	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
binding	NN	O	B-protein
proteins	NN	O	I-protein
compared	NN	O	O
with	NN	O	O
the	NN	O	O
double	NN	O	B-cell_line
transfectants	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
level	NN	O	O
of	NN	O	O
Oct-1	NN	O	B-protein
binding	NN	O	I-protein
proteins	NN	O	I-protein
remained	NN	O	O
similar	NN	O	O
in	NN	O	O
all	NN	O	O
samples	NN	O	O
.	NN	O	O

The	NN	O	O
erythroid	NN	O	O
differentiation	NN	O	O
of	NN	O	O
HEL	NN	O	B-cell_line
cells	NN	O	I-cell_line
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
recombinant	NN	O	B-protein
human	NN	O	I-protein
nm23-H1	NN	O	I-protein
,	NN	O	I-protein
-H2	NN	O	I-protein
,	NN	O	I-protein
mouse	NN	O	I-protein
nm23-M1	NN	O	I-protein
,	NN	O	I-protein
and	NN	O	I-protein
-M2	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

High	NN	O	O
levels	NN	O	O
of	NN	O	O
cytokine	NN	O	B-protein
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
also	NN	O	O
required	NN	O	O
both	NN	O	O
TCR	NN	O	B-protein
and	NN	O	O
costimulatory	NN	O	O
signals	NN	O	O
.	NN	O	O

3.	NN	O	O
Danazol	NN	O	O
decreased	NN	O	O
the	NN	O	O
transcription	NN	O	O
rate	NN	O	O
of	NN	O	O
ER	NN	O	B-DNA
gene	NN	O	I-DNA
to	NN	O	O
approximately	NN	O	O
50	NN	O	O
%	NN	O	O
in	NN	O	O
monocytes	NN	O	B-cell_type
in	NN	O	O
a	NN	O	O
run-on	NN	O	O
assay	NN	O	O
.	NN	O	O

Formation	NN	O	O
of	NN	O	O
the	NN	O	O
NFAT-1	NN	O	B-protein
transcriptional	NN	O	I-protein
complex	NN	O	I-protein
on	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
is	NN	O	O
essential	NN	O	O
for	NN	O	O
IL-2	NN	O	B-protein
transcription	NN	O	O
.	NN	O	O

Primer	NN	O	O
extension	NN	O	O
and	NN	O	O
ribonuclease	NN	O	B-protein
protection	NN	O	O
analyses	NN	O	O
indicate	NN	O	O
a	NN	O	O
single	NN	O	O
major	NN	O	B-DNA
transcriptional	NN	O	I-DNA
start	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Moreover	NN	O	O
,	NN	O	O
monocytes	NN	O	B-cell_type
express	NN	O	O
a	NN	O	O
novel	NN	O	O
IL-10-stimulated	NN	O	B-protein
STAT	NN	O	I-protein
protein	NN	O	I-protein
with	NN	O	O
an	NN	O	O
M	NN	O	O
(	NN	O	O
r	NN	O	O
)	NN	O	O
of	NN	O	O
70	NN	O	B-protein
kDa	NN	O	I-protein
that	NN	O	O
is	NN	O	O
recognized	NN	O	O
by	NN	O	O
the	NN	O	O
anti-STAT3	NN	O	B-protein
Ab	NN	O	I-protein
but	NN	O	O
is	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
cross-linking	NN	O	O
of	NN	O	O
CD30	NN	O	B-protein
leads	NN	O	O
to	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
and	NN	O	O
enhanced	NN	O	O
HIV	NN	O	O
transcription	NN	O	O
.	NN	O	O

The	NN	O	O
transcription	NN	O	O
activation	NN	O	O
function	NN	O	O
is	NN	O	O
provided	NN	O	O
by	NN	O	O
the	NN	O	O
N-terminal	NN	O	B-protein
acidic	NN	O	I-protein
domain	NN	O	I-protein
(	NN	O	O
amino	NN	O	B-protein
acids	NN	O	I-protein
26-137	NN	O	I-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
experimentally	NN	O	O
exchangeable	NN	O	O
with	NN	O	O
a	NN	O	O
heterologous	NN	O	B-protein
viral	NN	O	I-protein
transcription-activating	NN	O	I-protein
domain	NN	O	I-protein
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
a	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
promoter	NN	O	I-DNA
,	NN	O	O
whose	NN	O	O
activity	NN	O	O
is	NN	O	O
controlled	NN	O	O
through	NN	O	O
chi	NN	O	B-protein
B	NN	O	I-protein
factors	NN	O	I-protein
,	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
active	NN	O	O
in	NN	O	O
the	NN	O	O
IL-2	NN	O	B-cell_line
producing	NN	O	I-cell_line
EBV-B	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
but	NN	O	O
inactive	NN	O	O
in	NN	O	O
the	NN	O	O
non-IL-2-producing	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Latent	NN	O	B-protein
membrane	NN	O	I-protein
protein-1	NN	O	I-protein
induces	NN	O	O
cyclin	NN	O	B-protein
D2	NN	O	I-protein
expression	NN	O	O
,	NN	O	O
pRb	NN	O	B-protein
hyperphosphorylation	NN	O	O
,	NN	O	O
and	NN	O	O
loss	NN	O	O
of	NN	O	O
TGF-beta	NN	O	B-protein
1	NN	O	I-protein
-mediated	NN	O	O
growth	NN	O	O
inhibition	NN	O	O
in	NN	O	O
EBV-positive	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Chemical	NN	O	O
cross-linking	NN	O	O
with	NN	O	O
125I-labeled	NN	O	B-protein
TGF-beta	NN	O	I-protein
1	NN	O	I-protein
showed	NN	O	O
an	NN	O	O
essentially	NN	O	O
normal	NN	O	O
TGF-beta	NN	O	B-protein
receptor	NN	O	I-protein
profile	NN	O	O
in	NN	O	O
EBV-positive	NN	O	B-cell_line
and	NN	O	I-cell_line
EBV-negative	NN	O	I-cell_line
Burkitt	NN	O	I-cell_line
's	NN	O	I-cell_line
lymphoma	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
these	NN	O	O
receptors	NN	O	O
were	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
functional	NN	O	O
in	NN	O	O
transducing	NN	O	O
signals	NN	O	O
,	NN	O	O
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
the	NN	O	O
TGF-beta	NN	O	B-protein
1	NN	O	I-protein
-mediated	NN	O	O
modulation	NN	O	O
of	NN	O	O
junB	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
TGF-beta	NN	O	B-protein
1	NN	O	I-protein
did	NN	O	O
not	NN	O	O
induce	NN	O	O
dephosphorylation	NN	O	O
of	NN	O	O
pRb	NN	O	B-protein
in	NN	O	O
EBV	NN	O	B-cell_line
(	NN	O	I-cell_line
or	NN	O	I-cell_line
LMP-1	NN	O	I-cell_line
)	NN	O	I-cell_line
-positive	NN	O	I-cell_line
cells	NN	O	I-cell_line
as	NN	O	O
opposed	NN	O	O
to	NN	O	O
EBV-negative	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
dichotomy	NN	O	O
in	NN	O	O
the	NN	O	O
TGF-beta	NN	O	B-protein
1	NN	O	I-protein
signaling	NN	O	O
pathway	NN	O	O
leading	NN	O	O
to	NN	O	O
separable	NN	O	O
gene	NN	O	O
regulatory	NN	O	O
and	NN	O	O
growth	NN	O	O
inhibitory	NN	O	O
responses	NN	O	O
.	NN	O	O

Does	NN	O	O
thyroidectomy	NN	O	O
,	NN	O	O
radioactive	NN	O	O
iodine	NN	O	O
therapy	NN	O	O
,	NN	O	O
or	NN	O	O
antithyroid	NN	O	O
drug	NN	O	O
treatment	NN	O	O
alter	NN	O	O
reactivity	NN	O	O
of	NN	O	O
patients	NN	O	O
'	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
to	NN	O	O
epitopes	NN	O	O
of	NN	O	O
thyrotropin	NN	O	B-protein
receptor	NN	O	I-protein
in	NN	O	O
autoimmune	NN	O	O
thyroid	NN	O	O
diseases	NN	O	O
?	NN	O	O

Six	NN	O	O
to	NN	O	O
8	NN	O	O
weeks	NN	O	O
after	NN	O	O
subtotal	NN	O	O
thyroidectomy	NN	O	O
,	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
'	NN	O	O
PBMC	NN	O	B-cell_type
responding	NN	O	O
to	NN	O	O
any	NN	O	O
peptide	NN	O	O
and	NN	O	O
the	NN	O	O
average	NN	O	O
number	NN	O	O
of	NN	O	O
recognized	NN	O	O
peptides	NN	O	O
decreased	NN	O	O
.	NN	O	O

A	NN	O	O
further	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
T	NN	O	O
cell	NN	O	O
reactivity	NN	O	O
to	NN	O	O
TSHR	NN	O	B-protein
peptides	NN	O	O
was	NN	O	O
observed	NN	O	O
3-6	NN	O	O
months	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

Three	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
RAI	NN	O	O
,	NN	O	O
T	NN	O	O
cell	NN	O	O
responses	NN	O	O
to	NN	O	O
TSHR	NN	O	B-protein
peptides	NN	O	O
were	NN	O	O
less	NN	O	O
than	NN	O	O
those	NN	O	O
6-8	NN	O	O
weeks	NN	O	O
after	NN	O	O
RAI	NN	O	O
therapy	NN	O	O
,	NN	O	O
but	NN	O	O
still	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
values	NN	O	O
on	NN	O	O
day	NN	O	O
0	NN	O	O
.	NN	O	O

Molecular	NN	O	O
events	NN	O	O
that	NN	O	O
underlie	NN	O	O
the	NN	O	O
well-defined	NN	O	O
phenotypic	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
differentiating	NN	O	B-cell_type
thymocyte	NN	O	I-cell_type
are	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

-DOCSTART-	O

Interaction	NN	O	O
between	NN	O	O
the	NN	O	O
stage	NN	O	B-DNA
selector	NN	O	I-DNA
element	NN	O	I-DNA
(	NN	O	O
SSE	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
proximal	NN	O	B-DNA
gamma-globin	NN	O	I-DNA
promoter	NN	O	I-DNA
and	NN	O	O
hypersensitivity	NN	O	B-DNA
site	NN	O	I-DNA
2	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
locus	NN	O	B-DNA
control	NN	O	I-DNA
region	NN	O	I-DNA
partly	NN	O	O
mediates	NN	O	O
the	NN	O	O
competitive	NN	O	O
silencing	NN	O	O
of	NN	O	O
the	NN	O	O
beta-globin	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
fetal	NN	O	O
developmental	NN	O	O
stage	NN	O	O
.	NN	O	O

Utilizing	NN	O	O
transient	NN	O	O
transfection	NN	O	O
assays	NN	O	O
in	NN	O	O
the	NN	O	O
fetal	NN	O	B-cell_line
erythroid	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	O
K562	NN	O	B-cell_line
,	NN	O	O
we	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
the	NN	O	O
core	NN	O	B-DNA
enhancer	NN	O	I-DNA
of	NN	O	O
hypersensitivity	NN	O	B-DNA
site	NN	O	I-DNA
2	NN	O	I-DNA
can	NN	O	O
preferentially	NN	O	O
interact	NN	O	O
with	NN	O	O
the	NN	O	O
proximal	NN	O	B-DNA
gamma-promoter	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
the	NN	O	O
SSE	NN	O	B-DNA
,	NN	O	O
completely	NN	O	O
silencing	NN	O	O
a	NN	O	O
linked	NN	O	B-DNA
beta-promoter	NN	O	I-DNA
.	NN	O	O

Fine	NN	O	O
mutagenesis	NN	O	O
dissected	NN	O	O
these	NN	O	O
activities	NN	O	O
to	NN	O	O
different	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
5'-UTR	NN	O	B-DNA
.	NN	O	O

These	NN	O	O
included	NN	O	O
vimentin	NN	O	B-protein
,	NN	O	O
correlating	NN	O	O
to	NN	O	O
cell	NN	O	O
shape	NN	O	O
changes	NN	O	O
,	NN	O	O
cytokeratins	NN	O	B-protein
8	NN	O	I-protein
and	NN	O	I-protein
18	NN	O	I-protein
,	NN	O	O
associated	NN	O	O
with	NN	O	O
differentiated	NN	O	B-cell_type
cell	NN	O	I-cell_type
types	NN	O	I-cell_type
of	NN	O	O
prostate	NN	O	O
epithelia	NN	O	O
,	NN	O	O
and	NN	O	O
neuron-specific	NN	O	B-protein
enolase	NN	O	I-protein
and	NN	O	O
serotonin	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
neuroendocrine	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

This	NN	O	O
function	NN	O	O
of	NN	O	O
PAF	NN	O	B-protein
was	NN	O	O
observed	NN	O	O
at	NN	O	O
nanomolar	NN	O	O
concentrations	NN	O	O
of	NN	O	O
the	NN	O	O
ligand	NN	O	O
,	NN	O	O
starting	NN	O	O
at	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
stimulation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Mapping	NN	O	O
of	NN	O	O
the	NN	O	O
interaction	NN	O	B-protein
site	NN	O	I-protein
of	NN	O	O
the	NN	O	O
defective	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
in	NN	O	O
the	NN	O	O
class	NN	O	B-cell_line
II	NN	O	I-cell_line
major	NN	O	I-cell_line
histocompatibility	NN	O	I-cell_line
complex	NN	O	I-cell_line
mutant	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
clone-13	NN	O	I-cell_line
to	NN	O	O
the	NN	O	O
divergent	NN	O	B-DNA
X2-box	NN	O	I-DNA
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
replacement	NN	O	O
of	NN	O	O
the	NN	O	O
DQB	NN	O	B-DNA
X2-box	NN	O	I-DNA
with	NN	O	O
the	NN	O	O
DRA	NN	O	B-DNA
X2-box	NN	O	I-DNA
markedly	NN	O	O
diminished	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
DQB	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
mutant	NN	O	B-cell_line
cell	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
ZEBRA	NN	O	B-protein
protein	NN	O	I-protein
has	NN	O	O
a	NN	O	O
unique	NN	O	O
biological	NN	O	O
function	NN	O	O
among	NN	O	O
herpesviral	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

This	NN	O	O
factor	NN	O	O
was	NN	O	O
designated	NN	O	O
IL-4	NN	O	B-protein
NAF	NN	O	I-protein
(	NN	O	O
IL-4-induced	NN	O	B-protein
nuclear-activating	NN	O	I-protein
factors	NN	O	I-protein
)	NN	O	O
and	NN	O	O
was	NN	O	O
identified	NN	O	O
as	NN	O	O
a	NN	O	O
tyrosine	NN	O	B-protein
phosphoprotein	NN	O	I-protein
,	NN	O	O
which	NN	O	O
translocates	NN	O	O
from	NN	O	O
the	NN	O	O
cytosol	NN	O	O
to	NN	O	O
the	NN	O	O
nucleus	NN	O	O
upon	NN	O	O
IL-4	NN	O	B-protein
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
IL-4	NN	O	B-protein
NAF	NN	O	I-protein
is	NN	O	O
IL-4	NN	O	B-protein
Stat	NN	O	I-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
activated	NN	O	O
by	NN	O	O
JAK3	NN	O	B-protein
in	NN	O	O
response	NN	O	O
to	NN	O	O
IL-4	NN	O	B-protein
receptor	NN	O	O
engagement	NN	O	O
.	NN	O	O

The	NN	O	O
HEL	NN	O	B-cell_line
cells	NN	O	I-cell_line
also	NN	O	O
exhibited	NN	O	O
a	NN	O	O
similar	NN	O	O
elevation	NN	O	O
of	NN	O	O
AhR	NN	O	B-RNA
mRNA	NN	O	I-RNA
level	NN	O	O
,	NN	O	O
when	NN	O	O
they	NN	O	O
had	NN	O	O
differentiated	NN	O	O
toward	NN	O	O
monocyte-macrophage	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
these	NN	O	O
combined	NN	O	O
inducers	NN	O	O
,	NN	O	O
but	NN	O	O
little	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
mRNA	NN	O	O
level	NN	O	O
was	NN	O	O
observed	NN	O	O
when	NN	O	O
the	NN	O	O
cells	NN	O	O
were	NN	O	O
induced	NN	O	O
to	NN	O	O
differentiate	NN	O	O
into	NN	O	O
other	NN	O	O
cell	NN	O	O
types	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
although	NN	O	O
PU.1	NN	O	B-protein
and	NN	O	O
Spi-B	NN	O	B-protein
may	NN	O	O
bind	NN	O	O
to	NN	O	O
similar	NN	O	O
DNA	NN	O	O
control	NN	O	O
elements	NN	O	O
and	NN	O	O
have	NN	O	O
redundancy	NN	O	O
of	NN	O	O
transactivation	NN	O	O
function	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
significant	NN	O	O
levels	NN	O	O
of	NN	O	O
Spi-B	NN	O	B-protein
in	NN	O	O
myeloid	NN	O	B-cell_type
cells	NN	O	I-cell_type
makes	NN	O	O
it	NN	O	O
unlikely	NN	O	O
that	NN	O	O
Spi-B	NN	O	B-protein
plays	NN	O	O
a	NN	O	O
significant	NN	O	O
role	NN	O	O
in	NN	O	O
myeloid	NN	O	O
lineage	NN	O	O
development	NN	O	O
and	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
a	NN	O	O
major	NN	O	O
positive	NN	O	B-DNA
regulatory	NN	O	I-DNA
element	NN	O	I-DNA
located	NN	O	O
5	NN	O	O
'	NN	O	O
to	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
zeta-globin	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
despite	NN	O	O
its	NN	O	O
essential	NN	O	O
role	NN	O	O
for	NN	O	O
releasing	NN	O	O
an	NN	O	O
elongation	NN	O	B-protein
block	NN	O	I-protein
,	NN	O	O
Tat	NN	O	B-protein
is	NN	O	O
not	NN	O	O
otherwise	NN	O	O
absolutely	NN	O	O
required	NN	O	O
for	NN	O	O
synthesis	NN	O	O
of	NN	O	O
full-length	NN	O	B-RNA
HIV	NN	O	I-RNA
transcripts	NN	O	I-RNA
and	NN	O	O
assembly	NN	O	O
of	NN	O	O
virus	NN	O	O
particles	NN	O	O
.	NN	O	O

-DOCSTART-	O

Whereas	NN	O	O
PHA	NN	O	B-protein
-induced	NN	O	O
proliferation	NN	O	O
of	NN	O	O
PBMCs	NN	O	B-cell_type
derived	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
breast	NN	O	O
cancer	NN	O	O
preoperatively	NN	O	O
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
data	NN	O	O
obtained	NN	O	O
in	NN	O	O
healthy	NN	O	O
control	NN	O	O
individuals	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
the	NN	O	O
defect	NN	O	O
in	NN	O	O
PHA	NN	O	B-protein
-induced	NN	O	O
proliferation	NN	O	O
of	NN	O	O
PBMCs	NN	O	B-cell_type
depended	NN	O	O
upon	NN	O	O
the	NN	O	O
tumour	NN	O	O
burden	NN	O	O
as	NN	O	O
manifested	NN	O	O
by	NN	O	O
tumour	NN	O	O
size	NN	O	O
and	NN	O	O
axillary	NN	O	O
lymph	NN	O	O
node	NN	O	O
involvement	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.003	NN	O	O
in	NN	O	O
each	NN	O	O
case	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
previously	NN	O	O
unrecognized	NN	O	O
element	NN	O	O
,	NN	O	O
located	NN	O	O
downstream	NN	O	O
of	NN	O	O
the	NN	O	O
start	NN	O	B-DNA
site	NN	O	I-DNA
of	NN	O	I-DNA
transcription	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
first	NN	O	O
exon	NN	O	B-DNA
of	NN	O	O
the	NN	O	O
DR	NN	O	B-DNA
alpha	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
has	NN	O	O
been	NN	O	O
defined	NN	O	O
that	NN	O	O
enhances	NN	O	O
promoter	NN	O	O
activity	NN	O	O
up	NN	O	O
to	NN	O	O
eightfold	NN	O	O
in	NN	O	O
a	NN	O	O
position-dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

This	NN	O	O
protein	NN	O	O
,	NN	O	O
previously	NN	O	O
identified	NN	O	O
by	NN	O	O
its	NN	O	O
binding	NN	O	O
to	NN	O	O
the	NN	O	O
Ig	NN	O	B-DNA
kappa	NN	O	I-DNA
3	NN	O	I-DNA
'	NN	O	I-DNA
enhancer	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
Ig	NN	O	B-DNA
heavy	NN	O	I-DNA
chain	NN	O	I-DNA
mu	NN	O	I-DNA
E1	NN	O	I-DNA
site	NN	O	I-DNA
,	NN	O	O
thus	NN	O	O
also	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
quite	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
MHC	NN	O	B-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
gene	NN	O	I-DNA
expression	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
involvement	NN	O	O
of	NN	O	O
NFATp	NN	O	B-protein
in	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
interleukin-2	NN	O	B-protein
and	NN	O	O
TNF	NN	O	B-DNA
alpha	NN	O	I-DNA
genes	NN	O	I-DNA
suggests	NN	O	O
that	NN	O	O
this	NN	O	O
factor	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
coordinate	NN	O	O
induction	NN	O	O
of	NN	O	O
multiple	NN	O	O
cytokine	NN	O	B-DNA
genes	NN	O	I-DNA
,	NN	O	O
starting	NN	O	O
at	NN	O	O
the	NN	O	O
earliest	NN	O	O
stages	NN	O	O
of	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
analysis	NN	O	O
of	NN	O	O
sucrose	NN	O	O
gradient	NN	O	O
fractions	NN	O	O
in	NN	O	O
the	NN	O	O
gel	NN	O	O
retardation	NN	O	O
assay	NN	O	O
provided	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
LMP	NN	O	B-protein
promoter-binding	NN	O	I-protein
proteins	NN	O	I-protein
form	NN	O	O
a	NN	O	O
complex	NN	O	O
of	NN	O	O
higher	NN	O	O
M	NN	O	O
(	NN	O	O
r	NN	O	O
)	NN	O	O
in	NN	O	O
EBNA-2-positive	NN	O	B-cell_type
cell	NN	O	I-cell_type
extracts	NN	O	O
.	NN	O	O

To	NN	O	O
gain	NN	O	O
further	NN	O	O
insight	NN	O	O
into	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
control	NN	O	O
tal-1	NN	O	B-DNA
expression	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
tal-1	NN	O	B-DNA
chromatin	NN	O	O
structure	NN	O	O
in	NN	O	O
erythroid/megakaryocytic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
and	NN	O	O
in	NN	O	O
T-cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
either	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
tal-1	NN	O	B-DNA
rearrangements	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
long	NN	O	O
term	NN	O	O
cultures	NN	O	O
are	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
M-TAT/EPO	NN	O	B-cell_line
,	NN	O	I-cell_line
M-TAT/GM-CSF	NN	O	I-cell_line
,	NN	O	I-cell_line
and	NN	O	I-cell_line
M-TAT/SCF	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
GM-CSF	NN	O	B-protein
to	NN	O	O
the	NN	O	O
M-TAT/EPO	NN	O	B-cell_line
cell	NN	O	I-cell_line
culture	NN	O	I-cell_line
decreased	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
hemoglobin	NN	O	O
,	NN	O	O
even	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
EPO	NN	O	B-protein
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
EPO	NN	O	B-protein
signal	NN	O	O
for	NN	O	O
erythroid	NN	O	O
differentiation	NN	O	O
is	NN	O	O
suppressed	NN	O	O
by	NN	O	O
GM-CSF	NN	O	B-protein
.	NN	O	O

E2F	NN	O	B-protein
binding	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
both	NN	O	O
granulocytes	NN	O	B-cell_type
and	NN	O	O
monocytes	NN	O	B-cell_type
.	NN	O	O

This	NN	O	O
pattern	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B-related	NN	O	I-protein
moieties	NN	O	I-protein
differs	NN	O	O
from	NN	O	O
the	NN	O	O
latently	NN	O	B-cell_line
infected	NN	O	I-cell_line
T	NN	O	I-cell_line
lymphocytic	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
ACH-2	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
from	NN	O	O
the	NN	O	O
U937	NN	O	B-cell_line
monocytic	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	O
the	NN	O	O
parental	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
of	NN	O	O
the	NN	O	O
U1	NN	O	B-cell_line
cellular	NN	O	I-cell_line
clone	NN	O	I-cell_line
.	NN	O	O

Different	NN	O	O
elements	NN	O	O
thus	NN	O	O
contribute	NN	O	O
to	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
in	NN	O	O
different	NN	O	O
cells	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
HIV	NN	O	O
protease	NN	O	O
on	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
precursor	NN	O	O
activation	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
Jurkat	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
introducing	NN	O	O
a	NN	O	O
protease	NN	O	B-DNA
expression	NN	O	I-DNA
vector	NN	O	I-DNA
into	NN	O	O
the	NN	O	O
cells	NN	O	O
.	NN	O	O

Enhancement	NN	O	O
of	NN	O	O
IFNA	NN	O	B-protein
synthesis	NN	O	O
observed	NN	O	O
upon	NN	O	O
HIV-1	NN	O	O
infection	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
inhibition	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
replication	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
30	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
genes	NN	O	O
KOX	NN	O	B-DNA
4	NN	O	I-DNA
and	NN	O	O
KOX	NN	O	B-DNA
9	NN	O	I-DNA
,	NN	O	O
mapped	NN	O	O
on	NN	O	O
chromosome	NN	O	B-DNA
8q24	NN	O	I-DNA
,	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
located	NN	O	O
within	NN	O	O
a	NN	O	O
DNA	NN	O	B-DNA
fragment	NN	O	I-DNA
of	NN	O	O
450	NN	O	O
kb	NN	O	O
.	NN	O	O

Fewer	NN	O	O
virus-exposed	NN	O	O
cells	NN	O	O
from	NN	O	O
elderly	NN	O	O
donors	NN	O	O
stained	NN	O	O
for	NN	O	O
Fos	NN	O	B-protein
and	NN	O	O
Jun	NN	O	B-protein
at	NN	O	O
each	NN	O	O
data	NN	O	O
point	NN	O	O
compared	NN	O	O
with	NN	O	O
cells	NN	O	O
from	NN	O	O
young	NN	O	O
donors	NN	O	O
.	NN	O	O

Accompanying	NN	O	O
the	NN	O	O
rapid	NN	O	O
turnover	NN	O	O
of	NN	O	O
the	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
protein	NN	O	I-protein
is	NN	O	O
simultaneous	NN	O	O
translocation	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B-related	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
to	NN	O	O
nuclei	NN	O	O
of	NN	O	O
adhered	NN	O	O
monocytes	NN	O	O
.	NN	O	O

It	NN	O	O
contains	NN	O	O
a	NN	O	O
basic	NN	O	B-protein
helix-loop-helix	NN	O	I-protein
(	NN	O	I-protein
bHLH	NN	O	I-protein
)	NN	O	I-protein
motif	NN	O	I-protein
contiguous	NN	O	O
with	NN	O	O
a	NN	O	O
Per-Arnt-Sim	NN	O	B-protein
(	NN	O	I-protein
PAS	NN	O	I-protein
)	NN	O	I-protein
homology	NN	O	I-protein
region	NN	O	I-protein
.	NN	O	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
depended	NN	O	O
on	NN	O	O
calcium	NN	O	O
mobilization	NN	O	O
and	NN	O	O
PKC	NN	O	B-protein
activation	NN	O	O
.	NN	O	O

Interleukin-2	NN	O	B-protein
induces	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
stat3	NN	O	B-protein
in	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

An	NN	O	O
early	NN	O	O
biochemical	NN	O	O
event	NN	O	O
associated	NN	O	O
with	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
through	NN	O	O
the	NN	O	O
interleukin-2	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
IL-2R	NN	O	B-protein
)	NN	O	O
is	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
several	NN	O	O
intracellular	NN	O	O
substrates	NN	O	O
.	NN	O	O

Since	NN	O	O
IL-2	NN	O	B-protein
induced	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
the	NN	O	O
84	NN	O	B-protein
kDa	NN	O	I-protein
protein	NN	O	I-protein
and	NN	O	O
stat3	NN	O	B-protein
followed	NN	O	O
identical	NN	O	O
kinetics	NN	O	O
,	NN	O	O
p84	NN	O	B-protein
is	NN	O	O
a	NN	O	O
candidate	NN	O	O
for	NN	O	O
a	NN	O	O
new	NN	O	O
,	NN	O	O
yet	NN	O	O
undefined	NN	O	O
,	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
STAT	NN	O	O
family	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
IL-2	NN	O	B-protein
induces	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
subsequent	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
stat3	NN	O	B-protein
and	NN	O	O
an	NN	O	O
as	NN	O	O
yet	NN	O	O
undefined	NN	O	O
84-kDa	NN	O	B-protein
protein	NN	O	I-protein
in	NN	O	O
antigen-specific	NN	O	B-cell_line
human	NN	O	I-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

HTLV-I	NN	O	B-protein
Tax	NN	O	I-protein
expression	NN	O	O
leads	NN	O	O
to	NN	O	O
the	NN	O	O
constitutive	NN	O	O
nuclear	NN	O	O
expression	NN	O	O
of	NN	O	O
biologically	NN	O	O
active	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
c-Rel	NN	O	B-protein
complexes	NN	O	I-protein
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
biochemical	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
underlying	NN	O	O
this	NN	O	O
response	NN	O	O
remains	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
prior	NN	O	O
in	NN	O	O
vitro	NN	O	O
studies	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
fraction	NN	O	O
of	NN	O	O
the	NN	O	O
phosphorylated	NN	O	O
form	NN	O	O
of	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
remains	NN	O	O
physically	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
complex	NN	O	I-protein
in	NN	O	O
vivo	NN	O	O
but	NN	O	O
is	NN	O	O
subject	NN	O	O
to	NN	O	O
rapid	NN	O	O
degradation	NN	O	O
,	NN	O	O
thereby	NN	O	O
promoting	NN	O	O
the	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
the	NN	O	O
active	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
complex	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

Serum	NN	O	O
osteocalcin	NN	O	B-protein
decreased	NN	O	O
significantly	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
both	NN	O	O
BUD	NN	O	O
and	NN	O	O
FP	NN	O	O
.	NN	O	O

Serum	NN	O	O
cortisol	NN	O	O
decreased	NN	O	O
after	NN	O	O
1	NN	O	O
week	NN	O	O
of	NN	O	O
treatment	NN	O	O
whereas	NN	O	O
urinary	NN	O	O
cortisol	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
until	NN	O	O
the	NN	O	O
second	NN	O	O
week	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
cycloheximide	NN	O	O
prevented	NN	O	O
the	NN	O	O
p65	NN	O	B-protein
and	NN	O	O
c-rel	NN	O	B-protein
translocation	NN	O	O
and	NN	O	O
consequent	NN	O	O
formation	NN	O	O
of	NN	O	O
active	NN	O	O
binding	NN	O	O
heterodimers	NN	O	O
,	NN	O	O
at	NN	O	O
early	NN	O	O
and	NN	O	O
late	NN	O	O
times	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
GC-box	NN	O	B-DNA
binding	NN	O	O
activity	NN	O	O
A1	NN	O	B-protein
was	NN	O	O
purified	NN	O	O
and	NN	O	O
identified	NN	O	O
as	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
Sp1	NN	O	I-protein
.	NN	O	O

The	NN	O	O
NR2	NN	O	B-cell_line
hybrid	NN	O	I-cell_line
allowed	NN	O	O
us	NN	O	O
to	NN	O	O
exclude	NN	O	O
three	NN	O	O
candidate	NN	O	B-DNA
genes	NN	O	I-DNA
for	NN	O	O
AGS	NN	O	O
:	NN	O	O
hepatic	NN	O	B-DNA
nuclear	NN	O	I-DNA
factor	NN	O	I-DNA
3	NN	O	I-DNA
beta	NN	O	I-DNA
(	NN	O	O
HNF3	NN	O	B-DNA
beta	NN	O	I-DNA
)	NN	O	O
,	NN	O	O
paired	NN	O	B-DNA
box	NN	O	I-DNA
1	NN	O	I-DNA
(	NN	O	O
PAX1	NN	O	B-DNA
)	NN	O	O
,	NN	O	O
and	NN	O	O
cystatin	NN	O	B-DNA
C	NN	O	I-DNA
(	NN	O	O
CST3	NN	O	B-DNA
)	NN	O	O
as	NN	O	O
shown	NN	O	O
by	NN	O	O
their	NN	O	O
localization	NN	O	O
outside	NN	O	O
of	NN	O	O
the	NN	O	O
deletion	NN	O	O
.	NN	O	O

Posttranscriptional	NN	O	O
regulation	NN	O	O
of	NN	O	O
macrophage	NN	O	O
tissue	NN	O	B-protein
factor	NN	O	I-protein
expression	NN	O	O
by	NN	O	O
antioxidants	NN	O	O
.	NN	O	O

Two	NN	O	O
gel	NN	O	B-protein
shift	NN	O	I-protein
complexes	NN	O	I-protein
(	NN	O	O
Mono	NN	O	B-protein
A	NN	O	I-protein
and	NN	O	O
Mono	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
were	NN	O	O
formed	NN	O	O
with	NN	O	O
separate	NN	O	O
sequence	NN	O	O
elements	NN	O	O
within	NN	O	O
this	NN	O	O
region	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
HL-60	NN	O	O
cells	NN	O	O
or	NN	O	O
thymocytes	NN	O	B-cell_type
with	NN	O	O
100-500	NN	O	O
microM	NN	O	O
OP	NN	O	O
for	NN	O	O
2	NN	O	O
hr	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
10-60	NN	O	O
mM	NN	O	O
NAC	NN	O	O
,	NN	O	O
suppressed	NN	O	O
subsequent	NN	O	O
occurrence	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
etoposide	NN	O	O
.	NN	O	O

The	NN	O	O
truncation	NN	O	O
resulted	NN	O	O
from	NN	O	O
limited	NN	O	O
proteolysis	NN	O	O
of	NN	O	O
p65	NN	O	B-protein
during	NN	O	O
cellular	NN	O	O
extraction	NN	O	O
which	NN	O	O
released	NN	O	O
particular	NN	O	O
lysosomal	NN	O	B-protein
serine	NN	O	I-protein
proteases	NN	O	I-protein
,	NN	O	O
such	NN	O	O
as	NN	O	O
elastase	NN	O	B-protein
,	NN	O	O
cathepsin	NN	O	B-protein
G	NN	O	I-protein
,	NN	O	O
and	NN	O	O
proteinase	NN	O	B-protein
3	NN	O	I-protein
.	NN	O	O

A	NN	O	O
germline	NN	O	B-DNA
TaqI	NN	O	I-DNA
restriction	NN	O	I-DNA
fragment	NN	O	I-DNA
length	NN	O	I-DNA
polymorphism	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
progesterone	NN	O	B-DNA
receptor	NN	O	I-DNA
gene	NN	O	I-DNA
in	NN	O	O
ovarian	NN	O	O
carcinoma	NN	O	O
[	NN	O	O
see	NN	O	O
comments	NN	O	O
]	NN	O	O

Recent	NN	O	O
biochemical	NN	O	O
and	NN	O	O
genetic	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
octamer-binding	NN	O	B-protein
proteins	NN	O	I-protein
Oct-1	NN	O	B-protein
and	NN	O	O
Oct-2	NN	O	B-protein
,	NN	O	O
other	NN	O	O
B	NN	O	B-protein
cell	NN	O	I-protein
components	NN	O	I-protein
are	NN	O	O
required	NN	O	O
for	NN	O	O
lymphoid-restricted	NN	O	O
,	NN	O	O
octamer	NN	O	O
site-mediated	NN	O	O
immunoglobulin	NN	O	B-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
.	NN	O	O

HIV-infected	NN	O	O
individuals	NN	O	O
and	NN	O	O
SIV-infected	NN	O	O
rhesus	NN	O	O
macaques	NN	O	O
have	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
average	NN	O	O
,	NN	O	O
decreased	NN	O	O
plasma	NN	O	O
cysteine	NN	O	O
and	NN	O	O
cystine	NN	O	O
concentrations	NN	O	O
and	NN	O	O
decreased	NN	O	O
intracellular	NN	O	O
glutathione	NN	O	O
levels	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
point	NN	O	O
to	NN	O	O
two	NN	O	O
major	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
early	NN	O	O
and	NN	O	O
the	NN	O	O
late	NN	O	O
IL-6	NN	O	B-protein
-induced	NN	O	O
junB	NN	O	B-DNA
transcription	NN	O	O
waves	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
phospholipase	NN	O	B-protein
C	NN	O	I-protein
gamma	NN	O	I-protein
1	NN	O	I-protein
,	NN	O	O
ligation	NN	O	O
of	NN	O	O
this	NN	O	O
receptor	NN	O	O
also	NN	O	O
seems	NN	O	O
to	NN	O	O
activate	NN	O	O
a	NN	O	O
calcium-independent	NN	O	O
,	NN	O	O
CD28	NN	O	B-protein
-specific	NN	O	O
pathway	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
studies	NN	O	O
,	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-cell_line
monocytic	NN	O	I-cell_line
line	NN	O	I-cell_line
Mono	NN	O	B-cell_line
Mac	NN	O	I-cell_line
6	NN	O	I-cell_line
,	NN	O	O
cultured	NN	O	O
in	NN	O	O
medium	NN	O	O
containing	NN	O	O
fetal-calf	NN	O	O
serum	NN	O	O
and	NN	O	O
low	NN	O	O
levels	NN	O	O
of	NN	O	O
lipopolysaccharide	NN	O	O
(	NN	O	O
LPS	NN	O	O
)	NN	O	O
,	NN	O	O
also	NN	O	O
exhibit	NN	O	O
such	NN	O	O
'constitutive	NN	O	O
'	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
,	NN	O	O
as	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
mobility-shift	NN	O	O
analysis	NN	O	O
of	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
when	NN	O	O
inducing	NN	O	O
differentiation	NN	O	O
in	NN	O	O
Mono	NN	O	B-cell_line
Mac	NN	O	I-cell_line
6	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
with	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
,	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
constitutive	NN	O	O
or	NN	O	O
inducible	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
can	NN	O	O
be	NN	O	O
detected	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
SCL	NN	O	O
in	NN	O	O
the	NN	O	O
proliferation	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
burst-forming	NN	O	I-cell_type
unit-erythroid	NN	O	I-cell_type
(	NN	O	O
BFU-E	NN	O	B-cell_type
)	NN	O	O
and	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
Steel	NN	O	B-protein
factor	NN	O	I-protein
on	NN	O	O
SCL	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
proliferating	NN	O	B-cell_type
erythroid	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
alpha	NN	O	I-protein
(	NN	O	O
TNF	NN	O	B-protein
alpha	NN	O	I-protein
)	NN	O	O
is	NN	O	O
particularly	NN	O	O
important	NN	O	O
in	NN	O	O
this	NN	O	O
process	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
regulate	NN	O	O
other	NN	O	O
inflammatory	NN	O	O
mediators	NN	O	O
in	NN	O	O
an	NN	O	O
autocrine	NN	O	O
and	NN	O	O
paracrine	NN	O	O
fashion	NN	O	O
.	NN	O	O

Recent	NN	O	O
studies	NN	O	O
have	NN	O	O
identified	NN	O	O
calcineurin	NN	O	B-protein
as	NN	O	O
a	NN	O	O
key	NN	O	O
enzyme	NN	O	O
for	NN	O	O
interleukin	NN	O	O
(	NN	O	O
IL	NN	O	O
)	NN	O	O
-2	NN	O	O
and	NN	O	O
IL-4	NN	O	O
promoter	NN	O	O
activation	NN	O	O
.	NN	O	O

Similar	NN	O	O
results	NN	O	O
were	NN	O	O
obtained	NN	O	O
when	NN	O	O
a	NN	O	O
construct	NN	O	O
containing	NN	O	O
the	NN	O	O
IL-4	NN	O	B-DNA
promoter	NN	O	I-DNA
also	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
ICAM-1	NN	O	B-protein
and	NN	O	O
LFA-3	NN	O	B-protein
by	NN	O	O
Tax1	NN	O	B-protein
of	NN	O	O
human	NN	O	O
T-cell	NN	O	O
leukemia	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
and	NN	O	O
mechanism	NN	O	O
of	NN	O	O
down-regulation	NN	O	O
of	NN	O	O
ICAM-1	NN	O	B-protein
or	NN	O	O
LFA-1	NN	O	B-protein
in	NN	O	O
adult-T-cell-leukemia	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

T.	NN	O	B-cell_type
annulata-infected	NN	O	I-cell_type
leucocytes	NN	O	I-cell_type
produce	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
novel	NN	O	O
metalloproteinase	NN	O	B-protein
activities	NN	O	O
.	NN	O	O

EBNA2	NN	O	B-protein
is	NN	O	O
thus	NN	O	O
required	NN	O	O
not	NN	O	O
only	NN	O	O
for	NN	O	O
initiation	NN	O	O
but	NN	O	O
also	NN	O	O
for	NN	O	O
maintenance	NN	O	O
of	NN	O	O
transformation	NN	O	O
.	NN	O	O

Growth	NN	O	O
arrest	NN	O	O
is	NN	O	O
reversible	NN	O	O
for	NN	O	O
G1/G0	NN	O	B-cell_type
cells	NN	O	I-cell_type
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
the	NN	O	O
sequential	NN	O	O
accumulation	NN	O	O
and	NN	O	O
modification	NN	O	O
of	NN	O	O
cell	NN	O	B-protein
cycle	NN	O	I-protein
regulating	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

Functional	NN	O	O
Myc-Max	NN	O	B-protein
heterodimer	NN	O	I-protein
is	NN	O	O
required	NN	O	O
for	NN	O	O
activation-induced	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
hybridomas	NN	O	I-cell_line
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
SBMA	NN	O	O
sperm	NN	O	B-cell_type
typing	NN	O	O
results	NN	O	O
with	NN	O	O
mutation	NN	O	O
frequency	NN	O	O
data	NN	O	O
on	NN	O	O
normal	NN	O	O
alleles	NN	O	O
supports	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
trinucleotide	NN	O	B-DNA
repeat	NN	O	I-DNA
expansions	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
different	NN	O	O
molecular	NN	O	O
origin	NN	O	O
than	NN	O	O
contractions	NN	O	O
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
T-cells	NN	O	B-cell_type
by	NN	O	O
agonistic	NN	O	O
anti-CD28	NN	O	B-protein
antibodies	NN	O	I-protein
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
phorbol	NN	O	O
12-myristate	NN	O	O
13-acetate	NN	O	O
(	NN	O	O
PMA	NN	O	O
)	NN	O	O
-	NN	O	O
or	NN	O	O
TcR	NN	O	B-protein
-derived	NN	O	O
signals	NN	O	O
induces	NN	O	O
the	NN	O	O
enhanced	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
.	NN	O	O

An	NN	O	O
intricate	NN	O	O
arrangement	NN	O	O
of	NN	O	O
binding	NN	O	O
sites	NN	O	O
for	NN	O	O
the	NN	O	O
Ets	NN	O	B-protein
family	NN	O	I-protein
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
regulates	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
alpha	NN	O	B-DNA
4	NN	O	I-DNA
integrin	NN	O	I-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Concomitant	NN	O	O
with	NN	O	O
this	NN	O	O
loss	NN	O	O
of	NN	O	O
a	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	B-protein
Ets-1-containing	NN	O	I-protein
complex	NN	O	I-protein
``	NN	O	O
c	NN	O	B-protein
``	NN	O	O
appeared	NN	O	O
.	NN	O	O

-DOCSTART-	O

To	NN	O	O
identify	NN	O	O
ets-related	NN	O	B-protein
transcriptional	NN	O	I-protein
regulators	NN	O	I-protein
expressed	NN	O	O
in	NN	O	O
pre-B	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
that	NN	O	O
may	NN	O	O
interact	NN	O	O
with	NN	O	O
either	NN	O	O
the	NN	O	O
pi	NN	O	B-DNA
or	NN	O	O
the	NN	O	O
microB	NN	O	B-DNA
site	NN	O	I-DNA
,	NN	O	O
we	NN	O	O
have	NN	O	O
used	NN	O	O
a	NN	O	O
PCR	NN	O	O
approach	NN	O	O
with	NN	O	O
degenerate	NN	O	O
oligonucleotides	NN	O	O
encoding	NN	O	O
conserved	NN	O	O
sequences	NN	O	O
in	NN	O	O
all	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
ets	NN	O	B-DNA
family	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
ERP	NN	O	B-protein
might	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
B-cell	NN	O	B-cell_type
development	NN	O	O
and	NN	O	O
in	NN	O	O
IgH	NN	O	B-DNA
gene	NN	O	I-DNA
regulation	NN	O	O
.	NN	O	O

Purification	NN	O	O
and	NN	O	O
cloning	NN	O	O
of	NN	O	O
this	NN	O	O
protein	NN	O	O
,	NN	O	O
termed	NN	O	O
early	NN	O	O
B-cell	NN	O	B-protein
factor	NN	O	I-protein
(	NN	O	O
EBF	NN	O	B-protein
)	NN	O	O
,	NN	O	O
from	NN	O	O
murine	NN	O	B-cell_type
B	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
and	NN	O	O
independent	NN	O	O
cloning	NN	O	O
of	NN	O	O
a	NN	O	O
protein	NN	O	O
,	NN	O	O
termed	NN	O	O
Olf-1	NN	O	B-protein
,	NN	O	O
from	NN	O	O
olfactory	NN	O	B-cell_type
neuronal	NN	O	I-cell_type
cells	NN	O	I-cell_type
revealed	NN	O	O
virtual	NN	O	O
complete	NN	O	O
amino	NN	O	O
acid	NN	O	O
sequence	NN	O	O
identity	NN	O	O
between	NN	O	O
these	NN	O	O
proteins	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
PRL	NN	O	I-DNA
(	NN	O	I-DNA
hPRL	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
in	NN	O	O
extrapituitary	NN	O	O
sites	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
uterus	NN	O	O
(	NN	O	O
decidualized	NN	O	O
endometrial	NN	O	O
stroma	NN	O	O
and	NN	O	O
myometrium	NN	O	O
)	NN	O	O
and	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
hematopoietic	NN	O	B-cell_type
lineage	NN	O	I-cell_type
is	NN	O	O
directed	NN	O	O
by	NN	O	O
an	NN	O	O
alternative	NN	O	B-DNA
promoter	NN	O	I-DNA
which	NN	O	O
is	NN	O	O
located	NN	O	O
approximately	NN	O	O
6	NN	O	B-DNA
kilobases	NN	O	I-DNA
(	NN	O	I-DNA
kb	NN	O	I-DNA
)	NN	O	I-DNA
upstream	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
pituitary-specific	NN	O	B-DNA
start	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

JNK	NN	O	B-protein
is	NN	O	O
involved	NN	O	O
in	NN	O	O
signal	NN	O	O
integration	NN	O	O
during	NN	O	O
costimulation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

Alone	NN	O	O
,	NN	O	O
each	NN	O	O
stimulus	NN	O	O
resulted	NN	O	O
in	NN	O	O
little	NN	O	O
or	NN	O	O
no	NN	O	O
activation	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
liposomal	NN	O	O
formulation	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
(	NN	O	O
MPL	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
lymphocyte	NN	O	O
proliferation	NN	O	O
in	NN	O	O
spleen	NN	O	B-cell_type
cells	NN	O	I-cell_type
was	NN	O	O
investigated	NN	O	O
following	NN	O	O
IV	NN	O	O
dosing	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Inhibition	NN	O	O
effects	NN	O	O
versus	NN	O	O
time	NN	O	O
were	NN	O	O
described	NN	O	O
by	NN	O	O
a	NN	O	O
pharmacodynamic	NN	O	O
model	NN	O	O
using	NN	O	O
MPL	NN	O	O
concentrations	NN	O	O
in	NN	O	O
plasma	NN	O	B-cell_type
as	NN	O	O
an	NN	O	O
input	NN	O	O
function	NN	O	O
.	NN	O	O

A	NN	O	O
nonlinear	NN	O	O
relationship	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
suppression	NN	O	O
of	NN	O	O
splenocyte	NN	O	B-cell_type
proliferation	NN	O	O
and	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
bound	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
spleen	NN	O	O
.	NN	O	O

Function	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-DNA
B/Rel	NN	O	I-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
major	NN	O	B-DNA
histocompatibility	NN	O	I-DNA
complex	NN	O	I-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
invariant	NN	O	I-DNA
chain	NN	O	I-DNA
promoter	NN	O	I-DNA
is	NN	O	O
dependent	NN	O	O
on	NN	O	O
cell-specific	NN	O	O
binding	NN	O	O
of	NN	O	O
different	NN	O	O
NF-kappa	NN	O	B-protein
B/Rel	NN	O	I-protein
subunits	NN	O	I-protein
.	NN	O	O

Again	NN	O	O
,	NN	O	O
in	NN	O	O
vitro	NN	O	O
supershift	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
p52	NN	O	B-protein
,	NN	O	O
p65	NN	O	B-protein
,	NN	O	O
and	NN	O	O
cRel	NN	O	B-protein
correlates	NN	O	O
with	NN	O	O
positive	NN	O	O
function	NN	O	O
whereas	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
only	NN	O	O
p50	NN	O	B-protein
and	NN	O	O
p52	NN	O	B-protein
correlates	NN	O	O
with	NN	O	O
negative	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
work	NN	O	O
has	NN	O	O
studied	NN	O	O
mechanisms	NN	O	O
responsible	NN	O	O
for	NN	O	O
induction	NN	O	O
of	NN	O	O
early	NN	O	B-DNA
growth	NN	O	I-DNA
response	NN	O	I-DNA
1	NN	O	I-DNA
(	NN	O	I-DNA
EGR-1	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
expression	NN	O	O
during	NN	O	O
monocytic	NN	O	O
differentiation	NN	O	O
of	NN	O	O
U-937	NN	O	B-cell_line
myeloid	NN	O	I-cell_line
leukemia	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Cell	NN	O	O
adhesion	NN	O	O
to	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
stimulated	NN	O	B-protein
by	NN	O	I-protein
tumor	NN	O	I-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
(	NN	O	O
TNF	NN	O	B-protein
)	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
induction	NN	O	O
of	NN	O	O
surface	NN	O	B-protein
receptors	NN	O	I-protein
,	NN	O	O
such	NN	O	O
as	NN	O	O
vascular	NN	O	B-protein
cell	NN	O	I-protein
adhesion	NN	O	I-protein
molecule-1	NN	O	I-protein
(	NN	O	O
VCAM-1	NN	O	B-protein
)	NN	O	O
.	NN	O	O

The	NN	O	O
antioxidant	NN	O	O
pyrrolidine	NN	O	O
dithiocarbamate	NN	O	O
(	NN	O	O
PDTC	NN	O	O
)	NN	O	O
specifically	NN	O	O
inhibits	NN	O	O
activation	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor-kappa	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
.	NN	O	O

Sodium	NN	O	O
salicylate	NN	O	O
and	NN	O	O
aspirin	NN	O	O
also	NN	O	O
inhibited	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
-dependent	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
Ig	NN	O	B-DNA
kappa	NN	O	I-DNA
enhancer	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
(	NN	O	I-DNA
HIV	NN	O	I-DNA
)	NN	O	I-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
(	NN	O	O
LTR	NN	O	B-DNA
)	NN	O	O
in	NN	O	O
transfected	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
c-myb	NN	O	B-DNA
gene	NN	O	I-DNA
in	NN	O	O
erythroid	NN	O	O
differentiation	NN	O	O
of	NN	O	O
K562	NN	O	B-cell_line
cell	NN	O	I-cell_line
induced	NN	O	O
by	NN	O	O
hemin	NN	O	B-protein
(	NN	O	O
Hm	NN	O	B-protein
)	NN	O	O
and	NN	O	O
erythropoietin	NN	O	B-protein
(	NN	O	O
Epo	NN	O	B-protein
)	NN	O	O
,	NN	O	O
we	NN	O	O
constructed	NN	O	O
recombinant	NN	O	B-DNA
plasmid	NN	O	I-DNA
that	NN	O	O
could	NN	O	O
produce	NN	O	O
antisense	NN	O	B-RNA
myb	NN	O	I-RNA
RNA	NN	O	I-RNA
after	NN	O	O
induction	NN	O	O
with	NN	O	O
dexamethasone	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
after	NN	O	O
novelty	NN	O	O
stress	NN	O	O
the	NN	O	O
HRBC	NN	O	B-cell_type
group	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
LPS	NN	O	B-cell_line
group	NN	O	I-cell_line
,	NN	O	O
showed	NN	O	O
increased	NN	O	O
ACTH	NN	O	O
and	NN	O	O
corticosterone	NN	O	O
levels	NN	O	O
.	NN	O	O

Antioxidant	NN	O	O
molecules	NN	O	O
have	NN	O	O
been	NN	O	O
suggested	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
therapeutic	NN	O	O
value	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
HIV-infected	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
gelatinase	NN	O	O
granules	NN	O	O
,	NN	O	O
defined	NN	O	O
as	NN	O	O
peroxidase-negative	NN	O	O
granules	NN	O	O
containing	NN	O	O
gelatinase	NN	O	B-protein
but	NN	O	O
lacking	NN	O	O
lactoferrin	NN	O	B-protein
,	NN	O	O
contain	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
total	NN	O	O
cell	NN	O	O
gelatinase	NN	O	B-protein
,	NN	O	O
with	NN	O	O
the	NN	O	O
remaining	NN	O	O
residing	NN	O	O
in	NN	O	O
specific	NN	O	O
granules	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
20	NN	O	O
%	NN	O	O
to	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
adhesion	NN	O	B-protein
protein	NN	O	I-protein
Mac-1	NN	O	I-protein
and	NN	O	O
the	NN	O	O
NADPH-oxidase	NN	O	B-protein
component	NN	O	I-protein
cytochrome	NN	O	I-protein
b558	NN	O	B-protein
is	NN	O	O
localized	NN	O	O
in	NN	O	O
gelatinase	NN	O	B-protein
granules	NN	O	O
.	NN	O	O

The	NN	O	O
regulation	NN	O	O
of	NN	O	O
interleukin-2	NN	O	B-protein
receptor	NN	O	I-protein
alpha	NN	O	I-protein
chain	NN	O	I-protein
(	NN	O	O
IL-2R	NN	O	B-protein
alpha	NN	O	I-protein
)	NN	O	O
expression	NN	O	O
and	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
(	NN	O	O
NF	NN	O	O
)	NN	O	O
activation	NN	O	O
by	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
(	NN	O	O
PKC	NN	O	B-protein
)	NN	O	O
in	NN	O	O
resting	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
has	NN	O	O
been	NN	O	O
studied	NN	O	O
.	NN	O	O

Binding	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
complexes	NN	O	O
to	NN	O	O
CRE	NN	O	B-DNA
is	NN	O	O
prevented	NN	O	O
by	NN	O	O
dephosphorylation	NN	O	O
of	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
and	NN	O	O
is	NN	O	O
restored	NN	O	O
by	NN	O	O
rephosphorylation	NN	O	O
with	NN	O	O
cAMP-dependent	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
or	NN	O	O
endogenous	NN	O	B-protein
kinases	NN	O	I-protein
.	NN	O	O

The	NN	O	O
inhibition	NN	O	O
correlated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
steady	NN	O	O
state	NN	O	O
levels	NN	O	O
of	NN	O	O
E-selectin	NN	O	B-RNA
mRNA	NN	O	I-RNA
and	NN	O	O
cell	NN	O	O
surface	NN	O	O
expression	NN	O	O
of	NN	O	O
E-selectin	NN	O	B-protein
which	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
a	NN	O	O
monoclonal	NN	O	B-protein
antibody	NN	O	I-protein
to	NN	O	O
E-selectin	NN	O	B-protein
to	NN	O	O
inhibit	NN	O	O
monocytic	NN	O	O
cell	NN	O	O
adhesion	NN	O	O
in	NN	O	O
this	NN	O	O
system	NN	O	O
.	NN	O	O

Internal	NN	O	O
ribosomal	NN	O	O
binding	NN	O	O
requires	NN	O	O
a	NN	O	O
cis-acting	NN	O	B-DNA
element	NN	O	I-DNA
termed	NN	O	O
the	NN	O	O
internal	NN	O	B-DNA
ribosomal	NN	O	I-DNA
entry	NN	O	I-DNA
site	NN	O	I-DNA
(	NN	O	O
IRES	NN	O	B-DNA
)	NN	O	O
.	NN	O	O

These	NN	O	O
increases	NN	O	O
occur	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
but	NN	O	O
are	NN	O	O
dependent	NN	O	O
on	NN	O	O
inactivation	NN	O	O
of	NN	O	O
the	NN	O	O
v-abl	NN	O	B-protein
protein	NN	O	I-protein
tyrosine	NN	O	I-protein
kinase	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
p50	NN	O	B-protein
and	NN	O	I-protein
p65	NN	O	I-protein
NF-kappa	NN	O	I-protein
B	NN	O	I-protein
subunits	NN	O	I-protein
was	NN	O	O
also	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
regulated	NN	O	O
differentially	NN	O	O
after	NN	O	O
exposures	NN	O	O
to	NN	O	O
1.0	NN	O	O
and	NN	O	O
2.0	NN	O	O
Gy	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
ATRA-induced	NN	O	O
expression	NN	O	O
of	NN	O	O
CD38	NN	O	B-protein
antigen	NN	O	I-protein
in	NN	O	O
myeloid	NN	O	B-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
mediated	NN	O	O
through	NN	O	O
retinoic	NN	O	B-protein
acid-alpha	NN	O	I-protein
receptor	NN	O	I-protein
(	NN	O	O
RAR	NN	O	B-protein
alpha	NN	O	I-protein
)	NN	O	O
.	NN	O	O

Because	NN	O	O
there	NN	O	O
is	NN	O	O
the	NN	O	O
theoretical	NN	O	O
possibility	NN	O	O
of	NN	O	O
an	NN	O	O
E1a-	NN	O	O
replication-deficient	NN	O	O
vector	NN	O	O
replicating	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
recombination	NN	O	O
or	NN	O	O
complementation	NN	O	O
with	NN	O	O
Ad	NN	O	B-DNA
2/5	NN	O	I-DNA
E1a	NN	O	I-DNA
sequences	NN	O	I-DNA
present	NN	O	O
in	NN	O	O
the	NN	O	O
target	NN	O	O
cell	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
directed	NN	O	O
toward	NN	O	O
evaluating	NN	O	O
respiratory	NN	O	O
epithelium	NN	O	O
of	NN	O	O
normals	NN	O	O
and	NN	O	O
individuals	NN	O	O
with	NN	O	O
CF	NN	O	O
for	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
E1a	NN	O	O
sequences	NN	O	O
.	NN	O	O

Functional	NN	O	O
block	NN	O	O
for	NN	O	O
1	NN	O	O
alpha	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3-mediated	NN	O	O
gene	NN	O	O
regulation	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
B	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

A	NN	O	O
5.5-kilobase	NN	O	B-DNA
genomic	NN	O	I-DNA
clone	NN	O	I-DNA
contained	NN	O	O
the	NN	O	O
full-length	NN	O	O
CD14	NN	O	B-DNA
coding	NN	O	I-DNA
sequence	NN	O	I-DNA
and	NN	O	O
4.2	NN	O	B-DNA
kilobases	NN	O	I-DNA
of	NN	O	I-DNA
5'-upstream	NN	O	I-DNA
sequence	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Binding	NN	O	O
data	NN	O	O
were	NN	O	O
derived	NN	O	O
from	NN	O	O
Scatchard	NN	O	O
analysis	NN	O	O
.	NN	O	O

The	NN	O	O
involvement	NN	O	O
of	NN	O	O
a	NN	O	O
CD28	NN	O	B-DNA
response	NN	O	I-DNA
element	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
IL-8	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
activated	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
may	NN	O	O
provide	NN	O	O
new	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
and	NN	O	O
persistence	NN	O	O
of	NN	O	O
immune	NN	O	O
disorders	NN	O	O
characterized	NN	O	O
by	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-8	NN	O	B-protein
,	NN	O	O
such	NN	O	O
as	NN	O	O
psoriasis	NN	O	O
and	NN	O	O
rheumatoid	NN	O	O
arthritis	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
lymphocytes	NN	O	B-cell_type
in	NN	O	O
RA	NN	O	O
patients	NN	O	O
compared	NN	O	O
with	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

METHODS	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
that	NN	O	O
RA	NN	O	O
did	NN	O	O
not	NN	O	O
induced	NN	O	O
neutrophil	NN	O	O
differentiation	NN	O	O
in	NN	O	O
serum-free	NN	O	B-cell_line
grown	NN	O	I-cell_line
HL60	NN	O	I-cell_line
cells	NN	O	I-cell_line
whereas	NN	O	O
50	NN	O	O
nM	NN	O	O
1	NN	O	O
alpha	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3	NN	O	O
(	NN	O	O
D3	NN	O	O
)	NN	O	O
induced	NN	O	O
maximal	NN	O	O
monocyte	NN	O	O
differentiation	NN	O	O
.	NN	O	O

RARs	NN	O	B-protein
are	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
steroid/thyroid	NN	O	B-protein
hormone	NN	O	I-protein
receptor	NN	O	I-protein
superfamily	NN	O	I-protein
and	NN	O	O
exhibit	NN	O	O
a	NN	O	O
molecular	NN	O	O
structure	NN	O	O
that	NN	O	O
possess	NN	O	O
discrete	NN	O	O
DNA-binding	NN	O	O
and	NN	O	O
RA	NN	O	B-protein
(	NN	O	I-protein
ligand	NN	O	I-protein
)	NN	O	I-protein
-binding	NN	O	I-protein
domains	NN	O	I-protein
.	NN	O	O

IL-8	NN	O	B-DNA
gene	NN	O	I-DNA
induction	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
increased	NN	O	O
binding	NN	O	O
activity	NN	O	O
in	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
from	NN	O	O
hypoxic	NN	O	B-cell_type
ECs	NN	O	I-cell_type
for	NN	O	O
the	NN	O	O
NF-kB	NN	O	O
site	NN	O	O
.	NN	O	O

Thrombin	NN	O	B-protein
and	NN	O	O
TRP	NN	O	O
also	NN	O	O
caused	NN	O	O
translocation	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
from	NN	O	O
the	NN	O	O
cytosol	NN	O	O
to	NN	O	O
the	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
.	NN	O	O

The	NN	O	O
magnitude	NN	O	O
of	NN	O	O
the	NN	O	O
thrombin	NN	O	B-protein
response	NN	O	O
in	NN	O	O
the	NN	O	O
different	NN	O	O
cell	NN	O	O
types	NN	O	O
paralleled	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
thrombin	NN	O	B-RNA
receptor	NN	O	I-RNA
mRNA	NN	O	I-RNA
.	NN	O	O

We	NN	O	O
have	NN	O	O
detected	NN	O	O
activatable	NN	O	O
PLD	NN	O	B-protein
in	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
we	NN	O	O
have	NN	O	O
found	NN	O	O
that	NN	O	O
addition	NN	O	O
of	NN	O	O
phosphatidic	NN	O	O
acid	NN	O	O
(	NN	O	O
PA	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
physiologic	NN	O	O
product	NN	O	O
of	NN	O	O
PLD	NN	O	B-protein
action	NN	O	O
on	NN	O	O
phospholipids	NN	O	O
,	NN	O	O
is	NN	O	O
rapidly	NN	O	O
incorporated	NN	O	O
into	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
leads	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
AP-1	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

IL-4	NN	O	B-protein
did	NN	O	O
not	NN	O	O
exert	NN	O	O
significant	NN	O	O
influence	NN	O	O
on	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
expression	NN	O	O
of	NN	O	O
IL-1-RA	NN	O	B-protein
or	NN	O	O
various	NN	O	O
CSFs	NN	O	B-protein
by	NN	O	O
IL-2	NN	O	B-protein
,	NN	O	O
IL-3	NN	O	B-protein
,	NN	O	O
and	NN	O	O
GM-CSF	NN	O	B-protein
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
proto-oncogene	NN	O	B-DNA
and	NN	O	O
cytokine	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
human	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
the	NN	O	O
monocytic	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
THP-1	NN	O	B-cell_line
after	NN	O	O
stimulation	NN	O	O
with	NN	O	O
mycoplasma-derived	NN	O	O
material	NN	O	O
MDHM	NN	O	O
.	NN	O	O

Binding	NN	O	O
of	NN	O	O
1	NN	O	O
nM	NN	O	O
[	NN	O	O
125I	NN	O	O
]	NN	O	O
-aldosterone	NN	O	O
was	NN	O	O
found	NN	O	O
at	NN	O	O
a	NN	O	O
molecular	NN	O	O
weight	NN	O	O
of	NN	O	O
approximately	NN	O	O
50	NN	O	O
kDa	NN	O	O
which	NN	O	O
was	NN	O	O
absent	NN	O	O
with	NN	O	O
1	NN	O	O
microM	NN	O	O
cold	NN	O	O
aldosterone	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
cortisol	NN	O	O
in	NN	O	O
the	NN	O	O
binding	NN	O	O
media	NN	O	O
.	NN	O	O

Site	NN	O	B-DNA
B	NN	O	I-DNA
(	NN	O	O
nt	NN	O	B-DNA
4519	NN	O	I-DNA
to	NN	O	I-DNA
4545	NN	O	I-DNA
)	NN	O	O
specifically	NN	O	O
bound	NN	O	O
four	NN	O	O
distinct	NN	O	O
nuclear	NN	O	B-protein
protein	NN	O	I-protein
complexes	NN	O	I-protein
:	NN	O	O
a	NN	O	O
ubiquitous	NN	O	B-protein
factor	NN	O	I-protein
,	NN	O	O
a	NN	O	O
T-cell-specific	NN	O	B-protein
factor	NN	O	I-protein
,	NN	O	O
a	NN	O	O
B-cell-specific	NN	O	B-protein
factor	NN	O	I-protein
,	NN	O	O
and	NN	O	O
the	NN	O	O
monocyte/macrophage-	NN	O	B-protein
and	NN	O	I-protein
B-cell-specific	NN	O	I-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
PU.1/Spi-1	NN	O	B-protein
.	NN	O	O

The	NN	O	O
implications	NN	O	O
for	NN	O	O
T	NN	O	B-protein
cell	NN	O	I-protein
receptor	NN	O	I-protein
signaling	NN	O	O
and	NN	O	O
HIV-1	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
are	NN	O	O
considered	NN	O	O
.	NN	O	O

Deletion	NN	O	O
constructs	NN	O	O
of	NN	O	O
the	NN	O	O
pCD41	NN	O	B-DNA
clone	NN	O	I-DNA
demonstrated	NN	O	O
that	NN	O	O
ORF-A	NN	O	B-protein
was	NN	O	O
critical	NN	O	O
for	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
LTR	NN	O	I-DNA
activation	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
investigators	NN	O	O
have	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
CD14	NN	O	B-protein
-mediated	NN	O	O
signaling	NN	O	O
is	NN	O	O
effected	NN	O	O
through	NN	O	O
a	NN	O	O
receptor-associated	NN	O	O
tyrosine	NN	O	B-protein
kinase	NN	O	I-protein
(	NN	O	O
TK	NN	O	O
)	NN	O	O
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
multicomponent	NN	O	O
receptor	NN	O	O
model	NN	O	O
of	NN	O	O
LPS	NN	O	O
signaling	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
imply	NN	O	O
that	NN	O	O
TK	NN	O	O
activity	NN	O	O
is	NN	O	O
not	NN	O	O
obligatory	NN	O	O
for	NN	O	O
CD14	NN	O	B-protein
-mediated	NN	O	O
signal	NN	O	O
transduction	NN	O	O
to	NN	O	O
occur	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
LPS	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-protein
immunodeficiency	NN	O	I-protein
virus	NN	O	I-protein
(	NN	O	I-protein
HIV-1	NN	O	I-protein
)	NN	O	I-protein
Nef	NN	O	I-protein
protein	NN	O	I-protein
in	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
pathways	NN	O	O
was	NN	O	O
investigated	NN	O	O
using	NN	O	O
a	NN	O	O
Jurkat	NN	O	B-cell_line
CD4+	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
stably	NN	O	O
transfected	NN	O	O
with	NN	O	O
a	NN	O	O
Nef	NN	O	O
expression	NN	O	O
vector	NN	O	O
.	NN	O	O

The	NN	O	O
Tax	NN	O	B-protein
protein	NN	O	I-protein
of	NN	O	O
HTLV-I	NN	O	O
,	NN	O	O
a	NN	O	O
positive	NN	O	B-protein
transcriptional	NN	O	I-protein
activator	NN	O	I-protein
of	NN	O	O
HTLV-I	NN	O	O
gene	NN	O	O
expression	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
viral	NN	O	O
oncogene	NN	O	O
that	NN	O	O
also	NN	O	O
increases	NN	O	O
transcription	NN	O	O
of	NN	O	O
cellular	NN	O	B-DNA
genes	NN	O	I-DNA
including	NN	O	O
GM-CSF	NN	O	B-protein
,	NN	O	O
IL-2R	NN	O	B-protein
alpha	NN	O	I-protein
and	NN	O	O
IL-2	NN	O	B-protein
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
phosphatidylinositol	NN	O	O
turnover	NN	O	O
and	NN	O	O
EGR-1	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
by	NN	O	O
crosslinking	NN	O	O
of	NN	O	O
surface	NN	O	O
IgM	NN	O	B-protein
and	NN	O	O
IgD	NN	O	B-protein
in	NN	O	O
the	NN	O	O
human	NN	O	B-cell_line
B	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
B104	NN	O	I-cell_line
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
the	NN	O	O
nucleotide	NN	O	B-DNA
sequences	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
CD11a	NN	O	B-DNA
,	NN	O	I-DNA
CD11b	NN	O	I-DNA
,	NN	O	I-DNA
and	NN	O	I-DNA
CD11c	NN	O	I-DNA
gene	NN	O	I-DNA
promoters	NN	O	I-DNA
to	NN	O	O
identify	NN	O	O
common	NN	O	O
elements	NN	O	O
that	NN	O	O
might	NN	O	O
contribute	NN	O	O
to	NN	O	O
inducible	NN	O	O
expression	NN	O	O
.	NN	O	O

Multiple	NN	O	O
TRAF3	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
containing	NN	O	O
a	NN	O	O
PXQXT/S	NN	O	B-DNA
core	NN	O	I-DNA
sequence	NN	O	I-DNA
can	NN	O	O
be	NN	O	O
identified	NN	O	O
in	NN	O	O
the	NN	O	O
simian	NN	O	B-protein
EBV	NN	O	I-protein
LMP1s	NN	O	I-protein
by	NN	O	O
an	NN	O	O
in	NN	O	O
vitro	NN	O	O
binding	NN	O	O
assay	NN	O	O
.	NN	O	O

A	NN	O	O
PXQXT/S-containing	NN	O	B-DNA
sequence	NN	O	I-DNA
is	NN	O	O
also	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
the	NN	O	O
Hodgkin	NN	O	O
's	NN	O	O
disease	NN	O	O
marker	NN	O	O
,	NN	O	O
CD30	NN	O	B-protein
,	NN	O	O
and	NN	O	O
binds	NN	O	O
TRAF3	NN	O	B-protein
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
their	NN	O	O
specific	NN	O	O
function	NN	O	O
in	NN	O	O
these	NN	O	O
processes	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
clearly	NN	O	O
defined	NN	O	O
.	NN	O	O

In	NN	O	O
some	NN	O	O
donors	NN	O	O
,	NN	O	O
increased	NN	O	O
IL-6	NN	O	B-protein
and	NN	O	O
TNF-alpha	NN	O	B-protein
activity	NN	O	O
also	NN	O	O
was	NN	O	O
detected	NN	O	O
after	NN	O	O
R24	NN	O	B-protein
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
cellular	NN	O	B-protein
gene	NN	O	I-protein
regulatory	NN	O	I-protein
molecules	NN	O	I-protein
induced	NN	O	O
with	NN	O	O
anti-Ig	NN	O	O
may	NN	O	O
cooperatively	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
part	NN	O	O
in	NN	O	O
achieving	NN	O	O
efficient	NN	O	O
EBV	NN	O	O
activation	NN	O	O
as	NN	O	O
seen	NN	O	O
with	NN	O	O
anti-Ig	NN	O	B-protein
treatment	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Contrary	NN	O	O
to	NN	O	O
the	NN	O	O
idea	NN	O	O
that	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
is	NN	O	O
involved	NN	O	O
in	NN	O	O
TCR	NN	O	B-protein
-mediated	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
,	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
staurosporine	NN	O	O
did	NN	O	O
not	NN	O	O
interfere	NN	O	O
with	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
by	NN	O	O
PHA	NN	O	B-protein
,	NN	O	O
while	NN	O	O
the	NN	O	O
same	NN	O	O
dose	NN	O	O
of	NN	O	O
staurosporine	NN	O	O
completely	NN	O	O
blocked	NN	O	O
activation	NN	O	O
by	NN	O	O
PMA	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
phenotype	NN	O	O
of	NN	O	O
mouse	NN	O	B-cell_line
transgenic	NN	O	I-cell_line
lines	NN	O	I-cell_line
obtained	NN	O	O
by	NN	O	O
inducing	NN	O	O
tal-1	NN	O	B-protein
protein	NN	O	I-protein
expression	NN	O	O
in	NN	O	O
lymphoid	NN	O	O
tissues	NN	O	O
using	NN	O	O
the	NN	O	O
LCK	NN	O	B-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Histopathological	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
lymphomas	NN	O	O
of	NN	O	O
T-cell	NN	O	O
type	NN	O	O
,	NN	O	O
often	NN	O	O
comprising	NN	O	O
a	NN	O	O
minor	NN	O	O
B-cell	NN	O	O
component	NN	O	O
.	NN	O	O

Apoptosis	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
in	NN	O	O
normal	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
:	NN	O	O
differential	NN	O	O
activity	NN	O	O
of	NN	O	O
Bcl-2	NN	O	B-protein
and	NN	O	O
IL-1beta-converting	NN	O	B-protein
enzyme	NN	O	I-protein
family	NN	O	I-protein
protease	NN	O	O
inhibitors	NN	O	O
on	NN	O	O
glucocorticoid-	NN	O	O
and	NN	O	O
Fas-mediated	NN	O	O
cytotoxicity	NN	O	O
.	NN	O	O

Restimulation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
blasts	NN	O	I-cell_type
up-regulates	NN	O	O
Fas	NN	O	B-protein
and	NN	O	O
Fas	NN	O	B-protein
ligand	NN	O	O
expression	NN	O	O
,	NN	O	O
with	NN	O	O
subsequent	NN	O	O
interaction	NN	O	O
leading	NN	O	O
to	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

Transient	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Bcl-2	NN	O	B-protein
in	NN	O	O
mouse	NN	O	O
and	NN	O	O
human	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
blasts	NN	O	I-cell_type
did	NN	O	O
not	NN	O	O
block	NN	O	O
Fas	NN	O	B-protein
-mediated	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
whereas	NN	O	O
etoposide-	NN	O	O
and	NN	O	O
glucocorticoid-induced	NN	O	O
cytotoxicity	NN	O	O
was	NN	O	O
potently	NN	O	O
inhibited	NN	O	O
.	NN	O	O

In	NN	O	O
S107	NN	O	B-cell_line
cells	NN	O	I-cell_line
stably	NN	O	O
transfected	NN	O	O
with	NN	O	O
relB	NN	O	B-DNA
genes	NN	O	I-DNA
,	NN	O	O
stimulation	NN	O	O
of	NN	O	O
nuclear	NN	O	O
RelB	NN	O	B-protein
translocation	NN	O	O
by	NN	O	O
CD40	NN	O	B-protein
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Identification	NN	O	O
and	NN	O	O
characterization	NN	O	O
of	NN	O	O
a	NN	O	O
leukocyte-specific	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	O
body	NN	O	O
.	NN	O	O

The	NN	O	O
granulocyte-macrophage	NN	O	B-DNA
colony-stimulating	NN	O	I-DNA
factor	NN	O	I-DNA
(	NN	O	I-DNA
GM-CSF	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
has	NN	O	O
been	NN	O	O
studied	NN	O	O
extensively	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
system	NN	O	O
of	NN	O	O
transcriptional	NN	O	O
induction	NN	O	O
during	NN	O	O
T-lymphocyte	NN	O	O
activation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Prevalence	NN	O	O
of	NN	O	O
aneuploidy	NN	O	O
,	NN	O	O
overexpressed	NN	O	O
ER	NN	O	B-protein
,	NN	O	O
and	NN	O	O
overexpressed	NN	O	O
EGFR	NN	O	B-protein
in	NN	O	O
random	NN	O	O
breast	NN	O	O
aspirates	NN	O	O
of	NN	O	O
women	NN	O	O
at	NN	O	O
high	NN	O	O
and	NN	O	O
low	NN	O	O
risk	NN	O	O
for	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
that	NN	O	O
dexamethasone	NN	O	O
dramatically	NN	O	O
inhibited	NN	O	O
RANTES	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
dose	NN	O	O
dependently	NN	O	O
in	NN	O	O
anti-CD3	NN	O	B-cell_line
activated	NN	O	I-cell_line
Hut-78	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
human	NN	O	B-cell_type
PBMCs	NN	O	I-cell_type
.	NN	O	O

To	NN	O	O
this	NN	O	O
aim	NN	O	O
,	NN	O	O
allergen-specific	NN	O	B-cell_line
CD4+	NN	O	I-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
clones	NN	O	I-cell_line
(	NN	O	O
TCC	NN	O	B-cell_line
)	NN	O	O
were	NN	O	O
generated	NN	O	O
from	NN	O	O
the	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
of	NN	O	O
three	NN	O	O
atopic	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
cytokine	NN	O	B-protein
profiles	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
sera	NN	O	O
of	NN	O	O
EBV-negative	NN	O	O
individuals	NN	O	O
(	NN	O	O
0/3	NN	O	O
)	NN	O	O
or	NN	O	O
healthy	NN	O	O
carriers	NN	O	O
(	NN	O	O
0/33	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
contain	NN	O	O
detectable	NN	O	O
levels	NN	O	O
of	NN	O	O
antibodies	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
mononucleosis	NN	O	O
(	NN	O	O
5/18	NN	O	O
)	NN	O	O
,	NN	O	O
chronic	NN	O	O
EBV	NN	O	O
infection	NN	O	O
(	NN	O	O
2/7	NN	O	O
)	NN	O	O
,	NN	O	O
EBV	NN	O	O
reactivation	NN	O	O
(	NN	O	O
7/20	NN	O	O
)	NN	O	O
and	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
infection	NN	O	O
(	NN	O	O
5/24	NN	O	O
)	NN	O	O
showed	NN	O	O
elevated	NN	O	O
antibody	NN	O	O
titres	NN	O	O
against	NN	O	O
the	NN	O	O
enzyme	NN	O	O
.	NN	O	O

The	NN	O	O
enzyme	NN	O	O
might	NN	O	O
therefore	NN	O	O
be	NN	O	O
a	NN	O	O
potential	NN	O	O
target	NN	O	O
for	NN	O	O
drug	NN	O	O
therapy	NN	O	O
under	NN	O	O
conditions	NN	O	O
of	NN	O	O
active	NN	O	O
DNA	NN	O	O
replication	NN	O	O
.	NN	O	O

-DOCSTART-	O

Furthermore	NN	O	O
,	NN	O	O
PU.1	NN	O	B-protein
transactivates	NN	O	O
the	NN	O	O
M-CSF	NN	O	B-DNA
receptor	NN	O	I-DNA
promoter	NN	O	I-DNA
in	NN	O	O
nonmacrophage	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
breast	NN	O	O
cancer	NN	O	O
,	NN	O	O
NK	NN	O	B-cell_type
cell	NN	O	I-cell_type
activity	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
compared	NN	O	O
with	NN	O	O
patients	NN	O	O
with	NN	O	O
benign	NN	O	B-cell_type
tumors	NN	O	I-cell_type
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.006	NN	O	O
)	NN	O	O
or	NN	O	O
healthy	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

-DOCSTART-	O

Expression	NN	O	O
of	NN	O	O
DR3	NN	O	B-protein
appears	NN	O	O
to	NN	O	O
be	NN	O	O
restricted	NN	O	O
to	NN	O	O
tissues	NN	O	O
enriched	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
.	NN	O	O

Differential	NN	O	O
nuclear	NN	O	O
localization	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
p52	NN	O	B-protein
,	NN	O	O
and	NN	O	O
RelB	NN	O	B-protein
proteins	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
accessory	NN	O	I-cell_type
cells	NN	O	I-cell_type
of	NN	O	O
the	NN	O	O
immune	NN	O	O
response	NN	O	O
in	NN	O	O
situ	NN	O	O
.	NN	O	O

In	NN	O	O
germinal	NN	O	O
centers	NN	O	O
GC	NN	O	O
,	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
p52	NN	O	B-protein
,	NN	O	O
and	NN	O	O
RelB	NN	O	B-protein
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
nuclei	NN	O	O
of	NN	O	O
FDC	NN	O	B-cell_type
only	NN	O	O
and	NN	O	O
were	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
nuclei	NN	O	O
of	NN	O	O
CD68+	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

Furthermore	NN	O	O
,	NN	O	O
these	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
appear	NN	O	O
resistant	NN	O	O
to	NN	O	O
lysis	NN	O	O
by	NN	O	O
natural	NN	O	B-cell_type
killer	NN	O	I-cell_type
(	NN	O	I-cell_type
NK	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
footprinting	NN	O	O
analysis	NN	O	O
within	NN	O	O
this	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
revealed	NN	O	O
two	NN	O	O
Sp1	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
PU-box	NN	O	B-DNA
.	NN	O	O

We	NN	O	O
have	NN	O	O
developed	NN	O	O
a	NN	O	O
monoclonal	NN	O	B-protein
antibody	NN	O	I-protein
,	NN	O	O
Yae	NN	O	B-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
specific	NN	O	O
for	NN	O	O
Pan/E2A	NN	O	B-protein
proteins	NN	O	I-protein
,	NN	O	O
and	NN	O	O
have	NN	O	O
used	NN	O	O
the	NN	O	O
Yae	NN	O	B-protein
antibody	NN	O	I-protein
to	NN	O	O
examine	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
endocrine	NN	O	B-cell_type
and	NN	O	I-cell_type
nonendocrine	NN	O	I-cell_type
cell	NN	O	I-cell_type
lineages	NN	O	I-cell_type
for	NN	O	O
differences	NN	O	O
in	NN	O	O
Pan/	NN	O	O
E2A	NN	O	B-protein
protein	NN	O	I-protein
expression	NN	O	O
,	NN	O	O
subcellular	NN	O	O
localization	NN	O	O
,	NN	O	O
and	NN	O	O
heteromeric	NN	O	O
complex	NN	O	O
formation	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
is	NN	O	O
blocked	NN	O	O
by	NN	O	O
anti-VCAM	NN	O	B-protein
antibodies	NN	O	I-protein
.	NN	O	O

ISH	NN	O	O
for	NN	O	O
EBV-encoded	NN	O	B-RNA
small	NN	O	I-RNA
non-polyadenylated	NN	O	I-RNA
RNAs	NN	O	I-RNA
showed	NN	O	O
that	NN	O	O
all	NN	O	O
cases	NN	O	O
,	NN	O	O
whether	NN	O	O
NK	NN	O	O
or	NN	O	O
T	NN	O	O
,	NN	O	O
harboured	NN	O	O
EBV	NN	O	O
in	NN	O	O
virtually	NN	O	O
all	NN	O	O
tumour	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
in-vitro	NN	O	O
experiments	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
dexamethasone	NN	O	O
,	NN	O	O
of	NN	O	O
further	NN	O	O
glucocorticoids	NN	O	O
,	NN	O	O
and	NN	O	O
of	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
RU	NN	O	O
486	NN	O	O
,	NN	O	O
on	NN	O	O
structural	NN	O	O
order	NN	O	O
of	NN	O	O
human	NN	O	O
erythrocyte	NN	O	O
ghost	NN	O	O
membranes	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
determining	NN	O	O
the	NN	O	O
steady-state	NN	O	O
fluorescence	NN	O	O
anisotropy	NN	O	O
of	NN	O	O
diphenylhexatriene	NN	O	O
(	NN	O	O
DPH	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
glucocorticoid-induced	NN	O	O
membrane	NN	O	O
perturbation	NN	O	O
,	NN	O	O
the	NN	O	O
possibility	NN	O	O
to	NN	O	O
inhibit	NN	O	O
it	NN	O	O
by	NN	O	O
RU	NN	O	O
486	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
inactivity	NN	O	O
of	NN	O	O
the	NN	O	O
structurally	NN	O	O
related	NN	O	O
progesterone	NN	O	O
,	NN	O	O
refer	NN	O	O
to	NN	O	O
relatively	NN	O	O
specific	NN	O	O
binding	NN	O	B-DNA
sites	NN	O	I-DNA
for	NN	O	O
the	NN	O	O
glucocorticoids	NN	O	O
in	NN	O	O
the	NN	O	O
membrane	NN	O	O
of	NN	O	O
erythrocyte	NN	O	B-cell_type
ghosts	NN	O	I-cell_type
.	NN	O	O

This	NN	O	O
mutant	NN	O	O
inhibited	NN	O	O
TCR	NN	O	B-protein
-induced	NN	O	O
activation	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	I-protein
activated	NN	O	I-protein
T	NN	O	I-protein
cells	NN	O	I-protein
by	NN	O	O
interfering	NN	O	O
with	NN	O	O
both	NN	O	O
intracellular	NN	O	O
calcium	NN	O	O
increase	NN	O	O
and	NN	O	O
Ras	NN	O	B-protein
-regulated	NN	O	O
activation	NN	O	O
of	NN	O	O
extracellular	NN	O	B-protein
signal-regulated	NN	O	I-protein
kinases	NN	O	I-protein
.	NN	O	O

Synthetic	NN	O	O
glucocorticoids	NN	O	O
vary	NN	O	O
in	NN	O	O
their	NN	O	O
binding	NN	O	O
affinity	NN	O	O
for	NN	O	O
the	NN	O	O
glucocorticoid	NN	O	O
receptor	NN	O	O
(	NN	O	O
GCR	NN	O	O
)	NN	O	O
.	NN	O	O

p27Kip1	NN	O	B-DNA
directly	NN	O	O
inhibits	NN	O	O
the	NN	O	O
catalytic	NN	O	O
activity	NN	O	O
of	NN	O	O
cyclin/cdks	NN	O	B-protein
(	NN	O	I-protein
cyclin-dependent	NN	O	I-protein
kinase	NN	O	I-protein
)	NN	O	I-protein
complexes	NN	O	I-protein
and/or	NN	O	O
interferes	NN	O	O
physically	NN	O	O
with	NN	O	O
cyclin/cdks	NN	O	B-protein
activation	NN	O	O
by	NN	O	O
CAK	NN	O	B-protein
.	NN	O	O

-DOCSTART-	O

Cells	NN	O	O
need	NN	O	O
to	NN	O	O
distinguish	NN	O	O
between	NN	O	O
transient	NN	O	O
Ca2+	NN	O	O
signals	NN	O	O
that	NN	O	O
induce	NN	O	O
events	NN	O	O
such	NN	O	O
as	NN	O	O
muscle	NN	O	O
contraction	NN	O	O
,	NN	O	O
secretion	NN	O	O
,	NN	O	O
adhesion	NN	O	O
and	NN	O	O
synaptic	NN	O	O
transmission	NN	O	O
,	NN	O	O
and	NN	O	O
sustained	NN	O	O
Ca2+	NN	O	O
signals	NN	O	O
that	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
sustained	NN	O	O
high	NN	O	O
concentrations	NN	O	O
of	NN	O	O
Ca2+	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
transient	NN	O	O
pulses	NN	O	O
,	NN	O	O
are	NN	O	O
required	NN	O	O
to	NN	O	O
maintain	NN	O	O
NF-AT	NN	O	B-protein
transcription	NN	O	B-protein
factors	NN	O	I-protein
in	NN	O	O
the	NN	O	O
nucleus	NN	O	O
,	NN	O	O
where	NN	O	O
they	NN	O	O
participate	NN	O	O
in	NN	O	O
Ca2+-dependent	NN	O	O
induction	NN	O	O
of	NN	O	O
genes	NN	O	B-DNA
required	NN	O	O
for	NN	O	O
lymphocyte	NN	O	B-cell_type
activation	NN	O	O
and	NN	O	O
proliferation	NN	O	O
.	NN	O	O

Thus	NN	O	O
a	NN	O	O
primary	NN	O	O
effect	NN	O	O
of	NN	O	O
these	NN	O	O
immunosuppressive	NN	O	O
reagents	NN	O	O
is	NN	O	O
to	NN	O	O
control	NN	O	O
the	NN	O	O
subcellular	NN	O	O
localization	NN	O	O
of	NN	O	O
the	NN	O	O
NF-AT	NN	O	B-protein
family	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

RelA	NN	O	B-protein
(	NN	O	O
p65	NN	O	B-protein
)	NN	O	O
functions	NN	O	O
as	NN	O	O
the	NN	O	O
critical	NN	O	O
transactivating	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
heterodimeric	NN	O	B-protein
p50-p65	NN	O	I-protein
NF-kappa	NN	O	I-protein
B	NN	O	I-protein
complex	NN	O	I-protein
and	NN	O	O
contains	NN	O	O
a	NN	O	O
high-affinity	NN	O	B-protein
binding	NN	O	I-protein
site	NN	O	I-protein
for	NN	O	O
its	NN	O	O
cytoplasmic	NN	O	B-protein
inhibitor	NN	O	I-protein
,	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
.	NN	O	O

Subsequent	NN	O	O
studies	NN	O	O
have	NN	O	O
revealed	NN	O	O
that	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
cytoplasmic	NN	O	B-protein
RelA	NN	O	I-protein
is	NN	O	O
stably	NN	O	O
associated	NN	O	O
not	NN	O	O
only	NN	O	O
with	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
but	NN	O	O
also	NN	O	O
with	NN	O	O
other	NN	O	O
ankyrin	NN	O	B-protein
motif-rich	NN	O	I-protein
proteins	NN	O	I-protein
including	NN	O	O
the	NN	O	O
products	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-DNA
B2	NN	O	I-DNA
(	NN	O	I-DNA
p100	NN	O	I-DNA
)	NN	O	I-DNA
and	NN	O	I-DNA
NF-kappa	NN	O	I-DNA
B1	NN	O	I-DNA
(	NN	O	I-DNA
p105	NN	O	I-DNA
)	NN	O	I-DNA
genes	NN	O	I-DNA
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
RelA	NN	O	B-protein
-I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
,	NN	O	O
RelA-p100	NN	O	B-protein
cytoplasmic	NN	O	I-protein
complexes	NN	O	I-protein
are	NN	O	O
not	NN	O	O
dissociated	NN	O	O
following	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
alpha	NN	O	I-protein
activation	NN	O	O
;	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
p100	NN	O	B-protein
functions	NN	O	O
as	NN	O	O
a	NN	O	O
potent	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
RelA	NN	O	B-protein
-mediated	NN	O	O
transcription	NN	O	O
in	NN	O	O
vivo	NN	O	O
;	NN	O	O
(	NN	O	O
iv	NN	O	O
)	NN	O	O
the	NN	O	O
interaction	NN	O	O
of	NN	O	O
RelA	NN	O	B-protein
and	NN	O	O
p100	NN	O	B-protein
involves	NN	O	O
the	NN	O	O
conserved	NN	O	B-protein
Rel	NN	O	I-protein
homology	NN	O	I-protein
domain	NN	O	I-protein
of	NN	O	O
both	NN	O	O
proteins	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
localization	NN	O	I-protein
signal	NN	O	I-protein
of	NN	O	O
RelA	NN	O	B-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
binding	NN	O	O
;	NN	O	O
(	NN	O	O
v	NN	O	O
)	NN	O	O
p100	NN	O	B-protein
inhibition	NN	O	O
of	NN	O	O
RelA	NN	O	B-protein
function	NN	O	O
requires	NN	O	O
the	NN	O	O
C-terminal	NN	O	B-protein
ankyrin	NN	O	I-protein
motif	NN	O	I-protein
domain	NN	O	I-protein
,	NN	O	O
which	NN	O	O
mediates	NN	O	O
cytoplasmic	NN	O	O
retention	NN	O	O
of	NN	O	O
RelA	NN	O	B-protein
;	NN	O	O
and	NN	O	O
(	NN	O	O
vi	NN	O	O
)	NN	O	O
as	NN	O	O
observed	NN	O	O
with	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
,	NN	O	O
nuclear	NN	O	O
RelA	NN	O	B-protein
stimulates	NN	O	O
p100	NN	O	B-RNA
mRNA	NN	O	I-RNA
and	NN	O	O
protein	NN	O	O
expression	NN	O	O
.	NN	O	O

Second	NN	O	O
,	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
which	NN	O	O
lack	NN	O	O
CD45	NN	O	B-protein
and	NN	O	O
can	NN	O	O
not	NN	O	O
signal	NN	O	O
via	NN	O	O
the	NN	O	O
TCR	NN	O	B-protein
,	NN	O	O
supported	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
viral	NN	O	O
replication	NN	O	O
and	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
CN	NN	O	B-protein
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
coordinated	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
GM-CSF	NN	O	B-DNA
and	NN	O	I-DNA
IL-2	NN	O	I-DNA
genes	NN	O	I-DNA
and	NN	O	O
that	NN	O	O
the	NN	O	O
CLE0	NN	O	B-DNA
sequence	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
GM-CSF	NN	O	B-DNA
gene	NN	O	I-DNA
is	NN	O	O
a	NN	O	O
functional	NN	O	O
analogue	NN	O	O
of	NN	O	O
the	NN	O	O
NF-AT-binding	NN	O	B-DNA
site	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
,	NN	O	O
which	NN	O	O
mediates	NN	O	O
signals	NN	O	O
downstream	NN	O	O
of	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
.	NN	O	O

TCDD	NN	O	O
mediates	NN	O	O
atrophy	NN	O	O
induction	NN	O	O
through	NN	O	O
its	NN	O	O
specific	NN	O	O
receptor	NN	O	O
(	NN	O	O
the	NN	O	O
AhR	NN	O	B-protein
)	NN	O	O
and	NN	O	O
not	NN	O	O
through	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
estrogen	NN	O	O
receptor	NN	O	O
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
Bcd	NN	O	B-DNA
,	NN	O	O
a	NN	O	O
novel	NN	O	O
proto-oncogene	NN	O	B-DNA
expressed	NN	O	O
in	NN	O	O
B-cells	NN	O	B-cell_type
.	NN	O	O

Mutation	NN	O	O
of	NN	O	O
this	NN	O	O
motif	NN	O	O
almost	NN	O	O
completely	NN	O	O
,	NN	O	O
and	NN	O	O
specifically	NN	O	O
,	NN	O	O
abolished	NN	O	O
the	NN	O	O
binding	NN	O	O
of	NN	O	O
two	NN	O	O
low-mobility	NN	O	B-protein
complexes	NN	O	I-protein
and	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
95	NN	O	O
%	NN	O	O
decrease	NN	O	O
of	NN	O	O
constitutive	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
a	NN	O	O
reporter	NN	O	O
construct	NN	O	O
IL-1beta	NN	O	B-protein
(	NN	O	O
-170/+108	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
,	NN	O	O
while	NN	O	O
lipopolysaccharide-induced	NN	O	O
expression	NN	O	O
of	NN	O	O
inflammatory	NN	O	B-protein
mediators	NN	O	I-protein
requires	NN	O	O
tyrosine	NN	O	B-protein
kinase	NN	O	I-protein
activity	NN	O	O
,	NN	O	O
tyrosine	NN	O	B-protein
kinase	NN	O	I-protein
activity	NN	O	O
is	NN	O	O
not	NN	O	O
obligatory	NN	O	O
for	NN	O	O
lipopolysaccharide	NN	O	O
signal	NN	O	O
transduction	NN	O	O
.	NN	O	O

A	NN	O	O
direct	NN	O	O
temporal	NN	O	O
correlation	NN	O	O
exists	NN	O	O
between	NN	O	O
HIV	NN	O	O
infection	NN	O	O
and	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
DNA-binding	NN	O	O
activity	NN	O	O
in	NN	O	O
myelomonoblastic	NN	O	B-cell_line
PLB-985	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Constitutive	NN	O	O
PKR	NN	O	B-protein
activity	NN	O	O
was	NN	O	O
also	NN	O	O
detected	NN	O	O
in	NN	O	O
HIV-1-infected	NN	O	B-cell_line
cells	NN	O	I-cell_line
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
low-level	NN	O	O
IFN	NN	O	B-protein
production	NN	O	O
,	NN	O	O
since	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
anti-IFN-alpha/beta	NN	O	B-protein
antibody	NN	O	I-protein
to	NN	O	O
the	NN	O	O
cells	NN	O	O
decreased	NN	O	O
PKR	NN	O	B-protein
expression	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
analysis	NN	O	O
of	NN	O	O
IkappaBalpha	NN	O	B-protein
turnover	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
increased	NN	O	O
degradation	NN	O	O
of	NN	O	O
IkappaBalpha	NN	O	B-protein
in	NN	O	O
HIV-1-infected	NN	O	B-cell_line
cells	NN	O	I-cell_line
that	NN	O	O
may	NN	O	O
account	NN	O	O
for	NN	O	O
the	NN	O	O
constitutive	NN	O	B-DNA
DNA	NN	O	I-DNA
binding	NN	O	O
activity	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
HIV-1	NN	O	O
infection	NN	O	O
of	NN	O	O
myeloid	NN	O	B-cell_type
cells	NN	O	I-cell_type
induces	NN	O	O
IFN	NN	O	B-protein
production	NN	O	O
and	NN	O	O
PKR	NN	O	B-protein
activity	NN	O	O
,	NN	O	O
which	NN	O	O
in	NN	O	O
turn	NN	O	O
contribute	NN	O	O
to	NN	O	O
enhanced	NN	O	O
IkappaBalpha	NN	O	B-protein
phosphorylation	NN	O	O
and	NN	O	O
subsequent	NN	O	O
degradation	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
recombinant	NN	O	O
GHF-1	NN	O	B-protein
interacted	NN	O	O
directly	NN	O	O
with	NN	O	O
c-Jun	NN	O	B-protein
but	NN	O	O
not	NN	O	O
c-Fos	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

The	NN	O	O
NB4	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	O
which	NN	O	O
is	NN	O	O
derived	NN	O	O
from	NN	O	O
the	NN	O	O
bone	NN	O	O
marrow	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
APL	NN	O	O
during	NN	O	O
relapse	NN	O	O
,	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
system	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
growth	NN	O	O
and	NN	O	O
differentiation	NN	O	O
of	NN	O	O
APL	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

We	NN	O	O
have	NN	O	O
identified	NN	O	O
two	NN	O	O
new	NN	O	O
isoforms	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
NFAT1	NN	O	B-protein
(	NN	O	O
previously	NN	O	O
termed	NN	O	O
NFATp	NN	O	B-protein
)	NN	O	O
that	NN	O	O
are	NN	O	O
the	NN	O	O
predominant	NN	O	O
isoforms	NN	O	O
expressed	NN	O	O
in	NN	O	O
murine	NN	O	B-cell_type
and	NN	O	I-cell_type
human	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Immunocytochemical	NN	O	O
analysis	NN	O	O
indicates	NN	O	O
that	NN	O	O
recombinant	NN	O	O
NFAT1	NN	O	B-protein
localizes	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasm	NN	O	O
of	NN	O	O
transiently	NN	O	B-cell_type
transfected	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
translocates	NN	O	O
into	NN	O	O
the	NN	O	O
nucleus	NN	O	O
in	NN	O	O
a	NN	O	O
CsA-sensitive	NN	O	O
manner	NN	O	O
following	NN	O	O
ionomycin	NN	O	O
stimulation	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
MM	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
normal	NN	O	O
splenic	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
express	NN	O	O
dephosphorylated	NN	O	B-protein
pRB	NN	O	I-protein
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
ectopic	NN	O	B-protein
Id1	NN	O	I-protein
repressed	NN	O	O
E	NN	O	B-DNA
(	NN	O	I-DNA
gre	NN	O	I-DNA
)	NN	O	I-DNA
-directed	NN	O	O
but	NN	O	O
not	NN	O	O
EA/S	NN	O	B-DNA
-directed	NN	O	O
MLV	NN	O	O
transcription	NN	O	O
in	NN	O	O
lymphoid	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
immunization	NN	O	O
with	NN	O	O
synthetic	NN	O	O
peptides	NN	O	O
can	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
elimination	NN	O	O
of	NN	O	O
anti-tumor	NN	O	O
CTL	NN	O	O
responses	NN	O	O
.	NN	O	O

[	NN	O	O
NGFI-B/nur77	NN	O	B-protein
family	NN	O	I-protein
involved	NN	O	O
in	NN	O	O
T-cell	NN	O	O
apoptosis	NN	O	O
]	NN	O	O

NGFI-B/nur77	NN	O	B-protein
and	NN	O	O
its	NN	O	O
related	NN	O	O
genes	NN	O	O
constitute	NN	O	O
a	NN	O	O
family	NN	O	O
and	NN	O	O
the	NN	O	O
NGFI-B/nur77	NN	O	B-protein
family	NN	O	I-protein
consists	NN	O	O
of	NN	O	O
three	NN	O	O
subtypes	NN	O	O
,	NN	O	O
named	NN	O	O
nur77	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	O
nur77	NN	O	B-protein
beta	NN	O	I-protein
,	NN	O	O
nur77	NN	O	B-protein
gamma	NN	O	I-protein
.	NN	O	O

p38	NN	O	B-protein
and	NN	O	O
p63	NN	O	B-protein
may	NN	O	O
provide	NN	O	O
a	NN	O	O
docking	NN	O	O
site	NN	O	O
for	NN	O	O
Grb2	NN	O	B-protein
,	NN	O	O
thereby	NN	O	O
linking	NN	O	O
Grb2	NN	O	B-protein
SH3-binding	NN	O	I-protein
proteins	NN	O	I-protein
SOS1	NN	O	B-protein
,	NN	O	O
SLP-76	NN	O	B-protein
,	NN	O	O
and	NN	O	O
p120	NN	O	B-protein
to	NN	O	O
downstream	NN	O	O
signalling	NN	O	O
events	NN	O	O
.	NN	O	O

The	NN	O	O
activated	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
interferon-induced	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
complex	NN	O	I-protein
ISGF3	NN	O	B-protein
was	NN	O	O
also	NN	O	O
detected	NN	O	O
in	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
from	NN	O	O
uninduced	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Culture	NN	O	O
supernatants	NN	O	O
from	NN	O	O
uninduced	NN	O	B-cell_line
U937	NN	O	I-cell_line
cells	NN	O	I-cell_line
were	NN	O	O
also	NN	O	O
found	NN	O	O
to	NN	O	O
activate	NN	O	O
an	NN	O	O
ISRE	NN	O	B-DNA
cloned	NN	O	O
upstream	NN	O	O
of	NN	O	O
the	NN	O	O
luciferase	NN	O	B-DNA
reporter	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
indicating	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
endogenous	NN	O	B-protein
IFN	NN	O	I-protein
activity	NN	O	O
equivalent	NN	O	O
to	NN	O	O
approximately	NN	O	O
0.3	NN	O	O
to	NN	O	O
0.5	NN	O	O
IU/mL	NN	O	O
.	NN	O	O

-DOCSTART-	O

No	NN	O	O
glucocorticoid	NN	O	B-DNA
recognition	NN	O	I-DNA
sequences	NN	O	I-DNA
are	NN	O	O
present	NN	O	O
in	NN	O	O
this	NN	O	O
promoter	NN	O	B-DNA
region	NN	O	I-DNA
and	NN	O	O
dexamethasone	NN	O	O
is	NN	O	O
still	NN	O	O
able	NN	O	O
to	NN	O	O
repress	NN	O	O
transcription	NN	O	O
when	NN	O	O
the	NN	O	O
multimerized	NN	O	B-DNA
NF-kappa	NN	O	I-DNA
B	NN	O	I-DNA
sequence	NN	O	I-DNA
is	NN	O	O
transactivated	NN	O	O
by	NN	O	O
TNF-alpha	NN	O	B-protein
upon	NN	O	O
transfection	NN	O	O
in	NN	O	O
293	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
molecular	NN	O	O
differences	NN	O	O
between	NN	O	O
primary	NN	O	O
anaplastic	NN	O	O
astrocytomas/glioblastomas	NN	O	O
and	NN	O	O
their	NN	O	O
subsequent	NN	O	O
recurrences	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
clinically	NN	O	O
indistinguishable	NN	O	O
,	NN	O	O
may	NN	O	O
provide	NN	O	O
better	NN	O	O
therapeutic	NN	O	O
options	NN	O	O
for	NN	O	O
treatment	NN	O	O
.	NN	O	O

On	NN	O	O
this	NN	O	O
basis	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
all-trans	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
ATRA	NN	O	O
)	NN	O	O
and	NN	O	O
its	NN	O	O
isomer	NN	O	O
9-cis	NN	O	O
RA	NN	O	O
in	NN	O	O
FL	NN	O	O
hematopoiesis	NN	O	O
.	NN	O	O

High	NN	O	O
concentrations	NN	O	O
of	NN	O	O
either	NN	O	O
compound	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
drastically	NN	O	O
reduced	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
primary	NN	O	O
HPP-CFC	NN	O	B-cell_line
colonies	NN	O	I-cell_line
and	NN	O	O
totally	NN	O	O
abolished	NN	O	O
their	NN	O	O
recloning	NN	O	O
capacity	NN	O	O
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
inhibited	NN	O	O
HSC	NN	O	B-cell_type
proliferation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Similarly	NN	O	O
,	NN	O	O
CTL	NN	O	B-cell_type
raised	NN	O	O
against	NN	O	O
the	NN	O	O
parent	NN	O	O
peptide	NN	O	O
did	NN	O	O
not	NN	O	O
recognize	NN	O	O
the	NN	O	O
succinimide	NN	O	O
derivative	NN	O	O
of	NN	O	O
this	NN	O	O
peptide	NN	O	O
.	NN	O	O

A	NN	O	O
decrease	NN	O	O
in	NN	O	O
helicase	NN	O	O
and	NN	O	O
DNA-dependent	NN	O	B-protein
ATPase	NN	O	I-protein
activities	NN	O	O
was	NN	O	O
also	NN	O	O
observed	NN	O	O
with	NN	O	O
the	NN	O	O
mutated	NN	O	O
recombinant	NN	O	O
XPB	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

PU.1	NN	O	B-protein
is	NN	O	O
completely	NN	O	O
absent	NN	O	O
from	NN	O	O
peripheral	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
most	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
based	NN	O	O
on	NN	O	O
sensitive	NN	O	O
RT-PCR	NN	O	O
assays	NN	O	O
.	NN	O	O

Chloramphenicol	NN	O	B-protein
acetyltransferase	NN	O	I-protein
(	NN	O	O
CAT	NN	O	B-protein
)	NN	O	O
activities	NN	O	O
directed	NN	O	O
by	NN	O	O
5	NN	O	B-DNA
'	NN	O	I-DNA
upstream	NN	O	I-DNA
promoter	NN	O	I-DNA
were	NN	O	O
detected	NN	O	O
preferentially	NN	O	O
in	NN	O	O
perforin-expressing	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
erythropoietin	NN	O	B-protein
receptor	NN	O	I-protein
caused	NN	O	O
specific	NN	O	O
DNA-binding	NN	O	O
of	NN	O	O
Stat	NN	O	B-protein
5b	NN	O	I-protein
,	NN	O	O
but	NN	O	O
failed	NN	O	O
to	NN	O	O
induce	NN	O	O
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
.	NN	O	O

The	NN	O	O
recognition	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
POU	NN	O	B-DNA
domain	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
octamer	NN	O	B-DNA
sequence	NN	O	I-DNA
by	NN	O	O
OCA-B	NN	O	B-protein
provides	NN	O	O
a	NN	O	O
mechanism	NN	O	O
for	NN	O	O
differential	NN	O	O
regulation	NN	O	O
of	NN	O	O
octamer	NN	O	B-DNA
sites	NN	O	I-DNA
containing	NN	O	O
genes	NN	O	O
by	NN	O	O
the	NN	O	O
ubiquitous	NN	O	B-protein
factor	NN	O	I-protein
Oct-1	NN	O	B-protein
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
inactive	NN	O	B-DNA
X	NN	O	I-DNA
specific	NN	O	O
methylation	NN	O	O
at	NN	O	O
the	NN	O	O
androgen	NN	O	B-DNA
receptor	NN	O	I-DNA
gene	NN	O	I-DNA
showed	NN	O	O
unbalanced	NN	O	O
inactivation	NN	O	O
in	NN	O	O
the	NN	O	O
twins	NN	O	O
'	NN	O	O
fibroblasts	NN	O	O
and	NN	O	O
in	NN	O	O
opposite	NN	O	O
directions	NN	O	O
.	NN	O	O

To	NN	O	O
overcome	NN	O	O
this	NN	O	O
problem	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
exploited	NN	O	O
the	NN	O	O
observation	NN	O	O
that	NN	O	O
activated	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cell	NN	O	I-cell_type
blasts	NN	O	I-cell_type
can	NN	O	O
be	NN	O	O
stimulated	NN	O	O
via	NN	O	O
the	NN	O	O
CD28	NN	O	B-protein
surface	NN	O	I-protein
molecule	NN	O	I-protein
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
antigenic	NN	O	O
challenge	NN	O	O
;	NN	O	O
thus	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
been	NN	O	O
able	NN	O	O
to	NN	O	O
observe	NN	O	O
the	NN	O	O
response	NN	O	O
of	NN	O	O
normal	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
to	NN	O	O
CD28	NN	O	B-protein
activation	NN	O	O
in	NN	O	O
isolation	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
AP-1	NN	O	B-protein
generation	NN	O	O
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
wortmannin	NN	O	O
and	NN	O	O
was	NN	O	O
also	NN	O	O
variably	NN	O	O
sensitive	NN	O	O
to	NN	O	O
chloroquine	NN	O	O
.	NN	O	O

Alpha	NN	O	B-protein
4	NN	O	I-protein
beta	NN	O	I-protein
1	NN	O	I-protein
(	NN	O	I-protein
CD49d/CD29	NN	O	I-protein
)	NN	O	I-protein
integrin	NN	O	I-protein
costimulation	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
enhances	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
and	NN	O	O
cytokine	NN	O	O
induction	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
altered	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
anti-CD3	NN	O	B-protein
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
integrin	NN	O	B-protein
alpha	NN	O	I-protein
4	NN	O	I-protein
beta	NN	O	I-protein
1	NN	O	I-protein
can	NN	O	O
provide	NN	O	O
a	NN	O	O
costimulus	NN	O	O
to	NN	O	O
induce	NN	O	O
IL-2	NN	O	B-protein
secretion	NN	O	O
and	NN	O	O
IL-2R	NN	O	B-protein
expression	NN	O	O
leading	NN	O	O
to	NN	O	O
enhanced	NN	O	O
proliferation	NN	O	O
of	NN	O	O
purified	NN	O	O
,	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
freshly	NN	O	B-cell_type
isolated	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
in	NN	O	O
vitro-cultured	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
did	NN	O	O
not	NN	O	O
require	NN	O	O
costimulation	NN	O	O
for	NN	O	O
cytokine	NN	O	B-protein
secretion	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
anti-CD3	NN	O	B-protein
alone	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
inhibition	NN	O	O
of	NN	O	O
mRNA	NN	O	B-RNA
synthesis	NN	O	O
with	NN	O	O
actinomycin	NN	O	O
D	NN	O	O
indicated	NN	O	O
that	NN	O	O
DOX	NN	O	O
induced	NN	O	O
an	NN	O	O
increased	NN	O	O
stability	NN	O	O
of	NN	O	O
PBGD	NN	O	B-RNA
and	NN	O	I-RNA
GATA-1	NN	O	I-RNA
mRNAs	NN	O	I-RNA
,	NN	O	O
whereas	NN	O	O
ACLA	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
half-lives	NN	O	O
of	NN	O	O
these	NN	O	O
mRNAs	NN	O	B-RNA
.	NN	O	O

Indeed	NN	O	O
,	NN	O	O
erythroid	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
be	NN	O	O
regulated	NN	O	O
transcriptionally	NN	O	O
by	NN	O	O
ACLA	NN	O	O
and	NN	O	O
mainly	NN	O	O
posttranscriptionally	NN	O	O
by	NN	O	O
DOX	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
JAK	NN	O	B-protein
/STAT	NN	O	B-protein
pathway	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
IL-7R	NN	O	B-protein
signaling	NN	O	O
.	NN	O	O

The	NN	O	O
percentage	NN	O	O
of	NN	O	O
cells	NN	O	O
expressing	NN	O	O
CD40	NN	O	B-protein
in	NN	O	O
T	NN	O	B-cell_line
and	NN	O	I-cell_line
B	NN	O	I-cell_line
cell	NN	O	I-cell_line
co-cultures	NN	O	I-cell_line
increased	NN	O	O
from	NN	O	O
4.2	NN	O	O
%	NN	O	O
to	NN	O	O
13.8	NN	O	O
%	NN	O	O
after	NN	O	O
oligo	NN	O	O
stimulation	NN	O	O
in	NN	O	O
patients	NN	O	O
,	NN	O	O
while	NN	O	O
it	NN	O	O
increased	NN	O	O
form	NN	O	O
4.7	NN	O	O
%	NN	O	O
to	NN	O	O
48.6	NN	O	O
%	NN	O	O
in	NN	O	O
healthy	NN	O	O
controls	NN	O	O
.	NN	O	O

Class	NN	O	B-protein
II	NN	O	I-protein
molecules	NN	O	I-protein
are	NN	O	O
not	NN	O	O
expressed	NN	O	O
in	NN	O	O
plasma	NN	O	B-cell_type
cells	NN	O	I-cell_type
because	NN	O	O
of	NN	O	O
an	NN	O	O
active	NN	O	O
suppression	NN	O	O
resulting	NN	O	O
in	NN	O	O
the	NN	O	O
abrogation	NN	O	O
of	NN	O	O
class	NN	O	B-DNA
II	NN	O	I-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
unambiguously	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
plasmacytoma	NN	O	B-cell_line
x	NN	O	I-cell_line
B	NN	O	I-cell_line
cell	NN	O	I-cell_line
hybrids	NN	O	I-cell_line
carrying	NN	O	O
an	NN	O	O
AIR-1	NN	O	B-DNA
locus	NN	O	I-DNA
derived	NN	O	O
from	NN	O	O
CIITA-expressing	NN	O	B-cell_line
cells	NN	O	I-cell_line
do	NN	O	O
not	NN	O	O
express	NN	O	O
CIITA-specific	NN	O	B-RNA
transcripts	NN	O	I-RNA
.	NN	O	O

Transfection	NN	O	O
of	NN	O	O
a	NN	O	O
cDNA	NN	O	O
containing	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
CIITA	NN	O	I-DNA
coding	NN	O	I-DNA
sequence	NN	O	I-DNA
under	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
an	NN	O	O
heterologous	NN	O	B-DNA
promoter	NN	O	I-DNA
restores	NN	O	O
expression	NN	O	O
of	NN	O	O
human	NN	O	B-DNA
MHC	NN	O	I-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
hybrids	NN	O	O
and	NN	O	O
is	NN	O	O
responsible	NN	O	O
for	NN	O	O
de	NN	O	O
novo	NN	O	O
expression	NN	O	O
of	NN	O	O
mouse	NN	O	B-DNA
MHC	NN	O	I-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
both	NN	O	O
the	NN	O	O
mouse	NN	O	B-cell_line
plasmacytoma	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
and	NN	O	O
the	NN	O	O
hybrids	NN	O	B-cell_line
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
two	NN	O	O
previously	NN	O	O
characterized	NN	O	O
mutants	NN	O	B-protein
with	NN	O	O
point	NN	O	O
mutations	NN	O	O
in	NN	O	O
Tax	NN	O	B-protein
,	NN	O	O
M32	NN	O	B-protein
(	NN	O	O
Y196A	NN	O	O
,	NN	O	O
K197S	NN	O	O
)	NN	O	O
and	NN	O	O
M41	NN	O	B-protein
(	NN	O	O
H287A	NN	O	O
,	NN	O	O
P288S	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
defective	NN	O	O
in	NN	O	O
Tax	NN	O	B-protein
-activated	NN	O	O
transcription	NN	O	O
were	NN	O	O
unable	NN	O	O
to	NN	O	O
interact	NN	O	O
with	NN	O	O
TFIIA	NN	O	B-protein
in	NN	O	O
this	NN	O	O
assay	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
TFIIA	NN	O	B-protein
facilitates	NN	O	O
Tax	NN	O	B-protein
transactivation	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
immediate	NN	O	B-DNA
early	NN	O	I-DNA
gene	NN	O	I-DNA
c-jun	NN	O	B-DNA
in	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
phorbol	NN	O	O
12-myristate	NN	O	O
13-acetate	NN	O	O
(	NN	O	O
PMA	NN	O	O
)	NN	O	O
-induced	NN	O	O
differentiation	NN	O	O
in	NN	O	O
U937	NN	O	B-cell_line
human	NN	O	I-cell_line
monoblastic	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
using	NN	O	O
c-jun	NN	O	B-DNA
-specific	NN	O	O
antisense	NN	O	O
(	NN	O	O
AS	NN	O	O
)	NN	O	O
phosphorothioate	NN	O	O
oligonucleotides	NN	O	O
.	NN	O	O

The	NN	O	O
strong	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
IL-6	NN	O	B-protein
transcription	NN	O	O
rate	NN	O	O
prompted	NN	O	O
us	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
IL-10	NN	O	B-protein
and	NN	O	O
IL-4	NN	O	B-protein
on	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

However	NN	O	O
,	NN	O	O
PHA/PMA	NN	O	O
but	NN	O	O
not	NN	O	O
oxidative	NN	O	O
signals	NN	O	O
induced	NN	O	O
the	NN	O	O
coordinate	NN	O	O
activation	NN	O	O
of	NN	O	O
reporter	NN	O	B-DNA
constructs	NN	O	I-DNA
containing	NN	O	O
the	NN	O	O
AP-1-TRE	NN	O	B-DNA
,	NN	O	I-DNA
NF-AT	NN	O	I-DNA
,	NN	O	I-DNA
and	NN	O	I-DNA
IL-2	NN	O	I-DNA
promoter	NN	O	I-DNA
regions	NN	O	I-DNA
along	NN	O	O
with	NN	O	O
IL-2	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
.	NN	O	O

Pb-induced	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
is	NN	O	O
blocked	NN	O	O
by	NN	O	O
antibodies	NN	O	B-protein
for	NN	O	O
p65	NN	O	B-protein
and	NN	O	O
p50	NN	O	B-protein
subunits	NN	O	O
but	NN	O	O
not	NN	O	O
cRel	NN	O	B-protein
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
p65	NN	O	B-protein
:	NN	O	I-protein
p50	NN	O	I-protein
heterodimer	NN	O	I-protein
(	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
is	NN	O	O
involved	NN	O	O
.	NN	O	O

-DOCSTART-	O

By	NN	O	O
double-immunogold	NN	O	O
labeling	NN	O	O
of	NN	O	O
PML	NN	O	B-cell_type
and	NN	O	O
LYSP100	NN	O	B-DNA
,	NN	O	O
some	NN	O	O
LANDs	NN	O	O
were	NN	O	O
shown	NN	O	O
to	NN	O	O
contain	NN	O	O
both	NN	O	O
PML	NN	O	B-cell_type
and	NN	O	O
LYSP100	NN	O	B-DNA
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
GIG18	NN	O	B-DNA
was	NN	O	O
rapidly	NN	O	O
induced	NN	O	O
to	NN	O	O
comparable	NN	O	O
levels	NN	O	O
by	NN	O	O
both	NN	O	O
AR	NN	O	B-protein
and	NN	O	O
GR	NN	O	B-protein
,	NN	O	O
demonstrating	NN	O	O
that	NN	O	O
AR	NN	O	B-protein
can	NN	O	O
indeed	NN	O	O
function	NN	O	O
as	NN	O	O
a	NN	O	O
transcriptional	NN	O	O
activator	NN	O	O
in	NN	O	O
S49	NN	O	B-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
,	NN	O	O
moreover	NN	O	O
,	NN	O	O
that	NN	O	O
GIG18	NN	O	B-DNA
induction	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
early	NN	O	O
apoptotic	NN	O	O
events	NN	O	O
in	NN	O	O
steroid-treated	NN	O	O
cells	NN	O	O
.	NN	O	O

Acute	NN	O	O
promyelocytic	NN	O	O
leukemia	NN	O	O
(	NN	O	O
APL	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
specific	NN	O	O
type	NN	O	O
of	NN	O	O
acute	NN	O	O
myeloid	NN	O	O
leukemia	NN	O	O
characterized	NN	O	O
by	NN	O	O
the	NN	O	O
morphology	NN	O	O
of	NN	O	O
the	NN	O	O
blast	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
a	NN	O	O
specific	NN	O	O
t	NN	O	O
(	NN	O	O
15	NN	O	O
;	NN	O	O
17	NN	O	O
)	NN	O	O
translocation	NN	O	O
,	NN	O	O
and	NN	O	O
risks	NN	O	O
of	NN	O	O
definite	NN	O	O
coagulopathy	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
complex	NN	O	O
role	NN	O	O
for	NN	O	O
VitD3	NN	O	O
in	NN	O	O
modifying	NN	O	O
the	NN	O	O
retinoid	NN	O	O
differentiation	NN	O	O
pathway	NN	O	O
and	NN	O	O
may	NN	O	O
have	NN	O	O
implications	NN	O	O
for	NN	O	O
differentiation-inducing	NN	O	O
therapy	NN	O	O
of	NN	O	O
hematopoietic	NN	O	O
tumors	NN	O	O
.	NN	O	O

Recent	NN	O	O
studies	NN	O	O
have	NN	O	O
identified	NN	O	O
homologues	NN	O	O
of	NN	O	O
STAT5	NN	O	B-protein
,	NN	O	O
STAT5A	NN	O	B-protein
,	NN	O	O
and	NN	O	O
STAT5B	NN	O	B-protein
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
lower	NN	O	O
molecular	NN	O	O
weight	NN	O	O
variants	NN	O	O
of	NN	O	O
STAT5	NN	O	B-protein
.	NN	O	O

IFN-gamma	NN	O	B-protein
has	NN	O	O
potent	NN	O	O
antiproliferative	NN	O	O
and	NN	O	O
apoptotic	NN	O	O
effects	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
that	NN	O	O
are	NN	O	O
important	NN	O	O
in	NN	O	O
determining	NN	O	O
T	NN	O	O
cell	NN	O	O
development	NN	O	O
and	NN	O	O
polarized	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Both	NN	O	O
IL-13	NN	O	B-protein
and	NN	O	O
IL-4	NN	O	B-protein
induced	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
IL-4	NN	O	B-protein
STAT	NN	O	I-protein
(	NN	O	O
STAT6	NN	O	B-protein
)	NN	O	O
but	NN	O	O
not	NN	O	O
STAT1	NN	O	B-protein
,	NN	O	O
STAT3	NN	O	B-protein
,	NN	O	O
or	NN	O	O
STAT5	NN	O	B-protein
.	NN	O	O

We	NN	O	O
demonstrate	NN	O	O
here	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
that	NN	O	O
NFAT	NN	O	B-protein
can	NN	O	O
be	NN	O	O
activated	NN	O	O
,	NN	O	O
and	NN	O	O
significant	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-2	NN	O	B-protein
can	NN	O	O
be	NN	O	O
produced	NN	O	O
by	NN	O	O
the	NN	O	O
CsA-resistant	NN	O	O
CD28	NN	O	B-protein
-signaling	NN	O	O
pathway	NN	O	O
.	NN	O	O

-DOCSTART-	O

Two-dimensional	NN	O	O
electrophoretic	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
protein	NN	O	O
phosphorylation	NN	O	O
pattern	NN	O	O
from	NN	O	O
the	NN	O	O
B	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
CESS	NN	O	I-cell_line
demonstrated	NN	O	O
the	NN	O	O
identity	NN	O	O
between	NN	O	O
the	NN	O	O
p60	NN	O	B-protein
protein	NN	O	I-protein
expressed	NN	O	O
in	NN	O	O
this	NN	O	O
cell	NN	O	O
line	NN	O	O
and	NN	O	O
that	NN	O	O
expressed	NN	O	O
in	NN	O	O
B-CLL	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
present	NN	O	O
data	NN	O	O
demonstrating	NN	O	O
that	NN	O	O
HIV	NN	O	O
LTR	NN	O	B-DNA
activation	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
general	NN	O	O
consequence	NN	O	O
of	NN	O	O
cellular	NN	O	B-DNA
DNA	NN	O	I-DNA
damage	NN	O	O
,	NN	O	O
but	NN	O	O
rather	NN	O	O
a	NN	O	O
process	NN	O	O
unique	NN	O	O
to	NN	O	O
specific	NN	O	O
genotoxic	NN	O	O
stimuli	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
it	NN	O	O
does	NN	O	O
not	NN	O	O
necessarily	NN	O	O
depend	NN	O	O
on	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
.	NN	O	O

The	NN	O	O
IL-10R	NN	O	B-protein
,	NN	O	O
together	NN	O	O
with	NN	O	O
reporter	NN	O	O
gene	NN	O	O
constructs	NN	O	O
containing	NN	O	O
different	NN	O	O
IL-6-responsive	NN	O	B-DNA
gene	NN	O	I-DNA
elements	NN	O	I-DNA
,	NN	O	O
reconstituted	NN	O	O
in	NN	O	O
hepatoma	NN	O	B-cell_type
cells	NN	O	I-cell_type
an	NN	O	O
induction	NN	O	O
of	NN	O	O
transcription	NN	O	O
by	NN	O	O
IL-10	NN	O	B-protein
that	NN	O	O
was	NN	O	O
comparable	NN	O	O
to	NN	O	O
that	NN	O	O
by	NN	O	O
IL-6	NN	O	B-protein
.	NN	O	O

These	NN	O	O
receptor	NN	O	O
functions	NN	O	O
required	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
box	NN	O	B-protein
3	NN	O	I-protein
motifs	NN	O	I-protein
,	NN	O	O
as	NN	O	O
shown	NN	O	O
by	NN	O	O
the	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
mouse	NN	O	O
IL-10R	NN	O	B-protein
constructs	NN	O	O
containing	NN	O	O
progressively	NN	O	B-protein
truncated	NN	O	I-protein
cytoplasmic	NN	O	I-protein
domains	NN	O	I-protein
.	NN	O	O

The	NN	O	O
activating	NN	O	O
and	NN	O	O
inhibitory	NN	O	O
domains	NN	O	O
function	NN	O	O
together	NN	O	O
as	NN	O	O
an	NN	O	O
independent	NN	O	O
regulatory	NN	O	O
module	NN	O	O
in	NN	O	O
different	NN	O	O
cell	NN	O	O
types	NN	O	O
as	NN	O	O
shown	NN	O	O
by	NN	O	O
fusion	NN	O	O
to	NN	O	O
the	NN	O	O
GAL4	NN	O	B-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
.	NN	O	O

Transient	NN	O	O
expression	NN	O	O
experiments	NN	O	O
of	NN	O	O
5'-deletion	NN	O	B-DNA
fragments	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
CD36	NN	O	B-DNA
promoter	NN	O	I-DNA
coupled	NN	O	O
to	NN	O	O
luciferase	NN	O	B-protein
demonstrated	NN	O	O
that	NN	O	O
as	NN	O	O
few	NN	O	O
as	NN	O	O
158	NN	O	B-DNA
base	NN	O	I-DNA
pairs	NN	O	I-DNA
upstream	NN	O	I-DNA
from	NN	O	O
the	NN	O	O
transcription	NN	O	B-DNA
initiation	NN	O	I-DNA
site	NN	O	I-DNA
were	NN	O	O
sufficient	NN	O	O
to	NN	O	O
direct	NN	O	O
the	NN	O	O
monocyte-specific	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

We	NN	O	O
questioned	NN	O	O
whether	NN	O	O
one	NN	O	O
can	NN	O	O
use	NN	O	O
the	NN	O	O
limited	NN	O	O
expression	NN	O	O
of	NN	O	O
lymphoid	NN	O	B-protein
markers	NN	O	I-protein
or	NN	O	O
the	NN	O	O
limited	NN	O	O
gene	NN	O	O
rearrangement	NN	O	O
to	NN	O	O
conclude	NN	O	O
that	NN	O	O
H-RS	NN	O	B-cell_line
cells	NN	O	I-cell_line
have	NN	O	O
a	NN	O	O
lymphoid	NN	O	O
origin	NN	O	O
,	NN	O	O
because	NN	O	O
these	NN	O	O
markers	NN	O	O
may	NN	O	O
be	NN	O	O
aberrant	NN	O	O
in	NN	O	O
tumor	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
absence	NN	O	O
of	NN	O	O
GATA-3	NN	O	B-protein
was	NN	O	O
confirmed	NN	O	O
in	NN	O	O
H-RS	NN	O	B-cell_line
cells	NN	O	I-cell_line
in	NN	O	O
tissues	NN	O	O
by	NN	O	O
an	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
technique	NN	O	O
.	NN	O	O

-DOCSTART-	O

Within	NN	O	O
this	NN	O	O
region	NN	O	O
,	NN	O	O
an	NN	O	O
NF-kappaB	NN	O	B-DNA
site	NN	O	I-DNA
at	NN	O	O
-59	NN	O	B-DNA
to	NN	O	I-DNA
-50	NN	O	I-DNA
and	NN	O	O
its	NN	O	O
adjacent	NN	O	O
20-base	NN	O	B-DNA
pair	NN	O	I-DNA
upstream	NN	O	I-DNA
sequence	NN	O	I-DNA
were	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
critical	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
IL-9	NN	O	B-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
.	NN	O	O

ML-9	NN	O	O
induced	NN	O	O
nitroblue	NN	O	O
tetrazolium	NN	O	O
(	NN	O	O
NBT	NN	O	O
)	NN	O	O
-reducing	NN	O	O
activity	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_line
cell	NN	O	I-cell_line
more	NN	O	O
rapidly	NN	O	O
than	NN	O	O
VD3	NN	O	O
:	NN	O	O
This	NN	O	O
differentiation	NN	O	O
marker	NN	O	O
was	NN	O	O
induced	NN	O	O
significantly	NN	O	O
after	NN	O	O
incubation	NN	O	O
with	NN	O	O
ML-9	NN	O	O
and	NN	O	O
VD3	NN	O	O
for	NN	O	O
4	NN	O	O
hours	NN	O	O
and	NN	O	O
1	NN	O	O
day	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Modulation	NN	O	O
of	NN	O	O
endogenous	NN	O	O
IL-1	NN	O	B-protein
beta	NN	O	I-protein
and	NN	O	O
IL-1	NN	O	B-protein
receptor	NN	O	I-protein
antagonist	NN	O	O
results	NN	O	O
in	NN	O	O
opposing	NN	O	O
effects	NN	O	O
on	NN	O	O
HIV	NN	O	O
expression	NN	O	O
in	NN	O	O
chronically	NN	O	B-cell_line
infected	NN	O	I-cell_line
monocytic	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

A	NN	O	O
proportion	NN	O	O
of	NN	O	O
HIV-infected	NN	O	O
individuals	NN	O	O
experience	NN	O	O
episodes	NN	O	O
of	NN	O	O
localized	NN	O	O
or	NN	O	O
systemic	NN	O	O
bacterial	NN	O	O
infections	NN	O	O
caused	NN	O	O
by	NN	O	O
Gram-negative	NN	O	O
bacteria	NN	O	O
.	NN	O	O

In	NN	O	O
part	NN	O	O
,	NN	O	O
this	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
altered	NN	O	O
intercellular	NN	O	O
signalling	NN	O	O
systems	NN	O	O
and	NN	O	O
intracellular	NN	O	O
signal	NN	O	O
transduction	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
HIV	NN	O	O
infections	NN	O	O
often	NN	O	O
show	NN	O	O
elevated	NN	O	O
circulating	NN	O	O
levels	NN	O	O
of	NN	O	O
cortisol	NN	O	O
,	NN	O	O
suggesting	NN	O	O
some	NN	O	O
misfunction	NN	O	O
in	NN	O	O
the	NN	O	O
regulatory	NN	O	O
systems	NN	O	O
that	NN	O	O
maintain	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
this	NN	O	O
critical	NN	O	O
hormone	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
the	NN	O	O
processing	NN	O	O
rate	NN	O	O
of	NN	O	O
p105	NN	O	B-protein
is	NN	O	O
markedly	NN	O	O
inhibited	NN	O	O
in	NN	O	O
cells	NN	O	O
co-transfected	NN	O	O
with	NN	O	O
p50	NN	O	B-protein
or	NN	O	O
other	NN	O	O
NF-kappaB	NN	O	B-protein
subunits	NN	O	I-protein
,	NN	O	O
including	NN	O	O
RelA	NN	O	B-protein
and	NN	O	O
c-Rel	NN	O	B-protein
,	NN	O	O
that	NN	O	O
physically	NN	O	O
interact	NN	O	O
with	NN	O	O
p105	NN	O	B-protein
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
processing	NN	O	O
of	NN	O	O
p105	NN	O	B-protein
is	NN	O	O
subject	NN	O	O
to	NN	O	O
negative	NN	O	O
regulation	NN	O	O
by	NN	O	O
the	NN	O	O
various	NN	O	O
NF-kappaB	NN	O	B-protein
subunits	NN	O	I-protein
.	NN	O	O

We	NN	O	O
further	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
p105	NN	O	B-protein
undergoes	NN	O	O
degradation	NN	O	O
in	NN	O	O
lipopolysaccharide-stimulated	NN	O	B-cell_line
human	NN	O	I-cell_line
monocytic	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
inducible	NN	O	O
degradation	NN	O	O
of	NN	O	O
p105	NN	O	B-protein
is	NN	O	O
not	NN	O	O
coupled	NN	O	O
with	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
footprinting	NN	O	O
by	NN	O	O
ligation-mediated	NN	O	O
PCR	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
correlate	NN	O	O
in	NN	O	O
vivo	NN	O	O
protein	NN	O	O
binding	NN	O	O
with	NN	O	O
functional	NN	O	O
activity	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
fresh	NN	O	O
leukemic	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
whatever	NN	O	O
their	NN	O	O
stage	NN	O	O
of	NN	O	O
differentiation	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
myelomonocytic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
respond	NN	O	O
to	NN	O	O
VD	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
RXR	NN	O	B-protein
alpha	NN	O	I-protein
levels	NN	O	O
.	NN	O	O

Interferon-gamma	NN	O	B-protein
modulates	NN	O	O
the	NN	O	O
lipopolysaccharide-induced	NN	O	O
expression	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
and	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
at	NN	O	O
the	NN	O	O
mRNA	NN	O	O
and	NN	O	O
protein	NN	O	O
level	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
IFN-gamma	NN	O	B-protein
priming	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
p105	NN	O	B-RNA
transcripts	NN	O	I-RNA
but	NN	O	O
enhanced	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
p65	NN	O	B-RNA
mRNA	NN	O	I-RNA
(	NN	O	O
two-fold	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
human	NN	O	B-cell_line
Jurkat	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
its	NN	O	O
subclone	NN	O	O
Wurzburg	NN	O	B-cell_line
cells	NN	O	I-cell_line
oxidant	NN	O	O
challenge	NN	O	O
elevated	NN	O	O
[	NN	O	O
Ca2+	NN	O	O
]	NN	O	O
i	NN	O	O
by	NN	O	O
mobilizing	NN	O	O
Ca2+	NN	O	O
from	NN	O	O
intracellular	NN	O	O
stores	NN	O	O
.	NN	O	O

In	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
that	NN	O	O
are	NN	O	O
not	NN	O	O
sensitive	NN	O	O
to	NN	O	O
H2O2-induced	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
,	NN	O	O
H2O2	NN	O	O
potentiated	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
sustained	NN	O	O
high	NN	O	O
[	NN	O	O
Ca2+	NN	O	O
]	NN	O	O
i	NN	O	O
following	NN	O	O
thapsigargin	NN	O	O
treatment	NN	O	O
.	NN	O	O

Human	NN	O	B-cell_line
T-cell	NN	O	I-cell_line
leukemia	NN	O	I-cell_line
virus	NN	O	I-cell_line
type	NN	O	I-cell_line
I	NN	O	I-cell_line
(	NN	O	I-cell_line
HTLV-I	NN	O	I-cell_line
)	NN	O	I-cell_line
-infected	NN	O	I-cell_line
T-cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
constitutively	NN	O	O
produce	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
interleukin-1alpha	NN	O	B-protein
(	NN	O	O
IL-1alpha	NN	O	B-protein
)	NN	O	O
.	NN	O	O

-DOCSTART-	O

Plasmids	NN	O	O
containing	NN	O	O
151	NN	O	B-DNA
bp	NN	O	I-DNA
of	NN	O	O
5'-flanking	NN	O	B-DNA
sequences	NN	O	I-DNA
confer	NN	O	O
myeloid-cell-specific	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Indeed	NN	O	O
,	NN	O	O
monocytes	NN	O	B-cell_type
pretreated	NN	O	O
with	NN	O	O
IL-10	NN	O	B-protein
are	NN	O	O
able	NN	O	O
so	NN	O	O
inhibit	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
nuclear	NN	O	O
activity	NN	O	O
in	NN	O	O
purified	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
stimulated	NN	O	O
with	NN	O	O
OKT3	NN	O	B-protein
.	NN	O	O

Protein	NN	O	O
expression	NN	O	O
paralleled	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
RNA	NN	O	O
.	NN	O	O

Both	NN	O	O
proteins	NN	O	O
were	NN	O	O
identified	NN	O	O
by	NN	O	O
peptide	NN	O	O
microsequencing	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
complementary	NN	O	B-DNA
DNA	NN	O	I-DNA
encoding	NN	O	O
the	NN	O	O
histone	NN	O	B-protein
deacetylase	NN	O	I-protein
catalytic	NN	O	I-protein
subunit	NN	O	I-protein
(	NN	O	O
HD1	NN	O	B-protein
)	NN	O	O
was	NN	O	O
cloned	NN	O	O
from	NN	O	O
a	NN	O	O
human	NN	O	O
Jurkat	NN	O	O
T	NN	O	O
cell	NN	O	O
library	NN	O	O
.	NN	O	O

-DOCSTART-	O

At	NN	O	O
the	NN	O	O
same	NN	O	O
concentration	NN	O	O
,	NN	O	O
Ro	NN	O	O
25-6603	NN	O	O
and	NN	O	O
Ro	NN	O	O
25-7386	NN	O	O
had	NN	O	O
little	NN	O	O
or	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
G-CSF	NN	O	B-protein
-induced	NN	O	O
colony	NN	O	O
formation	NN	O	O
,	NN	O	O
whereas	NN	O	O
they	NN	O	O
inhibited	NN	O	O
75	NN	O	O
%	NN	O	O
and	NN	O	O
53	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
of	NN	O	O
SCF	NN	O	B-protein
+	NN	O	O
Epo	NN	O	B-protein
-stimulated	NN	O	O
BFU-E	NN	O	O
colony	NN	O	O
growth	NN	O	O
.	NN	O	O

-DOCSTART-	O

Translocations	NN	O	O
involving	NN	O	O
the	NN	O	O
BCL-6	NN	O	B-DNA
gene	NN	O	I-DNA
are	NN	O	O
common	NN	O	O
in	NN	O	O
the	NN	O	O
diffuse	NN	O	O
large	NN	O	O
cell	NN	O	O
subtype	NN	O	O
of	NN	O	O
non-Hodgkin	NN	O	O
's	NN	O	O
lymphoma	NN	O	O
.	NN	O	O

Although	NN	O	O
polyclonal	NN	O	O
activation	NN	O	O
of	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
vitro	NN	O	O
invariably	NN	O	O
decreased	NN	O	O
BCL-6	NN	O	B-protein
MRNA	NN	O	O
expression	NN	O	O
,	NN	O	O
activated	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
from	NN	O	O
human	NN	O	O
germinal	NN	O	O
centers	NN	O	O
expressed	NN	O	O
BCL-6	NN	O	O
mRNA	NN	O	O
at	NN	O	O
levels	NN	O	O
comparable	NN	O	O
to	NN	O	O
the	NN	O	O
levels	NN	O	O
in	NN	O	O
resting	NN	O	O
B	NN	O	O
cells	NN	O	O
.	NN	O	O

Such	NN	O	O
repressive	NN	O	O
function	NN	O	O
is	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
seen	NN	O	O
in	NN	O	O
IRF-2	NN	O	B-protein
or	NN	O	O
ICSBP	NN	O	B-protein
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
B.pertussis	NN	O	O
,	NN	O	O
V.cholera.	NN	O	O
or	NN	O	O
C.botulinum	NN	O	O
toxin	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
histamine-induced	NN	O	O
[	NN	O	O
Ca2+	NN	O	O
]	NN	O	O
i	NN	O	O
rise	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
a	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
activator	NN	O	O
,	NN	O	O
phorbol	NN	O	O
12-myristate	NN	O	O
13-acetate	NN	O	O
,	NN	O	O
caused	NN	O	O
almost	NN	O	O
complete	NN	O	O
inhibition	NN	O	O
of	NN	O	O
histamine-induced	NN	O	O
[	NN	O	O
Ca2+	NN	O	O
]	NN	O	O
i	NN	O	O
rise	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
do	NN	O	O
so	NN	O	O
by	NN	O	O
activators	NN	O	O
of	NN	O	O
cAMP-	NN	O	B-protein
and	NN	O	I-protein
cGMP-dependent	NN	O	I-protein
protein	NN	O	I-protein
kinases	NN	O	I-protein
.	NN	O	O

An	NN	O	O
alternatively	NN	O	O
spliced	NN	O	O
isoform	NN	O	O
of	NN	O	O
the	NN	O	O
Spi-B	NN	O	B-protein
transcription	NN	O	B-protein
factor	NN	O	I-protein
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
-driven	NN	O	O
secreted	NN	O	O
alkaline	NN	O	B-protein
phosphatase	NN	O	I-protein
activity	NN	O	O
in	NN	O	O
transient	NN	O	O
assays	NN	O	O
showed	NN	O	O
that	NN	O	O
,	NN	O	O
unlike	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
,	NN	O	O
the	NN	O	O
SIV	NN	O	B-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
possesses	NN	O	O
an	NN	O	O
enhancer	NN	O	B-DNA
region	NN	O	I-DNA
just	NN	O	O
upstream	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-DNA
element	NN	O	I-DNA
which	NN	O	O
maintains	NN	O	O
significant	NN	O	O
levels	NN	O	O
of	NN	O	O
basal	NN	O	O
transcription	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-DNA
and	NN	O	I-DNA
Sp1	NN	O	I-DNA
sites	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
SIV	NN	O	B-DNA
TATA	NN	O	I-DNA
box	NN	O	I-DNA
was	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
stronger	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
previous	NN	O	O
reports	NN	O	O
of	NN	O	O
rare	NN	O	O
variant	NN	O	O
translocations	NN	O	O
in	NN	O	O
APL	NN	O	O
,	NN	O	O
indicate	NN	O	O
that	NN	O	O
while	NN	O	O
dysregulation	NN	O	O
of	NN	O	O
RARA	NN	O	B-DNA
by	NN	O	O
gene	NN	O	O
fusion	NN	O	O
may	NN	O	O
be	NN	O	O
essential	NN	O	O
for	NN	O	O
the	NN	O	O
APL	NN	O	O
phenotype	NN	O	O
,	NN	O	O
the	NN	O	O
particular	NN	O	O
fusion	NN	O	O
partner	NN	O	O
may	NN	O	O
determine	NN	O	O
clinicopathological	NN	O	O
aspects	NN	O	O
,	NN	O	O
including	NN	O	O
presentation	NN	O	O
,	NN	O	O
response	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
all-trans	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
ATRA	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
prognosis	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
repression	NN	O	O
is	NN	O	O
strongly	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
enhancer	NN	O	B-DNA
present	NN	O	O
in	NN	O	O
the	NN	O	O
reporter	NN	O	B-DNA
plasmid	NN	O	I-DNA
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
the	NN	O	O
cell	NN	O	B-cell_line
line	NN	O	I-cell_line
tested	NN	O	O
.	NN	O	O

This	NN	O	O
work	NN	O	O
aimed	NN	O	O
to	NN	O	O
ascertain	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
kappaB-responsive	NN	O	B-DNA
elements	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
1	NN	O	I-DNA
(	NN	O	I-DNA
HIV-1	NN	O	I-DNA
)	NN	O	I-DNA
enhancer	NN	O	I-DNA
not	NN	O	O
only	NN	O	O
in	NN	O	O
early	NN	O	O
initiation	NN	O	O
but	NN	O	O
also	NN	O	O
in	NN	O	O
long-term	NN	O	O
maintenance	NN	O	O
of	NN	O	O
proviral	NN	O	O
transcription	NN	O	O
in	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
monocytic	NN	O	B-cell_type
lineage	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
c-rel	NN	O	B-DNA
protooncogene	NN	O	I-DNA
encodes	NN	O	O
a	NN	O	O
subunit	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B-like	NN	O	I-protein
family	NN	O	I-protein
of	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
anti-CD3	NN	O	B-protein
and	NN	O	O
anti-CD28	NN	O	B-protein
stimulated	NN	O	O
Rel-/-	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
which	NN	O	O
fail	NN	O	O
to	NN	O	O
proliferate	NN	O	O
,	NN	O	O
make	NN	O	O
little	NN	O	O
or	NN	O	O
no	NN	O	O
detectable	NN	O	O
cytokines	NN	O	B-protein
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
bulk	NN	O	O
of	NN	O	O
protein-DNA	NN	O	O
interactions	NN	O	O
that	NN	O	O
underlies	NN	O	O
the	NN	O	O
developmental	NN	O	O
control	NN	O	O
of	NN	O	O
globin	NN	O	B-DNA
genes	NN	O	I-DNA
takes	NN	O	O
place	NN	O	O
in	NN	O	O
the	NN	O	O
gamma-	NN	O	B-DNA
and	NN	O	I-DNA
beta-globin	NN	O	I-DNA
gene	NN	O	I-DNA
promoters	NN	O	I-DNA
,	NN	O	O
and	NN	O	O
that	NN	O	O
GT	NN	O	B-DNA
motifs	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
beta-globin	NN	O	B-DNA
locus	NN	O	I-DNA
LCR	NN	O	B-DNA
may	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
developmental	NN	O	O
regulation	NN	O	O
of	NN	O	O
human	NN	O	O
beta-globin	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
,	NN	O	O
perhaps	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
probability	NN	O	O
of	NN	O	O
interaction	NN	O	O
of	NN	O	O
the	NN	O	O
LCR	NN	O	B-protein
holocomplex	NN	O	I-protein
with	NN	O	O
the	NN	O	O
fetal	NN	O	B-DNA
or	NN	O	I-DNA
the	NN	O	I-DNA
adult	NN	O	I-DNA
globin	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

Antisense	NN	O	O
inhibition	NN	O	O
of	NN	O	O
vitamin	NN	O	B-protein
D	NN	O	I-protein
receptor	NN	O	I-protein
expression	NN	O	O
induces	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
monoblastoid	NN	O	B-cell_line
U937	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

A	NN	O	O
2-kb	NN	O	B-DNA
VDR	NN	O	I-DNA
cDNA	NN	O	I-DNA
insert	NN	O	I-DNA
(	NN	O	O
including	NN	O	O
the	NN	O	O
complete	NN	O	O
VDR	NN	O	B-DNA
coding	NN	O	I-DNA
region	NN	O	I-DNA
)	NN	O	O
was	NN	O	O
cloned	NN	O	O
in	NN	O	O
an	NN	O	O
antisense	NN	O	O
orientation	NN	O	O
into	NN	O	O
the	NN	O	O
EBV	NN	O	O
episomal	NN	O	O
vector	NN	O	O
pMEP4	NN	O	O
under	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
an	NN	O	O
inducible	NN	O	B-DNA
promoter	NN	O	I-DNA
and	NN	O	O
transfected	NN	O	O
into	NN	O	O
U937	NN	O	B-cell_line
.	NN	O	O

We	NN	O	O
now	NN	O	O
report	NN	O	O
that	NN	O	O
galectin-3	NN	O	B-protein
is	NN	O	O
abundantly	NN	O	O
expressed	NN	O	O
in	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
human	NN	O	B-cell_line
T	NN	O	I-cell_line
lymphotropic	NN	O	I-cell_line
virus	NN	O	I-cell_line
(	NN	O	I-cell_line
HTLV	NN	O	I-cell_line
)	NN	O	I-cell_line
-I-infected	NN	O	I-cell_line
human	NN	O	I-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
including	NN	O	O
F6T	NN	O	B-cell_line
,	NN	O	O
HUT	NN	O	B-cell_line
102	NN	O	I-cell_line
,	NN	O	O
K3T	NN	O	B-cell_line
,	NN	O	O
MT-2	NN	O	B-cell_line
,	NN	O	O
and	NN	O	O
SLB-I	NN	O	B-cell_line
,	NN	O	O
but	NN	O	O
is	NN	O	O
not	NN	O	O
expressed	NN	O	O
in	NN	O	O
non-HTLV-I-infected	NN	O	B-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
such	NN	O	O
as	NN	O	O
Jurkat	NN	O	B-cell_line
,	NN	O	O
CEM	NN	O	B-cell_line
,	NN	O	O
and	NN	O	O
MOLT-4	NN	O	B-cell_line
.	NN	O	O

Nuclear	NN	O	O
extracts	NN	O	O
from	NN	O	O
LPS	NN	O	O
-and	NN	O	O
zymosan-treated	NN	O	B-cell_type
cells	NN	O	I-cell_type
showed	NN	O	O
strong	NN	O	O
AP-1	NN	O	B-protein
activity	NN	O	O
by	NN	O	O
gel-shift	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
supershift	NN	O	O
analysis	NN	O	O
showed	NN	O	O
the	NN	O	O
AP-1	NN	O	B-protein
complexes	NN	O	I-protein
contained	NN	O	O
specific	NN	O	O
members	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
jun	NN	O	B-DNA
and	NN	O	I-DNA
fos	NN	O	I-DNA
gene	NN	O	I-DNA
families	NN	O	I-DNA
.	NN	O	O

A	NN	O	O
cell	NN	O	B-DNA
type-specific	NN	O	I-DNA
enhancer	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
B7.1	NN	O	I-DNA
gene	NN	O	I-DNA
regulated	NN	O	O
by	NN	O	O
NF-kappaB	NN	O	B-protein
.	NN	O	O

Truncated	NN	O	B-protein
c-Jun	NN	O	I-protein
and	NN	O	I-protein
c-Fos	NN	O	I-protein
mutant	NN	O	I-protein
proteins	NN	O	I-protein
including	NN	O	O
wbJun	NN	O	B-protein
and	NN	O	O
wbFos	NN	O	B-protein
were	NN	O	O
also	NN	O	O
ubiquitinylated	NN	O	O
under	NN	O	O
the	NN	O	O
same	NN	O	O
conditions	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
sites	NN	O	O
of	NN	O	O
ubiquitinylation	NN	O	O
are	NN	O	O
located	NN	O	O
within	NN	O	O
the	NN	O	O
dimerization	NN	O	B-protein
and	NN	O	I-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
domains	NN	O	I-protein
of	NN	O	O
c-Jun	NN	O	B-protein
and	NN	O	O
c-Fos	NN	O	B-protein
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
cytokines	NN	O	B-protein
were	NN	O	O
distinguishable	NN	O	O
functionally	NN	O	O
since	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
TNF-alpha	NN	O	B-protein
attenuated	NN	O	O
the	NN	O	O
cytokine	NN	O	B-protein
cooperativity	NN	O	O
,	NN	O	O
while	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
IL-10	NN	O	B-protein
potentiated	NN	O	O
their	NN	O	O
cooperativity	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
IL-10	NN	O	B-protein
and	NN	O	O
TNF-alpha	NN	O	B-protein
play	NN	O	O
different	NN	O	O
roles	NN	O	O
in	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
virus	NN	O	O
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
interpret	NN	O	O
this	NN	O	O
as	NN	O	O
a	NN	O	O
reflection	NN	O	O
of	NN	O	O
a	NN	O	O
low	NN	O	O
threshold	NN	O	O
for	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
clone	NN	O	I-cell_line
,	NN	O	O
in	NN	O	O
which	NN	O	O
peptide-	NN	O	O
MHC	NN	O	B-protein
avidity	NN	O	O
is	NN	O	O
the	NN	O	O
over-riding	NN	O	O
determinant	NN	O	O
of	NN	O	O
the	NN	O	O
strength	NN	O	O
of	NN	O	O
ligand	NN	O	O
signal	NN	O	O
.	NN	O	O

IL-11	NN	O	B-RNA
mRNA	NN	O	I-RNA
and	NN	O	O
protein	NN	O	O
were	NN	O	O
both	NN	O	O
up-regulated	NN	O	O
during	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
this	NN	O	O
inflammatory	NN	O	O
response	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
BAL	NN	O	O
content	NN	O	O
of	NN	O	O
C5a	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
IL-11	NN	O	B-protein
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
Jak	NN	O	O
family	NN	O	O
of	NN	O	O
tyrosine	NN	O	B-protein
kinases	NN	O	I-protein
are	NN	O	O
known	NN	O	O
to	NN	O	O
mediate	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
cytokines	NN	O	B-protein
or	NN	O	O
hematopoietic	NN	O	B-protein
growth	NN	O	I-protein
factors	NN	O	I-protein
by	NN	O	O
recruitment	NN	O	O
and	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
Stat	NN	O	B-protein
(	NN	O	O
signal	NN	O	B-protein
transducers	NN	O	I-protein
and	NN	O	I-protein
activators	NN	O	I-protein
of	NN	O	I-protein
transcription	NN	O	I-protein
)	NN	O	O
proteins	NN	O	O
.	NN	O	O

Mechanisms	NN	O	O
that	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
lymphoid	NN	O	O
malignancies	NN	O	O
:	NN	O	O
roles	NN	O	O
for	NN	O	O
genetic	NN	O	O
alterations	NN	O	O
and	NN	O	O
cytokine	NN	O	B-protein
production	NN	O	O
.	NN	O	O

Both	NN	O	O
complexes	NN	O	O
were	NN	O	O
critically	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
NF-AT	NN	O	B-DNA
core	NN	O	I-DNA
sequence	NN	O	I-DNA
TTTCC	NN	O	O
in	NN	O	O
the	NN	O	O
E1	NN	O	B-DNA
element	NN	O	I-DNA
and	NN	O	O
were	NN	O	O
partially	NN	O	O
supershifted	NN	O	O
by	NN	O	O
anti-NF-ATp	NN	O	B-protein
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
dopamine	NN	O	O
and	NN	O	O
TNF-alpha	NN	O	B-protein
led	NN	O	O
to	NN	O	O
a	NN	O	O
stimulation	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
transcription	NN	O	O
and	NN	O	O
replication	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
reveal	NN	O	O
a	NN	O	O
new	NN	O	O
link	NN	O	O
between	NN	O	O
the	NN	O	O
dopamine	NN	O	O
system	NN	O	O
,	NN	O	O
cytokine	NN	O	B-protein
signaling	NN	O	O
pathway	NN	O	O
and	NN	O	O
regulation	NN	O	O
of	NN	O	O
gene	NN	O	O
expression	NN	O	O
via	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
PBMC	NN	O	B-cell_type
.	NN	O	O

Selective	NN	O	O
DNA-binding	NN	O	O
activity	NN	O	O
of	NN	O	O
interleukin-10-stimulated	NN	O	B-protein
STAT	NN	O	I-protein
molecules	NN	O	I-protein
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
analyzed	NN	O	O
the	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
IL-10-	NN	O	B-protein
and	NN	O	I-protein
IFN-gamma-activated	NN	O	I-protein
STAT	NN	O	I-protein
molecules	NN	O	I-protein
to	NN	O	O
two	NN	O	O
kinds	NN	O	O
of	NN	O	O
GAS	NN	O	B-DNA
-motif	NN	O	O
sequences	NN	O	O
.	NN	O	O

IL-10-activated	NN	O	B-protein
STAT1	NN	O	I-protein
could	NN	O	O
bind	NN	O	O
to	NN	O	O
the	NN	O	O
GAS-motif	NN	O	B-DNA
sequence	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
promoter	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
Fcgamma	NN	O	B-protein
receptor	NN	O	I-protein
,	NN	O	O
but	NN	O	O
not	NN	O	O
to	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
COX-2	NN	O	B-DNA
gene	NN	O	I-DNA
,	NN	O	O
whereas	NN	O	O
IFN-gamma-activated	NN	O	B-protein
STAT1	NN	O	I-protein
and	NN	O	O
STAT5	NN	O	B-protein
could	NN	O	O
bind	NN	O	O
to	NN	O	O
both	NN	O	O
sequences	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
explain	NN	O	O
the	NN	O	O
difference	NN	O	O
between	NN	O	O
IL-10	NN	O	B-protein
and	NN	O	O
IFN-gamma	NN	O	B-protein
in	NN	O	O
biological	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
IL-10	NN	O	B-protein
on	NN	O	O
IFN-gamma	NN	O	B-protein
activities	NN	O	O
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
cortisol	NN	O	O
incubation	NN	O	O
induced	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
IL-1ra	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
inhibition	NN	O	O
of	NN	O	O
IL-1ra	NN	O	B-protein
protein	NN	O	I-protein
secretion	NN	O	O
in	NN	O	O
cell	NN	O	O
cultures	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
stimulated	NN	O	O
with	NN	O	O
the	NN	O	O
bacterial	NN	O	O
endotoxin	NN	O	O
lipopolysaccharide	NN	O	O
(	NN	O	O
LPS	NN	O	O
)	NN	O	O
.	NN	O	O

Consistent	NN	O	O
with	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
STATs	NN	O	B-protein
in	NN	O	O
Qp	NN	O	B-DNA
function	NN	O	O
,	NN	O	O
Qp	NN	O	B-DNA
using	NN	O	O
Burkitt	NN	O	B-cell_line
's	NN	O	I-cell_line
lymphoma	NN	O	I-cell_line
Rael	NN	O	I-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
cultured	NN	O	B-cell_type
nasopharyngeal	NN	O	I-cell_type
carcinoma	NN	O	I-cell_type
(	NN	O	I-cell_type
NPC	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
contained	NN	O	O
nuclear	NN	O	O
STAT	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

We	NN	O	O
provide	NN	O	O
evidence	NN	O	O
that	NN	O	O
Zta	NN	O	B-protein
up-regulation	NN	O	O
of	NN	O	O
p53	NN	O	B-protein
leads	NN	O	O
to	NN	O	O
p53	NN	O	B-protein
-mediated	NN	O	O
interference	NN	O	O
with	NN	O	O
JAK	NN	O	B-protein
/STAT	NN	O	B-protein
activation	NN	O	O
of	NN	O	O
Qp	NN	O	B-DNA
.	NN	O	O

Deletion	NN	O	O
or	NN	O	O
substitution	NN	O	O
of	NN	O	O
a	NN	O	O
putative	NN	O	B-protein
NF-kappaB	NN	O	I-protein
binding	NN	O	I-protein
site	NN	O	I-protein
identified	NN	O	O
in	NN	O	O
the	NN	O	O
bcl-x	NN	O	B-DNA
promoter	NN	O	I-DNA
significantly	NN	O	O
decreased	NN	O	O
Tax	NN	O	B-protein
-induced	NN	O	O
transactivation	NN	O	O
.	NN	O	O

The	NN	O	O
beta-globin	NN	O	B-DNA
promoter	NN	O	I-DNA
is	NN	O	O
important	NN	O	O
for	NN	O	O
recruitment	NN	O	O
of	NN	O	O
erythroid	NN	O	B-protein
Kruppel-like	NN	O	I-protein
factor	NN	O	I-protein
to	NN	O	O
the	NN	O	O
locus	NN	O	B-DNA
control	NN	O	I-DNA
region	NN	O	I-DNA
in	NN	O	O
erythroid	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
putative	NN	O	O
targets	NN	O	O
of	NN	O	O
calcineurin	NN	O	B-protein
is	NN	O	O
the	NN	O	O
pre-existing	NN	O	O
,	NN	O	O
cytosolic	NN	O	B-protein
component	NN	O	I-protein
of	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	I-protein
activated	NN	O	I-protein
T	NN	O	I-protein
cells	NN	O	I-protein
(	NN	O	O
NFATp	NN	O	B-protein
;	NN	O	O
also	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
NFAT1	NN	O	B-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
one	NN	O	O
of	NN	O	O
several	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
required	NN	O	O
for	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
interleukin	NN	O	B-protein
2	NN	O	I-protein
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
calcium	NN	O	O
ionophore	NN	O	O
induced	NN	O	O
a	NN	O	O
shift	NN	O	O
in	NN	O	O
the	NN	O	O
molecular	NN	O	O
weight	NN	O	O
of	NN	O	O
NFATp	NN	O	B-protein
that	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
dephosphorylation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Using	NN	O	O
CD45-	NN	O	B-cell_line
or	NN	O	I-cell_line
CD3-negative	NN	O	I-cell_line
variants	NN	O	I-cell_line
of	NN	O	O
the	NN	O	O
Jurkat	NN	O	B-cell_line
leukemic	NN	O	I-cell_line
T-cell	NN	O	I-cell_line
line	NN	O	I-cell_line
we	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
different	NN	O	O
biochemical	NN	O	O
events	NN	O	O
induced	NN	O	O
by	NN	O	O
pervanadate	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
at	NN	O	O
the	NN	O	O
cell	NN	O	O
surface	NN	O	O
of	NN	O	O
either	NN	O	O
CD45	NN	O	B-protein
or	NN	O	O
CD3	NN	O	B-protein
.	NN	O	O

Rheumatoid	NN	O	O
arthritis	NN	O	O
(	NN	O	O
RA	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
chronic	NN	O	O
autoimmune	NN	O	O
inflammatory	NN	O	O
disease	NN	O	O
in	NN	O	O
which	NN	O	O
unknown	NN	O	O
arthrogenic	NN	O	B-protein
autoantigen	NN	O	I-protein
is	NN	O	O
presented	NN	O	O
to	NN	O	O
CD4+	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

This	NN	O	O
work	NN	O	O
aims	NN	O	O
at	NN	O	O
identifying	NN	O	O
the	NN	O	O
thymocyte	NN	O	O
subpopulation	NN	O	O
able	NN	O	O
to	NN	O	O
support	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
(	NN	O	O
HIV	NN	O	O
)	NN	O	O
replication	NN	O	O
under	NN	O	O
the	NN	O	O
biological	NN	O	O
stimuli	NN	O	O
of	NN	O	O
the	NN	O	O
thymic	NN	O	O
microenvironment	NN	O	O
.	NN	O	O

Together	NN	O	O
,	NN	O	O
these	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
despite	NN	O	O
an	NN	O	O
efficient	NN	O	O
entry	NN	O	O
of	NN	O	O
the	NN	O	O
virus	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
CD4	NN	O	B-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
subpopulations	NN	O	I-cell_type
,	NN	O	O
a	NN	O	O
high	NN	O	O
viral	NN	O	O
load	NN	O	O
may	NN	O	O
be	NN	O	O
generated	NN	O	O
exclusively	NN	O	O
within	NN	O	O
the	NN	O	O
mature	NN	O	B-cell_type
CD4	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
CD8	NN	O	I-cell_type
(	NN	O	I-cell_type
-	NN	O	I-cell_type
)	NN	O	I-cell_type
CD3	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
subset	NN	O	I-cell_type
of	NN	O	I-cell_type
thymocytes	NN	O	I-cell_type
.	NN	O	O

We	NN	O	O
also	NN	O	O
show	NN	O	O
that	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
B1	NN	O	B-RNA
transcript	NN	O	I-RNA
from	NN	O	O
a	NN	O	O
second	NN	O	O
gene	NN	O	O
,	NN	O	O
MTCP1	NN	O	B-DNA
,	NN	O	O
occurred	NN	O	O
at	NN	O	O
a	NN	O	O
relatively	NN	O	O
high	NN	O	O
level	NN	O	O
only	NN	O	O
in	NN	O	O
two	NN	O	O
T-PLL	NN	O	O
tumours	NN	O	O
from	NN	O	O
A-T	NN	O	O
patients	NN	O	O
with	NN	O	O
t	NN	O	O
(	NN	O	O
X	NN	O	O
;	NN	O	O
14	NN	O	O
)	NN	O	O
translocations	NN	O	O
whereas	NN	O	O
the	NN	O	O
MTCP1/A1	NN	O	B-RNA
transcript	NN	O	I-RNA
is	NN	O	O
much	NN	O	O
more	NN	O	O
widely	NN	O	O
expressed	NN	O	O
in	NN	O	O
both	NN	O	O
tumour	NN	O	B-cell_type
and	NN	O	I-cell_type
non	NN	O	I-cell_type
tumour	NN	O	I-cell_type
cells	NN	O	I-cell_type
of	NN	O	O
A-T	NN	O	O
and	NN	O	O
non-A-T	NN	O	O
individuals	NN	O	O
.	NN	O	O

-DOCSTART-	O

Affinity-driven	NN	O	O
peptide	NN	O	O
selection	NN	O	O
of	NN	O	O
an	NN	O	O
NFAT	NN	O	O
inhibitor	NN	O	O
more	NN	O	O
selective	NN	O	O
than	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
[	NN	O	O
see	NN	O	O
comments	NN	O	O
]	NN	O	O

IVS1-10T	NN	O	O
--	NN	O	O
>	NN	O	O
C	NN	O	O
is	NN	O	O
a	NN	O	O
unique	NN	O	O
BRCA1	NN	O	B-DNA
change	NN	O	O
that	NN	O	O
occurs	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
nucleotide	NN	O	O
of	NN	O	O
a	NN	O	O
consensus	NN	O	B-DNA
sequence	NN	O	I-DNA
for	NN	O	O
a	NN	O	O
branch	NN	O	B-DNA
site	NN	O	I-DNA
critical	NN	O	O
for	NN	O	O
RNA	NN	O	O
splicing	NN	O	O
.	NN	O	O

Retention	NN	O	O
of	NN	O	O
the	NN	O	O
normal	NN	O	O
BRCA1	NN	O	B-DNA
allele	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
tumor	NN	O	O
with	NN	O	O
the	NN	O	O
heterozygous	NN	O	O
germline	NN	O	O
BRCA1	NN	O	B-DNA
mutation	NN	O	O
,	NN	O	O
2418delA	NN	O	O
,	NN	O	O
indicated	NN	O	O
that	NN	O	O
mutational	NN	O	O
inactivation	NN	O	O
of	NN	O	O
both	NN	O	O
BRCA1	NN	O	B-DNA
alleles	NN	O	I-DNA
was	NN	O	O
not	NN	O	O
required	NN	O	O
for	NN	O	O
tumorigenesis	NN	O	O
.	NN	O	O

As	NN	O	O
far	NN	O	O
as	NN	O	O
we	NN	O	O
know	NN	O	O
,	NN	O	O
these	NN	O	O
myb-transformed	NN	O	B-cell_line
hemopoi-etic	NN	O	I-cell_line
cells	NN	O	I-cell_line
(	NN	O	O
MTHC	NN	O	B-cell_line
)	NN	O	O
differ	NN	O	O
from	NN	O	O
normal	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
unregulated	NN	O	O
expression	NN	O	O
of	NN	O	O
myb	NN	O	O
,	NN	O	O
a	NN	O	O
gene	NN	O	O
whose	NN	O	O
expression	NN	O	O
is	NN	O	O
obligatory	NN	O	O
for	NN	O	O
proliferation	NN	O	O
of	NN	O	O
hemopoietic	NN	O	O
cells	NN	O	O
.	NN	O	O

Cells	NN	O	O
within	NN	O	O
each	NN	O	O
category	NN	O	O
did	NN	O	O
not	NN	O	O
give	NN	O	O
any	NN	O	O
aberrant	NN	O	O
results	NN	O	O
.	NN	O	O

An	NN	O	O
extensive	NN	O	O
immunocytochemical	NN	O	O
evaluation	NN	O	O
of	NN	O	O
fixed	NN	O	O
tissues	NN	O	O
confirmed	NN	O	O
MNDA	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
normal	NN	O	B-cell_type
maturing	NN	O	I-cell_type
granulocytes	NN	O	I-cell_type
and	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
in	NN	O	O
acute	NN	O	O
nonlymphocytic	NN	O	O
leukemias	NN	O	O
and	NN	O	O
chronic	NN	O	O
myelogenous	NN	O	O
leukemia	NN	O	O
.	NN	O	O

-DOCSTART-	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
functionality	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
C/EBP-	NN	O	B-DNA
and	NN	O	I-DNA
GATA-	NN	O	I-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
,	NN	O	O
we	NN	O	O
analyzed	NN	O	O
whether	NN	O	O
C/EBPbeta	NN	O	B-protein
and	NN	O	O
GATA-1	NN	O	B-protein
can	NN	O	O
stimulate	NN	O	O
the	NN	O	O
MBP	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
C/EBPbeta	NN	O	B-cell_line
and	NN	O	I-cell_line
GATA-1	NN	O	I-cell_line
negative	NN	O	I-cell_line
Jurkat	NN	O	I-cell_line
T-cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
GST	NN	O	B-protein
pull-down	NN	O	O
experiments	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
physical	NN	O	O
interaction	NN	O	O
between	NN	O	O
human	NN	O	O
GATA-1	NN	O	B-protein
and	NN	O	O
C/EBPbeta	NN	O	B-protein
.	NN	O	O

Recent	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
cytoplasmic	NN	O	B-protein
serine	NN	O	I-protein
kinases	NN	O	I-protein
also	NN	O	O
phosphorylate	NN	O	O
STAT3	NN	O	B-protein
and	NN	O	O
are	NN	O	O
necessary	NN	O	O
for	NN	O	O
maximal	NN	O	O
gene	NN	O	O
activation	NN	O	O
.	NN	O	O

(	NN	O	O
2-Amino-3'-methoxyphenyl	NN	O	O
)	NN	O	O
oxanaphthalen-4-one	NN	O	O
(	NN	O	O
PD	NN	O	O
98059	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
extracellular	NN	O	O
signal-regulated	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
(	NN	O	O
ERK	NN	O	B-protein
)	NN	O	O
activation	NN	O	O
,	NN	O	O
blocked	NN	O	O
the	NN	O	O
serine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
STAT3	NN	O	B-protein
induced	NN	O	O
by	NN	O	O
chemotactic	NN	O	B-protein
factors	NN	O	I-protein
or	NN	O	O
PMA	NN	O	O
.	NN	O	O

Each	NN	O	O
volunteer	NN	O	O
performed	NN	O	O
these	NN	O	O
exercise	NN	O	O
twice	NN	O	O
,	NN	O	O
following	NN	O	O
either	NN	O	O
an	NN	O	O
intravenous	NN	O	O
injection	NN	O	O
of	NN	O	O
phosphocreatine	NN	O	O
(	NN	O	O
PCr	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
placebo	NN	O	O
of	NN	O	O
an	NN	O	O
isotonic	NN	O	O
NaCl	NN	O	O
solution	NN	O	O
.	NN	O	O

After	NN	O	O
exercise	NN	O	O
following	NN	O	O
placebo	NN	O	O
administration	NN	O	O
we	NN	O	O
observed	NN	O	O
increases	NN	O	O
in	NN	O	O
concentrations	NN	O	O
of	NN	O	O
blood	NN	O	O
substrates	NN	O	O
,	NN	O	O
plasma	NN	O	B-protein
adrenocorticotropin	NN	O	I-protein
(	NN	O	O
ACTH	NN	O	B-protein
)	NN	O	O
,	NN	O	O
growth	NN	O	O
hormone	NN	O	O
and	NN	O	O
cortisol	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
lymphocytes	NN	O	B-cell_type
without	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
dissociation	NN	O	O
constant	NN	O	O
.	NN	O	O

-DOCSTART-	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
within	NN	O	O
the	NN	O	O
TCR	NN	O	B-protein
/CD3	NN	O	B-protein
signal	NN	O	O
transduction	NN	O	O
pathway	NN	O	O
both	NN	O	O
PKC	NN	O	B-protein
and	NN	O	O
calcineurin	NN	O	B-protein
are	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
effective	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
IKK	NN	O	B-protein
complex	NN	O	I-protein
and	NN	O	O
NF-kappaB	NN	O	B-protein
in	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
minimal	NN	O	O
promoter	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
B29	NN	O	I-DNA
gene	NN	O	I-DNA
is	NN	O	O
contained	NN	O	O
within	NN	O	O
a	NN	O	O
193-bp	NN	O	B-DNA
region	NN	O	I-DNA
5	NN	O	O
'	NN	O	O
of	NN	O	O
these	NN	O	O
multiple	NN	O	B-DNA
start	NN	O	I-DNA
sites	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
B29	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
is	NN	O	O
controlled	NN	O	O
by	NN	O	O
the	NN	O	O
complex	NN	O	O
interplay	NN	O	O
of	NN	O	O
positive	NN	O	O
and	NN	O	O
negative	NN	O	B-DNA
regulatory	NN	O	I-DNA
elements	NN	O	I-DNA
.	NN	O	O

Possible	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
different	NN	O	O
glucocorticoid	NN	O	O
hormone	NN	O	O
compounds	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
selenium	NN	O	O
,	NN	O	O
an	NN	O	O
integral	NN	O	O
component	NN	O	O
of	NN	O	O
glutathione	NN	O	B-protein
peroxidase	NN	O	I-protein
(	NN	O	O
GPX	NN	O	B-protein
)	NN	O	O
,	NN	O	O
on	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
.	NN	O	O

ROS	NN	O	O
generation	NN	O	O
inhibition	NN	O	O
paralleled	NN	O	O
NF-kappaB	NN	O	B-protein
levels	NN	O	O
in	NN	O	O
the	NN	O	O
nucleus	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
study	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
by	NN	O	O
GC	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
understanding	NN	O	O
of	NN	O	O
LPS-	NN	O	O
and	NN	O	O
TNF-induced	NN	O	O
signaling	NN	O	O
may	NN	O	O
allow	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
specific	NN	O	O
strategies	NN	O	O
to	NN	O	O
treat	NN	O	O
sepsis-associated	NN	O	O
disease	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
accompanied	NN	O	O
by	NN	O	O
opposite	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
changes	NN	O	O
,	NN	O	O
respectively	NN	O	O
opposing	NN	O	O
and	NN	O	O
favoring	NN	O	O
glucocorticoid	NN	O	O
actions	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
32Dcl3	NN	O	B-cell_line
cells	NN	O	I-cell_line
stably	NN	O	O
expressing	NN	O	O
AML1/ETO	NN	O	B-DNA
were	NN	O	O
completely	NN	O	O
resistant	NN	O	O
to	NN	O	O
differentiation	NN	O	O
and	NN	O	O
continued	NN	O	O
to	NN	O	O
grow	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
G-CSF	NN	O	B-protein
.	NN	O	O

Human	NN	O	B-protein
Toll-like	NN	O	I-protein
receptor	NN	O	I-protein
2	NN	O	I-protein
(	NN	O	I-protein
TLR2	NN	O	I-protein
)	NN	O	I-protein
is	NN	O	O
a	NN	O	O
signaling	NN	O	B-protein
receptor	NN	O	I-protein
that	NN	O	O
responds	NN	O	O
to	NN	O	O
LPS	NN	O	O
and	NN	O	O
activates	NN	O	O
NF-kappaB	NN	O	B-protein
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
both	NN	O	O
deletion	NN	O	O
mutants	NN	O	O
could	NN	O	O
still	NN	O	O
form	NN	O	O
complexes	NN	O	O
with	NN	O	O
wild-type	NN	O	B-protein
TLR2	NN	O	I-protein
and	NN	O	O
act	NN	O	O
in	NN	O	O
a	NN	O	O
dominant-negative	NN	O	O
(	NN	O	O
DN	NN	O	O
)	NN	O	O
fashion	NN	O	O
to	NN	O	O
block	NN	O	O
TLR2	NN	O	B-protein
-mediated	NN	O	O
signal	NN	O	O
transduction	NN	O	O
.	NN	O	O

IRF-1	NN	O	B-protein
is	NN	O	O
a	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
regulated	NN	O	O
by	NN	O	O
IFNs	NN	O	B-protein
that	NN	O	O
is	NN	O	O
also	NN	O	O
essential	NN	O	O
for	NN	O	O
Th1	NN	O	B-cell_type
responses	NN	O	O
.	NN	O	O

This	NN	O	O
remodeling	NN	O	O
of	NN	O	O
promoter	NN	O	O
chromatin	NN	O	O
structure	NN	O	O
resulted	NN	O	O
in	NN	O	O
3-fold	NN	O	O
increases	NN	O	O
in	NN	O	O
beta-globin	NN	O	B-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
and	NN	O	O
induction	NN	O	O
,	NN	O	O
and	NN	O	O
inhibited	NN	O	O
long-term	NN	O	O
beta-globin	NN	O	B-DNA
gene	NN	O	I-DNA
silencing	NN	O	O
.	NN	O	O

The	NN	O	O
NF90	NN	O	B-protein
protein	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
expressed	NN	O	O
not	NN	O	O
only	NN	O	O
in	NN	O	O
T-cells	NN	O	B-cell_type
,	NN	O	O
but	NN	O	O
also	NN	O	O
in	NN	O	O
nonimmune	NN	O	B-cell_line
HeLa	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

IL-8	NN	O	B-protein
secretion	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
accumulation	NN	O	O
of	NN	O	O
IL-8	NN	O	B-RNA
mRNA	NN	O	I-RNA
in	NN	O	O
the	NN	O	O
cytosol	NN	O	O
and	NN	O	O
by	NN	O	O
nuclear	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
kappaB	NN	O	B-protein
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
within	NN	O	O
30	NN	O	O
minutes	NN	O	O
.	NN	O	O

In	NN	O	O
chronic	NN	O	O
bronchitis	NN	O	O
,	NN	O	O
few	NN	O	O
cells	NN	O	O
were	NN	O	O
GCRbeta-positive	NN	O	B-cell_type
and	NN	O	O
their	NN	O	O
numbers	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
normal	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

After	NN	O	O
binding	NN	O	O
of	NN	O	O
ligand	NN	O	O
,	NN	O	O
the	NN	O	O
EPOR	NN	O	B-protein
activates	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
that	NN	O	O
ultimately	NN	O	O
control	NN	O	O
cellular	NN	O	O
proliferation	NN	O	O
,	NN	O	O
survival	NN	O	O
,	NN	O	O
and	NN	O	O
specific	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Looking	NN	O	O
back	NN	O	O
at	NN	O	O
successes	NN	O	O
and	NN	O	O
failures	NN	O	O
in	NN	O	O
newer	NN	O	O
approaches	NN	O	O
to	NN	O	O
treating	NN	O	O
IBD	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
tempting	NN	O	O
--	NN	O	O
although	NN	O	O
still	NN	O	O
difficult	NN	O	O
--	NN	O	O
to	NN	O	O
draw	NN	O	O
conclusions	NN	O	O
about	NN	O	O
pathogenesis	NN	O	O
.	NN	O	O

It	NN	O	O
now	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
investigated	NN	O	O
which	NN	O	O
parameters	NN	O	O
determine	NN	O	O
the	NN	O	O
repertoire	NN	O	O
of	NN	O	O
the	NN	O	O
memory	NN	O	O
response	NN	O	O
and	NN	O	O
possibly	NN	O	O
restrict	NN	O	O
its	NN	O	O
diversity	NN	O	O
after	NN	O	O
subsequent	NN	O	O
antigenic	NN	O	O
challenges	NN	O	O
.	NN	O	O

-DOCSTART-	O

Our	NN	O	O
findings	NN	O	O
show	NN	O	O
that	NN	O	O
suppression	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activity	NN	O	O
with	NN	O	O
cell-permeable	NN	O	O
SN50	NN	O	O
peptide	NN	O	O
,	NN	O	O
which	NN	O	O
masks	NN	O	O
the	NN	O	O
nuclear	NN	O	O
localization	NN	O	O
sequence	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B1	NN	O	I-protein
dimers	NN	O	I-protein
and	NN	O	O
prevents	NN	O	O
their	NN	O	O
nuclear	NN	O	O
localization	NN	O	O
,	NN	O	O
induces	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
resting	NN	O	B-cell_type
normal	NN	O	I-cell_type
human	NN	O	I-cell_type
PBL	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
both	NN	O	O
atopic	NN	O	O
and	NN	O	O
nonatopic	NN	O	O
asthma	NN	O	O
,	NN	O	O
elevated	NN	O	O
IL-5	NN	O	B-protein
has	NN	O	O
been	NN	O	O
detected	NN	O	O
in	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
and	NN	O	O
the	NN	O	O
airways	NN	O	O
.	NN	O	O

Defining	NN	O	O
therapeutic	NN	O	O
targets	NN	O	O
by	NN	O	O
using	NN	O	O
adenovirus	NN	O	O
:	NN	O	O
blocking	NN	O	O
NF-kappaB	NN	O	B-protein
inhibits	NN	O	O
both	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
destructive	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
rheumatoid	NN	O	O
synovium	NN	O	O
but	NN	O	O
spares	NN	O	O
anti-inflammatory	NN	O	B-protein
mediators	NN	O	I-protein
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
NF-kappaB	NN	O	B-protein
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
rheumatoid	NN	O	O
arthritis	NN	O	O
has	NN	O	O
long	NN	O	O
been	NN	O	O
a	NN	O	O
subject	NN	O	O
of	NN	O	O
controversy	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
downregulation	NN	O	O
of	NN	O	O
WT1	NN	O	B-DNA
during	NN	O	O
induced	NN	O	O
differentiation	NN	O	O
of	NN	O	O
K562	NN	O	B-cell_line
cells	NN	O	I-cell_line
is	NN	O	O
not	NN	O	O
a	NN	O	O
prerequisite	NN	O	O
for	NN	O	O
erythroid	NN	O	O
or	NN	O	O
megakaryocytic	NN	O	O
differentiation	NN	O	O
of	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

-DOCSTART-	O

Consistent	NN	O	O
with	NN	O	O
its	NN	O	O
Rel/NF-kappaB	NN	O	B-protein
-dependent	NN	O	O
induction	NN	O	O
,	NN	O	O
Jagged1	NN	O	B-protein
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
highly	NN	O	O
expressed	NN	O	O
in	NN	O	O
splenic	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
where	NN	O	O
c-Rel	NN	O	B-protein
is	NN	O	O
expressed	NN	O	O
constitutively	NN	O	O
.	NN	O	O

227.0	NN	O	O
+/-	NN	O	O
90.8	NN	O	O
dpm	NN	O	O
mg-1	NN	O	O
cytosol	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
P	NN	O	O
=	NN	O	O
0.007	NN	O	O
)	NN	O	O
and	NN	O	O
IBD	NN	O	O
patients	NN	O	O
not	NN	O	O
receiving	NN	O	O
glucocorticoid	NN	O	O
treatment	NN	O	O
(	NN	O	O
179.7	NN	O	O
+/-	NN	O	O
171.3	NN	O	O
dpm	NN	O	O
mg-1	NN	O	O
cytosol	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
P	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

ICSAT	NN	O	B-protein
(	NN	O	O
Interferon	NN	O	B-protein
Consensus	NN	O	I-protein
Sequence	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
for	NN	O	I-protein
Activated	NN	O	I-protein
T	NN	O	I-protein
cells	NN	O	I-protein
)	NN	O	O
is	NN	O	O
a	NN	O	O
lymphocyte-specific	NN	O	O
member	NN	O	O
of	NN	O	O
the	NN	O	O
interferon	NN	O	B-protein
regulatory	NN	O	I-protein
factor	NN	O	I-protein
(	NN	O	I-protein
IRF	NN	O	I-protein
)	NN	O	I-protein
family	NN	O	I-protein
of	NN	O	O
transcription	NN	O	O
factors	NN	O	O
,	NN	O	O
originally	NN	O	O
identified	NN	O	O
through	NN	O	O
Southwestern	NN	O	O
screening	NN	O	O
of	NN	O	O
the	NN	O	O
ATL	NN	O	B-DNA
(	NN	O	I-DNA
Adult	NN	O	I-DNA
T-cell	NN	O	I-DNA
leukemia	NN	O	I-DNA
)	NN	O	I-DNA
-16T	NN	O	I-DNA
expression	NN	O	I-DNA
library	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

Here	NN	O	O
we	NN	O	O
document	NN	O	O
that	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Id3	NN	O	B-protein
,	NN	O	O
in	NN	O	O
progenitors	NN	O	B-cell_type
that	NN	O	O
have	NN	O	O
initiated	NN	O	O
TCR	NN	O	B-DNA
gene	NN	O	I-DNA
rearrangements	NN	O	I-DNA
(	NN	O	O
pre-T	NN	O	B-cell_type
cells	NN	O	I-cell_type
)	NN	O	O
,	NN	O	O
inhibits	NN	O	O
development	NN	O	O
into	NN	O	O
TCRalpha	NN	O	B-cell_line
beta	NN	O	I-cell_line
but	NN	O	O
not	NN	O	O
into	NN	O	O
TCRgamma	NN	O	B-cell_line
delta	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
Id3	NN	O	B-protein
impedes	NN	O	O
expression	NN	O	O
of	NN	O	O
recombination	NN	O	O
activating	NN	O	O
genes	NN	O	O
and	NN	O	O
downregulates	NN	O	O
pre-Talpha	NN	O	B-RNA
mRNA	NN	O	I-RNA
.	NN	O	O

Inhibition	NN	O	O
studies	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
select	NN	O	O
the	NN	O	O
monoclonal	NN	O	B-protein
antibodies	NN	O	I-protein
(	NN	O	O
mAECA	NN	O	B-protein
)	NN	O	O
which	NN	O	O
share	NN	O	O
the	NN	O	O
same	NN	O	O
EC	NN	O	O
epitope	NN	O	O
binding	NN	O	O
specificity	NN	O	O
as	NN	O	O
the	NN	O	O
total	NN	O	B-protein
IgG-AECA	NN	O	I-protein
from	NN	O	O
the	NN	O	O
Takayasu	NN	O	O
arteritis	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
4	NN	O	O
mAECA	NN	O	B-protein
induced	NN	O	O
EC	NN	O	O
expression	NN	O	O
of	NN	O	O
adhesion	NN	O	B-protein
molecules	NN	O	I-protein
and	NN	O	O
increased	NN	O	O
adhesion	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_type
monocytic	NN	O	I-cell_type
cells	NN	O	I-cell_type
to	NN	O	O
EC	NN	O	B-cell_type
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
PPARalpha	NN	O	B-protein
activators	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
adhesion	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
to	NN	O	O
cultured	NN	O	B-cell_type
human	NN	O	I-cell_type
ECs	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

USF/c-Myc	NN	O	B-protein
enhances	NN	O	O
,	NN	O	O
while	NN	O	O
Yin-Yang	NN	O	B-protein
1	NN	O	I-protein
suppresses	NN	O	O
,	NN	O	O
the	NN	O	O
promoter	NN	O	O
activity	NN	O	O
of	NN	O	O
CXCR4	NN	O	B-protein
,	NN	O	O
a	NN	O	O
coreceptor	NN	O	B-protein
for	NN	O	O
HIV-1	NN	O	O
entry	NN	O	O
.	NN	O	O

-DOCSTART-	O

Endogenous	NN	O	O
and	NN	O	O
therapeutic	NN	O	O
steroid	NN	O	O
hormones	NN	O	O
affect	NN	O	O
the	NN	O	O
immune	NN	O	O
system	NN	O	O
,	NN	O	O
and	NN	O	O
inflammatory	NN	O	O
diseases	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
hypothalamic-pituitary-adrenal	NN	O	O
axis	NN	O	O
,	NN	O	O
providing	NN	O	O
evidence	NN	O	O
of	NN	O	O
an	NN	O	O
immune-endocrine	NN	O	O
interplay	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
anorexia	NN	O	O
nervosa	NN	O	O
do	NN	O	O
not	NN	O	O
display	NN	O	O
cushingoid	NN	O	O
features	NN	O	O
in	NN	O	O
spite	NN	O	O
of	NN	O	O
elevated	NN	O	O
cortisol	NN	O	O
plasma	NN	O	O
levels	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
differential	NN	O	O
lineage	NN	O	O
requirements	NN	O	O
for	NN	O	O
expression	NN	O	O
within	NN	O	O
the	NN	O	O
HS	NN	O	B-DNA
I	NN	O	I-DNA
element	NN	O	I-DNA
.	NN	O	O

Non-steroidal	NN	O	O
anti-inflammatory	NN	O	O
drugs	NN	O	O
inhibit	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
cytokines	NN	O	B-protein
and	NN	O	O
induce	NN	O	O
HSP70	NN	O	B-protein
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

Immortalization	NN	O	O
of	NN	O	O
CD4	NN	O	B-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
and	NN	O	I-cell_type
CD8	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
by	NN	O	O
human	NN	O	O
T-cell	NN	O	O
leukemia	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
Tax	NN	O	B-protein
mutants	NN	O	I-protein
expressed	NN	O	O
in	NN	O	O
a	NN	O	O
functional	NN	O	B-cell_line
molecular	NN	O	I-cell_line
clone	NN	O	I-cell_line
.	NN	O	O

While	NN	O	O
virus	NN	O	O
derived	NN	O	O
from	NN	O	O
the	NN	O	O
clone	NN	O	O
containing	NN	O	O
the	NN	O	O
M47	NN	O	B-protein
mutation	NN	O	O
retained	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
immortalize	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
,	NN	O	O
the	NN	O	O
M22	NN	O	B-protein
mutant	NN	O	O
lost	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
immortalize	NN	O	O
infected	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

3-deazaadenosine	NN	O	O
,	NN	O	O
a	NN	O	O
S-adenosylhomocysteine	NN	O	B-protein
hydrolase	NN	O	I-protein
inhibitor	NN	O	O
,	NN	O	O
has	NN	O	O
dual	NN	O	O
effects	NN	O	O
on	NN	O	O
NF-kappaB	NN	O	B-protein
regulation	NN	O	O
.	NN	O	O

Similar	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
after	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
cytochalasin	NN	O	O
D	NN	O	O
.	NN	O	O

-DOCSTART-	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
characterized	NN	O	O
the	NN	O	O
CD28	NN	O	B-protein
augmentation	NN	O	O
of	NN	O	O
TCR	NN	O	B-protein
-mediated	NN	O	O
signaling	NN	O	O
in	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
through	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
an	NN	O	O
IL-2	NN	O	B-protein
promoter	NN	O	O
CD28	NN	O	B-DNA
response	NN	O	I-DNA
element	NN	O	I-DNA
(	NN	O	O
CD28RE	NN	O	B-DNA
)	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
enhanced	NN	O	O
mRNA	NN	O	O
stability	NN	O	O
.	NN	O	O

-DOCSTART-	O

Apoptosis	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
cell	NN	O	O
morphology	NN	O	O
,	NN	O	O
flow	NN	O	O
cytometry	NN	O	O
,	NN	O	O
annexin	NN	O	O
V	NN	O	O
protein	NN	O	O
level	NN	O	O
,	NN	O	O
and	NN	O	O
terminal	NN	O	B-protein
deoxynucleotidyl	NN	O	I-protein
transferase	NN	O	I-protein
labeling	NN	O	O
of	NN	O	O
DNA	NN	O	B-DNA
fragments	NN	O	I-DNA
.	NN	O	O

Caspase-3	NN	O	B-protein
activation	NN	O	O
,	NN	O	O
usually	NN	O	O
resulting	NN	O	O
from	NN	O	O
delta	NN	O	O
psi	NN	O	O
(	NN	O	O
m	NN	O	O
)	NN	O	O
collapse	NN	O	O
,	NN	O	O
was	NN	O	O
not	NN	O	O
always	NN	O	O
associated	NN	O	O
with	NN	O	O
As2O3-induced	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

NF-kappaB	NN	O	B-protein
functions	NN	O	O
as	NN	O	O
both	NN	O	O
a	NN	O	O
proapoptotic	NN	O	B-protein
and	NN	O	I-protein
antiapoptotic	NN	O	I-protein
regulatory	NN	O	I-protein
factor	NN	O	I-protein
within	NN	O	O
a	NN	O	O
single	NN	O	O
cell	NN	O	O
type	NN	O	O
.	NN	O	O

Unicellular-unilineage	NN	O	B-cell_line
erythropoietic	NN	O	I-cell_line
cultures	NN	O	I-cell_line
:	NN	O	O
molecular	NN	O	O
analysis	NN	O	O
of	NN	O	O
regulatory	NN	O	O
gene	NN	O	O
expression	NN	O	O
at	NN	O	O
sibling	NN	O	O
cell	NN	O	O
level	NN	O	O
.	NN	O	O

Of	NN	O	O
86	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
chronic	NN	O	O
MPD	NN	O	O
,	NN	O	O
71	NN	O	O
(	NN	O	O
82	NN	O	O
%	NN	O	O
)	NN	O	O
exhibited	NN	O	O
an	NN	O	O
allele	NN	O	B-DNA
ratio	NN	O	O
greater	NN	O	O
than	NN	O	O
3	NN	O	O
:	NN	O	O
1	NN	O	O
,	NN	O	O
whereas	NN	O	O
only	NN	O	O
10	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
86	NN	O	O
age-matched	NN	O	O
control	NN	O	O
subjects	NN	O	O
showed	NN	O	O
a	NN	O	O
skewed	NN	O	O
XCI	NN	O	O
pattern	NN	O	O
.	NN	O	O

Consistent	NN	O	O
with	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
bcl-xL	NN	O	B-protein
in	NN	O	O
mediating	NN	O	O
GATA-1	NN	O	B-protein
-induced	NN	O	O
erythroid	NN	O	O
cell	NN	O	O
survival	NN	O	O
,	NN	O	O
in	NN	O	O
vitro-differentiated	NN	O	B-cell_line
bcl-xL-/-	NN	O	I-cell_line
embryonic	NN	O	I-cell_line
stem	NN	O	I-cell_line
cells	NN	O	I-cell_line
fail	NN	O	O
to	NN	O	O
generate	NN	O	O
viable	NN	O	O
mature	NN	O	O
definitive	NN	O	O
erythroid	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
a	NN	O	O
phenotype	NN	O	O
resembling	NN	O	O
that	NN	O	O
of	NN	O	O
GATA-1	NN	O	B-DNA
gene	NN	O	I-DNA
disruption	NN	O	O
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

Our	NN	O	O
results	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
growth-regulated	NN	O	O
expression	NN	O	O
of	NN	O	O
mammalian	NN	O	B-DNA
MCM5	NN	O	I-DNA
and	NN	O	I-DNA
MCM6	NN	O	I-DNA
genes	NN	O	I-DNA
,	NN	O	O
and	NN	O	O
presumably	NN	O	O
other	NN	O	O
MCM	NN	O	O
members	NN	O	O
,	NN	O	O
is	NN	O	O
primarily	NN	O	O
regulated	NN	O	O
by	NN	O	O
E2F	NN	O	B-protein
through	NN	O	O
binding	NN	O	O
to	NN	O	O
multiple	NN	O	B-DNA
E2F	NN	O	I-DNA
sites	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
promoters	NN	O	B-DNA
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
alpha	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
mediator	NN	O	O
of	NN	O	O
septic	NN	O	O
shock	NN	O	O
.	NN	O	O

NF-kappaB	NN	O	B-protein
DNA	NN	O	O
binding	NN	O	O
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assay	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
LPS-induced	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
and	NN	O	O
TNF-alpha	NN	O	B-protein
release	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
are	NN	O	O
independent	NN	O	O
of	NN	O	O
PKC	NN	O	B-protein
activity	NN	O	O
.	NN	O	O

A	NN	O	O
human	NN	O	B-DNA
IFNGR1	NN	O	I-DNA
small	NN	O	I-DNA
deletion	NN	O	I-DNA
hotspot	NN	O	I-DNA
associated	NN	O	O
with	NN	O	O
dominant	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
mycobacterial	NN	O	O
infection	NN	O	O
[	NN	O	O
see	NN	O	O
comments	NN	O	O
]	NN	O	O

These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
human	NN	O	B-protein
PCD/DCoH	NN	O	I-protein
is	NN	O	O
not	NN	O	O
only	NN	O	O
present	NN	O	O
in	NN	O	O
cells	NN	O	O
where	NN	O	O
tetrahydrobiopterin	NN	O	B-protein
is	NN	O	O
synthesized	NN	O	O
or	NN	O	O
HNF1	NN	O	B-protein
is	NN	O	O
present	NN	O	O
but	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
distributed	NN	O	O
protein	NN	O	O
.	NN	O	O

Because	NN	O	O
extinction	NN	O	O
of	NN	O	O
IL-12	NN	O	B-protein
signaling	NN	O	O
in	NN	O	O
early	NN	O	O
Th2	NN	O	O
development	NN	O	O
could	NN	O	O
potentially	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
imprinting	NN	O	O
a	NN	O	O
more	NN	O	O
permanent	NN	O	O
Th2	NN	O	O
phenotype	NN	O	O
on	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
we	NN	O	O
have	NN	O	O
also	NN	O	O
examined	NN	O	O
various	NN	O	O
parameters	NN	O	O
regulating	NN	O	O
the	NN	O	O
IL-12	NN	O	B-protein
signaling	NN	O	O
pathway	NN	O	O
.	NN	O	O

Whereas	NN	O	O
IL-4	NN	O	B-protein
appears	NN	O	O
to	NN	O	O
repress	NN	O	O
functional	NN	O	O
IL-12	NN	O	B-protein
signaling	NN	O	O
through	NN	O	O
inhibition	NN	O	O
of	NN	O	O
IL-12R	NN	O	B-protein
beta	NN	O	I-protein
2	NN	O	I-protein
expression	NN	O	O
,	NN	O	O
IFN-gamma	NN	O	B-protein
in	NN	O	O
the	NN	O	O
mouse	NN	O	O
,	NN	O	O
and	NN	O	O
IFN-alpha	NN	O	B-protein
in	NN	O	O
the	NN	O	O
human	NN	O	O
appear	NN	O	O
to	NN	O	O
induce	NN	O	O
IL-12R	NN	O	B-protein
beta	NN	O	I-protein
2	NN	O	I-protein
expression	NN	O	O
and	NN	O	O
promote	NN	O	O
IL-12	NN	O	B-protein
responsiveness	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
whether	NN	O	O
E2	NN	O	O
and	NN	O	O
Prog	NN	O	O
could	NN	O	O
interfere	NN	O	O
with	NN	O	O
TNF-alpha	NN	O	B-protein
-induced	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
the	NN	O	O
monoblastoid	NN	O	B-cell_line
U937	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
3-carboranyl-substituted	NN	O	O
compounds	NN	O	O
(	NN	O	O
8	NN	O	O
,	NN	O	O
12	NN	O	O
)	NN	O	O
showed	NN	O	O
potential	NN	O	O
agonistic	NN	O	O
activity	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
antagonistic	NN	O	O
activity	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
to	NN	O	O
produce	NN	O	O
cytokines	NN	O	B-protein
is	NN	O	O
regulated	NN	O	O
by	NN	O	O
the	NN	O	O
counterbalance	NN	O	O
of	NN	O	O
protein-tyrosine	NN	O	B-protein
kinases	NN	O	I-protein
and	NN	O	O
protein-tyrosine	NN	O	O
phosphatases	NN	O	O
,	NN	O	O
many	NN	O	O
of	NN	O	O
which	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
degree	NN	O	O
of	NN	O	O
substrate	NN	O	O
specificity	NN	O	O
because	NN	O	O
of	NN	O	O
physical	NN	O	O
association	NN	O	O
with	NN	O	O
their	NN	O	O
targets	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
show	NN	O	O
that	NN	O	O
DFX	NN	O	O
treatment	NN	O	O
limits	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
,	NN	O	O
a	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
involved	NN	O	O
in	NN	O	O
both	NN	O	O
TNF-alpha	NN	O	B-protein
gene	NN	O	O
transcription	NN	O	O
and	NN	O	O
TNF-alpha	NN	O	B-protein
signalling	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.005	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
proinflammatory	NN	O	B-protein
mediator	NN	O	I-protein
,	NN	O	O
thrombin	NN	O	B-protein
,	NN	O	O
released	NN	O	O
during	NN	O	O
intravascular	NN	O	O
coagulation	NN	O	O
and	NN	O	O
tissue	NN	O	O
injury	NN	O	O
,	NN	O	O
induces	NN	O	O
ICAM-1	NN	O	B-protein
(	NN	O	O
CD54	NN	O	B-protein
)	NN	O	O
expression	NN	O	O
in	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
CyA	NN	O	O
and	NN	O	O
indomethacin	NN	O	O
did	NN	O	O
not	NN	O	O
suppress	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
-induced	NN	O	O
adhesion	NN	O	O
molecule	NN	O	O
expression	NN	O	O
on	NN	O	O
HUVECs	NN	O	B-cell_type
,	NN	O	O
whereas	NN	O	O
aspirin	NN	O	O
had	NN	O	O
an	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
FasL	NN	O	B-protein
versus	NN	O	O
cytokine	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
is	NN	O	O
differentially	NN	O	O
sensitive	NN	O	O
to	NN	O	O
NF-kappaB	NN	O	B-protein
deprivation	NN	O	O
.	NN	O	O

Despite	NN	O	O
this	NN	O	O
drastic	NN	O	O
effect	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
immortalization	NN	O	O
of	NN	O	O
erythropoietin-dependent	NN	O	B-cell_type
erythroid	NN	O	I-cell_type
progenitors	NN	O	I-cell_type
unexpectedly	NN	O	O
occurred	NN	O	O
at	NN	O	O
low	NN	O	O
frequency	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
four	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
established	NN	O	O
expressed	NN	O	O
both	NN	O	O
erythrocytic	NN	O	B-protein
(	NN	O	I-protein
globins	NN	O	I-protein
)	NN	O	I-protein
and	NN	O	I-protein
megakaryocytic	NN	O	I-protein
markers	NN	O	I-protein
(	NN	O	O
glycoprotein	NN	O	B-protein
IIb	NN	O	I-protein
,	NN	O	O
platelet	NN	O	B-protein
factor	NN	O	I-protein
4	NN	O	I-protein
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
Spi-1	NN	O	B-protein
and	NN	O	O
Fli-1	NN	O	B-protein
transcripts	NN	O	I-protein
at	NN	O	O
permissive	NN	O	O
temperature	NN	O	O
.	NN	O	O

Fludarabine-induced	NN	O	O
immunosuppression	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
inhibition	NN	O	O
of	NN	O	O
STAT1	NN	O	B-protein
signaling	NN	O	O
.	NN	O	O

Spi-C	NN	O	B-protein
was	NN	O	O
encoded	NN	O	O
by	NN	O	O
a	NN	O	O
single-copy	NN	O	B-DNA
gene	NN	O	I-DNA
that	NN	O	O
was	NN	O	O
mapped	NN	O	O
to	NN	O	O
chromosome	NN	O	B-DNA
10	NN	O	I-DNA
,	NN	O	O
region	NN	O	B-DNA
C	NN	O	I-DNA
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
positive	NN	O	O
autoregulation	NN	O	O
is	NN	O	O
a	NN	O	O
necessary	NN	O	O
component	NN	O	O
of	NN	O	O
glucocorticoid-induced	NN	O	O
cell	NN	O	O
death	NN	O	O
,	NN	O	O
a	NN	O	O
wild-type	NN	O	B-DNA
GR	NN	O	I-DNA
gene	NN	O	I-DNA
under	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
a	NN	O	O
tetracycline-regulated	NN	O	B-DNA
promoter	NN	O	I-DNA
was	NN	O	O
stably	NN	O	O
transfected	NN	O	O
into	NN	O	O
glucocorticoid-resistant	NN	O	B-cell_line
cells	NN	O	I-cell_line
lacking	NN	O	O
endogenous	NN	O	O
functional	NN	O	O
receptor	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
MAPk	NN	O	B-protein
kinase	NN	O	I-protein
(	NN	O	O
MKK	NN	O	B-protein
)	NN	O	O
that	NN	O	O
activates	NN	O	O
p38	NN	O	B-protein
MAPk	NN	O	I-protein
in	NN	O	O
response	NN	O	O
to	NN	O	O
LPS	NN	O	O
,	NN	O	O
the	NN	O	O
p38	NN	O	B-protein
MAPk	NN	O	I-protein
isoforms	NN	O	I-protein
that	NN	O	O
are	NN	O	O
activated	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
this	NN	O	O
pathway	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
functional	NN	O	O
responses	NN	O	O
affected	NN	O	O
by	NN	O	O
p38	NN	O	B-protein
MAPk	NN	O	I-protein
activation	NN	O	O
.	NN	O	O

The	NN	O	O
I	NN	O	B-protein
gamma	NN	O	I-protein
3	NN	O	I-protein
ECS	NN	O	B-DNA
lies	NN	O	O
upstream	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	B-DNA
I	NN	O	I-DNA
gamma	NN	O	I-DNA
3	NN	O	I-DNA
transcription	NN	O	I-DNA
initiation	NN	O	I-DNA
site	NN	O	I-DNA
and	NN	O	O
displays	NN	O	O
more	NN	O	O
than	NN	O	O
90	NN	O	O
%	NN	O	O
identity	NN	O	O
with	NN	O	O
the	NN	O	O
corresponding	NN	O	O
human	NN	O	B-DNA
I	NN	O	I-DNA
gamma	NN	O	I-DNA
1	NN	O	I-DNA
,	NN	O	O
I	NN	O	B-DNA
gamma	NN	O	I-DNA
2	NN	O	I-DNA
,	NN	O	O
and	NN	O	O
I	NN	O	B-DNA
gamma	NN	O	I-DNA
4	NN	O	I-DNA
regions	NN	O	O
.	NN	O	O

These	NN	O	O
partially	NN	O	O
overlapping	NN	O	O
CD40L	NN	O	B-DNA
and	NN	O	I-DNA
IL-4	NN	O	I-DNA
responsive	NN	O	I-DNA
elements	NN	O	I-DNA
are	NN	O	O
functionally	NN	O	O
cooperative	NN	O	O
as	NN	O	O
the	NN	O	O
disruption	NN	O	O
of	NN	O	O
one	NN	O	O
of	NN	O	O
them	NN	O	O
prevents	NN	O	O
synergistic	NN	O	O
promoter	NN	O	O
activation	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
MHC	NN	O	B-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
promoters	NN	O	I-DNA
requires	NN	O	O
binding	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
three	NN	O	O
distinct	NN	O	O
multi-protein	NN	O	B-protein
complexes	NN	O	I-protein
(	NN	O	O
RFX	NN	O	B-protein
,	NN	O	O
X2BP	NN	O	B-protein
and	NN	O	O
NF-Y	NN	O	B-protein
)	NN	O	O
.	NN	O	O

Role	NN	O	O
of	NN	O	O
cellular	NN	O	B-protein
tumor	NN	O	I-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
receptor-associated	NN	O	I-protein
factors	NN	O	I-protein
in	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
and	NN	O	O
lymphocyte	NN	O	B-cell_type
transformation	NN	O	O
by	NN	O	O
herpesvirus	NN	O	O
Saimiri	NN	O	O
STP	NN	O	B-protein
.	NN	O	O

In-vitro	NN	O	O
cleavage	NN	O	O
of	NN	O	O
recombinant	NN	O	B-protein
SP1	NN	O	I-protein
by	NN	O	O
recombinant	NN	O	B-protein
caspase	NN	O	I-protein
3	NN	O	I-protein
(	NN	O	O
CPP32	NN	O	B-protein
)	NN	O	O
or	NN	O	O
caspase	NN	O	B-protein
7	NN	O	I-protein
(	NN	O	O
Mch	NN	O	B-protein
3	NN	O	I-protein
)	NN	O	O
results	NN	O	O
in	NN	O	O
similar	NN	O	O
cleavage	NN	O	O
products	NN	O	O
as	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

The	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
SP1	NN	O	B-protein
cleavage	NN	O	O
during	NN	O	O
anti-IgM-induced	NN	O	O
apoptosis	NN	O	O
is	NN	O	O
paralleled	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
caspase	NN	O	O
activity	NN	O	O
measured	NN	O	O
by	NN	O	O
DEVD-p-nitroanilide	NN	O	O
(	NN	O	O
DEVD-pNA	NN	O	O
)	NN	O	O
cleavage	NN	O	O
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
CD40	NN	O	B-protein
on	NN	O	O
immunogenic	NN	O	O
human	NN	O	O
malignant	NN	O	O
melanomas	NN	O	O
augments	NN	O	O
their	NN	O	O
cytotoxic	NN	O	B-cell_type
T	NN	O	I-cell_type
lymphocyte	NN	O	I-cell_type
-mediated	NN	O	O
lysis	NN	O	O
and	NN	O	O
induces	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

-DOCSTART-	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
reported	NN	O	O
that	NN	O	O
the	NN	O	O
histogenesis	NN	O	O
of	NN	O	O
HD	NN	O	O
of	NN	O	O
the	NN	O	O
general	NN	O	O
population	NN	O	O
may	NN	O	O
be	NN	O	O
assessed	NN	O	O
by	NN	O	O
monitoring	NN	O	O
the	NN	O	O
expression	NN	O	O
pattern	NN	O	O
of	NN	O	O
BCL-6	NN	O	B-protein
,	NN	O	O
a	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
expressed	NN	O	O
in	NN	O	O
germinal	NN	O	B-cell_line
center	NN	O	I-cell_line
(	NN	O	I-cell_line
GC	NN	O	I-cell_line
)	NN	O	I-cell_line
B	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
of	NN	O	O
CD138/syndecan-1	NN	O	B-protein
(	NN	O	O
syn-1	NN	O	B-protein
)	NN	O	O
,	NN	O	O
a	NN	O	O
proteoglycan	NN	O	O
associated	NN	O	O
with	NN	O	O
post-GC	NN	O	O
,	NN	O	O
terminal	NN	O	O
B-cell	NN	O	B-cell_type
differentiation	NN	O	O
.	NN	O	O

The	NN	O	O
immunolabeling	NN	O	O
of	NN	O	O
Rap1	NN	O	B-protein
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.001	NN	O	O
)	NN	O	O
in	NN	O	O
untreated	NN	O	O
euthymic	NN	O	O
,	NN	O	O
depressed	NN	O	O
,	NN	O	O
and	NN	O	O
manic	NN	O	O
patients	NN	O	O
than	NN	O	O
in	NN	O	O
healthy	NN	O	O
persons	NN	O	O
.	NN	O	O

Cytokine	NN	O	B-protein
expression	NN	O	O
by	NN	O	O
immune	NN	O	O
system	NN	O	O
cells	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
immune	NN	O	O
response	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
demonstration	NN	O	O
that	NN	O	O
lithium	NN	O	O
can	NN	O	O
alter	NN	O	O
gene	NN	O	O
expression	NN	O	O
of	NN	O	O
Tcf-responsive	NN	O	B-DNA
genes	NN	O	I-DNA
,	NN	O	O
and	NN	O	O
points	NN	O	O
to	NN	O	O
a	NN	O	O
difference	NN	O	O
in	NN	O	O
regulation	NN	O	O
of	NN	O	O
Wnt	NN	O	O
signaling	NN	O	O
between	NN	O	O
fibroblasts	NN	O	B-cell_type
and	NN	O	O
lymphocytes	NN	O	B-cell_type
.	NN	O	O

We	NN	O	O
describe	NN	O	O
here	NN	O	O
a	NN	O	O
novel	NN	O	O
molecule	NN	O	O
of	NN	O	O
this	NN	O	O
group	NN	O	O
termed	NN	O	O
SIT	NN	O	B-protein
(	NN	O	O
SHP2	NN	O	B-protein
interacting	NN	O	I-protein
transmembrane	NN	O	I-protein
adaptor	NN	O	I-protein
protein	NN	O	I-protein
)	NN	O	O
.	NN	O	O

Freshly	NN	O	O
isolated	NN	O	O
monocytes	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
protein	NN	O	O
phosphatase	NN	O	O
inhibitor	NN	O	O
okadaic	NN	O	O
acid	NN	O	O
secreted	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
IL-6	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
which	NN	O	O
coincided	NN	O	O
with	NN	O	O
enhanced	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
as	NN	O	O
well	NN	O	O
as	NN	O	O
with	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
ERK1/2	NN	O	B-protein
and	NN	O	I-protein
JNK	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

These	NN	O	O
redox	NN	O	O
changes	NN	O	O
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
observed	NN	O	O
with	NN	O	O
anoxia/reoxygenation	NN	O	O
.	NN	O	O

In	NN	O	O
uterine	NN	O	O
decidua	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
29.9	NN	O	O
%	NN	O	O
CD3+	NN	O	B-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
2.2	NN	O	O
%	NN	O	O
of	NN	O	O
CD3+	NN	O	O
were	NN	O	O
CD8+	NN	O	O
)	NN	O	O
,	NN	O	O
51.6	NN	O	O
%	NN	O	O
CD56+	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
18.5	NN	O	O
%	NN	O	O
CD68+	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Fewer	NN	O	O
apoptotic	NN	O	B-cell_type
cell	NN	O	I-cell_type
bodies	NN	O	I-cell_type
were	NN	O	O
present	NN	O	O
in	NN	O	O
ectopic	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Angiotensin	NN	O	B-protein
II	NN	O	I-protein
activates	NN	O	O
the	NN	O	O
proinflammatory	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
nuclear	NN	O	B-protein
factor-kappaB	NN	O	I-protein
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

Dephosphorylation	NN	O	O
of	NN	O	O
4E-BP1	NN	O	B-protein
was	NN	O	O
also	NN	O	O
observed	NN	O	O
when	NN	O	O
U-937	NN	O	B-cell_line
cells	NN	O	I-cell_line
were	NN	O	O
induced	NN	O	O
to	NN	O	O
differentiate	NN	O	O
into	NN	O	O
monocytes/macrophages	NN	O	B-cell_type
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
or	NN	O	O
DMSO	NN	O	O
.	NN	O	O

-DOCSTART-	O

5.	NN	O	O
Neutrophil	NN	O	O
apoptosis	NN	O	O
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
neutrophil	NN	O	O
function	NN	O	O
were	NN	O	O
induced	NN	O	O
at	NN	O	O
lower	NN	O	O
concentrations	NN	O	O
of	NN	O	O
SMX-NHOH	NN	O	O
and	NN	O	O
SMX-NO	NN	O	O
than	NN	O	O
those	NN	O	O
inducing	NN	O	O
loss	NN	O	O
of	NN	O	O
membrane	NN	O	O
viability	NN	O	O
,	NN	O	O
with	NN	O	O
SMX	NN	O	O
having	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
reported	NN	O	O
cases	NN	O	O
of	NN	O	O
angioimmunoblastic	NN	O	O
T-cell	NN	O	O
lymphoma	NN	O	O
(	NN	O	O
AITL	NN	O	O
)	NN	O	O
with	NN	O	O
hyperplastic	NN	O	O
GCs	NN	O	O
(	NN	O	O
AITL/GC	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
observed	NN	O	O
that	NN	O	O
borders	NN	O	O
of	NN	O	O
enlarged	NN	O	O
GCs	NN	O	O
were	NN	O	O
ill	NN	O	O
defined	NN	O	O
,	NN	O	O
with	NN	O	O
features	NN	O	O
suggestive	NN	O	O
of	NN	O	O
an	NN	O	O
outward	NN	O	O
migration	NN	O	O
of	NN	O	O
GC	NN	O	B-cell_type
cells	NN	O	I-cell_type
to	NN	O	O
surrounding	NN	O	O
interfollicular	NN	O	O
zones	NN	O	O
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
nuclear	NN	O	O
localization	NN	O	O
of	NN	O	O
I	NN	O	B-protein
(	NN	O	I-protein
kappa	NN	O	I-protein
)	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	I-protein
alpha	NN	O	I-protein
)	NN	O	I-protein
in	NN	O	O
PBL	NN	O	B-cell_type
by	NN	O	O
different	NN	O	O
techniques	NN	O	O
:	NN	O	O
Western	NN	O	O
blot	NN	O	O
,	NN	O	O
indirect	NN	O	O
immunofluorescence	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
.	NN	O	O

We	NN	O	O
introduce	NN	O	O
a	NN	O	O
new	NN	O	O
experimental	NN	O	O
system	NN	O	O
combining	NN	O	O
adenovirus-mediated	NN	O	O
gene	NN	O	O
transfer	NN	O	O
and	NN	O	O
fetal	NN	O	O
thymic	NN	O	O
organ	NN	O	O
culture	NN	O	O
(	NN	O	O
FTOC	NN	O	O
)	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
relationship	NN	O	O
between	NN	O	O
Ca2+-ATPase	NN	O	B-protein
and	NN	O	O
freely	NN	O	O
exchangeable	NN	O	O
Ca2+	NN	O	O
in	NN	O	O
the	NN	O	O
dense	NN	O	O
tubules	NN	O	O
:	NN	O	O
a	NN	O	O
study	NN	O	O
in	NN	O	O
platelets	NN	O	B-cell_type
from	NN	O	O
women	NN	O	O
.	NN	O	O

The	NN	O	O
FECa2+	NN	O	O
was	NN	O	O
measured	NN	O	O
as	NN	O	O
the	NN	O	O
ionomycin-evoked	NN	O	O
Ca2+	NN	O	O
release	NN	O	O
(	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
thapsigargin	NN	O	O
)	NN	O	O
in	NN	O	O
Ca2+-free	NN	O	O
medium	NN	O	O
.	NN	O	O

Relative	NN	O	O
expressions	NN	O	O
of	NN	O	O
SERCA	NN	O	B-protein
2	NN	O	O
and	NN	O	O
3	NN	O	O
isoforms	NN	O	O
and	NN	O	O
Ras-related	NN	O	B-protein
protein	NN	O	I-protein
(	NN	O	I-protein
Rap	NN	O	I-protein
)	NN	O	I-protein
1	NN	O	I-protein
in	NN	O	O
platelet	NN	O	O
membranes	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
Western	NN	O	O
immunoblots	NN	O	O
.	NN	O	O

We	NN	O	O
utilized	NN	O	O
CoCl2	NN	O	O
as	NN	O	O
a	NN	O	O
mimetic	NN	O	O
molecule	NN	O	O
for	NN	O	O
hypoxia	NN	O	O
to	NN	O	O
study	NN	O	O
cellular	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
role	NN	O	O
and	NN	O	O
involvement	NN	O	O
of	NN	O	O
interleukin-1	NN	O	B-protein
(	NN	O	O
IL-1	NN	O	B-protein
)	NN	O	O
and	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
signal	NN	O	B-protein
transducer	NN	O	I-protein
molecules	NN	O	I-protein
in	NN	O	O
LPS	NN	O	O
signaling	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
dermal	NN	O	I-cell_type
microvessel	NN	O	I-cell_type
endothelial	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
HDMEC	NN	O	B-cell_type
)	NN	O	O
and	NN	O	O
THP-1	NN	O	B-cell_line
monocytic	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
We	NN	O	O
reported	NN	O	O
on	NN	O	O
the	NN	O	O
constitutive	NN	O	O
interferon-gamma	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
IFN-gammaR	NN	O	B-protein
)	NN	O	O
expression	NN	O	O
on	NN	O	O
eosinophils	NN	O	B-cell_type
.	NN	O	O

Gel-shift	NN	O	O
assay	NN	O	O
was	NN	O	O
also	NN	O	O
examined	NN	O	O
to	NN	O	O
show	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
Stat1alpha-DNA	NN	O	B-protein
complexes	NN	O	I-protein
.	NN	O	O

The	NN	O	O
multiple	NN	O	O
biologic	NN	O	O
activities	NN	O	O
of	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
RA	NN	O	O
)	NN	O	O
are	NN	O	O
mediated	NN	O	O
through	NN	O	O
RAR	NN	O	B-protein
and	NN	O	O
retinoid	NN	O	B-protein
X	NN	O	I-protein
receptor	NN	O	I-protein
(	NN	O	I-protein
RXR	NN	O	I-protein
)	NN	O	I-protein
nuclear	NN	O	I-protein
receptors	NN	O	I-protein
that	NN	O	O
interact	NN	O	O
with	NN	O	O
specific	NN	O	O
DNA	NN	O	B-DNA
target	NN	O	I-DNA
sequences	NN	O	I-DNA
as	NN	O	O
heterodimers	NN	O	B-protein
(	NN	O	O
RXR-RAR	NN	O	B-protein
)	NN	O	O
or	NN	O	O
homodimers	NN	O	B-protein
(	NN	O	O
RXR-RXR	NN	O	B-protein
)	NN	O	O
.	NN	O	O

Unexpectedly	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
that	NN	O	O
an	NN	O	O
RXR	NN	O	B-protein
-specific	NN	O	O
,	NN	O	O
rather	NN	O	O
than	NN	O	O
an	NN	O	O
RAR	NN	O	B-protein
-specific	NN	O	O
,	NN	O	O
agonist	NN	O	O
induces	NN	O	O
terminal	NN	O	O
granulocytic	NN	O	O
differentiation	NN	O	O
of	NN	O	O
MPRO	NN	O	B-cell_type
promyelocytes	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
this	NN	O	O
differentiation	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
activation	NN	O	O
of	NN	O	O
DNA	NN	O	B-DNA
response	NN	O	I-DNA
elements	NN	O	I-DNA
corresponding	NN	O	O
to	NN	O	O
RAR-RXR	NN	O	B-protein
heterodimers	NN	O	I-protein
rather	NN	O	O
than	NN	O	O
RXR-RXR	NN	O	B-protein
homodimers	NN	O	I-protein
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
optimal	NN	O	O
activation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
IL-12	NN	O	B-protein
and	NN	O	O
IL-2	NN	O	B-protein
may	NN	O	O
depend	NN	O	O
on	NN	O	O
an	NN	O	O
interaction	NN	O	O
between	NN	O	O
the	NN	O	O
p38	NN	O	B-protein
MAP	NN	O	I-protein
kinase	NN	O	I-protein
and	NN	O	O
Janus	NN	O	B-protein
kinase/STAT	NN	O	I-protein
signaling	NN	O	O
pathways	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2Ralpha	NN	O	B-protein
in	NN	O	O
bronchoalveolar	NN	O	B-cell_type
lavage	NN	O	I-cell_type
(	NN	O	I-cell_type
BAL	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
active	NN	O	O
pulmonary	NN	O	O
tuberculosis	NN	O	O
,	NN	O	O
and	NN	O	O
evaluated	NN	O	O
the	NN	O	O
mechanism	NN	O	O
Mycobacterium	NN	O	O
tuberculosis	NN	O	O
induces	NN	O	O
in	NN	O	O
the	NN	O	O
IL-2Ralpha	NN	O	B-protein
using	NN	O	O
the	NN	O	O
THP-1	NN	O	B-cell_line
mononuclear	NN	O	I-cell_line
phagocyte	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

Functional	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2Ralpha	NN	O	B-protein
on	NN	O	O
mononuclear	NN	O	B-cell_type
phagocytes	NN	O	I-cell_type
in	NN	O	O
M.	NN	O	O
tuberculosis	NN	O	O
infection	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
immunomodulatory	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
host	NN	O	O
response	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
conclude	NN	O	O
that	NN	O	O
common	NN	O	O
polymorphisms	NN	O	O
within	NN	O	O
the	NN	O	O
VDR	NN	O	B-DNA
3'-UTR	NN	O	I-DNA
do	NN	O	O
not	NN	O	O
influence	NN	O	O
message	NN	O	O
stability	NN	O	O
.	NN	O	O

This	NN	O	O
modulation	NN	O	O
of	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
mediated	NN	O	O
through	NN	O	O
the	NN	O	O
dephosphorylation	NN	O	O
of	NN	O	O
DP1	NN	O	B-protein
and	NN	O	O
E2F4	NN	O	B-protein
could	NN	O	O
help	NN	O	O
to	NN	O	O
explain	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
in	NN	O	O
vivo	NN	O	O
DNA	NN	O	O
footprinting	NN	O	O
in	NN	O	O
late	NN	O	O
G1	NN	O	O
and	NN	O	O
S	NN	O	O
phases	NN	O	O
of	NN	O	O
gene	NN	O	B-DNA
promoters	NN	O	I-DNA
negatively	NN	O	O
regulated	NN	O	O
through	NN	O	O
E2F	NN	O	B-DNA
sites	NN	O	I-DNA
and	NN	O	O
suggests	NN	O	O
a	NN	O	O
novel	NN	O	O
mechanism	NN	O	O
for	NN	O	O
controlling	NN	O	O
E2F	NN	O	B-protein
transcriptional	NN	O	O
activity	NN	O	O
during	NN	O	O
the	NN	O	O
transition	NN	O	O
from	NN	O	O
quiescence	NN	O	O
to	NN	O	O
proliferation	NN	O	O
.	NN	O	O

Our	NN	O	O
studies	NN	O	O
thus	NN	O	O
indicate	NN	O	O
that	NN	O	O
,	NN	O	O
despite	NN	O	O
the	NN	O	O
rapidity	NN	O	O
of	NN	O	O
NK	NN	O	O
cell-mediated	NN	O	O
lysis	NN	O	O
,	NN	O	O
AP-1	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
is	NN	O	O
activated	NN	O	O
during	NN	O	O
the	NN	O	O
early	NN	O	O
stage	NN	O	O
of	NN	O	O
NK	NN	O	O
cell	NN	O	O
cytolytic	NN	O	O
programs	NN	O	O
and	NN	O	O
that	NN	O	O
engagement	NN	O	O
of	NN	O	O
NK	NN	O	B-protein
cell	NN	O	I-protein
inhibitory	NN	O	I-protein
receptors	NN	O	I-protein
for	NN	O	O
MHC	NN	O	B-protein
class	NN	O	I-protein
I	NN	O	I-protein
molecules	NN	O	I-protein
impairs	NN	O	O
the	NN	O	O
very	NN	O	O
early	NN	O	O
activation	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
.	NN	O	O

The	NN	O	O
tissue	NN	O	O
from	NN	O	O
both	NN	O	O
patients	NN	O	O
generated	NN	O	O
a	NN	O	O
polyclonal	NN	O	O
pattern	NN	O	O
of	NN	O	O
X	NN	O	B-DNA
chromosome	NN	O	I-DNA
inactivation	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
androgen	NN	O	I-DNA
receptor	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
AML	NN	O	O
,	NN	O	O
chromosomal	NN	O	O
aberrations	NN	O	O
result	NN	O	O
in	NN	O	O
oncoproteins	NN	O	B-protein
such	NN	O	O
as	NN	O	O
AML1/ETO	NN	O	B-protein
,	NN	O	O
PML/RARalpha	NN	O	B-protein
,	NN	O	O
or	NN	O	O
activated	NN	O	B-protein
Ras	NN	O	I-protein
,	NN	O	O
which	NN	O	O
can	NN	O	O
deregulate	NN	O	O
genes	NN	O	O
important	NN	O	O
for	NN	O	O
normal	NN	O	O
myelopoiesis	NN	O	O
.	NN	O	O

Thus	NN	O	O
CTL	NN	O	B-cell_line
clones	NN	O	I-cell_line
that	NN	O	O
recognized	NN	O	O
the	NN	O	O
viral	NN	O	O
,	NN	O	O
self	NN	O	O
,	NN	O	O
and	NN	O	O
bacterial	NN	O	O
peptides	NN	O	O
expressed	NN	O	O
a	NN	O	O
highly	NN	O	O
restricted	NN	O	O
alphabeta	NN	O	O
TCR	NN	O	B-protein
phenotype	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
expression	NN	O	O
of	NN	O	O
FasL	NN	O	B-protein
protein	NN	O	I-protein
and	NN	O	O
mRNA	NN	O	B-RNA
in	NN	O	O
activated	NN	O	B-cell_type
NK	NN	O	I-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
also	NN	O	O
regulated	NN	O	O
by	NN	O	O
redox	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
association	NN	O	O
of	NN	O	O
phosphoinositide	NN	O	B-protein
3-kinase	NN	O	I-protein
with	NN	O	O
CD28	NN	O	B-protein
and	NN	O	O
enhanced	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
phospholipase	NN	O	O
Cgamma	NN	O	O
were	NN	O	O
seen	NN	O	O
after	NN	O	O
anti-CD28	NN	O	O
mAb	NN	O	O
and	NN	O	O
CHO-CD80	NN	O	O
stimulation	NN	O	O
but	NN	O	O
to	NN	O	O
a	NN	O	O
much	NN	O	O
lesser	NN	O	O
extent	NN	O	O
after	NN	O	O
CHO-CD86	NN	O	B-protein
stimulation	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
HMG-I	NN	O	B-protein
(	NN	O	I-protein
Y	NN	O	I-protein
)	NN	O	I-protein
expression	NN	O	O
is	NN	O	O
down-regulated	NN	O	O
during	NN	O	O
differentiation	NN	O	O
of	NN	O	O
primary	NN	O	B-cell_type
erythroid	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
CCAAT-box	NN	O	B-protein
binding	NN	O	I-protein
factor	NN	O	I-protein
NF-Y	NN	O	I-protein
is	NN	O	O
modulated	NN	O	O
through	NN	O	O
the	NN	O	O
regulated	NN	O	O
expression	NN	O	O
of	NN	O	O
its	NN	O	O
A	NN	O	B-protein
subunit	NN	O	I-protein
during	NN	O	O
monocyte	NN	O	O
to	NN	O	O
macrophage	NN	O	O
differentiation	NN	O	O
:	NN	O	O
regulation	NN	O	O
of	NN	O	O
tissue-specific	NN	O	B-DNA
genes	NN	O	I-DNA
through	NN	O	O
a	NN	O	O
ubiquitous	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
.	NN	O	O

Interdomain	NN	O	B-protein
B	NN	O	I-protein
in	NN	O	O
ZAP-70	NN	O	B-protein
regulates	NN	O	O
but	NN	O	O
is	NN	O	O
not	NN	O	O
required	NN	O	O
for	NN	O	O
ZAP-70	NN	O	B-protein
signaling	NN	O	O
function	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
.	NN	O	O

Based	NN	O	O
on	NN	O	O
these	NN	O	O
data	NN	O	O
,	NN	O	O
we	NN	O	O
concluded	NN	O	O
that	NN	O	O
interdomain	NN	O	B-protein
B	NN	O	I-protein
regulates	NN	O	O
but	NN	O	O
is	NN	O	O
not	NN	O	O
required	NN	O	O
for	NN	O	O
ZAP-70	NN	O	B-protein
signaling	NN	O	O
function	NN	O	O
leading	NN	O	O
to	NN	O	O
cellular	NN	O	O
responses	NN	O	O
.	NN	O	O

The	NN	O	O
B	NN	O	B-protein
cell-specific	NN	O	I-protein
cell	NN	O	I-protein
surface	NN	O	I-protein
molecule	NN	O	I-protein
CD19	NN	O	B-protein
is	NN	O	O
expressed	NN	O	O
at	NN	O	O
all	NN	O	O
stages	NN	O	O
of	NN	O	O
B	NN	O	O
cell	NN	O	O
development	NN	O	O
,	NN	O	O
including	NN	O	O
normal	NN	O	O
plasma	NN	O	O
cells	NN	O	O
,	NN	O	O
and	NN	O	O
mediates	NN	O	O
signal	NN	O	O
transduction	NN	O	O
via	NN	O	O
interaction	NN	O	O
with	NN	O	O
cytoplasmic	NN	O	B-protein
effector	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

Binding	NN	O	O
of	NN	O	O
c-Rel	NN	O	B-protein
to	NN	O	O
STAT5	NN	O	B-DNA
target	NN	O	I-DNA
sequences	NN	O	I-DNA
in	NN	O	O
HTLV-I-transformed	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Fas	NN	O	B-protein
(	NN	O	O
CD95	NN	O	B-protein
)	NN	O	O
and	NN	O	O
Fas	NN	O	B-protein
ligand	NN	O	I-protein
(	NN	O	O
CD95L	NN	O	B-protein
)	NN	O	O
are	NN	O	O
an	NN	O	O
interacting	NN	O	O
receptor-ligand	NN	O	O
pair	NN	O	O
required	NN	O	O
for	NN	O	O
immune	NN	O	O
homeostasis	NN	O	O
.	NN	O	O

Although	NN	O	O
resting	NN	O	B-cell_line
Jurkat	NN	O	I-cell_line
cells	NN	O	I-cell_line
express	NN	O	O
Fas	NN	O	B-protein
,	NN	O	O
Fas	NN	O	B-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
induced	NN	O	O
approximately	NN	O	O
10-fold	NN	O	O
in	NN	O	O
2	NN	O	O
h	NN	O	O
upon	NN	O	O
P/I	NN	O	O
stimulation	NN	O	O
.	NN	O	O

Sequence	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
previously	NN	O	O
unrecognized	NN	O	B-DNA
composite	NN	O	I-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
for	NN	O	O
both	NN	O	O
the	NN	O	O
Sp1	NN	O	B-protein
and	NN	O	O
NF-kappaB	NN	O	B-protein
transcription	NN	O	B-protein
factors	NN	O	I-protein
at	NN	O	O
positions	NN	O	B-DNA
-295	NN	O	I-DNA
to	NN	O	I-DNA
-286	NN	O	I-DNA
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
HTLV-I	NN	O	O
basal	NN	O	O
transcription	NN	O	O
and	NN	O	O
expression	NN	O	O
of	NN	O	O
CREB/ATF-1/CREM	NN	O	B-protein
family	NN	O	I-protein
members	NN	O	I-protein
in	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
Jurkat	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
indicated	NN	O	O
that	NN	O	O
inhibition	NN	O	O
of	NN	O	O
GTP-cyclohydrolase	NN	O	B-protein
I	NN	O	I-protein
(	NN	O	O
an	NN	O	O
enzyme	NN	O	O
involved	NN	O	O
in	NN	O	O
de	NN	O	O
novo	NN	O	O
synthesis	NN	O	O
of	NN	O	O
an	NN	O	O
important	NN	O	O
cofactor	NN	O	O
for	NN	O	O
NOS	NN	O	B-protein
activity	NN	O	O
,	NN	O	O
tetrahydrobiopterin	NN	O	O
)	NN	O	O
prevented	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
NO	NN	O	O
in	NN	O	O
A/R-tolerant	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
B29	NN	O	B-DNA
(	NN	O	I-DNA
immunoglobulin	NN	O	I-DNA
beta-chain	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
is	NN	O	O
a	NN	O	O
genetic	NN	O	O
target	NN	O	O
for	NN	O	O
early	NN	O	B-protein
B-cell	NN	O	I-protein
factor	NN	O	I-protein
.	NN	O	O

We	NN	O	O
here	NN	O	O
present	NN	O	O
data	NN	O	O
suggesting	NN	O	O
that	NN	O	O
EBF	NN	O	B-protein
interacts	NN	O	O
with	NN	O	O
three	NN	O	O
independent	NN	O	O
sites	NN	O	O
within	NN	O	O
the	NN	O	O
mouse	NN	O	B-DNA
B29	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Reactive	NN	O	O
oxygen	NN	O	O
intermediate-dependent	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
by	NN	O	O
interleukin-1beta	NN	O	B-protein
requires	NN	O	O
5-lipoxygenase	NN	O	B-protein
or	NN	O	O
NADPH	NN	O	O
oxidase	NN	O	O
activity	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
JunB	NN	O	B-protein
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
other	NN	O	O
Jun	NN	O	B-protein
family	NN	O	I-protein
members	NN	O	I-protein
,	NN	O	O
was	NN	O	O
selectively	NN	O	O
induced	NN	O	O
in	NN	O	O
Th2	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
not	NN	O	O
in	NN	O	O
Th1	NN	O	B-cell_type
cells	NN	O	I-cell_type
during	NN	O	O
differentiation	NN	O	O
.	NN	O	O

In	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
,	NN	O	O
elevated	NN	O	O
JunB	NN	O	B-protein
levels	NN	O	O
caused	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
several	NN	O	O
Th2	NN	O	B-protein
cytokines	NN	O	I-protein
in	NN	O	O
developing	NN	O	O
Th1	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Human	NN	O	O
T-cell	NN	O	O
leukemia	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
(	NN	O	O
HTLV-1	NN	O	O
)	NN	O	O
is	NN	O	O
the	NN	O	O
etiologic	NN	O	O
agent	NN	O	O
of	NN	O	O
adult	NN	O	O
T-cell	NN	O	O
leukemia	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
extinguishing	NN	O	O
mechanism	NN	O	O
is	NN	O	O
effective	NN	O	O
very	NN	O	O
early	NN	O	O
after	NN	O	O
fusion	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
extinction	NN	O	O
of	NN	O	O
Ig	NN	O	B-DNA
genes	NN	O	I-DNA
is	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
global	NN	O	O
mechanism	NN	O	O
that	NN	O	O
suppresses	NN	O	O
the	NN	O	O
differentiation	NN	O	O
program	NN	O	O
foreign	NN	O	O
to	NN	O	O
the	NN	O	O
HeLa	NN	O	B-cell_line
phenotype	NN	O	I-cell_line
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
high-level	NN	O	O
IL-4	NN	O	B-protein
production	NN	O	O
in	NN	O	O
atopic	NN	O	B-cell_type
Th2	NN	O	I-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
associated	NN	O	O
with	NN	O	O
selective	NN	O	O
reduction	NN	O	O
of	NN	O	O
suppressive	NN	O	O
NFAT1	NN	O	B-protein
activity	NN	O	O
at	NN	O	O
the	NN	O	O
IL-4	NN	O	B-DNA
P0	NN	O	I-DNA
element	NN	O	I-DNA
and	NN	O	O
that	NN	O	O
some	NN	O	O
patients	NN	O	O
with	NN	O	O
this	NN	O	O
multifactorial	NN	O	O
disease	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
putative	NN	O	O
systemic	NN	O	O
disorder	NN	O	O
at	NN	O	O
this	NN	O	O
level	NN	O	O
.	NN	O	O

The	NN	O	O
prevalent	NN	O	O
complex	NN	O	O
is	NN	O	O
the	NN	O	O
heterodimer	NN	O	B-protein
p50-p65	NN	O	I-protein
.	NN	O	O

The	NN	O	O
human	NN	O	B-protein
glucocorticoid	NN	O	I-protein
receptor	NN	O	I-protein
(	NN	O	O
GR	NN	O	B-protein
)	NN	O	O
is	NN	O	O
expressed	NN	O	O
as	NN	O	O
two	NN	O	O
alternatively	NN	O	O
spliced	NN	O	O
isoforms	NN	O	O
,	NN	O	O
GRalpha	NN	O	B-protein
and	NN	O	O
GRbeta	NN	O	B-protein
.	NN	O	O

Characterization	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
elk-1	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

C-fos	NN	O	B-DNA
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
immediate	NN	O	B-DNA
early	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
signal	NN	O	O
transduction	NN	O	O
systems	NN	O	O
after	NN	O	O
many	NN	O	O
kinds	NN	O	O
of	NN	O	O
stresses	NN	O	O
,	NN	O	O
including	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
.	NN	O	O

Three	NN	O	O
of	NN	O	O
the	NN	O	O
27	NN	O	O
patients	NN	O	O
with	NN	O	O
squamous	NN	O	O
cell	NN	O	O
carcinoma	NN	O	O
showed	NN	O	O
slight	NN	O	O
expression	NN	O	O
of	NN	O	O
c-fos	NN	O	O
in	NN	O	O
their	NN	O	O
tumor	NN	O	O
cells	NN	O	O
before	NN	O	O
and/or	NN	O	O
at	NN	O	O
4	NN	O	O
or	NN	O	O
10	NN	O	O
Gy	NN	O	O
of	NN	O	O
radiotherapy	NN	O	O
.	NN	O	O

T	NN	O	O
cell	NN	O	O
reactivity	NN	O	O
to	NN	O	O
Sjogren	NN	O	O
's	NN	O	O
syndrome	NN	O	O
related	NN	O	O
antigen	NN	O	O
La	NN	O	B-protein
(	NN	O	I-protein
SSB	NN	O	I-protein
)	NN	O	I-protein
.	NN	O	O

METHODS	NN	O	O
.	NN	O	O

Precursor	NN	O	O
frequency	NN	O	O
of	NN	O	O
anti-SSB	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
was	NN	O	O
1	NN	O	O
:	NN	O	O
77	NN	O	O
,	NN	O	O
040	NN	O	O
and	NN	O	O
1	NN	O	O
:	NN	O	O
115	NN	O	O
,	NN	O	O
000	NN	O	O
in	NN	O	O
2	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
and	NN	O	O
1	NN	O	O
:	NN	O	O
230	NN	O	O
,	NN	O	O
250	NN	O	O
and	NN	O	O
1	NN	O	O
:	NN	O	O
103	NN	O	O
,	NN	O	O
034	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
SS	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
of	NN	O	O
15	NN	O	O
patients	NN	O	O
with	NN	O	O
SS	NN	O	O
and	NN	O	O
4/17	NN	O	O
controls	NN	O	O
were	NN	O	O
HLA-DR3	NN	O	B-protein
positive	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
apparent	NN	O	O
association	NN	O	O
of	NN	O	O
HLA-DR3	NN	O	B-protein
with	NN	O	O
SSB	NN	O	B-protein
reactivity	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

Tuberculosis	NN	O	O
and	NN	O	O
chronic	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
virus	NN	O	O
infection	NN	O	O
in	NN	O	O
Africans	NN	O	O
and	NN	O	O
variation	NN	O	O
in	NN	O	O
the	NN	O	O
vitamin	NN	O	B-DNA
D	NN	O	I-DNA
receptor	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

LysoPC	NN	O	O
may	NN	O	O
thus	NN	O	O
attenuate	NN	O	O
activation	NN	O	O
of	NN	O	O
coagulation	NN	O	O
during	NN	O	O
inflammation	NN	O	O
and	NN	O	O
atherosclerosis	NN	O	O
.	NN	O	O

Chicken	NN	O	O
IL2	NN	O	B-protein
contains	NN	O	O
five	NN	O	O
repeats	NN	O	O
of	NN	O	O
the	NN	O	O
``	NN	O	O
instability	NN	O	O
''	NN	O	O
motif	NN	O	O
ATTTA	NN	O	O
in	NN	O	O
the	NN	O	O
3'untranslated	NN	O	B-DNA
region	NN	O	I-DNA
in	NN	O	O
exon	NN	O	B-DNA
4	NN	O	I-DNA
.	NN	O	O

When	NN	O	O
we	NN	O	O
analyzed	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
STAT	NN	O	B-protein
proteins	NN	O	I-protein
capable	NN	O	O
of	NN	O	O
binding	NN	O	O
to	NN	O	O
IL-2Ralpha	NN	O	B-protein
,	NN	O	O
pim-1	NN	O	B-DNA
,	NN	O	I-DNA
and	NN	O	I-DNA
IRF-1	NN	O	I-DNA
GAS	NN	O	I-DNA
elements	NN	O	I-DNA
after	NN	O	O
cytokine	NN	O	B-protein
stimulation	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
IFN-alpha	NN	O	B-protein
-induced	NN	O	O
binding	NN	O	O
of	NN	O	O
STAT1	NN	O	B-protein
,	NN	O	O
STAT3	NN	O	B-protein
,	NN	O	O
and	NN	O	O
STAT4	NN	O	B-protein
,	NN	O	O
but	NN	O	O
not	NN	O	O
STAT5	NN	O	B-protein
to	NN	O	O
all	NN	O	O
of	NN	O	O
these	NN	O	O
elements	NN	O	O
.	NN	O	O

IFN-alpha	NN	O	B-protein
enhanced	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
STAT1	NN	O	O
,	NN	O	O
STAT3	NN	O	B-protein
,	NN	O	O
STAT4	NN	O	B-protein
,	NN	O	O
STAT5a	NN	O	B-protein
,	NN	O	O
and	NN	O	O
STAT5b	NN	O	B-protein
.	NN	O	O

We	NN	O	O
have	NN	O	O
now	NN	O	O
identified	NN	O	O
a	NN	O	O
229-bp	NN	O	B-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
distal	NN	O	B-DNA
5	NN	O	I-DNA
'	NN	O	I-DNA
flank	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
alpha2	NN	O	B-DNA
integrin	NN	O	I-DNA
gene	NN	O	I-DNA
required	NN	O	O
for	NN	O	O
high-level	NN	O	B-cell_type
enhancer	NN	O	I-cell_type
activity	NN	O	I-cell_type
in	NN	O	I-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
megakaryocytic	NN	O	O
features	NN	O	O
.	NN	O	O

Using	NN	O	O
the	NN	O	O
coiled-coil	NN	O	O
region	NN	O	O
of	NN	O	O
Stat5b	NN	O	B-protein
as	NN	O	O
the	NN	O	O
bait	NN	O	O
in	NN	O	O
a	NN	O	O
yeast	NN	O	O
two-hybrid	NN	O	O
screen	NN	O	O
,	NN	O	O
we	NN	O	O
identified	NN	O	O
the	NN	O	O
association	NN	O	O
of	NN	O	O
Nmi	NN	O	B-protein
,	NN	O	O
a	NN	O	O
protein	NN	O	O
of	NN	O	O
unknown	NN	O	O
function	NN	O	O
previously	NN	O	O
reported	NN	O	O
as	NN	O	O
an	NN	O	O
N-Myc	NN	O	B-protein
interactor	NN	O	O
.	NN	O	O

We	NN	O	O
further	NN	O	O
show	NN	O	O
that	NN	O	O
Nmi	NN	O	B-protein
interacts	NN	O	O
with	NN	O	O
all	NN	O	O
STATs	NN	O	B-protein
except	NN	O	O
Stat2	NN	O	B-protein
.	NN	O	O

TNF	NN	O	B-protein
and	NN	O	O
LPS	NN	O	O
stimulated	NN	O	O
vascular	NN	O	B-protein
cell	NN	O	I-protein
adhesion	NN	O	I-protein
molecule	NN	O	I-protein
(	NN	O	O
VCAM	NN	O	B-protein
)	NN	O	O
-1	NN	O	O
surface	NN	O	O
expression	NN	O	O
and	NN	O	O
adhesion	NN	O	O
of	NN	O	O
U-937	NN	O	B-cell_line
monocyte-like	NN	O	I-cell_line
cells	NN	O	I-cell_line
to	NN	O	O
HUVECs	NN	O	B-cell_type
but	NN	O	O
not	NN	O	O
to	NN	O	O
HUAECs	NN	O	B-cell_type
.	NN	O	O

Using	NN	O	O
the	NN	O	O
wild-type	NN	O	B-protein
or	NN	O	I-protein
mutated	NN	O	I-protein
human	NN	O	I-protein
retinoic	NN	O	I-protein
acid	NN	O	I-protein
receptor	NN	O	I-protein
alpha	NN	O	I-protein
as	NN	O	O
a	NN	O	O
model	NN	O	O
,	NN	O	O
kDa	NN	O	O
values	NN	O	O
determined	NN	O	O
by	NN	O	O
classical	NN	O	O
competition	NN	O	O
binding	NN	O	O
assays	NN	O	O
using	NN	O	O
tritiated	NN	O	O
ligands	NN	O	O
are	NN	O	O
in	NN	O	O
agreement	NN	O	O
with	NN	O	O
those	NN	O	O
measured	NN	O	O
by	NN	O	O
the	NN	O	O
proteolytic	NN	O	O
assay	NN	O	O
.	NN	O	O

To	NN	O	O
assess	NN	O	O
the	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
serine	NN	O	O
residues	NN	O	O
of	NN	O	O
STAT1	NN	O	B-protein
and	NN	O	O
STAT3	NN	O	B-protein
in	NN	O	O
CLL	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
we	NN	O	O
raised	NN	O	O
antibodies	NN	O	O
that	NN	O	O
specifically	NN	O	O
recognize	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
STAT1	NN	O	B-protein
phosphorylated	NN	O	O
on	NN	O	O
ser-727	NN	O	O
and	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
STAT3	NN	O	B-protein
phosphorylated	NN	O	O
on	NN	O	O
ser-727	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Because	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
immunohistochemistry	NN	O	O
in	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
granulosa	NN	O	O
cell	NN	O	O
tumor	NN	O	O
(	NN	O	O
GCT	NN	O	O
)	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
fully	NN	O	O
explored	NN	O	O
,	NN	O	O
routinely	NN	O	O
processed	NN	O	O
(	NN	O	O
formalin-fixed	NN	O	O
,	NN	O	O
paraffin-embedded	NN	O	O
)	NN	O	O
tissue	NN	O	O
from	NN	O	O
11	NN	O	O
GCT	NN	O	O
,	NN	O	O
adult	NN	O	O
type	NN	O	O
,	NN	O	O
was	NN	O	O
investigated	NN	O	O
immunohistochemically	NN	O	O
(	NN	O	O
ABC	NN	O	O
method	NN	O	O
)	NN	O	O
with	NN	O	O
a	NN	O	O
broad	NN	O	O
spectrum	NN	O	O
of	NN	O	O
antibodies	NN	O	O
against	NN	O	O
various	NN	O	O
markers	NN	O	O
,	NN	O	O
including	NN	O	O
p53	NN	O	B-protein
and	NN	O	O
Ki-67	NN	O	B-protein
.	NN	O	O

Clinical	NN	O	O
outcome	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
immunophenotypic	NN	O	O
differences	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
suppress	NN	O	O
IL-1RI	NN	O	O
and	NN	O	O
IL-1RII	NN	O	B-protein
mRNA	NN	O	O
levels	NN	O	O
was	NN	O	O
not	NN	O	O
unique	NN	O	O
to	NN	O	O
IFN-gamma	NN	O	B-protein
because	NN	O	O
IL-10	NN	O	B-protein
also	NN	O	O
inhibited	NN	O	O
expression	NN	O	O
of	NN	O	O
these	NN	O	O
genes	NN	O	O
in	NN	O	O
IL-4/IL-13-stimulated	NN	O	B-cell_line
monocytes	NN	O	I-cell_line
.	NN	O	O

These	NN	O	O
adherent	NN	O	B-cell_type
cells	NN	O	I-cell_type
have	NN	O	O
an	NN	O	O
eccentrically	NN	O	O
placed	NN	O	O
,	NN	O	O
round	NN	O	O
nucleus	NN	O	O
,	NN	O	O
and	NN	O	O
express	NN	O	O
low	NN	O	O
levels	NN	O	O
of	NN	O	O
TRAP	NN	O	B-protein
and	NN	O	O
sodium	NN	O	B-protein
fluoride-resistant-	NN	O	I-protein
alpha-naphthyl-acetate-esterase	NN	O	I-protein
(	NN	O	O
NaF-R-NSE	NN	O	B-protein
)	NN	O	O
.	NN	O	O

When	NN	O	O
cultured	NN	O	O
on	NN	O	O
bone	NN	O	O
,	NN	O	O
VR+	NN	O	B-cell_line
,	NN	O	I-cell_line
TRAP+	NN	O	I-cell_line
cells	NN	O	I-cell_line
of	NN	O	O
low	NN	O	O
multinuclearity	NN	O	O
appear	NN	O	O
and	NN	O	O
cover	NN	O	O
up	NN	O	O
to	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
surface	NN	O	O
.	NN	O	O

Whereas	NN	O	O
the	NN	O	O
signal	NN	O	B-protein
transducer	NN	O	I-protein
and	NN	O	I-protein
activator	NN	O	I-protein
of	NN	O	I-protein
transcription	NN	O	I-protein
3	NN	O	I-protein
(	NN	O	O
Stat3	NN	O	B-protein
)	NN	O	O
was	NN	O	O
phosphorylated	NN	O	O
and	NN	O	O
activated	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
either	NN	O	O
Stat1	NN	O	B-protein
or	NN	O	O
Stat5	NN	O	B-protein
.	NN	O	O

-DOCSTART-	O

It	NN	O	O
was	NN	O	O
previously	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
stimulation	NN	O	O
of	NN	O	O
monocytic	NN	O	O
cells	NN	O	O
with	NN	O	O
either	NN	O	O
LPS	NN	O	O
or	NN	O	O
LAMPf	NN	O	B-protein
led	NN	O	O
to	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
common	NN	O	O
downstream	NN	O	O
signaling	NN	O	O
events	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
tyrosine	NN	O	I-protein
kinase	NN	O	I-protein
and	NN	O	O
of	NN	O	O
mitogen-activated	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
cascades	NN	O	O
.	NN	O	O

C3a	NN	O	B-protein
or	NN	O	O
C3a	NN	O	B-protein
(	NN	O	I-protein
desArg	NN	O	I-protein
)	NN	O	I-protein
alone	NN	O	O
exhibited	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
expression	NN	O	O
or	NN	O	O
secretion	NN	O	O
of	NN	O	O
IL-6	NN	O	B-protein
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
PBMCs	NN	O	B-cell_type
with	NN	O	O
pertussis	NN	O	B-protein
toxin	NN	O	I-protein
blocked	NN	O	O
the	NN	O	O
functions	NN	O	O
of	NN	O	O
C3a	NN	O	B-protein
and	NN	O	O
C3a	NN	O	B-protein
(	NN	O	I-protein
desArg	NN	O	I-protein
)	NN	O	I-protein
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
actions	NN	O	O
of	NN	O	O
these	NN	O	O
two	NN	O	O
molecules	NN	O	O
are	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
G	NN	O	B-protein
protein	NN	O	I-protein
-coupled	NN	O	O
pathway	NN	O	O
.	NN	O	O

Phenylarsine	NN	O	O
oxide	NN	O	O
(	NN	O	O
PAO	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
described	NN	O	O
as	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
tyrosine	NN	O	B-protein
phosphatase	NN	O	I-protein
activity	NN	O	O
,	NN	O	O
inhibits	NN	O	O
H2O2	NN	O	O
release	NN	O	O
from	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
PBMCs	NN	O	B-cell_type
)	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
electrochemistry	NN	O	O
.	NN	O	O

We	NN	O	O
detected	NN	O	O
binding	NN	O	O
for	NN	O	O
the	NN	O	O
EWS/FLI-1	NN	O	O
peptide	NN	O	O
and	NN	O	O
for	NN	O	O
5	NN	O	O
RAS	NN	O	O
peptides	NN	O	O
(	NN	O	O
1	NN	O	O
wild	NN	O	O
type	NN	O	O
and	NN	O	O
4	NN	O	O
mutated	NN	O	O
)	NN	O	O
.	NN	O	O

Cell	NN	O	O
cycle	NN	O	O
progression	NN	O	O
initiated	NN	O	O
by	NN	O	O
interleukin-2	NN	O	B-protein
(	NN	O	O
IL-2	NN	O	B-protein
)	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
critical	NN	O	O
for	NN	O	O
lymphoproliferation	NN	O	O
and	NN	O	O
an	NN	O	O
immune	NN	O	O
response	NN	O	O
.	NN	O	O

Protein	NN	O	B-protein
kinase	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	O
PKB	NN	O	B-protein
)	NN	O	O
is	NN	O	O
activated	NN	O	O
by	NN	O	O
IL-2	NN	O	B-protein
via	NN	O	O
PI3K	NN	O	B-protein
.	NN	O	O

High-level	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
also	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
critical	NN	O	O
component	NN	O	O
of	NN	O	O
long-term	NN	O	O
outgrowth	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
model	NN	O	O
system	NN	O	O
,	NN	O	O
the	NN	O	O
activities	NN	O	O
of	NN	O	O
late	NN	O	B-DNA
promoter-reporter	NN	O	I-DNA
fusions	NN	O	I-DNA
are	NN	O	O
measured	NN	O	O
following	NN	O	O
transient	NN	O	O
transfection	NN	O	O
into	NN	O	O
tissue	NN	O	B-cell_line
culture	NN	O	I-cell_line
cells	NN	O	I-cell_line
expressing	NN	O	O
EBV	NN	O	O
during	NN	O	O
different	NN	O	O
stages	NN	O	O
of	NN	O	O
the	NN	O	O
lytic	NN	O	O
cycle	NN	O	O
.	NN	O	O

In	NN	O	O
competition	NN	O	O
and	NN	O	O
antibody	NN	O	O
supershift	NN	O	O
assays	NN	O	O
in	NN	O	O
EMSA	NN	O	O
,	NN	O	O
complexes	NN	O	O
formed	NN	O	O
with	NN	O	O
P	NN	O	B-DNA
or	NN	O	O
P2	NN	O	B-DNA
proved	NN	O	O
to	NN	O	O
contain	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	I-protein
activated	NN	O	I-protein
T	NN	O	I-protein
cells	NN	O	I-protein
(	NN	O	I-protein
NFAT	NN	O	I-protein
)	NN	O	I-protein
family	NN	O	I-protein
proteins	NN	O	I-protein
as	NN	O	O
major	NN	O	O
components	NN	O	O
.	NN	O	O

Activator	NN	O	B-protein
protein	NN	O	I-protein
(	NN	O	I-protein
AP	NN	O	I-protein
)	NN	O	I-protein
-1	NN	O	I-protein
family	NN	O	I-protein
proteins	NN	O	I-protein
interacted	NN	O	O
with	NN	O	O
CLE0	NN	O	B-DNA
,	NN	O	O
P	NN	O	O
,	NN	O	O
P2	NN	O	B-DNA
and	NN	O	O
P4	NN	O	B-DNA
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
JNK	NN	O	B-protein
activation	NN	O	O
in	NN	O	O
calcineurin-stimulated	NN	O	B-cell_line
cells	NN	O	I-cell_line
caused	NN	O	O
nuclear	NN	O	O
exclusion	NN	O	O
of	NN	O	O
NFAT4	NN	O	B-protein
.	NN	O	O

The	NN	O	O
v-myb	NN	O	B-DNA
oncogene	NN	O	I-DNA
,	NN	O	O
carried	NN	O	O
by	NN	O	O
avian	NN	O	O
defective	NN	O	O
retroviruses	NN	O	O
,	NN	O	O
causes	NN	O	O
leukaemias	NN	O	O
in	NN	O	O
the	NN	O	O
chicken	NN	O	O
and	NN	O	O
transforms	NN	O	O
haematopoietic	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

A-myb	NN	O	B-protein
expression	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
neoplastic	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
representing	NN	O	O
the	NN	O	O
whole	NN	O	O
spectrum	NN	O	O
of	NN	O	O
B	NN	O	O
cell	NN	O	O
differentiation	NN	O	O
.	NN	O	O

With	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
immunohistochemistry	NN	O	O
,	NN	O	O
bcl-6	NN	O	B-protein
protein	NN	O	I-protein
was	NN	O	O
shown	NN	O	O
to	NN	O	O
stain	NN	O	O
intensely	NN	O	O
on	NN	O	O
normal	NN	O	B-cell_line
prickle	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
but	NN	O	O
none	NN	O	O
to	NN	O	O
only	NN	O	O
slightly	NN	O	O
on	NN	O	O
epidermal	NN	O	B-cell_type
basal	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
complex	NN	O	O
on	NN	O	O
the	NN	O	O
proximal	NN	O	B-DNA
site	NN	O	I-DNA
(	NN	O	O
NF	NN	O	B-protein
kappa	NN	O	I-protein
B2	NN	O	I-protein
)	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
composed	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
and	NN	O	O
relB	NN	O	B-protein
.	NN	O	O

Considering	NN	O	O
that	NN	O	O
nuclear	NN	O	B-protein
regulatory	NN	O	I-protein
factor-kappa	NN	O	I-protein
beta	NN	O	I-protein
(	NN	O	B-protein
NF-kappa	NN	O	I-protein
B	NN	O	I-protein
)	NN	O	I-protein
/Rel	NN	O	I-protein
is	NN	O	O
a	NN	O	O
common	NN	O	O
regulatory	NN	O	B-protein
element	NN	O	I-protein
of	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
inflammatory	NN	O	B-DNA
cytokine	NN	O	I-DNA
genes	NN	O	I-DNA
,	NN	O	O
herein	NN	O	O
,	NN	O	O
we	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
acute	NN	O	O
ethanol	NN	O	O
affects	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

Here	NN	O	O
the	NN	O	O
wild	NN	O	B-DNA
type	NN	O	I-DNA
motif	NN	O	I-DNA
gives	NN	O	O
efficient	NN	O	O
binding	NN	O	O
of	NN	O	O
p50p50	NN	O	B-protein
that	NN	O	O
again	NN	O	O
is	NN	O	O
upregulated	NN	O	O
in	NN	O	O
tolerant	NN	O	B-cell_type
cells	NN	O	I-cell_type
whereas	NN	O	O
a	NN	O	O
mutant	NN	O	O
with	NN	O	O
a	NN	O	O
3	NN	O	O
'	NN	O	O
G	NN	O	O
shows	NN	O	O
hardly	NN	O	O
any	NN	O	O
binding	NN	O	O
of	NN	O	O
p50p50	NN	O	B-protein
.	NN	O	O

c-Rel	NN	O	B-protein
and	NN	O	I-protein
p65	NN	O	I-protein
subunits	NN	O	I-protein
bind	NN	O	O
to	NN	O	O
an	NN	O	O
upstream	NN	O	B-DNA
NF-kappaB	NN	O	I-DNA
site	NN	O	I-DNA
in	NN	O	O
human	NN	O	B-DNA
granulocyte	NN	O	I-DNA
macrophage-colony	NN	O	I-DNA
stimulating	NN	O	I-DNA
factor	NN	O	I-DNA
promoter	NN	O	I-DNA
involved	NN	O	O
in	NN	O	O
phorbol	NN	O	O
ester	NN	O	O
response	NN	O	O
in	NN	O	O
5637	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

-DOCSTART-	O

Interactions	NN	O	O
between	NN	O	O
the	NN	O	O
canonical	NN	O	O
and	NN	O	O
unique	NN	O	O
GATA	NN	O	B-DNA
site	NN	O	I-DNA
3	NN	O	I-DNA
and	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
were	NN	O	O
also	NN	O	O
studied	NN	O	O
in	NN	O	O
real	NN	O	O
time	NN	O	O
and	NN	O	O
provided	NN	O	O
information	NN	O	O
on	NN	O	O
its	NN	O	O
association	NN	O	O
and	NN	O	O
dissociation	NN	O	O
rates	NN	O	O
for	NN	O	O
native	NN	O	O
huGATA-3	NN	O	B-protein
.	NN	O	O

Although	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
RA	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
known	NN	O	O
for	NN	O	O
many	NN	O	O
years	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
modulating	NN	O	O
agent	NN	O	O
that	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
generating	NN	O	O
both	NN	O	O
granulocytes	NN	O	B-cell_type
and	NN	O	O
monocytes	NN	O	B-cell_type
,	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanism	NN	O	O
underlying	NN	O	O
this	NN	O	O
role	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
defined	NN	O	O
in	NN	O	O
the	NN	O	O
monoblast	NN	O	B-cell_type
lineage	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
keeping	NN	O	O
with	NN	O	O
this	NN	O	O
finding	NN	O	O
,	NN	O	O
we	NN	O	O
showed	NN	O	O
that	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
the	NN	O	O
rapid	NN	O	O
disappearance	NN	O	O
of	NN	O	O
the	NN	O	O
105	NN	O	O
,	NN	O	O
000-	NN	O	O
to	NN	O	O
110	NN	O	O
,	NN	O	O
000-molecular-weight	NN	O	O
pRB	NN	O	B-protein
forms	NN	O	O
concomitantly	NN	O	O
with	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
a	NN	O	O
smear	NN	O	O
of	NN	O	O
immunoreactive	NN	O	O
products	NN	O	O
with	NN	O	O
a	NN	O	O
molecular	NN	O	O
weight	NN	O	O
of	NN	O	O
greater	NN	O	O
than	NN	O	O
250	NN	O	O
,	NN	O	O
000	NN	O	O
.	NN	O	O

The	NN	O	O
shift	NN	O	O
in	NN	O	O
pRB	NN	O	B-protein
molecular	NN	O	O
weight	NN	O	O
was	NN	O	O
reproduced	NN	O	O
by	NN	O	O
adding	NN	O	O
exogenous	NN	O	O
purified	NN	O	O
tTG	NN	O	O
to	NN	O	O
extracts	NN	O	O
obtained	NN	O	O
from	NN	O	O
viable	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
dansylcadaverine	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
tTG	NN	O	B-protein
,	NN	O	O
acting	NN	O	O
on	NN	O	O
the	NN	O	O
pRB	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
might	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
cell	NN	O	O
progression	NN	O	O
through	NN	O	O
the	NN	O	O
death	NN	O	O
program	NN	O	O
.	NN	O	O

We	NN	O	O
now	NN	O	O
show	NN	O	O
that	NN	O	O
IL-2	NN	O	B-protein
regulation	NN	O	O
of	NN	O	O
STAT3	NN	O	B-protein
proteins	NN	O	I-protein
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
is	NN	O	O
a	NN	O	O
complex	NN	O	O
response	NN	O	O
involving	NN	O	O
activation	NN	O	O
of	NN	O	O
two	NN	O	O
forms	NN	O	O
of	NN	O	O
STAT3	NN	O	B-protein
:	NN	O	O
90-kDa	NN	O	O
STAT3alpha	NN	O	B-protein
and	NN	O	O
an	NN	O	O
83-kDa	NN	O	B-protein
carboxyl-terminal	NN	O	I-protein
truncated	NN	O	I-protein
STAT3beta	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
distinct	NN	O	O
N-terminal	NN	O	B-protein
half	NN	O	I-protein
of	NN	O	O
MZF-2	NN	O	B-protein
carries	NN	O	O
two	NN	O	O
characteristic	NN	O	O
domains	NN	O	O
,	NN	O	O
a	NN	O	O
leucine-rich	NN	O	B-protein
domain	NN	O	I-protein
called	NN	O	O
LeR	NN	O	B-protein
and	NN	O	O
an	NN	O	O
acidic	NN	O	B-protein
domain	NN	O	I-protein
,	NN	O	O
which	NN	O	O
suggests	NN	O	O
a	NN	O	O
unique	NN	O	O
function	NN	O	O
of	NN	O	O
MZF-2	NN	O	B-protein
in	NN	O	O
neutrophil	NN	O	O
development	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
considered	NN	O	O
associations	NN	O	O
of	NN	O	O
these	NN	O	O
variables	NN	O	O
with	NN	O	O
plasma	NN	O	O
renin	NN	O	B-protein
activity	NN	O	O
,	NN	O	O
aldosterone	NN	O	O
,	NN	O	O
cortisol	NN	O	O
,	NN	O	O
corticotropin	NN	O	O
,	NN	O	O
and	NN	O	O
electrolyte	NN	O	O
concentrations	NN	O	O
.	NN	O	O

We	NN	O	O
measured	NN	O	O
plasma	NN	O	O
hormones	NN	O	O
by	NN	O	O
radioimmunoassay	NN	O	O
.	NN	O	O

PU.1/Pip	NN	O	B-protein
and	NN	O	O
basic	NN	O	B-protein
helix	NN	O	I-protein
loop	NN	O	I-protein
helix	NN	O	I-protein
zipper	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
interact	NN	O	O
with	NN	O	O
binding	NN	O	B-DNA
sites	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
CD20	NN	O	B-DNA
promoter	NN	O	I-DNA
to	NN	O	O
help	NN	O	O
confer	NN	O	O
lineage-	NN	O	O
and	NN	O	O
stage-specific	NN	O	O
expression	NN	O	O
of	NN	O	O
CD20	NN	O	B-protein
in	NN	O	O
B	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

Glucocorticoids	NN	O	O
and	NN	O	O
the	NN	O	O
immune	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
infection	NN	O	O
:	NN	O	O
a	NN	O	O
study	NN	O	O
in	NN	O	O
hypercortisolemic	NN	O	O
and	NN	O	O
cortisol-resistant	NN	O	O
patients	NN	O	O
.	NN	O	O

Monochloramine	NN	O	O
derivatives	NN	O	O
are	NN	O	O
long	NN	O	O
lived	NN	O	O
physiological	NN	O	O
oxidants	NN	O	O
produced	NN	O	O
by	NN	O	O
neutrophils	NN	O	B-cell_type
during	NN	O	O
the	NN	O	O
respiratory	NN	O	O
burst	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
CN	NN	O	B-protein
inhibition	NN	O	O
was	NN	O	O
reflected	NN	O	O
by	NN	O	O
a	NN	O	O
similar	NN	O	O
degree	NN	O	O
of	NN	O	O
reduction	NN	O	O
in	NN	O	O
lymphocyte	NN	O	O
proliferation	NN	O	O
and	NN	O	O
IFN-gamma	NN	O	B-protein
production	NN	O	O
in	NN	O	O
the	NN	O	O
allogeneic	NN	O	B-cell_line
mixed	NN	O	I-cell_line
lymphocyte	NN	O	I-cell_line
cultures	NN	O	I-cell_line
.	NN	O	O

While	NN	O	O
we	NN	O	O
can	NN	O	O
not	NN	O	O
exclude	NN	O	O
that	NN	O	O
alterations	NN	O	O
in	NN	O	O
TSG101	NN	O	B-DNA
and	NN	O	O
FHIT	NN	O	B-DNA
occur	NN	O	O
during	NN	O	O
cancer	NN	O	O
development	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
in	NN	O	O
this	NN	O	O
context	NN	O	O
the	NN	O	O
commonly	NN	O	O
observed	NN	O	O
transcript	NN	O	O
abnormalities	NN	O	O
are	NN	O	O
misleading	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
IL-7	NN	O	B-protein
-induced	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
AP-1	NN	O	B-protein
-DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
is	NN	O	O
not	NN	O	O
cyclosporin	NN	O	O
A-sensitive	NN	O	O
.	NN	O	O

Five	NN	O	O
healthy	NN	O	O
human	NN	O	O
leukocyte	NN	O	O
antigen-B8	NN	O	O
(	NN	O	O
HLA-B8	NN	O	O
)	NN	O	O
-positive	NN	O	O
virus	NN	O	O
carriers	NN	O	O
were	NN	O	O
studied	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
CD8+	NN	O	B-cell_type
cytotoxic	NN	O	I-cell_type
T	NN	O	I-cell_type
lymphocyte	NN	O	I-cell_type
(	NN	O	O
CTL	NN	O	O
)	NN	O	O
response	NN	O	O
to	NN	O	O
an	NN	O	O
HLA-B8-restricted	NN	O	O
peptide	NN	O	O
,	NN	O	O
RAKFKQLLQ	NN	O	O
,	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
Epstein-Barr	NN	O	B-protein
virus	NN	O	I-protein
(	NN	O	I-protein
EBV	NN	O	I-protein
)	NN	O	I-protein
immediate-early	NN	O	I-protein
trans-activator	NN	O	I-protein
protein	NN	O	I-protein
,	NN	O	O
BZLF1	NN	O	B-protein
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
Egr-1	NN	O	B-protein
seems	NN	O	O
to	NN	O	O
control	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
downstream	NN	O	B-DNA
target	NN	O	I-DNA
genes	NN	O	I-DNA
not	NN	O	O
only	NN	O	O
as	NN	O	O
a	NN	O	O
transcriptional	NN	O	O
activator	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
as	NN	O	O
a	NN	O	O
repressor	NN	O	B-protein
molecule	NN	O	I-protein
.	NN	O	O

A	NN	O	O
phosphoform	NN	O	O
of	NN	O	O
newly	NN	O	O
synthesized	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
is	NN	O	O
visible	NN	O	O
when	NN	O	O
degradation	NN	O	O
by	NN	O	O
the	NN	O	O
proteasome	NN	O	B-protein
is	NN	O	O
inhibited	NN	O	O
and	NN	O	O
new	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
displays	NN	O	O
the	NN	O	O
same	NN	O	O
properties	NN	O	O
regarding	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
degradation	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
second	NN	O	O
inducer	NN	O	O
.	NN	O	O

Selection	NN	O	O
of	NN	O	O
a	NN	O	O
diverse	NN	O	O
TCR	NN	O	B-protein
repertoire	NN	O	I-protein
in	NN	O	O
response	NN	O	O
to	NN	O	O
an	NN	O	O
Epstein-Barr	NN	O	B-protein
virus-encoded	NN	O	I-protein
transactivator	NN	O	I-protein
protein	NN	O	I-protein
BZLF1	NN	O	B-protein
by	NN	O	O
CD8+	NN	O	B-cell_type
cytotoxic	NN	O	I-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
during	NN	O	O
primary	NN	O	O
and	NN	O	O
persistent	NN	O	O
infection	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
activation	NN	O	O
of	NN	O	O
monocytes	NN	O	B-cell_type
during	NN	O	O
active	NN	O	O
tuberculosis	NN	O	O
and	NN	O	O
by	NN	O	O
M.	NN	O	O
tuberculosis	NN	O	O
.	NN	O	O

Rel/NF-kappa	NN	O	B-protein
B	NN	O	I-protein
is	NN	O	O
a	NN	O	O
ubiquitous	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
that	NN	O	O
consists	NN	O	O
of	NN	O	O
multiple	NN	O	B-protein
polypeptide	NN	O	I-protein
subunits	NN	O	I-protein
,	NN	O	O
and	NN	O	O
is	NN	O	O
subject	NN	O	O
to	NN	O	O
complex	NN	O	O
regulatory	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
involve	NN	O	O
protein-protein	NN	O	O
interactions	NN	O	O
,	NN	O	O
phosphorylation	NN	O	O
,	NN	O	O
ubiquitination	NN	O	O
,	NN	O	O
proteolytic	NN	O	O
degradation	NN	O	O
,	NN	O	O
and	NN	O	O
nucleocytoplasmic	NN	O	O
translocation	NN	O	O
.	NN	O	O

Experiments	NN	O	O
with	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
hybridomas	NN	O	I-cell_line
confirmed	NN	O	O
these	NN	O	O
findings	NN	O	O
and	NN	O	O
suggested	NN	O	O
that	NN	O	O
a	NN	O	O
unique	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
may	NN	O	O
be	NN	O	O
essential	NN	O	O
for	NN	O	O
human	NN	O	O
IL-5	NN	O	B-protein
gene	NN	O	O
transcription	NN	O	O
.	NN	O	O

As	NN	O	O
shown	NN	O	O
by	NN	O	O
reverse	NN	O	O
transcription-polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
and	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assay	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
treatment	NN	O	O
with	NN	O	O
CsA	NN	O	O
leads	NN	O	O
to	NN	O	O
decreased	NN	O	O
TF	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
and	NN	O	O
reduced	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
TF	NN	O	B-DNA
promotor	NN	O	I-DNA
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
both	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
n-acetyl-L-cysteine	NN	O	O
(	NN	O	O
NAC	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
thiol	NN	O	O
antioxidant	NN	O	O
,	NN	O	O
inhibited	NN	O	O
the	NN	O	O
triggering	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	O
expression	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
by	NN	O	O
IL-4	NN	O	B-protein
and	NN	O	O
by	NN	O	O
anti-CD40	NN	O	B-protein
monoclonal	NN	O	I-protein
antibody	NN	O	I-protein
.	NN	O	O

Although	NN	O	O
IL-4	NN	O	B-protein
activated	NN	O	O
signal	NN	O	B-protein
transducers	NN	O	I-protein
and	NN	O	I-protein
activators	NN	O	I-protein
of	NN	O	I-protein
transcription	NN	O	I-protein
(	NN	O	I-protein
STAT	NN	O	I-protein
)	NN	O	I-protein
6	NN	O	I-protein
in	NN	O	O
addition	NN	O	O
to	NN	O	O
NF-kappaB	NN	O	B-protein
,	NN	O	O
NAC	NN	O	O
treatment	NN	O	O
or	NN	O	O
the	NN	O	O
transfection	NN	O	O
of	NN	O	O
decoy	NN	O	O
oligodeoxynucleotides	NN	O	O
for	NN	O	O
NF-kappaB	NN	O	B-protein
or	NN	O	O
STAT6	NN	O	B-protein
only	NN	O	O
partly	NN	O	O
blocked	NN	O	O
IL-4	NN	O	B-protein
-induced	NN	O	O
germline	NN	O	B-DNA
Cepsilon	NN	O	O
transcription	NN	O	O
.	NN	O	O

Early	NN	O	O
studies	NN	O	O
concentrated	NN	O	O
on	NN	O	O
the	NN	O	O
histogenesis	NN	O	O
of	NN	O	O
the	NN	O	O
endometriotic	NN	O	O
lesion	NN	O	O
.	NN	O	O

Dimers	NN	O	O
encoded	NN	O	O
by	NN	O	O
HLA-DR	NN	O	B-protein
haplotypes	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
primary	NN	O	B-DNA
restriction	NN	O	I-DNA
elements	NN	O	I-DNA
for	NN	O	O
lectin-like	NN	O	O
,	NN	O	O
gliadin	NN	O	O
peptides	NN	O	O
while	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
immune	NN	O	O
suppression	NN	O	O
(	NN	O	O
or	NN	O	O
lack	NN	O	O
thereof	NN	O	O
)	NN	O	O
to	NN	O	O
ingested	NN	O	O
gliadins	NN	O	O
is	NN	O	O
governed	NN	O	O
by	NN	O	O
inherited	NN	O	O
HLA-DQ	NN	O	B-DNA
haplotypes	NN	O	O
.	NN	O	O

4.	NN	O	O
When	NN	O	O
apoptotic	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
from	NN	O	O
exposed	NN	O	O
individuals	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
apoptotic	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
from	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
statistically-significant	NN	O	O
differences	NN	O	O
between	NN	O	O
each	NN	O	O
mean	NN	O	O
group	NN	O	O
were	NN	O	O
detected	NN	O	O
(	NN	O	O
26.4	NN	O	O
+/-	NN	O	O
1.8	NN	O	O
and	NN	O	O
12.1	NN	O	O
+/-	NN	O	O
1.3	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
indicating	NN	O	O
an	NN	O	O
increased	NN	O	O
rate	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
80.5	NN	O	O
%	NN	O	O
of	NN	O	O
exposed	NN	O	O
individuals	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.0001	NN	O	O
,	NN	O	O
Mann-Whitney	NN	O	O
U-Test	NN	O	O
)	NN	O	O
.	NN	O	O

MTBE	NN	O	O
and	NN	O	O
benzene-induced	NN	O	O
apoptosis	NN	O	O
is	NN	O	O
attributed	NN	O	O
to	NN	O	O
a	NN	O	O
discrete	NN	O	O
block	NN	O	O
within	NN	O	O
the	NN	O	O
cell	NN	O	O
cycle	NN	O	O
progression	NN	O	O
.	NN	O	O

-DOCSTART-	O

Anti-TNF-alpha	NN	O	B-protein
also	NN	O	O
prevented	NN	O	O
nuclear	NN	O	B-protein
factor-kappa	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
activation	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
good	NN	O	O
correlation	NN	O	O
between	NN	O	O
this	NN	O	O
inhibition	NN	O	O
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
HIV	NN	O	O
replication	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

The	NN	O	O
compound	NN	O	O
induced	NN	O	O
G1	NN	O	O
arrest	NN	O	O
and	NN	O	O
granulocytic	NN	O	O
differentiation	NN	O	O
of	NN	O	O
HL-60	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
although	NN	O	O
the	NN	O	O
differentiation-inducing	NN	O	O
effect	NN	O	O
was	NN	O	O
modest	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Cultured	NN	O	O
bovine	NN	O	O
corneal	NN	O	O
endothelium	NN	O	O
was	NN	O	O
stimulated	NN	O	O
for	NN	O	O
6	NN	O	O
hours	NN	O	O
by	NN	O	O
40	NN	O	O
micron/ml	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
alpha	NN	O	I-protein
(	NN	O	O
TNFalpha	NN	O	B-protein
)	NN	O	O
.	NN	O	O

After	NN	O	O
stimulation	NN	O	O
,	NN	O	O
neutrophils	NN	O	O
separated	NN	O	O
from	NN	O	O
a	NN	O	O
healthy	NN	O	O
human	NN	O	O
volunteer	NN	O	O
were	NN	O	O
added	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
anti-CD18	NN	O	B-protein
antibody	NN	O	I-protein
.	NN	O	O

Immunocytochemistry	NN	O	O
60	NN	O	O
minutes	NN	O	O
after	NN	O	O
stimulation	NN	O	O
revealed	NN	O	O
that	NN	O	O
NFkappaB	NN	O	B-protein
was	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasm	NN	O	O
in	NN	O	O
unstimulated	NN	O	B-cell_type
cells	NN	O	I-cell_type
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
TNFalpha	NN	O	B-protein
caused	NN	O	O
NFkappaB	NN	O	B-protein
to	NN	O	O
translocate	NN	O	O
into	NN	O	O
the	NN	O	O
nucleus	NN	O	O
.	NN	O	O

The	NN	O	O
NGAL	NN	O	B-protein
gene	NN	O	O
is	NN	O	O
highly	NN	O	O
homologous	NN	O	O
to	NN	O	O
the	NN	O	O
mouse	NN	O	B-DNA
gene	NN	O	I-DNA
24p3	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
ability	NN	O	O
of	NN	O	O
BHRF1	NN	O	B-protein
to	NN	O	O
inhibit	NN	O	O
apoptosis	NN	O	O
is	NN	O	O
dependent	NN	O	O
on	NN	O	O
stimulus	NN	O	O
and	NN	O	O
cell	NN	O	O
type	NN	O	O
.	NN	O	O

We	NN	O	O
here	NN	O	O
describe	NN	O	O
the	NN	O	O
genomic	NN	O	O
organisation	NN	O	O
(	NN	O	O
3	NN	O	O
exons	NN	O	B-DNA
of	NN	O	O
132	NN	O	O
,	NN	O	O
112	NN	O	O
and	NN	O	O
542	NN	O	O
bp	NN	O	O
and	NN	O	O
2	NN	O	O
introns	NN	O	B-DNA
of	NN	O	O
1211	NN	O	O
and	NN	O	O
378	NN	O	O
bp	NN	O	O
)	NN	O	O
and	NN	O	O
sequence	NN	O	O
including	NN	O	O
3	NN	O	O
kb	NN	O	O
of	NN	O	O
DNA	NN	O	O
from	NN	O	O
the	NN	O	O
immediate	NN	O	O
5	NN	O	B-DNA
'	NN	O	I-DNA
upstream	NN	O	I-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
eotaxin	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
C/EBP	NN	O	B-DNA
motif	NN	O	I-DNA
is	NN	O	O
bound	NN	O	O
by	NN	O	O
Ig/EBP-1	NN	O	B-protein
in	NN	O	O
pre-B	NN	O	O
cell	NN	O	O
and	NN	O	O
T	NN	O	O
cell	NN	O	O
extracts	NN	O	O
,	NN	O	O
but	NN	O	O
is	NN	O	O
replaced	NN	O	O
by	NN	O	O
nuclear	NN	O	B-protein
factor-IL-6beta	NN	O	I-protein
or	NN	O	O
a	NN	O	O
nuclear	NN	O	B-protein
factor-IL-6beta-Ig/EBP-1	NN	O	I-protein
heterodimer	NN	O	I-protein
in	NN	O	O
plasmacytoma	NN	O	O
cell	NN	O	O
extracts	NN	O	O
.	NN	O	O

Regulation	NN	O	O
of	NN	O	O
B-cell	NN	O	O
commitment	NN	O	O
to	NN	O	O
plasma	NN	O	B-cell_type
cells	NN	O	I-cell_type
or	NN	O	O
to	NN	O	O
memory	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

Overexpression	NN	O	O
of	NN	O	O
HSF2-beta	NN	O	B-protein
inhibits	NN	O	O
hemin	NN	O	B-protein
-induced	NN	O	O
heat	NN	O	O
shock	NN	O	O
gene	NN	O	O
expression	NN	O	O
and	NN	O	O
erythroid	NN	O	O
differentiation	NN	O	O
in	NN	O	O
K562	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
class	NN	O	B-protein
II-specific	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
RFX	NN	O	B-protein
and	NN	O	O
CIITA	NN	O	B-protein
are	NN	O	O
also	NN	O	O
required	NN	O	O
for	NN	O	O
expression	NN	O	O
,	NN	O	O
as	NN	O	O
cell	NN	O	O
lines	NN	O	O
deficient	NN	O	O
in	NN	O	O
these	NN	O	O
factors	NN	O	O
failed	NN	O	O
to	NN	O	O
allow	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
DM	NN	O	B-DNA
promoters	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
DNA	NN	O	O
methylation	NN	O	O
,	NN	O	O
chromatin	NN	O	B-DNA
structure	NN	O	O
,	NN	O	O
and	NN	O	O
transactivation	NN	O	O
at	NN	O	O
an	NN	O	O
Sp1	NN	O	B-DNA
site	NN	O	I-DNA
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
highly	NN	O	O
restricted	NN	O	O
expression	NN	O	O
of	NN	O	O
this	NN	O	O
myelomonocytic	NN	O	B-DNA
lineage	NN	O	I-DNA
specific	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
bufalin	NN	O	O
in	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
was	NN	O	O
significantly	NN	O	O
inhibited	NN	O	O
by	NN	O	O
overexpression	NN	O	O
of	NN	O	O
the	NN	O	O
Bcl-2	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
prolonged	NN	O	O
degradation	NN	O	O
of	NN	O	O
IkappaB-alpha	NN	O	B-protein
and	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
were	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
THP-1	NN	O	B-cell_line
cells	NN	O	I-cell_line
exposed	NN	O	O
to	NN	O	O
anti-E.	NN	O	O
chaffeensis	NN	O	O
serum	NN	O	O
and	NN	O	O
E.	NN	O	O
chaffeensis	NN	O	O
.	NN	O	O

This	NN	O	O
pattern	NN	O	O
of	NN	O	O
STAT	NN	O	B-protein
protein	NN	O	I-protein
phosphorylation	NN	O	O
is	NN	O	O
identical	NN	O	O
to	NN	O	O
IL-10	NN	O	B-protein
receptor	NN	O	I-protein
activation	NN	O	O
on	NN	O	O
normal	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
similar	NN	O	O
to	NN	O	O
IFN-alpha	NN	O	B-protein
(	NN	O	O
STAT1	NN	O	B-protein
and	NN	O	O
STAT3	NN	O	B-protein
)	NN	O	O
and	NN	O	O
IFN-gamma	NN	O	B-protein
(	NN	O	O
STAT1	NN	O	B-protein
)	NN	O	O
receptor	NN	O	O
activation	NN	O	O
in	NN	O	O
CLL	NN	O	B-cell_line
.	NN	O	O

-DOCSTART-	O

Emphasis	NN	O	O
is	NN	O	O
given	NN	O	O
to	NN	O	O
recent	NN	O	O
information	NN	O	O
about	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
prolactin	NN	O	O
receptor	NN	O	O
signal	NN	O	O
transduction	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
signaling	NN	O	B-protein
molecules	NN	O	I-protein
and	NN	O	O
prolactin-inducible	NN	O	B-DNA
target	NN	O	I-DNA
genes	NN	O	I-DNA
that	NN	O	O
participate	NN	O	O
in	NN	O	O
these	NN	O	O
responses	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
represents	NN	O	O
the	NN	O	O
first	NN	O	O
demonstration	NN	O	O
that	NN	O	O
phagocytic	NN	O	O
stimuli	NN	O	O
can	NN	O	O
induce	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
neutrophils	NN	O	I-cell_type
.	NN	O	O

Deletion	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
carboxyl-terminal	NN	O	B-protein
region	NN	O	I-protein
of	NN	O	O
Stat6	NN	O	B-protein
and	NN	O	O
recombination	NN	O	O
of	NN	O	O
this	NN	O	O
region	NN	O	O
with	NN	O	O
a	NN	O	O
heterologous	NN	O	B-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
allowed	NN	O	O
the	NN	O	O
delimitation	NN	O	O
and	NN	O	O
characterization	NN	O	O
of	NN	O	O
the	NN	O	O
transactivation	NN	O	O
domain	NN	O	O
of	NN	O	O
Stat6	NN	O	B-protein
.	NN	O	O

The	NN	O	O
potencies	NN	O	O
of	NN	O	O
the	NN	O	O
transactivation	NN	O	B-protein
domains	NN	O	I-protein
of	NN	O	O
Stat5	NN	O	B-protein
,	NN	O	O
Stat6	NN	O	B-protein
,	NN	O	O
and	NN	O	O
viral	NN	O	B-protein
protein	NN	O	I-protein
VP16	NN	O	I-protein
were	NN	O	O
compared	NN	O	O
.	NN	O	O

ETS1	NN	O	B-protein
is	NN	O	O
a	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	O
the	NN	O	O
ETS	NN	O	B-protein
family	NN	O	I-protein
that	NN	O	O
is	NN	O	O
expressed	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
ETS1	NN	O	B-protein
can	NN	O	O
transactivate	NN	O	O
a	NN	O	O
GM-CSF	NN	O	B-DNA
reporter	NN	O	I-DNA
construct	NN	O	I-DNA
in	NN	O	O
unstimulated	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
providing	NN	O	O
that	NN	O	O
either	NN	O	O
NFkappaB	NN	O	B-protein
or	NN	O	O
AP1	NN	O	B-protein
transcription	NN	O	B-protein
factors	NN	O	I-protein
are	NN	O	O
supplied	NN	O	O
by	NN	O	O
co-transfection	NN	O	O
.	NN	O	O

A	NN	O	O
role	NN	O	O
in	NN	O	O
thymic	NN	O	O
maturation	NN	O	O
for	NN	O	O
factors	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-protein
family	NN	O	I-protein
has	NN	O	O
long	NN	O	O
been	NN	O	O
suspected	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
yet	NN	O	O
proven	NN	O	O
.	NN	O	O

Little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
CD40	NN	O	B-protein
in	NN	O	O
fibroblasts	NN	O	B-cell_type
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
human	NN	O	B-protein
inosine-	NN	O	I-protein
5'-monophosphate	NN	O	I-protein
dehydrogenase	NN	O	I-protein
(	NN	O	I-protein
IMPDH	NN	O	I-protein
)	NN	O	I-protein
type	NN	O	I-protein
II	NN	O	I-protein
,	NN	O	O
an	NN	O	O
enzyme	NN	O	B-protein
catalyzing	NN	O	O
the	NN	O	O
rate-limiting	NN	O	O
step	NN	O	O
in	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
guanine	NN	O	O
nucleotides	NN	O	O
,	NN	O	O
is	NN	O	O
increased	NN	O	O
more	NN	O	O
than	NN	O	O
10-fold	NN	O	O
in	NN	O	O
activated	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
and	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
T	NN	O	O
cell	NN	O	O
activation	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
5'-regulatory	NN	O	B-DNA
sequences	NN	O	I-DNA
that	NN	O	O
are	NN	O	O
important	NN	O	O
for	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
regulation	NN	O	O
of	NN	O	O
this	NN	O	O
gene	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

APLs	NN	O	O
with	NN	O	O
the	NN	O	O
PML-RAR	NN	O	B-protein
alpha	NN	O	I-protein
or	NN	O	O
the	NN	O	O
PLZF-RAR	NN	O	B-protein
alpha	NN	O	I-protein
fusion	NN	O	I-protein
protein	NN	O	I-protein
are	NN	O	O
phenotypically	NN	O	O
indistinguishable	NN	O	O
except	NN	O	O
that	NN	O	O
they	NN	O	O
differ	NN	O	O
in	NN	O	O
their	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
RA	NN	O	O
)	NN	O	O
-induced	NN	O	O
differentiation	NN	O	O
:	NN	O	O
PML-RAR	NN	O	B-protein
alpha	NN	O	I-protein
blasts	NN	O	O
are	NN	O	O
sensitive	NN	O	O
to	NN	O	O
RA	NN	O	O
and	NN	O	O
patients	NN	O	O
enter	NN	O	O
disease	NN	O	O
remission	NN	O	O
after	NN	O	O
RA	NN	O	O
treatment	NN	O	O
,	NN	O	O
while	NN	O	O
patients	NN	O	O
with	NN	O	O
PLZF-RAR	NN	O	B-protein
alpha	NN	O	I-protein
do	NN	O	O
not	NN	O	O
.	NN	O	O

Like	NN	O	O
Drosophila	NN	O	O
Toll	NN	O	B-protein
,	NN	O	O
human	NN	O	B-protein
Toll	NN	O	I-protein
is	NN	O	O
a	NN	O	O
type	NN	O	O
I	NN	O	O
transmembrane	NN	O	O
protein	NN	O	O
with	NN	O	O
an	NN	O	O
extracellular	NN	O	O
domain	NN	O	O
consisting	NN	O	O
of	NN	O	O
a	NN	O	O
leucine-rich	NN	O	B-protein
repeat	NN	O	I-protein
(	NN	O	I-protein
LRR	NN	O	I-protein
)	NN	O	I-protein
domain	NN	O	I-protein
,	NN	O	O
and	NN	O	O
a	NN	O	O
cytoplasmic	NN	O	O
domain	NN	O	O
homologous	NN	O	O
to	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
the	NN	O	O
human	NN	O	B-protein
interleukin	NN	O	I-protein
(	NN	O	I-protein
IL	NN	O	I-protein
)	NN	O	I-protein
-1	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

The	NN	O	O
first	NN	O	O
product	NN	O	O
of	NN	O	O
ascorbate	NN	O	O
oxidation	NN	O	O
,	NN	O	O
the	NN	O	O
ascorbate	NN	O	O
free	NN	O	O
radical	NN	O	O
(	NN	O	O
AFR	NN	O	O
)	NN	O	O
,	NN	O	O
acts	NN	O	O
in	NN	O	O
biological	NN	O	O
systems	NN	O	O
mainly	NN	O	O
as	NN	O	O
an	NN	O	O
oxidant	NN	O	O
,	NN	O	O
and	NN	O	O
through	NN	O	O
its	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
redox	NN	O	O
system	NN	O	O
exerts	NN	O	O
different	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
cell	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
under	NN	O	O
some	NN	O	O
conditions	NN	O	O
,	NN	O	O
engagement	NN	O	O
of	NN	O	O
the	NN	O	O
TCR	NN	O	B-protein
leads	NN	O	O
instead	NN	O	O
to	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

alpha-Tocopheryl	NN	O	O
succinate	NN	O	O
inhibits	NN	O	O
monocytic	NN	O	O
cell	NN	O	O
adhesion	NN	O	O
to	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
suppressing	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
mobilization	NN	O	O
.	NN	O	O

TCP	NN	O	O
succinate	NN	O	O
(	NN	O	O
20	NN	O	O
microM	NN	O	O
,	NN	O	O
72	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
TCP	NN	O	O
(	NN	O	O
200	NN	O	O
microM	NN	O	O
,	NN	O	O
72	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
reduced	NN	O	O
U-937	NN	O	B-cell_line
cell	NN	O	I-cell_line
adhesion	NN	O	O
to	NN	O	O
TNF-alpha-stimulated	NN	O	B-cell_line
(	NN	O	I-cell_line
10	NN	O	I-cell_line
U/ml	NN	O	I-cell_line
,	NN	O	I-cell_line
6	NN	O	I-cell_line
h	NN	O	I-cell_line
)	NN	O	I-cell_line
HUVEC	NN	O	I-cell_line
by	NN	O	O
30	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.025	NN	O	O
)	NN	O	O
and	NN	O	O
to	NN	O	O
IL-1	NN	O	B-cell_line
beta-stimulated	NN	O	I-cell_line
HUVEC	NN	O	I-cell_line
by	NN	O	O
56	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.010	NN	O	O
)	NN	O	O
.	NN	O	O

Gal4-Eed	NN	O	B-protein
fusion	NN	O	I-protein
protein	NN	O	I-protein
represses	NN	O	O
transcription	NN	O	O
of	NN	O	O
a	NN	O	O
reporter	NN	O	O
gene	NN	O	O
driven	NN	O	O
by	NN	O	O
a	NN	O	O
promoter	NN	O	O
that	NN	O	O
contains	NN	O	O
Gal4-binding	NN	O	B-DNA
DNA	NN	O	I-DNA
elements	NN	O	I-DNA
.	NN	O	O

Eed	NN	O	B-protein
also	NN	O	O
represses	NN	O	O
transcription	NN	O	O
when	NN	O	O
recruited	NN	O	O
to	NN	O	O
a	NN	O	O
target	NN	O	O
promoter	NN	O	O
by	NN	O	O
Gal4-K	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

Interferons	NN	O	B-protein
up-regulate	NN	O	O
STAT1	NN	O	B-protein
,	NN	O	O
STAT2	NN	O	B-protein
,	NN	O	O
and	NN	O	O
IRF	NN	O	B-protein
family	NN	O	O
transcription	NN	O	O
factor	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
macrophages	NN	O	B-cell_type
.	NN	O	O

E2a-	NN	O	O
Pbx1	NN	O	B-protein
-induced	NN	O	O
apoptosis	NN	O	O
proceeded	NN	O	O
through	NN	O	O
a	NN	O	O
BCL2	NN	O	B-protein
-responsive	NN	O	O
checkpoint	NN	O	O
eventuating	NN	O	O
in	NN	O	O
PARP	NN	O	B-protein
inactivation	NN	O	O
but	NN	O	O
did	NN	O	O
require	NN	O	O
p53	NN	O	B-protein
.	NN	O	O

C/EBPepsilon	NN	O	B-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
greatly	NN	O	O
induced	NN	O	O
during	NN	O	O
in	NN	O	O
vitro	NN	O	O
granulocytic	NN	O	O
differentiation	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
primary	NN	O	I-cell_type
CD34	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
the	NN	O	O
DNA-binding	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
AP-2	NN	O	B-protein
was	NN	O	O
slightly	NN	O	O
reduced	NN	O	O
by	NN	O	O
TPA	NN	O	B-protein
-induced	NN	O	O
HL-60	NN	O	O
differentiation	NN	O	O
but	NN	O	O
unchanged	NN	O	O
during	NN	O	O
granulocyte	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Introduction	NN	O	O
of	NN	O	O
a	NN	O	O
cDNA	NN	O	O
expression	NN	O	O
library	NN	O	O
prepared	NN	O	O
from	NN	O	O
a	NN	O	O
human	NN	O	B-cell_line
T-cell	NN	O	I-cell_line
line	NN	O	I-cell_line
into	NN	O	O
the	NN	O	O
Oct-2	NN	O	B-protein
-harboring	NN	O	O
tester	NN	O	O
strain	NN	O	O
allowed	NN	O	O
selection	NN	O	O
of	NN	O	O
three	NN	O	O
Lac+clones	NN	O	O
out	NN	O	O
of	NN	O	O
1	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
transformants	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
over-expression	NN	O	O
of	NN	O	O
STAT2	NN	O	B-protein
by	NN	O	O
transfection	NN	O	O
of	NN	O	O
the	NN	O	O
cDNA	NN	O	O
prevented	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
clones	NN	O	I-cell_line
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
IFN-gamma-responsive	NN	O	B-DNA
genes	NN	O	I-DNA
requires	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
factor	NN	O	O
STAT-1alpha	NN	O	B-protein
(	NN	O	O
signal	NN	O	B-protein
transducer	NN	O	I-protein
and	NN	O	I-protein
activator	NN	O	I-protein
of	NN	O	I-protein
transcription-1alpha	NN	O	I-protein
)	NN	O	O
.	NN	O	O

Specific	NN	O	O
complex	NN	O	O
formation	NN	O	O
between	NN	O	O
the	NN	O	O
type	NN	O	B-protein
II	NN	O	I-protein
bare	NN	O	I-protein
lymphocyte	NN	O	I-protein
syndrome-associated	NN	O	I-protein
transactivators	NN	O	I-protein
CIITA	NN	O	B-protein
and	NN	O	O
RFX5	NN	O	B-protein
.	NN	O	O

-DOCSTART-	O

Acute	NN	O	O
leukemia	NN	O	O
with	NN	O	O
promyelocytic	NN	O	O
features	NN	O	O
in	NN	O	O
PML/RARalpha	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
.	NN	O	O

Constitutive	NN	O	O
and	NN	O	O
inducible	NN	O	O
protein/DNA	NN	O	O
interactions	NN	O	O
of	NN	O	O
the	NN	O	O
IFN-gamma	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
vivo	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
all	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
tested	NN	O	O
.	NN	O	O

ZEBRA	NN	O	B-protein
,	NN	O	O
a	NN	O	O
transcriptional	NN	O	O
activator	NN	O	O
,	NN	O	O
initiates	NN	O	O
the	NN	O	O
EBV	NN	O	O
lytic	NN	O	O
cascade	NN	O	O
by	NN	O	O
activating	NN	O	O
viral	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
confirmed	NN	O	O
in	NN	O	O
COS-7	NN	O	O
cells	NN	O	O
transfected	NN	O	O
with	NN	O	O
the	NN	O	O
cDNA	NN	O	O
of	NN	O	O
CCK	NN	O	B-protein
(	NN	O	I-protein
B	NN	O	I-protein
)	NN	O	I-protein
receptor	NN	O	I-protein
cloned	NN	O	O
from	NN	O	O
Jurkat	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

With	NN	O	O
the	NN	O	O
exception	NN	O	O
of	NN	O	O
LEF1	NN	O	B-protein
,	NN	O	O
these	NN	O	O
factors	NN	O	O
activate	NN	O	O
transcription	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
mitogenic	NN	O	O
combination	NN	O	O
of	NN	O	O
anti	NN	O	B-protein
CD2	NN	O	I-protein
+	NN	O	O
anti	NN	O	B-protein
CD28	NN	O	I-protein
released	NN	O	O
the	NN	O	O
footprint	NN	O	O
as	NN	O	O
cells	NN	O	O
were	NN	O	O
committed	NN	O	O
to	NN	O	O
proliferation	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
progression	NN	O	O
to	NN	O	O
subsequent	NN	O	O
events	NN	O	O
which	NN	O	O
comprise	NN	O	O
terminal	NN	O	O
differentiation	NN	O	O
and	NN	O	O
cell	NN	O	O
cycle	NN	O	O
arrest	NN	O	O
is	NN	O	O
halted	NN	O	O
during	NN	O	O
the	NN	O	O
adaptation	NN	O	O
to	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
25D3	NN	O	O
in	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
combined	NN	O	O
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
more	NN	O	O
durable	NN	O	O
inhibition	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
replication	NN	O	O
than	NN	O	O
was	NN	O	O
seen	NN	O	O
with	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
inhibitors	NN	O	O
alone	NN	O	O
or	NN	O	O
the	NN	O	O
anti-	NN	O	O
Tat	NN	O	B-protein
sFv	NN	O	I-protein
intrabodies	NN	O	I-protein
alone	NN	O	O
.	NN	O	O

Together	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
in	NN	O	O
future	NN	O	O
clinical	NN	O	O
gene	NN	O	O
therapy	NN	O	O
trials	NN	O	O
,	NN	O	O
a	NN	O	O
combined	NN	O	O
pharmacologic	NN	O	O
and	NN	O	O
genetic	NN	O	O
strategy	NN	O	O
like	NN	O	O
the	NN	O	O
one	NN	O	O
reported	NN	O	O
here	NN	O	O
may	NN	O	O
improve	NN	O	O
the	NN	O	O
survival	NN	O	O
of	NN	O	O
transduced	NN	O	B-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
prolong	NN	O	O
clinical	NN	O	O
benefit	NN	O	O
.	NN	O	O

-DOCSTART-	O

Thrombin	NN	O	B-protein
activation	NN	O	O
requires	NN	O	O
assembly	NN	O	O
of	NN	O	O
a	NN	O	O
prothrombinase	NN	O	B-protein
complex	NN	O	I-protein
of	NN	O	O
activated	NN	O	O
coagulation	NN	O	B-protein
factors	NN	O	I-protein
on	NN	O	O
an	NN	O	O
anionic	NN	O	O
phospholipid	NN	O	O
surface	NN	O	O
,	NN	O	O
classically	NN	O	O
provided	NN	O	O
by	NN	O	O
activated	NN	O	B-cell_type
platelets	NN	O	I-cell_type
.	NN	O	O

An	NN	O	O
isotype-specific	NN	O	O
activator	NN	O	O
of	NN	O	O
major	NN	O	B-DNA
histocompatibility	NN	O	I-DNA
complex	NN	O	I-DNA
(	NN	O	I-DNA
MHC	NN	O	I-DNA
)	NN	O	I-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
genes	NN	O	I-DNA
that	NN	O	O
is	NN	O	O
independent	NN	O	O
of	NN	O	O
class	NN	O	B-protein
II	NN	O	I-protein
transactivator	NN	O	I-protein
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
that	NN	O	O
ectopic	NN	O	O
expression	NN	O	O
of	NN	O	O
CIITA	NN	O	B-DNA
cDNAs	NN	O	I-DNA
derived	NN	O	O
by	NN	O	O
reverse	NN	O	O
transcriptase	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
from	NN	O	O
clone	NN	O	B-cell_line
13	NN	O	I-cell_line
do	NN	O	O
not	NN	O	O
restore	NN	O	O
expression	NN	O	O
of	NN	O	O
HLA-DQ	NN	O	B-DNA
in	NN	O	O
another	NN	O	O
CIITA-deficient	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	O
RJ2.2.5	NN	O	B-cell_line
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
an	NN	O	O
HLA-DQ	NN	O	B-protein
isotype-specific	NN	O	I-protein
trans-acting	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
which	NN	O	O
functions	NN	O	O
independently	NN	O	O
of	NN	O	O
CIITA	NN	O	B-protein
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
Elf-1	NN	O	B-protein
is	NN	O	O
able	NN	O	O
to	NN	O	O
stimulate	NN	O	O
gene	NN	O	O
transcription	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
lymphocytes	NN	O	B-cell_type
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
footprinting	NN	O	O
identified	NN	O	O
protected	NN	O	O
regions	NN	O	O
over	NN	O	O
the	NN	O	O
known	NN	O	O
high	NN	O	O
affinity	NN	O	O
B	NN	O	B-DNA
cell	NN	O	I-DNA
lineage-specific	NN	O	I-DNA
activator	NN	O	I-DNA
protein	NN	O	I-DNA
(	NN	O	I-DNA
BSAP	NN	O	I-DNA
)	NN	O	I-DNA
site	NN	O	I-DNA
,	NN	O	O
the	NN	O	O
low	NN	O	B-DNA
affinity	NN	O	I-DNA
BSAP	NN	O	I-DNA
site	NN	O	I-DNA
,	NN	O	O
a	NN	O	O
SP1/Egr-1	NN	O	B-DNA
site	NN	O	I-DNA
termed	NN	O	O
the	NN	O	O
CD19	NN	O	B-DNA
GC	NN	O	I-DNA
box	NN	O	I-DNA
,	NN	O	O
and	NN	O	O
two	NN	O	O
novel	NN	O	O
sites	NN	O	O
named	NN	O	O
the	NN	O	O
AT	NN	O	B-DNA
box	NN	O	I-DNA
and	NN	O	O
PyG	NN	O	B-DNA
box	NN	O	I-DNA
.	NN	O	O

However	NN	O	O
,	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
JAK-3	NN	O	B-protein
,	NN	O	O
which	NN	O	O
associates	NN	O	O
with	NN	O	O
gamma	NN	O	B-protein
(	NN	O	I-protein
c	NN	O	I-protein
)	NN	O	I-protein
,	NN	O	O
is	NN	O	O
not	NN	O	O
induced	NN	O	O
by	NN	O	O
SCF	NN	O	B-protein
in	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

Clonal	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
individual	NN	O	O
responses	NN	O	O
to	NN	O	O
the	NN	O	O
two	NN	O	O
immediate	NN	O	B-protein
early	NN	O	I-protein
proteins	NN	O	I-protein
BZLF1	NN	O	B-protein
and	NN	O	O
BRLF1	NN	O	B-protein
,	NN	O	O
and	NN	O	O
to	NN	O	O
three	NN	O	O
(	NN	O	O
BMLF1	NN	O	B-protein
,	NN	O	O
BMRF1	NN	O	B-protein
,	NN	O	O
and	NN	O	O
BALF2	NN	O	B-protein
)	NN	O	O
of	NN	O	O
the	NN	O	O
six	NN	O	O
early	NN	O	B-protein
proteins	NN	O	I-protein
tested	NN	O	O
.	NN	O	O

Secreted	NN	O	O
TNF-alpha	NN	O	B-protein
mediated	NN	O	O
the	NN	O	O
enhancement	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
and	NN	O	O
activator	NN	O	O
protein-1	NN	O	O
(	NN	O	O
AP-1	NN	O	B-protein
)	NN	O	O
binding	NN	O	O
activity	NN	O	O
;	NN	O	O
in	NN	O	O
fact	NN	O	O
,	NN	O	O
the	NN	O	O
triggering	NN	O	O
of	NN	O	O
HLA-DR	NN	O	B-protein
antigens	NN	O	I-protein
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
antihuman	NN	O	B-protein
TNF-alpha-neutralizing	NN	O	I-protein
antibodies	NN	O	I-protein
did	NN	O	O
not	NN	O	O
upregulate	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
AP-1	NN	O	B-protein
.	NN	O	O

During	NN	O	O
the	NN	O	O
differentiation	NN	O	O
of	NN	O	O
naive	NN	O	B-cell_type
CD4	NN	O	I-cell_type
(	NN	O	I-cell_type
+	NN	O	I-cell_type
)	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
isolated	NN	O	O
from	NN	O	O
T	NN	O	O
cell	NN	O	O
receptor	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
,	NN	O	O
GATA-3	NN	O	B-protein
gene	NN	O	O
expression	NN	O	O
was	NN	O	O
up-regulated	NN	O	O
in	NN	O	O
developing	NN	O	O
Th2	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
but	NN	O	O
was	NN	O	O
down-regulated	NN	O	O
in	NN	O	O
Th1	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
antigen-	NN	O	B-cell_type
or	NN	O	I-cell_type
cAMP-activated	NN	O	I-cell_type
Th2	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
but	NN	O	O
not	NN	O	O
Th1	NN	O	B-cell_type
cells	NN	O	I-cell_type
)	NN	O	O
expressed	NN	O	O
the	NN	O	O
GATA-3	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

For	NN	O	O
purposes	NN	O	O
of	NN	O	O
comparison	NN	O	O
,	NN	O	O
microglia	NN	O	B-cell_type
were	NN	O	O
also	NN	O	O
stimulated	NN	O	O
with	NN	O	O
bacterial	NN	O	O
LPS	NN	O	O
,	NN	O	O
a	NN	O	O
known	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
inducer	NN	O	O
.	NN	O	O

Collectively	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
might	NN	O	O
constitute	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
the	NN	O	O
inducible	NN	O	O
expression	NN	O	O
of	NN	O	O
kappa	NN	O	B-DNA
B-dependent	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
microglia	NN	O	B-cell_type
stimulated	NN	O	O
by	NN	O	O
A	NN	O	O
beta	NN	O	O
peptides	NN	O	O
and	NN	O	O
IFN	NN	O	B-protein
gamma	NN	O	I-protein
,	NN	O	O
or	NN	O	O
by	NN	O	O
LPS	NN	O	O
.	NN	O	O

Whereas	NN	O	O
the	NN	O	O
pathway	NN	O	O
responsible	NN	O	O
for	NN	O	O
this	NN	O	O
latter	NN	O	O
role	NN	O	O
is	NN	O	O
yet	NN	O	O
to	NN	O	O
be	NN	O	O
elucidated	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
unlikely	NN	O	O
to	NN	O	O
include	NN	O	O
CREB	NN	O	B-protein
phosphorylation	NN	O	O
.	NN	O	O

Inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
growth	NN	O	O
hormone	NN	O	O
on	NN	O	O
TNF-alpha	NN	O	B-protein
secretion	NN	O	O
and	NN	O	O
nuclear	NN	O	B-protein
factor-kappaB	NN	O	I-protein
translocation	NN	O	O
in	NN	O	O
lipopolysaccharide-stimulated	NN	O	B-cell_type
human	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
FCM	NN	O	O
produced	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
does	NN	O	O
not	NN	O	O
inhibit	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
by	NN	O	O
LPS	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
early	NN	O	O
signaling	NN	O	O
events	NN	O	O
in	NN	O	O
proliferating	NN	O	B-cell_type
and	NN	O	O
terminally	NN	O	B-cell_type
differentiated	NN	O	I-cell_type
cells	NN	O	I-cell_type
following	NN	O	O
G-CSF	NN	O	B-protein
stimulation	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
identical	NN	O	O
signaling	NN	O	O
cascades	NN	O	O
are	NN	O	O
activated	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
detectable	NN	O	O
activation	NN	O	O
in	NN	O	O
neutrophils	NN	O	B-cell_type
of	NN	O	O
the	NN	O	O
recently	NN	O	O
cloned	NN	O	O
Jak3	NN	O	B-protein
kinase	NN	O	I-protein
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
expressed	NN	O	O
at	NN	O	O
high	NN	O	O
levels	NN	O	O
as	NN	O	O
myeloid	NN	O	B-cell_type
cells	NN	O	I-cell_type
undergo	NN	O	O
terminal	NN	O	O
neutrophilic	NN	O	O
maturation	NN	O	O
.	NN	O	O

Our	NN	O	O
laboratory	NN	O	O
has	NN	O	O
shown	NN	O	O
that	NN	O	O
RA	NN	O	O
can	NN	O	O
enhance	NN	O	O
in	NN	O	O
vitro	NN	O	O
polyclonal	NN	O	O
B	NN	O	O
cell	NN	O	O
immunoglobulin	NN	O	B-protein
(	NN	O	O
Ig	NN	O	O
)	NN	O	O
response	NN	O	O
.	NN	O	O

Investigating	NN	O	O
cytokines	NN	O	B-protein
known	NN	O	O
to	NN	O	O
affect	NN	O	O
B	NN	O	O
cell	NN	O	O
differentiation	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
recently	NN	O	O
shown	NN	O	O
that	NN	O	O
IL-6	NN	O	B-protein
production	NN	O	O
is	NN	O	O
augmented	NN	O	O
by	NN	O	O
RA	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
RAR-alpha	NN	O	B-protein
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Cytomegalovirus	NN	O	B-protein
immediate	NN	O	I-protein
early	NN	O	I-protein
gene	NN	O	I-protein
products	NN	O	I-protein
significantly	NN	O	O
enhanced	NN	O	O
expression	NN	O	O
of	NN	O	O
IL-6	NN	O	B-protein
in	NN	O	O
LPS-stimulated	NN	O	O
cells	NN	O	O
.	NN	O	O

Constitutive	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
consisting	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
homodimers	NN	O	I-protein
was	NN	O	O
detected	NN	O	O
in	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
from	NN	O	O
both	NN	O	O
cell	NN	O	O
types	NN	O	O
.	NN	O	O

Nuclear	NN	O	B-protein
Rel-A	NN	O	I-protein
and	NN	O	I-protein
c-Rel	NN	O	I-protein
protein	NN	O	I-protein
complexes	NN	O	I-protein
are	NN	O	O
differentially	NN	O	O
distributed	NN	O	O
within	NN	O	O
human	NN	O	B-cell_type
thymocytes	NN	O	I-cell_type
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
intensity	NN	O	O
of	NN	O	O
p65	NN	O	B-protein
labeling	NN	O	O
was	NN	O	O
much	NN	O	O
higher	NN	O	O
in	NN	O	O
several	NN	O	O
thymocytes	NN	O	B-cell_type
from	NN	O	O
the	NN	O	O
medulla	NN	O	O
.	NN	O	O

ALY	NN	O	B-protein
,	NN	O	O
a	NN	O	O
context-dependent	NN	O	B-protein
coactivator	NN	O	I-protein
of	NN	O	O
LEF-1	NN	O	B-protein
and	NN	O	O
AML-1	NN	O	B-protein
,	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
TCRalpha	NN	O	B-DNA
enhancer	NN	O	I-DNA
function	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
ALY	NN	O	B-protein
mediates	NN	O	O
context-dependent	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
by	NN	O	O
facilitating	NN	O	O
the	NN	O	O
functional	NN	O	O
collaboration	NN	O	O
of	NN	O	O
multiple	NN	O	B-protein
proteins	NN	O	I-protein
in	NN	O	O
the	NN	O	O
TCR	NN	O	B-protein
alpha	NN	O	I-protein
enhancer	NN	O	I-protein
complex	NN	O	I-protein
.	NN	O	O

Identification	NN	O	O
of	NN	O	O
sequence	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
upstream	NN	O	B-DNA
regulatory	NN	O	I-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
estrogen	NN	O	B-DNA
receptor	NN	O	I-DNA
gene	NN	O	I-DNA
in	NN	O	O
an	NN	O	O
ER-negative	NN	O	B-cell_line
breast	NN	O	I-cell_line
cancer	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
anti-allergy	NN	O	O
agent	NN	O	O
azelastine	NN	O	O
hydrochloride	NN	O	O
(	NN	O	O
Azeptin	NN	O	O
)	NN	O	O
on	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
cytokines	NN	O	B-protein
and	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
various	NN	O	O
kinds	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
and	NN	O	I-cell_type
mouse	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
both	NN	O	O
inducible	NN	O	O
nitric	NN	O	B-protein
oxide	NN	O	I-protein
synthase	NN	O	I-protein
-mRNA	NN	O	O
level	NN	O	O
and	NN	O	O
NO	NN	O	O
generation	NN	O	O
in	NN	O	O
mouse	NN	O	B-cell_type
peritoneal	NN	O	I-cell_type
macrophages	NN	O	I-cell_type
were	NN	O	O
suppressed	NN	O	O
by	NN	O	O
10	NN	O	O
(	NN	O	O
-5	NN	O	O
)	NN	O	O
M	NN	O	O
Azeptin	NN	O	O
.	NN	O	O

-DOCSTART-	O

Intimate	NN	O	O
interactions	NN	O	O
between	NN	O	O
multipotential	NN	O	O
hemopoietic	NN	O	B-cell_type
stem	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
their	NN	O	O
microenvironment	NN	O	O
work	NN	O	O
towards	NN	O	O
redefining	NN	O	O
the	NN	O	O
identity	NN	O	O
and	NN	O	O
the	NN	O	O
differentiative	NN	O	O
fate	NN	O	O
of	NN	O	O
these	NN	O	O
primitive	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

NF-kappaB	NN	O	B-protein
nuclear	NN	O	O
activation	NN	O	O
was	NN	O	O
not	NN	O	O
detectable	NN	O	O
before	NN	O	O
1	NN	O	O
h	NN	O	O
after	NN	O	O
cell	NN	O	O
contact	NN	O	O
and	NN	O	O
was	NN	O	O
dependent	NN	O	O
on	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
showing	NN	O	O
that	NN	O	O
GC	NN	O	O
suppressed	NN	O	O
IL-5	NN	O	B-protein
production	NN	O	O
by	NN	O	O
human	NN	O	B-cell_type
CD4+	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
activated	NN	O	O
by	NN	O	O
two	NN	O	O
distinct	NN	O	O
stimuli	NN	O	O
,	NN	O	O
TCR	NN	O	B-protein
and	NN	O	O
IL-2R	NN	O	B-protein
stimulation	NN	O	O
,	NN	O	O
underscore	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
GC	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
allergic	NN	O	O
diseases	NN	O	O
via	NN	O	O
suppression	NN	O	O
of	NN	O	O
T-cell	NN	O	O
IL-5	NN	O	B-protein
synthesis	NN	O	O
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
CD2	NN	O	B-protein
or	NN	O	O
TCR/CD3	NN	O	B-protein
induced	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	I-protein
activated	NN	O	I-protein
T	NN	O	I-protein
cells	NN	O	I-protein
(	NN	O	O
NFAT	NN	O	B-protein
)	NN	O	O
,	NN	O	O
the	NN	O	O
binding	NN	O	B-DNA
site	NN	O	I-DNA
of	NN	O	O
which	NN	O	O
is	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
this	NN	O	O
approach	NN	O	O
was	NN	O	O
tested	NN	O	O
by	NN	O	O
immunizing	NN	O	O
mice	NN	O	O
with	NN	O	O
human	NN	O	O
group	NN	O	O
C	NN	O	O
adenoviruses	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
C3H	NN	O	O
mice	NN	O	O
inoculated	NN	O	O
with	NN	O	O
wild-type	NN	O	O
Ad	NN	O	O
recognized	NN	O	O
an	NN	O	O
epitope	NN	O	O
mapping	NN	O	O
within	NN	O	O
E1B	NN	O	B-DNA
.	NN	O	O
When	NN	O	O
inoculated	NN	O	O
twice	NN	O	O
with	NN	O	O
Ad	NN	O	O
vectors	NN	O	O
lacking	NN	O	O
both	NN	O	O
E1A	NN	O	B-DNA
and	NN	O	O
E1B	NN	O	B-DNA
,	NN	O	O
no	NN	O	O
immunorecessive	NN	O	B-protein
epitopes	NN	O	I-protein
were	NN	O	O
recognized	NN	O	O
.	NN	O	O

-DOCSTART-	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
RFX1	NN	O	B-protein
can	NN	O	O
bind	NN	O	O
to	NN	O	O
NRE	NN	O	B-DNA
gamma	NN	O	I-DNA
and	NN	O	O
transactivate	NN	O	O
the	NN	O	O
core	NN	O	B-DNA
promoter	NN	O	I-DNA
through	NN	O	O
this	NN	O	O
site	NN	O	O
.	NN	O	O

Clinical	NN	O	O
CR	NN	O	O
was	NN	O	O
achieved	NN	O	O
in	NN	O	O
nine	NN	O	O
of	NN	O	O
10	NN	O	O
(	NN	O	O
90	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
As2O3	NN	O	O
alone	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
five	NN	O	O
patients	NN	O	O
treated	NN	O	O
by	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
As2O3	NN	O	O
and	NN	O	O
low-dose	NN	O	O
chemotherapeutic	NN	O	O
drugs	NN	O	O
or	NN	O	O
ATRA	NN	O	O
.	NN	O	O

We	NN	O	O
generated	NN	O	O
a	NN	O	O
point	NN	O	O
mutant	NN	O	O
of	NN	O	O
ZEBRA	NN	O	B-protein
,	NN	O	O
Z	NN	O	B-protein
(	NN	O	I-protein
S186A	NN	O	I-protein
)	NN	O	I-protein
,	NN	O	O
that	NN	O	O
was	NN	O	O
not	NN	O	O
impaired	NN	O	O
in	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
activate	NN	O	O
transcription	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
this	NN	O	O
mutation	NN	O	O
abolished	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
initiate	NN	O	O
the	NN	O	O
viral	NN	O	O
lytic	NN	O	O
cascade	NN	O	O
.	NN	O	O

Also	NN	O	O
no	NN	O	O
significant	NN	O	O
partial	NN	O	O
correlations	NN	O	O
of	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
leukotriene	NN	O	O
B4	NN	O	O
(	NN	O	O
45.6	NN	O	O
+/-	NN	O	O
105.3	NN	O	O
ng/10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
cells	NN	O	O
)	NN	O	O
produced	NN	O	O
by	NN	O	O
monocytes	NN	O	B-cell_type
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
soluble	NN	O	O
interleukin-2	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
734	NN	O	O
+/-	NN	O	O
237	NN	O	O
ng/10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
cells	NN	O	O
)	NN	O	O
released	NN	O	O
by	NN	O	O
lymphocytes	NN	O	B-cell_type
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
(	NN	O	O
571	NN	O	O
+/-	NN	O	O
236	NN	O	O
ng/mL	NN	O	O
)	NN	O	O
in	NN	O	O
plasma	NN	O	O
with	NN	O	O
the	NN	O	O
symptom	NN	O	O
score	NN	O	O
after	NN	O	O
active	NN	O	O
treatment	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
whether	NN	O	O
this	NN	O	O
may	NN	O	O
be	NN	O	O
partly	NN	O	O
explained	NN	O	O
by	NN	O	O
changes	NN	O	O
in	NN	O	O
expression	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
with	NN	O	O
monocyte	NN	O	O
differentiation	NN	O	O
.	NN	O	O

The	NN	O	O
two	NN	O	O
most	NN	O	O
active	NN	O	O
NFAT-like	NN	O	B-DNA
elements	NN	O	I-DNA
were	NN	O	O
located	NN	O	O
at	NN	O	O
the	NN	O	O
center	NN	O	O
of	NN	O	O
the	NN	O	O
DNase	NN	O	B-DNA
I-hypersensitive	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
Ras	NN	O	O
and	NN	O	O
mitogen-activated	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
pathway	NN	O	O
by	NN	O	O
terminal	NN	O	B-protein
complement	NN	O	I-protein
complexes	NN	O	I-protein
is	NN	O	O
G	NN	O	B-protein
protein	NN	O	I-protein
dependent	NN	O	O
.	NN	O	O

Mutants	NN	O	O
of	NN	O	O
type	NN	O	O
5	NN	O	O
adenovirus	NN	O	O
(	NN	O	O
Ad5	NN	O	O
)	NN	O	O
with	NN	O	O
reiterated	NN	O	B-DNA
DNA	NN	O	I-DNA
sequences	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
E1a	NN	O	B-DNA
region	NN	O	I-DNA
appeared	NN	O	O
in	NN	O	O
a	NN	O	O
human	NN	O	B-cell_line
T-lymphocyte	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
,	NN	O	O
Molt-4	NN	O	B-cell_line
,	NN	O	O
persistently	NN	O	O
infected	NN	O	O
with	NN	O	O
H5sub304	NN	O	O
,	NN	O	O
a	NN	O	O
deletion/substitution	NN	O	O
mutant	NN	O	O
that	NN	O	O
has	NN	O	O
a	NN	O	O
wild-type	NN	O	O
phenotype	NN	O	O
in	NN	O	O
viral	NN	O	O
replication	NN	O	O
.	NN	O	O

These	NN	O	O
E1a	NN	O	O
reiteration	NN	O	O
mutants	NN	O	O
could	NN	O	O
be	NN	O	O
propagated	NN	O	O
in	NN	O	O
HeLa	NN	O	B-cell_line
,	NN	O	O
A549	NN	O	B-cell_line
,	NN	O	O
and	NN	O	O
KB	NN	O	B-cell_line
cells	NN	O	I-cell_line
;	NN	O	O
they	NN	O	O
were	NN	O	O
genetically	NN	O	O
stable	NN	O	O
;	NN	O	O
and	NN	O	O
they	NN	O	O
killed	NN	O	O
CREF	NN	O	B-cell_line
cells	NN	O	I-cell_line
at	NN	O	O
a	NN	O	O
strikingly	NN	O	O
high	NN	O	O
frequency	NN	O	O
.	NN	O	O

-DOCSTART-	O

No	NN	O	O
degradation	NN	O	O
of	NN	O	O
p105	NN	O	B-protein
and	NN	O	I-protein
p100	NN	O	I-protein
inhibitors	NN	O	I-protein
was	NN	O	O
observed	NN	O	O
under	NN	O	O
these	NN	O	O
conditions	NN	O	O
.	NN	O	O

V3-BH10	NN	O	B-protein
neither	NN	O	O
blocked	NN	O	O
radiolabeled	NN	O	O
IL-2	NN	O	B-protein
binding	NN	O	O
to	NN	O	O
IL-2	NN	O	B-protein
receptors	NN	O	I-protein
nor	NN	O	O
affected	NN	O	O
tyrosyl	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
several	NN	O	O
cellular	NN	O	B-protein
proteins	NN	O	I-protein
(	NN	O	O
p120	NN	O	B-protein
,	NN	O	O
p98	NN	O	B-protein
,	NN	O	O
p96	NN	O	B-protein
,	NN	O	O
p54	NN	O	B-protein
,	NN	O	O
and	NN	O	O
p38	NN	O	B-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
immediately	NN	O	O
induced	NN	O	O
by	NN	O	O
IL-2	NN	O	B-protein
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
existence	NN	O	O
of	NN	O	O
alternative	NN	O	O
Pax-5	NN	O	B-RNA
transcripts	NN	O	I-RNA
was	NN	O	O
confirmed	NN	O	O
using	NN	O	O
RNase	NN	O	B-protein
protection	NN	O	O
assays	NN	O	O
.	NN	O	O

The	NN	O	O
Syk	NN	O	B-protein
-mediated	NN	O	O
T	NN	O	B-protein
cell	NN	O	I-protein
antigen	NN	O	I-protein
receptor	NN	O	I-protein
-induced	NN	O	O
MAPK	NN	O	B-protein
activation	NN	O	O
was	NN	O	O
detectable	NN	O	O
within	NN	O	O
1	NN	O	O
min	NN	O	O
of	NN	O	O
receptor	NN	O	O
stimulation	NN	O	O
and	NN	O	O
peaked	NN	O	O
at	NN	O	O
3-5	NN	O	O
min	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
MEF2C	NN	O	B-protein
by	NN	O	O
the	NN	O	O
MAP	NN	O	B-protein
kinase	NN	O	I-protein
p38	NN	O	I-protein
in	NN	O	O
inflammation	NN	O	O
.	NN	O	O

The	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
by	NN	O	O
PDTC	NN	O	O
paralleled	NN	O	O
with	NN	O	O
an	NN	O	O
inhibition	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
cytotoxicity	NN	O	O
mediated	NN	O	O
by	NN	O	O
NK	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

We	NN	O	O
also	NN	O	O
studied	NN	O	O
blasts	NN	O	O
from	NN	O	O
18	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
myeloid	NN	O	O
leukaemia	NN	O	O
(	NN	O	O
AML	NN	O	O
)	NN	O	O
.	NN	O	O

Upon	NN	O	O
stimulation	NN	O	O
by	NN	O	O
various	NN	O	O
agents	NN	O	O
,	NN	O	O
I	NN	O	B-protein
kappaB	NN	O	I-protein
is	NN	O	O
proteolyzed	NN	O	O
and	NN	O	O
NF-kappaB	NN	O	B-protein
translocates	NN	O	O
to	NN	O	O
the	NN	O	O
nucleus	NN	O	O
,	NN	O	O
where	NN	O	O
it	NN	O	O
activates	NN	O	O
its	NN	O	O
target	NN	O	O
genes	NN	O	O
.	NN	O	O

As	NN	O	O
well	NN	O	O
as	NN	O	O
culminating	NN	O	O
in	NN	O	O
the	NN	O	O
inducible	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
I	NN	O	B-protein
kappaB	NN	O	I-protein
alpha	NN	O	O
on	NN	O	O
serines	NN	O	O
32	NN	O	O
and	NN	O	O
36	NN	O	O
,	NN	O	O
all	NN	O	O
the	NN	O	O
stimuli	NN	O	O
that	NN	O	O
are	NN	O	O
inactive	NN	O	O
on	NN	O	O
1.3E2	NN	O	B-cell_line
cells	NN	O	I-cell_line
exhibit	NN	O	O
a	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
pyrrolidine	NN	O	O
dithiocarbamate	NN	O	O
(	NN	O	O
PDTC	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
stimuli	NN	O	O
such	NN	O	O
as	NN	O	O
hyperosmotic	NN	O	O
shock	NN	O	O
or	NN	O	O
phosphatase	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
which	NN	O	O
use	NN	O	O
PDTC-insensitive	NN	O	O
pathways	NN	O	O
,	NN	O	O
induce	NN	O	O
I	NN	O	B-protein
kappaB	NN	O	I-protein
alpha	NN	O	O
degradation	NN	O	O
in	NN	O	O
1.3E2	NN	O	B-cell_line
.	NN	O	O

We	NN	O	O
also	NN	O	O
report	NN	O	O
that	NN	O	O
the	NN	O	O
human	NN	O	B-protein
T-cell	NN	O	I-protein
leukemia	NN	O	I-protein
virus	NN	O	I-protein
type	NN	O	I-protein
1	NN	O	I-protein
(	NN	O	I-protein
HTLV-1	NN	O	I-protein
)	NN	O	I-protein
-derived	NN	O	I-protein
Tax	NN	O	I-protein
trans-activator	NN	O	I-protein
induces	NN	O	O
NF-kappaB	NN	O	B-protein
activity	NN	O	O
in	NN	O	O
1.3E2	NN	O	B-cell_line
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
this	NN	O	O
viral	NN	O	O
protein	NN	O	O
does	NN	O	O
not	NN	O	O
operate	NN	O	O
via	NN	O	O
the	NN	O	O
defective	NN	O	O
pathway	NN	O	O
.	NN	O	O

When	NN	O	O
tested	NN	O	O
in	NN	O	O
cytotoxicity	NN	O	O
assays	NN	O	O
using	NN	O	O
T-lymphocytes	NN	O	B-cell_type
from	NN	O	O
VZV	NN	O	O
immune	NN	O	O
human	NN	O	O
donors	NN	O	O
,	NN	O	O
the	NN	O	O
range	NN	O	O
of	NN	O	O
precursor	NN	O	O
frequencies	NN	O	O
for	NN	O	O
T-lymphocytes	NN	O	B-cell_type
that	NN	O	O
recognized	NN	O	O
VZV	NN	O	B-protein
gE	NN	O	I-protein
or	NN	O	O
VZV	NN	O	B-protein
IE62	NN	O	I-protein
was	NN	O	O
similar	NN	O	O
whether	NN	O	O
these	NN	O	O
proteins	NN	O	O
were	NN	O	O
expressed	NN	O	O
by	NN	O	O
HSV-1	NN	O	O
or	NN	O	O
a	NN	O	O
vaccinia	NN	O	O
vector	NN	O	O
.	NN	O	O

In	NN	O	O
DNA	NN	O	O
binding	NN	O	O
assays	NN	O	O
,	NN	O	O
both	NN	O	O
PMA	NN	O	O
plus	NN	O	O
anti-CD28	NN	O	B-protein
and	NN	O	O
PMA	NN	O	O
plus	NN	O	O
ionomycin	NN	O	O
resulted	NN	O	O
in	NN	O	O
nuclear	NN	O	B-protein
NFAT	NN	O	I-protein
.	NN	O	O

We	NN	O	O
also	NN	O	O
identified	NN	O	O
a	NN	O	O
potent	NN	O	O
inhibitory	NN	O	B-protein
sequence	NN	O	I-protein
within	NN	O	O
its	NN	O	O
N-terminal	NN	O	B-protein
domain	NN	O	I-protein
.	NN	O	O

To	NN	O	O
define	NN	O	O
further	NN	O	O
the	NN	O	O
relation	NN	O	O
between	NN	O	O
Stat3	NN	O	B-protein
activation	NN	O	O
and	NN	O	O
enhanced	NN	O	O
IgM	NN	O	B-protein
production	NN	O	O
,	NN	O	O
we	NN	O	O
determined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chimeric	NN	O	O
gp130	NN	O	O
on	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
a	NN	O	O
genetic	NN	O	O
element	NN	O	O
linked	NN	O	O
to	NN	O	O
immunoglobulin	NN	O	B-protein
production	NN	O	O
,	NN	O	O
namely	NN	O	O
the	NN	O	O
immunoglobulin	NN	O	B-DNA
heavy	NN	O	I-DNA
chain	NN	O	I-DNA
enhancer	NN	O	I-DNA
(	NN	O	O
IgH-enhancer	NN	O	B-DNA
)	NN	O	O
.	NN	O	O

Parental	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
transfected	NN	O	O
SKW6.4	NN	O	B-cell_line
cells	NN	O	I-cell_line
were	NN	O	O
transiently	NN	O	O
transfected	NN	O	O
with	NN	O	O
an	NN	O	O
IgH-enhancer-luciferase	NN	O	B-DNA
construct	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
studied	NN	O	O
,	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
ferritin	NN	O	B-protein
expression	NN	O	O
was	NN	O	O
exerted	NN	O	O
mostly	NN	O	O
at	NN	O	O
the	NN	O	O
translational	NN	O	O
level	NN	O	O
.	NN	O	O

This	NN	O	O
cis	NN	O	B-DNA
element	NN	O	I-DNA
binds	NN	O	O
a	NN	O	O
protein	NN	O	O
complex	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
HRF	NN	O	B-protein
(	NN	O	O
heme-responsive	NN	O	B-protein
factor	NN	O	I-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
greatly	NN	O	O
enhanced	NN	O	O
both	NN	O	O
in	NN	O	O
heme-treated	NN	O	O
FLCs	NN	O	B-cell_line
and	NN	O	O
during	NN	O	O
monocyte-to-macrophage	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
such	NN	O	O
as	NN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
serve	NN	O	O
as	NN	O	O
second	NN	O	O
messengers	NN	O	O
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
NF-kappaB	NN	O	B-protein
,	NN	O	O
and	NN	O	O
hence	NN	O	O
in	NN	O	O
the	NN	O	O
activation	NN	O	O
and	NN	O	O
replication	NN	O	O
of	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
(	NN	O	O
HIV-1	NN	O	O
)	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
evolutionarily	NN	O	O
conserved	NN	O	O
physical	NN	O	O
interactions	NN	O	O
between	NN	O	O
Ets	NN	O	B-protein
and	NN	O	I-protein
NF-kappaB/NFAT	NN	O	I-protein
proteins	NN	O	I-protein
are	NN	O	O
important	NN	O	O
in	NN	O	O
regulating	NN	O	O
the	NN	O	O
inducible	NN	O	O
expression	NN	O	O
of	NN	O	O
T-cell	NN	O	B-DNA
genes	NN	O	I-DNA
and	NN	O	O
viruses	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
an	NN	O	O
altered	NN	O	O
expression	NN	O	O
level	NN	O	O
of	NN	O	O
AML1	NN	O	B-protein
along	NN	O	O
with	NN	O	O
the	NN	O	O
myeloid	NN	O	O
differentiation	NN	O	O
in	NN	O	O
several	NN	O	O
hemopoietic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

Stimulation	NN	O	O
with	NN	O	O
either	NN	O	O
PAF	NN	O	B-protein
or	NN	O	O
FMLP	NN	O	B-protein
resulted	NN	O	O
in	NN	O	O
equivalent	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
mitogen-activated	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
(	NN	O	I-protein
MAPk	NN	O	I-protein
)	NN	O	I-protein
homologue	NN	O	I-protein
38-kD	NN	O	B-protein
murine	NN	O	I-protein
MAP	NN	O	I-protein
kinase	NN	O	I-protein
homologous	NN	O	O
to	NN	O	O
HOG-1	NN	O	B-protein
(	NN	O	I-protein
p38	NN	O	I-protein
)	NN	O	I-protein
MAPk	NN	O	I-protein
.	NN	O	O

Under	NN	O	O
identical	NN	O	O
conditions	NN	O	O
,	NN	O	O
FMLP	NN	O	B-protein
but	NN	O	O
not	NN	O	O
PAF	NN	O	B-protein
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
p42/44	NN	O	B-protein
(	NN	O	I-protein
ERK	NN	O	I-protein
)	NN	O	I-protein
MAPk	NN	O	I-protein
activation	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
no	NN	O	O
induction	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
was	NN	O	O
seen	NN	O	O
in	NN	O	O
A6H	NN	O	B-protein
costimulated	NN	O	O
CD8+	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
substitutions	NN	O	O
per	NN	O	O
se	NN	O	O
were	NN	O	O
responsible	NN	O	O
for	NN	O	O
decreased	NN	O	O
affinity	NN	O	O
,	NN	O	O
squirrel	NN	O	O
monkey	NN	O	O
and	NN	O	O
human	NN	O	B-protein
glucocorticoid	NN	O	I-protein
receptors	NN	O	I-protein
were	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
TNT	NN	O	O
Coupled	NN	O	O
Reticulocyte	NN	O	O
Lysate	NN	O	O
System	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
gene	NN	O	O
disruption	NN	O	O
of	NN	O	O
either	NN	O	O
IL-7	NN	O	B-protein
or	NN	O	O
the	NN	O	O
IL-7	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	I-protein
IL-7R	NN	O	I-protein
)	NN	O	I-protein
alpha	NN	O	I-protein
subunit	NN	O	I-protein
in	NN	O	O
mice	NN	O	O
leads	NN	O	O
to	NN	O	O
immunological	NN	O	O
defects	NN	O	O
that	NN	O	O
are	NN	O	O
similar	NN	O	O
to	NN	O	O
human	NN	O	O
X-SCID	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
these	NN	O	O
studies	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
molecular	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
X-SCID	NN	O	O
is	NN	O	O
due	NN	O	O
primarily	NN	O	O
to	NN	O	O
gamma	NN	O	B-protein
(	NN	O	I-protein
c	NN	O	I-protein
)	NN	O	I-protein
-mediated	NN	O	O
defects	NN	O	O
in	NN	O	O
the	NN	O	O
IL-7	NN	O	B-protein
/IL-7R	NN	O	B-protein
system	NN	O	O

S-allyl	NN	O	O
cysteine	NN	O	O
inhibits	NN	O	O
activation	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
in	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
deregulated	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
viral	NN	O	B-DNA
gene	NN	O	I-DNA
,	NN	O	O
ORF	NN	O	B-DNA
50	NN	O	I-DNA
,	NN	O	O
which	NN	O	O
encodes	NN	O	O
a	NN	O	O
transactivator	NN	O	O
able	NN	O	O
to	NN	O	O
selectively	NN	O	O
upregulate	NN	O	O
delayed-early	NN	O	B-DNA
viral	NN	O	I-DNA
genes	NN	O	I-DNA
,	NN	O	O
suffices	NN	O	O
to	NN	O	O
disrupt	NN	O	O
latency	NN	O	O
and	NN	O	O
induce	NN	O	O
the	NN	O	O
lytic	NN	O	O
gene	NN	O	O
cascade	NN	O	O
in	NN	O	O
latently	NN	O	B-cell_type
infected	NN	O	I-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
transfected	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
expressed	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
spi-1	NN	O	B-RNA
mRNA	NN	O	I-RNA
and	NN	O	O
protein	NN	O	O
and	NN	O	O
high	NN	O	O
Spi-1	NN	O	B-protein
-DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
.	NN	O	O

The	NN	O	O
spi-1	NN	O	B-cell_line
transfected	NN	O	I-cell_line
cells	NN	O	I-cell_line
showed	NN	O	O
reduced	NN	O	O
growth	NN	O	O
rates	NN	O	O
and	NN	O	O
reduced	NN	O	O
clonogenic	NN	O	O
cell	NN	O	O
growth	NN	O	O
.	NN	O	O

-DOCSTART-	O

This	NN	O	O
chimera	NN	O	O
transduced	NN	O	O
IL-4	NN	O	B-protein
-specific	NN	O	O
signals	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
IL-2	NN	O	B-protein
binding	NN	O	O
and	NN	O	O
dramatically	NN	O	O
enhanced	NN	O	O
type	NN	O	O
2	NN	O	O
responses	NN	O	O
(	NN	O	O
IL-4	NN	O	B-protein
,	NN	O	O
IL-5	NN	O	B-protein
,	NN	O	O
and	NN	O	O
immunoglobulin	NN	O	B-protein
E	NN	O	I-protein
production	NN	O	O
)	NN	O	O
upon	NN	O	O
in	NN	O	O
vitro	NN	O	O
TCR	NN	O	B-protein
stimulation	NN	O	O
or	NN	O	O
in	NN	O	O
vivo	NN	O	O
antigen	NN	O	O
challenge	NN	O	O
.	NN	O	O

Deregulated	NN	O	O
TCR	NN	O	B-protein
-mediated	NN	O	O
responses	NN	O	O
and	NN	O	O
the	NN	O	O
fast	NN	O	O
kinetics	NN	O	O
of	NN	O	O
tumor	NN	O	O
development	NN	O	O
in	NN	O	O
these	NN	O	O
mutant	NN	O	B-cell_type
thymocytes	NN	O	I-cell_type
implicate	NN	O	O
Ikaros	NN	O	O
as	NN	O	O
a	NN	O	O
central	NN	O	B-DNA
tumor	NN	O	I-DNA
suppressor	NN	O	I-DNA
gene	NN	O	I-DNA
for	NN	O	O
the	NN	O	O
T	NN	O	B-cell_type
cell	NN	O	I-cell_type
lineage	NN	O	I-cell_type
.	NN	O	O

A	NN	O	O
model	NN	O	O
is	NN	O	O
proposed	NN	O	O
that	NN	O	O
defines	NN	O	O
Ikaros	NN	O	B-protein
as	NN	O	O
the	NN	O	O
backbone	NN	O	O
of	NN	O	O
a	NN	O	O
complex	NN	O	B-protein
regulatory	NN	O	I-protein
protein	NN	O	I-protein
network	NN	O	I-protein
that	NN	O	O
controls	NN	O	O
cell	NN	O	O
fate	NN	O	O
decisions	NN	O	O
and	NN	O	O
regulates	NN	O	O
homeostasis	NN	O	O
in	NN	O	O
the	NN	O	O
hemo-lymphoid	NN	O	O
system	NN	O	O
.	NN	O	O

Binding	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	O
factor	NN	O	O
to	NN	O	O
the	NN	O	O
GAS	NN	O	B-DNA
element	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
CAEV	NN	O	B-DNA
LTR	NN	O	I-DNA
is	NN	O	O
inhibited	NN	O	O
by	NN	O	O
antibody	NN	O	O
directed	NN	O	O
against	NN	O	O
STAT1	NN	O	B-protein
(	NN	O	O
p91/84	NN	O	B-protein
)	NN	O	O
.	NN	O	O

Mapping	NN	O	O
of	NN	O	O
the	NN	O	O
structural	NN	O	O
requirements	NN	O	O
for	NN	O	O
TRAF	NN	O	B-protein
/RANK	NN	O	B-protein
interaction	NN	O	O
revealed	NN	O	O
multiple	NN	O	O
TRAF	NN	O	B-protein
binding	NN	O	I-protein
sites	NN	O	I-protein
clustered	NN	O	O
in	NN	O	O
two	NN	O	O
distinct	NN	O	O
domains	NN	O	O
in	NN	O	O
the	NN	O	O
RANK	NN	O	B-protein
cytoplasmic	NN	O	I-protein
tail	NN	O	I-protein
.	NN	O	O

An	NN	O	O
NH2-terminal	NN	O	B-protein
truncation	NN	O	I-protein
mutant	NN	O	I-protein
of	NN	O	O
TRAF6	NN	O	B-protein
inhibited	NN	O	O
RANKL	NN	O	B-protein
-mediated	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
,	NN	O	O
but	NN	O	O
failed	NN	O	O
to	NN	O	O
affect	NN	O	O
constitutive	NN	O	O
signaling	NN	O	O
induced	NN	O	O
by	NN	O	O
receptor	NN	O	O
overexpression	NN	O	O
,	NN	O	O
revealing	NN	O	O
a	NN	O	O
selective	NN	O	O
role	NN	O	O
for	NN	O	O
TRAF6	NN	O	B-protein
in	NN	O	O
ligand-induced	NN	O	O
activation	NN	O	O
events	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
Stat6	NN	O	B-protein
is	NN	O	O
highly	NN	O	O
dependent	NN	O	O
on	NN	O	O
promoter	NN	O	O
context	NN	O	O
and	NN	O	O
that	NN	O	O
this	NN	O	O
factor	NN	O	O
promotes	NN	O	O
IL-4	NN	O	B-protein
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
an	NN	O	O
indirect	NN	O	O
manner	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
enforced	NN	O	O
expression	NN	O	O
of	NN	O	O
Bcl-2	NN	O	B-protein
inhibited	NN	O	O
triptolide-induced	NN	O	O
degradation	NN	O	O
of	NN	O	O
PARP	NN	O	B-protein
and	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

c-Jun	NN	O	O
and	NN	O	O
GST-pi	NN	O	O
expression	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
plasma	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
there	NN	O	O
has	NN	O	O
been	NN	O	O
some	NN	O	O
progress	NN	O	O
in	NN	O	O
the	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
signal	NN	O	O
transduction	NN	O	O
pathways	NN	O	O
activated	NN	O	O
by	NN	O	O
these	NN	O	O
cytokines	NN	O	B-protein
in	NN	O	O
eosinophils	NN	O	B-cell_type
.	NN	O	O

Previous	NN	O	O
reports	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
BA-induced	NN	O	O
overexpression	NN	O	O
of	NN	O	O
erythroid	NN	O	B-DNA
genes	NN	O	I-DNA
occurred	NN	O	O
at	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
level	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
erythroid	NN	O	B-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
.	NN	O	O

As	NN	O	O
a	NN	O	O
first	NN	O	O
step	NN	O	O
toward	NN	O	O
elucidating	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
Cbl	NN	O	B-protein
in	NN	O	O
TCR	NN	O	B-protein
-initiated	NN	O	O
signaling	NN	O	O
,	NN	O	O
we	NN	O	O
evaluated	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
wild-type	NN	O	B-protein
Cbl	NN	O	I-protein
or	NN	O	O
a	NN	O	O
transforming	NN	O	O
Cbl	NN	O	B-protein
mutant	NN	O	I-protein
(	NN	O	O
70Z/3	NN	O	O
)	NN	O	O
to	NN	O	O
induce	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
a	NN	O	O
nuclear	NN	O	B-DNA
factor	NN	O	I-DNA
of	NN	O	I-DNA
activated	NN	O	I-DNA
T	NN	O	I-DNA
cells	NN	O	I-DNA
(	NN	O	I-DNA
NFAT	NN	O	I-DNA
)	NN	O	I-DNA
element	NN	O	I-DNA
derived	NN	O	O
from	NN	O	O
the	NN	O	O
interleukin	NN	O	B-DNA
2	NN	O	I-DNA
(	NN	O	I-DNA
IL2	NN	O	I-DNA
)	NN	O	I-DNA
promoter	NN	O	I-DNA
in	NN	O	O
transiently	NN	O	O
cotransfected	NN	O	O
Jurkat-TAg	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Coexpression	NN	O	O
of	NN	O	O
dominant	NN	O	B-protein
negative	NN	O	I-protein
Ras	NN	O	I-protein
abrogated	NN	O	O
the	NN	O	O
basal	NN	O	O
or	NN	O	O
ionomycin-stimulated	NN	O	O
,	NN	O	O
70Z/3	NN	O	B-protein
-mediated	NN	O	O
NFAT	NN	O	B-protein
activation	NN	O	O
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
functional	NN	O	B-protein
Ras	NN	O	I-protein
is	NN	O	O
required	NN	O	O
for	NN	O	O
this	NN	O	O
activation	NN	O	O
.	NN	O	O

-DOCSTART-	O

-DOCSTART-	O

Our	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
altered	NN	O	O
CCAAT	NN	O	B-DNA
box	NN	O	I-DNA
(	NN	O	O
CCAAC	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
an	NN	O	O
EKLF	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
in	NN	O	O
delta-globin	NN	O	B-protein
contribute	NN	O	O
to	NN	O	O
its	NN	O	O
low	NN	O	O
level	NN	O	O
of	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
hAEC	NN	O	B-cell_line
model	NN	O	I-cell_line
as	NN	O	O
well	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
induction	NN	O	O
of	NN	O	O
STATs	NN	O	B-protein
by	NN	O	O
cytokines	NN	O	B-protein
,	NN	O	O
the	NN	O	O
IRF-1	NN	O	B-DNA
GAS	NN	O	I-DNA
-binding	NN	O	O
complex	NN	O	O
activated	NN	O	O
by	NN	O	O
CD40	NN	O	B-protein
,	NN	O	O
TNF-alpha	NN	O	B-protein
,	NN	O	O
or	NN	O	O
EBV	NN	O	O
contains	NN	O	O
Rel	NN	O	B-protein
proteins	NN	O	I-protein
,	NN	O	O
specifically	NN	O	O
p50	NN	O	B-protein
and	NN	O	O
p65	NN	O	B-protein
.	NN	O	O

The	NN	O	O
structural	NN	O	O
organization	NN	O	O
of	NN	O	O
the	NN	O	O
393	NN	O	B-protein
amino	NN	O	I-protein
acid	NN	O	I-protein
long	NN	O	I-protein
human	NN	O	I-protein
TRAMP	NN	O	I-protein
is	NN	O	O
most	NN	O	O
homologous	NN	O	O
to	NN	O	O
TNF	NN	O	B-protein
receptor	NN	O	I-protein
1	NN	O	I-protein
.	NN	O	O

Interleukin-10	NN	O	B-protein
(	NN	O	O
IL-10	NN	O	B-protein
)	NN	O	O
protects	NN	O	O
animals	NN	O	O
from	NN	O	O
lethal	NN	O	O
endotoxemia	NN	O	O
.	NN	O	O

This	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
is	NN	O	O
mediated	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
by	NN	O	O
inhibition	NN	O	O
of	NN	O	O
inflammatory	NN	O	B-protein
cytokine	NN	O	I-protein
production	NN	O	O
,	NN	O	O
including	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
.	NN	O	O

BASH	NN	O	B-protein
,	NN	O	O
a	NN	O	O
novel	NN	O	B-protein
signaling	NN	O	I-protein
molecule	NN	O	I-protein
preferentially	NN	O	O
expressed	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
of	NN	O	O
the	NN	O	O
bursa	NN	O	O
of	NN	O	O
Fabricius	NN	O	O
.	NN	O	O

StatG	NN	O	B-protein
in	NN	O	O
normal	NN	O	B-cell_type
immature	NN	O	I-cell_type
human	NN	O	I-cell_type
myeloid	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
i.e	NN	O	O
.	NN	O	O
adult	NN	O	B-cell_type
CD34+	NN	O	I-cell_type
bone	NN	O	I-cell_type
marrow	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
was	NN	O	O
composed	NN	O	O
of	NN	O	O
Stat3beta	NN	O	B-protein
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
investigated	NN	O	O
recognition	NN	O	O
by	NN	O	O
ovarian	NN	O	B-cell_type
tumor	NN	O	I-cell_type
associated	NN	O	I-cell_type
lymphocyte	NN	O	I-cell_type
(	NN	O	O
OVTAL	NN	O	B-cell_type
)	NN	O	O
,	NN	O	O
and	NN	O	O
breast	NN	O	B-cell_type
tumor	NN	O	I-cell_type
associated	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
(	NN	O	O
BRTAL	NN	O	B-cell_type
)	NN	O	O
,	NN	O	O
of	NN	O	O
peptides	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
sequence	NN	O	O
125-135	NN	O	B-protein
of	NN	O	I-protein
the	NN	O	I-protein
Aminoenhancer	NN	O	I-protein
of	NN	O	I-protein
split	NN	O	I-protein
(	NN	O	I-protein
AES	NN	O	I-protein
)	NN	O	I-protein
protein	NN	O	I-protein
.	NN	O	O

Here	NN	O	O
we	NN	O	O
extend	NN	O	O
those	NN	O	O
results	NN	O	O
by	NN	O	O
showing	NN	O	O
that	NN	O	O
the	NN	O	O
position	NN	O	O
of	NN	O	O
the	NN	O	O
ZEBRA	NN	O	B-protein
activation	NN	O	I-protein
domain	NN	O	I-protein
or	NN	O	O
a	NN	O	O
heterologous	NN	O	O
replacement	NN	O	O
domain	NN	O	O
does	NN	O	O
not	NN	O	O
influence	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
disruption	NN	O	O
of	NN	O	O
EBV	NN	O	O
latency	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
found	NN	O	O
a	NN	O	O
positive	NN	O	O
correlation	NN	O	O
between	NN	O	O
3-O-MG	NN	O	O
transport	NN	O	O
and	NN	O	O
GR	NN	O	B-protein
binding	NN	O	O
capacity	NN	O	O
in	NN	O	O
abdominal	NN	O	O
subjects	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.89	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
however	NN	O	O
we	NN	O	O
did	NN	O	O
not	NN	O	O
find	NN	O	O
such	NN	O	O
a	NN	O	O
correlation	NN	O	O
in	NN	O	O
Cushing	NN	O	O
's	NN	O	O
disease	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.60	NN	O	O
,	NN	O	O
p	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
these	NN	O	O
cytokines	NN	O	B-protein
predominantly	NN	O	O
activate	NN	O	O
an	NN	O	O
80	NN	O	B-protein
kDa	NN	O	I-protein
STAT5	NN	O	I-protein
isoform	NN	O	I-protein
in	NN	O	O
mature	NN	O	O
granulocytes	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
during	NN	O	O
maturation	NN	O	O
of	NN	O	O
both	NN	O	O
lineages	NN	O	O
(	NN	O	O
days	NN	O	O
21	NN	O	O
and	NN	O	O
28	NN	O	O
)	NN	O	O
,	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
functionally	NN	O	O
distinct	NN	O	O
80	NN	O	B-protein
kDa	NN	O	I-protein
STAT5	NN	O	I-protein
isoform	NN	O	I-protein
was	NN	O	O
observed	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
heterodimer	NN	O	B-protein
DNA-binding	NN	O	I-protein
complexes	NN	O	I-protein
containing	NN	O	O
both	NN	O	O
the	NN	O	O
94	NN	O	O
and	NN	O	O
80	NN	O	O
kDa	NN	O	O
STAT5	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

Treatment	NN	O	O
of	NN	O	O
PAEC	NN	O	B-cell_line
exposed	NN	O	O
to	NN	O	O
xenogeneic	NN	O	O
serum	NN	O	O
with	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
inhibitors	NN	O	O
pyrrolidinedithiocarbamate	NN	O	O
(	NN	O	O
PDTC	NN	O	O
,	NN	O	O
25	NN	O	O
microM	NN	O	O
)	NN	O	O
and	NN	O	O
tosyl-phechloromethylketone	NN	O	O
(	NN	O	O
TPCK	NN	O	O
,	NN	O	O
25	NN	O	O
microM	NN	O	O
)	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
reduced	NN	O	O
leukocyte	NN	O	O
adhesion	NN	O	O
in	NN	O	O
respect	NN	O	O
to	NN	O	O
PAEC	NN	O	B-cell_line
treated	NN	O	O
with	NN	O	O
human	NN	O	O
serum	NN	O	O
alone	NN	O	O
.	NN	O	O

C5a	NN	O	B-protein
and	NN	O	O
C3a	NN	O	B-protein
stimulation	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
resulted	NN	O	O
in	NN	O	O
nuclear	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
with	NN	O	O
specificity	NN	O	O
to	NN	O	O
the	NN	O	O
kappaB	NN	O	B-DNA
sequence	NN	O	I-DNA
.	NN	O	O

Glycation-dependent	NN	O	O
,	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species-mediated	NN	O	O
suppression	NN	O	O
of	NN	O	O
the	NN	O	O
insulin	NN	O	O
gene	NN	O	O
promoter	NN	O	O
activity	NN	O	O
in	NN	O	O
HIT	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
cDNA	NN	O	O
contains	NN	O	O
a	NN	O	O
546-nucleotide	NN	O	B-DNA
(	NN	O	I-DNA
nt	NN	O	I-DNA
)	NN	O	I-DNA
open	NN	O	I-DNA
reading	NN	O	I-DNA
frame	NN	O	I-DNA
(	NN	O	O
ORF	NN	O	B-DNA
)	NN	O	O
that	NN	O	O
codes	NN	O	O
for	NN	O	O
the	NN	O	O
carboxyl-terminal	NN	O	B-protein
180	NN	O	I-protein
amino	NN	O	I-protein
acids	NN	O	I-protein
(	NN	O	O
aa	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
recently	NN	O	O
identified	NN	O	O
fkhrl1	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
for	NN	O	O
fkhrl1	NN	O	B-DNA
is	NN	O	O
elevated	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
helper-induced	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
PHA-stimulated	NN	O	B-cell_line
T	NN	O	I-cell_line
lymphocytes	NN	O	I-cell_line
.	NN	O	O

Our	NN	O	O
previous	NN	O	O
investigations	NN	O	O
on	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
LCR	NN	O	B-DNA
HS4	NN	O	I-DNA
demonstrated	NN	O	O
that	NN	O	O
NF-E2	NN	O	B-DNA
and	NN	O	I-DNA
tandem	NN	O	I-DNA
,	NN	O	I-DNA
inverted	NN	O	I-DNA
GATA	NN	O	I-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
are	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
the	NN	O	O
native	NN	O	B-DNA
HS	NN	O	I-DNA
.	NN	O	O

Irrespective	NN	O	O
of	NN	O	O
the	NN	O	O
etiology	NN	O	O
,	NN	O	O
many	NN	O	O
kidney	NN	O	O
diseases	NN	O	O
result	NN	O	O
in	NN	O	O
inflammation	NN	O	O
and	NN	O	O
fibrosis	NN	O	O
of	NN	O	O
the	NN	O	O
tubulointerstitium	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
subsequent	NN	O	O
loss	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
tissular	NN	O	O
patterns	NN	O	O
of	NN	O	O
CIITA	NN	O	O
and	NN	O	O
MHC	NN	O	O
class	NN	O	O
II	NN	O	O
gene	NN	O	O
expression	NN	O	O
are	NN	O	O
tightly	NN	O	O
correlated	NN	O	O
:	NN	O	O
CIITA	NN	O	B-RNA
mRNA	NN	O	I-RNA
is	NN	O	O
highly	NN	O	O
expressed	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
is	NN	O	O
induced	NN	O	O
by	NN	O	O
interferon	NN	O	B-protein
gamma	NN	O	I-protein
(	NN	O	O
IFN-gamma	NN	O	B-protein
)	NN	O	O
in	NN	O	O
macrophage	NN	O	B-cell_line
and	NN	O	I-cell_line
epithelial	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
unusual	NN	O	O
CD56+	NN	O	B-cell_type
CD16-	NN	O	I-cell_type
eGLs	NN	O	I-cell_type
present	NN	O	O
in	NN	O	O
large	NN	O	O
numbers	NN	O	O
in	NN	O	O
late	NN	O	O
secretory	NN	O	O
phase	NN	O	O
eutopic	NN	O	O
endometrium	NN	O	O
were	NN	O	O
highly	NN	O	O
purified	NN	O	O
(	NN	O	O
>	NN	O	O
98	NN	O	O
%	NN	O	O
)	NN	O	O
by	NN	O	O
immunomagnetic	NN	O	O
separation	NN	O	O
.	NN	O	O

Their	NN	O	O
absence	NN	O	O
in	NN	O	O
endometriotic	NN	O	O
lesions	NN	O	O
together	NN	O	O
with	NN	O	O
increased	NN	O	O
CD+8	NN	O	B-cell_type
T-cell	NN	O	I-cell_type
numbers	NN	O	O
and	NN	O	O
increased	NN	O	O
oestrogen	NN	O	B-protein
receptor	NN	O	I-protein
and	NN	O	O
bcl-2	NN	O	B-protein
expression	NN	O	O
may	NN	O	O
have	NN	O	O
significant	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
and	NN	O	O
progression	NN	O	O
of	NN	O	O
endometriosis	NN	O	O
.	NN	O	O

Flow	NN	O	O
cytometric	NN	O	O
and	NN	O	O
morphological	NN	O	O
analyses	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
CD70	NN	O	O
transfectants	NN	O	O
to	NN	O	O
B	NN	O	B-cell_line
cell	NN	O	I-cell_line
cultures	NN	O	I-cell_line
remarkably	NN	O	O
promoted	NN	O	O
differentiation	NN	O	O
into	NN	O	O
plasma	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
IL-4	NN	O	B-protein
and	NN	O	O
CD40	NN	O	B-protein
signaling	NN	O	O
.	NN	O	O

Coincidentally	NN	O	O
,	NN	O	O
a	NN	O	O
deletion	NN	O	O
of	NN	O	O
this	NN	O	O
region	NN	O	O
enhanced	NN	O	O
the	NN	O	O
IL-2	NN	O	B-protein
-induced	NN	O	O
expression	NN	O	O
of	NN	O	O
beta-casein	NN	O	B-protein
.	NN	O	O

Engagement	NN	O	O
of	NN	O	O
any	NN	O	O
of	NN	O	O
these	NN	O	O
receptors	NN	O	O
induces	NN	O	O
the	NN	O	O
rapid	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
a	NN	O	O
shared	NN	O	O
group	NN	O	O
of	NN	O	O
intracellular	NN	O	B-protein
signaling	NN	O	I-protein
proteins	NN	O	I-protein
,	NN	O	O
including	NN	O	O
Vav	NN	O	B-protein
,	NN	O	O
Cbl	NN	O	B-protein
,	NN	O	O
p85	NN	O	B-protein
phosphoinositide	NN	O	I-protein
3-kinase	NN	O	I-protein
,	NN	O	O
and	NN	O	O
the	NN	O	O
Src	NN	O	B-protein
family	NN	O	I-protein
kinases	NN	O	I-protein
Lck	NN	O	B-protein
and	NN	O	O
Fyn	NN	O	B-protein
.	NN	O	O

Unlike	NN	O	O
ligation	NN	O	O
of	NN	O	O
CD3	NN	O	B-protein
,	NN	O	O
stimulation	NN	O	O
with	NN	O	O
anti-CD28	NN	O	B-protein
mAb	NN	O	I-protein
or	NN	O	O
CHO	NN	O	B-cell_line
cells	NN	O	I-cell_line
expressing	NN	O	O
the	NN	O	O
CD28	NN	O	B-protein
ligands	NN	O	I-protein
CD80	NN	O	B-protein
or	NN	O	O
CD86	NN	O	B-protein
did	NN	O	O
not	NN	O	O
lead	NN	O	O
to	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
HS1	NN	O	B-protein
in	NN	O	O
Jurkat	NN	O	B-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
activation-dependent	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
HS1	NN	O	B-protein
was	NN	O	O
not	NN	O	O
required	NN	O	O
for	NN	O	O
NFAT	NN	O	B-protein
transcriptional	NN	O	O
activation	NN	O	O
.	NN	O	O

Adult	NN	O	O
lymphocytes	NN	O	O
showed	NN	O	O
an	NN	O	O
equivalent	NN	O	O
increase	NN	O	O
in	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
of	NN	O	O
c-fos	NN	O	B-DNA
and	NN	O	O
c-jun	NN	O	B-DNA
(	NN	O	O
140+/-25	NN	O	O
and	NN	O	O
155+/-31	NN	O	O
%	NN	O	O
)	NN	O	O
at	NN	O	O
30	NN	O	O
min	NN	O	O
post-	NN	O	O
PHA	NN	O	B-protein
stimulation	NN	O	O
,	NN	O	O
while	NN	O	O
cord	NN	O	B-cell_type
lymphocyte	NN	O	I-cell_type
maximum	NN	O	O
c-fos	NN	O	O
and	NN	O	O
c-jun	NN	O	O
expression	NN	O	O
(	NN	O	O
82+/-6	NN	O	O
and	NN	O	O
142+/-12	NN	O	O
%	NN	O	O
)	NN	O	O
occurred	NN	O	O
at	NN	O	O
15	NN	O	O
min	NN	O	O
post-	NN	O	O
PHA	NN	O	B-protein
stimulation	NN	O	O
(	NN	O	O
c-fos	NN	O	B-DNA
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.0354	NN	O	O
;	NN	O	O
c-jun	NN	O	B-DNA
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.0112	NN	O	O
)	NN	O	O
.	NN	O	O

-DOCSTART-	O

BCL-6	NN	O	B-protein
mutations	NN	O	O
in	NN	O	O
normal	NN	O	B-cell_type
germinal	NN	O	I-cell_type
center	NN	O	I-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
:	NN	O	O
evidence	NN	O	O
of	NN	O	O
somatic	NN	O	O
hypermutation	NN	O	O
acting	NN	O	O
outside	NN	O	O
Ig	NN	O	B-DNA
loci	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
1	NN	O	O
)	NN	O	O
lipid	NN	O	O
A	NN	O	O
myristoyl	NN	O	O
fatty	NN	O	O
acid	NN	O	O
,	NN	O	O
although	NN	O	O
it	NN	O	O
is	NN	O	O
important	NN	O	O
for	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
inflammatory	NN	O	B-protein
cytokine	NN	O	I-protein
production	NN	O	O
by	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
,	NN	O	O
is	NN	O	O
not	NN	O	O
necessary	NN	O	O
for	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
Mn	NN	O	B-protein
SOD	NN	O	I-protein
,	NN	O	O
2	NN	O	O
)	NN	O	O
endotoxin	NN	O	B-protein
-mediated	NN	O	O
induction	NN	O	O
of	NN	O	O
Mn	NN	O	B-protein
SOD	NN	O	I-protein
and	NN	O	O
inflammatory	NN	O	O
cytokines	NN	O	B-protein
are	NN	O	O
regulated	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
through	NN	O	O
different	NN	O	O
signal	NN	O	O
transduction	NN	O	O
pathways	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
)	NN	O	O
failure	NN	O	O
of	NN	O	O
the	NN	O	O
mutant	NN	O	B-protein
endotoxin	NN	O	I-protein
to	NN	O	O
induce	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
production	NN	O	O
is	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
inability	NN	O	O
to	NN	O	O
activate	NN	O	O
mitogen-activated	NN	O	B-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
will	NN	O	O
help	NN	O	O
to	NN	O	O
understand	NN	O	O
the	NN	O	O
complex	NN	O	O
interactions	NN	O	O
occurring	NN	O	O
between	NN	O	O
HHV-6	NN	O	O
and	NN	O	O
the	NN	O	O
CD4	NN	O	B-DNA
promoter	NN	O	I-DNA
and	NN	O	O
provide	NN	O	O
additional	NN	O	O
information	NN	O	O
regarding	NN	O	O
the	NN	O	O
class	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
involved	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
CD4	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
a	NN	O	O
hormone-dependent	NN	O	O
activation	NN	O	O
of	NN	O	O
Tax	NN	O	B-protein
promotes	NN	O	O
an	NN	O	O
enhanced	NN	O	O
prooxidant	NN	O	O
state	NN	O	O
in	NN	O	O
stably	NN	O	B-cell_line
transfected	NN	O	I-cell_line
Jurkat	NN	O	I-cell_line
cells	NN	O	I-cell_line
as	NN	O	O
measured	NN	O	O
by	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
intracellular	NN	O	O
levels	NN	O	O
of	NN	O	O
glutathione	NN	O	O
and	NN	O	O
H2O2	NN	O	O
;	NN	O	O
these	NN	O	O
changes	NN	O	O
are	NN	O	O
followed	NN	O	O
by	NN	O	O
apoptotic	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

Our	NN	O	O
observations	NN	O	O
indicate	NN	O	O
that	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
intracellular	NN	O	O
redox	NN	O	O
status	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
determining	NN	O	O
factor	NN	O	O
in	NN	O	O
Tax	NN	O	B-protein
-mediated	NN	O	O
DNA	NN	O	O
damage	NN	O	O
,	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
and	NN	O	O
selection	NN	O	O
against	NN	O	O
the	NN	O	O
long-term	NN	O	O
expression	NN	O	O
of	NN	O	O
Tax	NN	O	B-protein
function	NN	O	O
.	NN	O	O

An	NN	O	O
allosteric	NN	O	O
drug	NN	O	O
,	NN	O	O
o	NN	O	O
,	NN	O	O
o'-bismyristoyl	NN	O	O
thiamine	NN	O	O
disulfide	NN	O	O
,	NN	O	O
suppresses	NN	O	O
HIV-1	NN	O	O
replication	NN	O	O
through	NN	O	O
prevention	NN	O	O
of	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
both	NN	O	O
HIV-1	NN	O	B-protein
Tat	NN	O	I-protein
and	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
.	NN	O	O

Minimizing	NN	O	O
energy	NN	O	O
studies	NN	O	O
of	NN	O	O
BMT	NN	O	O
structure	NN	O	O
reveal	NN	O	O
that	NN	O	O
a	NN	O	O
trans-disulfide	NN	O	O
of	NN	O	O
thiamine	NN	O	O
(	NN	O	O
holo	NN	O	O
drug	NN	O	O
)	NN	O	O
disulfide	NN	O	O
(	NN	O	O
TDS	NN	O	O
,	NN	O	O
protodrug	NN	O	O
)	NN	O	O
is	NN	O	O
allosterically	NN	O	O
transited	NN	O	O
to	NN	O	O
the	NN	O	O
reactive	NN	O	O
twisted	NN	O	O
disulfide	NN	O	O
of	NN	O	O
BMT	NN	O	O
(	NN	O	O
allo	NN	O	O
drug	NN	O	O
)	NN	O	O
by	NN	O	O
o	NN	O	O
,	NN	O	O
o'-bismyristoyl	NN	O	O
esterification	NN	O	O
of	NN	O	O
TDS	NN	O	O
.	NN	O	O

Glucocorticoid-induced	NN	O	O
apoptosis	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
glucocorticoid-sensitive	NN	O	B-cell_line
6TG1.1	NN	O	I-cell_line
and	NN	O	O
resistant	NN	O	B-cell_line
ICR27TK.3	NN	O	I-cell_line
human	NN	O	B-cell_type
leukemic	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
small	NN	O	O
molecule	NN	O	O
S9a	NN	O	O
was	NN	O	O
derived	NN	O	O
from	NN	O	O
an	NN	O	O
established	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor-alpha	NN	O	I-protein
(	NN	O	O
TNF-alpha	NN	O	B-protein
)	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
Canventol	NN	O	O
)	NN	O	O
by	NN	O	O
replacement	NN	O	O
of	NN	O	O
the	NN	O	O
isopropylidine	NN	O	O
group	NN	O	O
with	NN	O	O
a	NN	O	O
phenyl	NN	O	O
ring	NN	O	O
.	NN	O	O

Tobacco	NN	O	O
smoke	NN	O	O
induces	NN	O	O
coordinate	NN	O	O
activation	NN	O	O
of	NN	O	O
HSF	NN	O	B-protein
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NFkappaB	NN	O	B-protein
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
:	NN	O	O
effects	NN	O	O
on	NN	O	O
TNFalpha	NN	O	B-protein
release	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
helper	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
T	NN	O	O
cell	NN	O	O
receptor	NN	O	O
induces	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
biochemical	NN	O	O
events	NN	O	O
.	NN	O	O

-DOCSTART-	O

Down-regulation	NN	O	O
of	NN	O	O
17beta-HSD	NN	O	B-protein
IV	NN	O	I-protein
mRNA	NN	O	O
expression	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
enhanced	NN	O	O
estradiol	NN	O	O
inactivation	NN	O	O
by	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
link	NN	O	O
between	NN	O	O
estrogenic	NN	O	O
pathways	NN	O	O
and	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
.	NN	O	O

Experiments	NN	O	O
have	NN	O	O
been	NN	O	O
conducted	NN	O	O
to	NN	O	O
identify	NN	O	O
second	NN	O	B-protein
messengers	NN	O	I-protein
involved	NN	O	O
in	NN	O	O
this	NN	O	O
PGE2-dependent	NN	O	O
up-regulating	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
regulatory	NN	O	O
element	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
.	NN	O	O

-DOCSTART-	O

Also	NN	O	O
genes	NN	O	O
encoding	NN	O	O
proteins	NN	O	O
involved	NN	O	O
in	NN	O	O
DNA	NN	O	O
replication	NN	O	O
,	NN	O	O
binding	NN	O	O
,	NN	O	O
transcription	NN	O	O
and	NN	O	O
translation	NN	O	O
were	NN	O	O
induced	NN	O	O
.	NN	O	O

No	NN	O	O
effect	NN	O	O
was	NN	O	O
seen	NN	O	O
with	NN	O	O
non	NN	O	O
transfected	NN	O	B-cell_line
cells	NN	O	I-cell_line
or	NN	O	O
with	NN	O	O
cells	NN	O	O
transfected	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
plasmid	NN	O	O
.	NN	O	O

A	NN	O	O
typical	NN	O	O
seminoma	NN	O	O
was	NN	O	O
removed	NN	O	O
from	NN	O	O
the	NN	O	O
left	NN	O	O
adnexal	NN	O	O
region	NN	O	O
and	NN	O	O
an	NN	O	O
immature	NN	O	O
testis	NN	O	O
was	NN	O	O
identified	NN	O	O
separately	NN	O	O
as	NN	O	O
an	NN	O	O
associated	NN	O	O
right	NN	O	O
adnexal	NN	O	O
mass	NN	O	O
.	NN	O	O

Cepharanthine	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
suppress	NN	O	O
HIV-1	NN	O	B-DNA
LTR	NN	O	I-DNA
-driven	NN	O	O
gene	NN	O	O
expression	NN	O	O
through	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
activation	NN	O	O
.	NN	O	O

NF-kappaB	NN	O	B-protein
only	NN	O	O
partially	NN	O	O
mediates	NN	O	O
Epstein-Barr	NN	O	B-protein
virus	NN	O	I-protein
latent	NN	O	I-protein
membrane	NN	O	I-protein
protein	NN	O	I-protein
1	NN	O	I-protein
activation	NN	O	O
of	NN	O	O
B	NN	O	O
cells	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
even	NN	O	O
when	NN	O	O
LMP1	NN	O	B-protein
is	NN	O	O
unable	NN	O	O
to	NN	O	O
activate	NN	O	O
NF-kappaB	NN	O	B-protein
,	NN	O	O
it	NN	O	O
is	NN	O	O
still	NN	O	O
capable	NN	O	O
of	NN	O	O
inducing	NN	O	O
certain	NN	O	O
characteristics	NN	O	O
of	NN	O	O
activated	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
strongly	NN	O	O
suggesting	NN	O	O
that	NN	O	O
LMP1	NN	O	B-protein
can	NN	O	O
also	NN	O	O
activate	NN	O	O
cells	NN	O	O
independently	NN	O	O
of	NN	O	O
NF-kappaB	NN	O	B-protein
.	NN	O	O

A	NN	O	O
new	NN	O	O
human	NN	O	B-cell_line
leukemia	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
with	NN	O	O
an	NN	O	O
eosinophilic	NN	O	O
phenotype	NN	O	O
,	NN	O	O
designated	NN	O	O
YJ	NN	O	B-cell_line
,	NN	O	O
was	NN	O	O
established	NN	O	O
from	NN	O	O
the	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
cells	NN	O	I-cell_type
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
chronic	NN	O	O
myelomonocytic	NN	O	O
leukemia	NN	O	O
(	NN	O	O
CMMoL	NN	O	O
)	NN	O	O
with	NN	O	O
eosinophilia	NN	O	O
.	NN	O	O

Increased	NN	O	O
expression	NN	O	O
of	NN	O	O
Egr-1	NN	O	B-protein
was	NN	O	O
observed	NN	O	O
with	NN	O	O
macrophage	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Interleukin-6	NN	O	B-protein
production	NN	O	O
in	NN	O	O
hemorrhagic	NN	O	O
shock	NN	O	O
is	NN	O	O
accompanied	NN	O	O
by	NN	O	O
neutrophil	NN	O	O
recruitment	NN	O	O
and	NN	O	O
lung	NN	O	O
injury	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
another	NN	O	O
group	NN	O	O
of	NN	O	O
28	NN	O	O
patients	NN	O	O
(	NN	O	O
three	NN	O	O
individuals	NN	O	O
from	NN	O	O
the	NN	O	O
first	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
abnormal	NN	O	O
NFkappaB	NN	O	B-protein
activation	NN	O	O
was	NN	O	O
studied	NN	O	O
using	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assays	NN	O	O
after	NN	O	O
activation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
phorbol	NN	O	O
myristate	NN	O	O
acetate/ionomycin	NN	O	O
or	NN	O	O
anti-CD3	NN	O	B-protein
monoclonal	NN	O	I-protein
antibody	NN	O	I-protein
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
impaired	NN	O	O
activation	NN	O	O
of	NN	O	O
NFkappaB	NN	O	B-protein
does	NN	O	O
not	NN	O	O
appear	NN	O	O
linked	NN	O	O
to	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
TCRzeta	NN	O	B-protein
expression	NN	O	O
,	NN	O	O
because	NN	O	O
in	NN	O	O
five	NN	O	O
patients	NN	O	O
,	NN	O	O
normal	NN	O	O
TCRzeta	NN	O	B-protein
levels	NN	O	O
were	NN	O	O
present	NN	O	O
although	NN	O	O
kappaB	NN	O	B-protein
binding	NN	O	O
was	NN	O	O
not	NN	O	O
inducible	NN	O	O
.	NN	O	O

GATA-3	NN	O	B-protein
-dependent	NN	O	O
enhancer	NN	O	O
activity	NN	O	O
in	NN	O	O
IL-4	NN	O	B-DNA
gene	NN	O	I-DNA
regulation	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
analyzed	NN	O	O
de	NN	O	O
novo	NN	O	O
radiation-induced	NN	O	O
translocations	NN	O	O
between	NN	O	O
the	NN	O	O
Xi	NN	O	B-DNA
and	NN	O	O
autosomes	NN	O	B-DNA
to	NN	O	O
study	NN	O	O
the	NN	O	O
maintenance	NN	O	O
and	NN	O	O
spreading	NN	O	O
of	NN	O	O
X-chromosome	NN	O	B-DNA
inactivation	NN	O	O
(	NN	O	O
X	NN	O	O
inactivation	NN	O	O
)	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
position	NN	O	O
of	NN	O	O
the	NN	O	O
X-inactivation	NN	O	O
center	NN	O	O
(	NN	O	B-DNA
XIC	NN	O	I-DNA
)	NN	O	I-DNA
/XIST	NN	O	I-DNA
in	NN	O	O
differentiated	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

Jun	NN	O	B-protein
kinase	NN	O	I-protein
then	NN	O	O
facilitates	NN	O	O
the	NN	O	O
binding	NN	O	O
of	NN	O	O
c-Jun/c-Fos	NN	O	B-protein
heterodimers	NN	O	I-protein
to	NN	O	O
the	NN	O	O
AP-1	NN	O	B-DNA
consensus	NN	O	I-DNA
site	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
subsequent	NN	O	O
transcriptional	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
interleukin-2	NN	O	B-DNA
promoter	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
data	NN	O	O
elucidate	NN	O	O
differences	NN	O	O
between	NN	O	O
TCR	NN	O	B-protein
and	NN	O	O
CD2	NN	O	B-protein
signaling	NN	O	O
pathways	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

This	NN	O	O
stimulation	NN	O	O
is	NN	O	O
abrogated	NN	O	O
by	NN	O	O
mutations	NN	O	O
affecting	NN	O	O
the	NN	O	O
E2F-binding	NN	O	B-DNA
sites	NN	O	I-DNA
.	NN	O	O

Immunofluorescence	NN	O	O
studies	NN	O	O
using	NN	O	O
an	NN	O	O
Ab	NN	O	O
to	NN	O	O
the	NN	O	O
RelA	NN	O	B-protein
(	NN	O	I-protein
p65	NN	O	I-protein
)	NN	O	I-protein
subunit	NN	O	I-protein
of	NN	O	O
nuclear	NN	O	O
factor-kappa	NN	O	B-protein
B	NN	O	I-protein
revealed	NN	O	O
that	NN	O	O
iNO	NN	O	O
inhibited	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor-kappa	NN	O	I-protein
B	NN	O	I-protein
.	NN	O	O

Detection	NN	O	O
of	NN	O	O
oestrogen	NN	O	B-protein
receptor	NN	O	I-protein
variants	NN	O	I-protein
in	NN	O	O
endometrium	NN	O	O
,	NN	O	O
myometrium	NN	O	O
,	NN	O	O
leiomyoma	NN	O	O
and	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
:	NN	O	O
comparison	NN	O	O
to	NN	O	O
variants	NN	O	O
present	NN	O	O
in	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

Variants	NN	O	O
with	NN	O	O
exons	NN	O	B-DNA
2	NN	O	I-DNA
and	NN	O	I-DNA
7	NN	O	I-DNA
deleted	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
all	NN	O	O
specimens	NN	O	O
tested	NN	O	O
.	NN	O	O

The	NN	O	O
Duffy	NN	O	O
blood	NN	O	O
group	NN	O	O
system	NN	O	O
is	NN	O	O
of	NN	O	O
clinical	NN	O	O
and	NN	O	O
biological	NN	O	O
significance	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
report	NN	O	O
on	NN	O	O
the	NN	O	O
establishment	NN	O	O
and	NN	O	O
characterization	NN	O	O
of	NN	O	O
two	NN	O	O
novel	NN	O	O
lymphoma	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
(	NN	O	O
CRO-AP/3	NN	O	B-cell_line
and	NN	O	O
CRO-AP/5	NN	O	B-cell_line
)	NN	O	O
which	NN	O	O
carry	NN	O	O
infection	NN	O	O
by	NN	O	O
human	NN	O	O
herpesvirus	NN	O	O
type-8	NN	O	O
(	NN	O	O
HHV-8	NN	O	O
)	NN	O	O
and	NN	O	O
have	NN	O	O
derived	NN	O	O
from	NN	O	O
AIDS-related	NN	O	O
primary	NN	O	O
effusion	NN	O	O
lymphoma	NN	O	O
(	NN	O	O
PEL	NN	O	B-cell_line
)	NN	O	O
.	NN	O	O

Upon	NN	O	O
cell	NN	O	O
activation	NN	O	O
,	NN	O	O
displacement	NN	O	O
of	NN	O	O
the	NN	O	O
autoinhibitory	NN	O	B-protein
domain	NN	O	I-protein
by	NN	O	O
calmodulin	NN	O	B-protein
binding	NN	O	O
allows	NN	O	O
NFAT	NN	O	B-protein
to	NN	O	O
bind	NN	O	O
additionally	NN	O	O
to	NN	O	O
the	NN	O	O
calcineurin	NN	O	B-protein
active	NN	O	I-protein
site	NN	O	I-protein
,	NN	O	O
thus	NN	O	O
positioning	NN	O	O
NFAT	NN	O	B-protein
for	NN	O	O
immediate	NN	O	O
dephosphorylation	NN	O	O
at	NN	O	O
functional	NN	O	O
phosphoserine	NN	O	O
residues	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
age-related	NN	O	O
hyporesponsiveness	NN	O	O
can	NN	O	O
not	NN	O	O
be	NN	O	O
attributed	NN	O	O
to	NN	O	O
a	NN	O	O
skewing	NN	O	O
of	NN	O	O
the	NN	O	O
T	NN	O	O
cell	NN	O	O
population	NN	O	O
towards	NN	O	O
a	NN	O	O
memory	NN	O	O
phenotype	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

Molecular	NN	O	O
and	NN	O	O
cellular	NN	O	O
analysis	NN	O	O
of	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus-induced	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
lymphoblastoid	NN	O	B-protein
T-cell-line-expressing	NN	O	I-protein
wild-type	NN	O	I-protein
and	NN	O	I-protein
mutated	NN	O	I-protein
CD4	NN	O	I-protein
receptors	NN	O	I-protein
.	NN	O	O

Apoptosis	NN	O	O
was	NN	O	O
prevented	NN	O	O
when	NN	O	O
CD4	NN	O	B-protein
truncated	NN	O	O
at	NN	O	O
residue	NN	O	O
402	NN	O	O
was	NN	O	O
expressed	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
cells	NN	O	O
expressing	NN	O	O
mutated	NN	O	O
receptors	NN	O	O
that	NN	O	O
do	NN	O	O
not	NN	O	O
associate	NN	O	O
with	NN	O	O
p56	NN	O	B-protein
(	NN	O	I-protein
lck	NN	O	I-protein
)	NN	O	I-protein
(	NN	O	O
mutated	NN	O	O
at	NN	O	O
the	NN	O	O
dicysteine	NN	O	B-protein
motif	NN	O	I-protein
and	NN	O	O
truncated	NN	O	O
at	NN	O	O
residue	NN	O	O
418	NN	O	O
)	NN	O	O
but	NN	O	O
which	NN	O	O
conserved	NN	O	O
proximal	NN	O	O
domains	NN	O	O
of	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	B-protein
tail	NN	O	I-protein
underwent	NN	O	O
apoptosis	NN	O	O
like	NN	O	O
wild-	NN	O	B-protein
type	NN	O	I-protein
CD4	NN	O	I-protein
.	NN	O	O

During	NN	O	O
this	NN	O	O
process	NN	O	O
a	NN	O	O
sequence	NN	O	O
of	NN	O	O
cellular	NN	O	O
,	NN	O	O
humoral	NN	O	O
,	NN	O	O
non-specific	NN	O	O
and	NN	O	O
specific	NN	O	O
actions	NN	O	O
are	NN	O	O
evoked	NN	O	O
to	NN	O	O
combat	NN	O	O
the	NN	O	O
infection	NN	O	O
.	NN	O	O

Transfection	NN	O	O
with	NN	O	O
C/EBP	NN	O	B-protein
alpha	NN	O	I-protein
revealed	NN	O	O
a	NN	O	O
massive	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
MRP14	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
both	NN	O	O
,	NN	O	O
HL	NN	O	B-cell_type
60	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
granulocytic	NN	O	O
differentiated	NN	O	O
)	NN	O	O
and	NN	O	O
L132	NN	O	B-cell_type
fibroblasts	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
commonly	NN	O	O
prescribed	NN	O	O
anti-inflammatory	NN	O	O
drug	NN	O	O
,	NN	O	O
acetyl	NN	O	O
salicylic	NN	O	O
acid	NN	O	O
(	NN	O	O
ASA	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
IL-12	NN	O	B-protein
production	NN	O	O
and	NN	O	O
Th1	NN	O	O
cell	NN	O	O
development	NN	O	O
.	NN	O	O

The	NN	O	O
locus	NN	O	B-DNA
control	NN	O	I-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
beta-globin	NN	O	B-DNA
cluster	NN	O	I-DNA
contains	NN	O	O
five	NN	O	O
DNase	NN	O	B-DNA
I	NN	O	I-DNA
hypersensitive	NN	O	I-DNA
sites	NN	O	I-DNA
(	NN	O	O
5'HS1-5	NN	O	B-DNA
)	NN	O	O
required	NN	O	O
for	NN	O	O
locus	NN	O	O
activation	NN	O	O
.	NN	O	O

Because	NN	O	O
point	NN	O	O
mutagenesis	NN	O	O
can	NN	O	O
not	NN	O	O
distinguish	NN	O	O
between	NN	O	O
family	NN	O	O
members	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
which	NN	O	O
protein	NN	O	O
activates	NN	O	O
5'HS3	NN	O	B-DNA
.	NN	O	O

CIITA	NN	O	B-protein
B-cell-specific	NN	O	B-DNA
promoter	NN	O	I-DNA
suppression	NN	O	O
in	NN	O	O
MHC	NN	O	B-cell_line
class	NN	O	I-cell_line
II-silenced	NN	O	I-cell_line
cell	NN	O	I-cell_line
hybrids	NN	O	I-cell_line
.	NN	O	O

Class	NN	O	O
II	NN	O	O
transactivator-independent	NN	O	O
endothelial	NN	O	O
cell	NN	O	O
MHC	NN	O	B-protein
class	NN	O	I-protein
II	NN	O	I-protein
gene	NN	O	O
activation	NN	O	O
induced	NN	O	O
by	NN	O	O
lymphocyte	NN	O	O
adhesion	NN	O	O
.	NN	O	O

When	NN	O	O
used	NN	O	O
in	NN	O	O
combination	NN	O	O
,	NN	O	O
the	NN	O	O
polyamides	NN	O	O
inhibit	NN	O	O
virus	NN	O	O
replication	NN	O	O
by	NN	O	O
>	NN	O	O
99	NN	O	O
%	NN	O	O
in	NN	O	O
isolated	NN	O	B-cell_type
human	NN	O	I-cell_type
peripheral	NN	O	I-cell_type
blood	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
,	NN	O	O
with	NN	O	O
no	NN	O	O
detectable	NN	O	O
cell	NN	O	O
toxicity	NN	O	O
.	NN	O	O

Cytokines	NN	O	O
stimulate	NN	O	O
granulopoiesis	NN	O	O
through	NN	O	O
signaling	NN	O	O
via	NN	O	O
receptors	NN	O	O
whose	NN	O	O
expression	NN	O	O
is	NN	O	O
controlled	NN	O	O
by	NN	O	O
lineage-specific	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

Previously	NN	O	O
,	NN	O	O
we	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
granulocyte	NN	O	B-RNA
colony-stimulating	NN	O	I-RNA
factor	NN	O	I-RNA
(	NN	O	I-RNA
G-CSF	NN	O	I-RNA
)	NN	O	I-RNA
receptor	NN	O	I-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
undetectable	NN	O	O
and	NN	O	O
granulocyte	NN	O	O
maturation	NN	O	O
blocked	NN	O	O
in	NN	O	O
CCAAT	NN	O	B-protein
enhancer	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
alpha	NN	O	I-protein
(	NN	O	O
C/EBPalpha	NN	O	B-protein
)	NN	O	O
-deficient	NN	O	O
mice	NN	O	O
.	NN	O	O

Using	NN	O	O
retinoids	NN	O	O
with	NN	O	O
different	NN	O	O
receptor	NN	O	O
binding	NN	O	O
specificity	NN	O	O
(	NN	O	O
CD336	NN	O	O
,	NN	O	O
CD437	NN	O	O
,	NN	O	O
CD2019	NN	O	O
,	NN	O	O
CD367	NN	O	O
)	NN	O	O
,	NN	O	O
dose-dependent	NN	O	O
inhibition	NN	O	O
of	NN	O	O
IgE	NN	O	B-protein
synthesis	NN	O	O
was	NN	O	O
shown	NN	O	O
by	NN	O	O
all	NN	O	O
four	NN	O	O
derivates	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
most	NN	O	O
marked	NN	O	O
by	NN	O	O
an	NN	O	O
RA	NN	O	O
binding	NN	O	O
the	NN	O	O
alpha	NN	O	B-protein
receptor	NN	O	I-protein
with	NN	O	O
high	NN	O	O
specificity	NN	O	O
.	NN	O	O

Transfection	NN	O	O
of	NN	O	O
kinase-deficient	NN	O	O
mutants	NN	O	O
of	NN	O	O
IKKalpha	NN	O	B-protein
and	NN	O	O
IKKbeta	NN	O	B-protein
into	NN	O	O
either	NN	O	O
human	NN	O	B-cell_line
Jurkat	NN	O	I-cell_line
T	NN	O	I-cell_line
or	NN	O	I-cell_line
293	NN	O	I-cell_line
cells	NN	O	I-cell_line
also	NN	O	O
inhibits	NN	O	O
NF-kappaB	NN	O	B-protein
-dependent	NN	O	O
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
induced	NN	O	O
by	NN	O	O
Tax	NN	O	B-protein
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
reported	NN	O	O
that	NN	O	O
the	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
and	NN	O	O
interleukin	NN	O	B-protein
1	NN	O	I-protein
signaling	NN	O	O
pathways	NN	O	O
activate	NN	O	O
two	NN	O	O
kinases	NN	O	O
,	NN	O	O
IKK1	NN	O	B-protein
and	NN	O	O
IKK2	NN	O	B-protein
.	NN	O	O

In	NN	O	O
this	NN	O	O
communication	NN	O	O
,	NN	O	O
we	NN	O	O
present	NN	O	O
evidence	NN	O	O
to	NN	O	O
show	NN	O	O
that	NN	O	O
these	NN	O	O
proteins	NN	O	O
inhibit	NN	O	O
tumor	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
by	NN	O	O
participating	NN	O	O
in	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
tumor	NN	O	O
cell	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Transcription	NN	O	B-protein
factor	NN	O	I-protein
activation	NN	O	O
in	NN	O	O
lymphokine	NN	O	O
activated	NN	O	O
killer	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
lymphocytes	NN	O	B-cell_type
from	NN	O	O
patients	NN	O	O
receiving	NN	O	O
IL-2	NN	O	B-protein
immunotherapy	NN	O	O
.	NN	O	O

One	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
describe	NN	O	O
the	NN	O	O
profile	NN	O	O
of	NN	O	O
transcription	NN	O	O
factor	NN	O	O
activation	NN	O	O
in	NN	O	O
these	NN	O	O
different	NN	O	O
populations	NN	O	O
,	NN	O	O
and	NN	O	O
assess	NN	O	O
whether	NN	O	O
the	NN	O	O
patterns	NN	O	O
observed	NN	O	O
correlated	NN	O	O
with	NN	O	O
functional	NN	O	O
differences	NN	O	O
in	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Monolayers	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
umbilical	NN	O	I-cell_type
vein	NN	O	I-cell_type
endothelial	NN	O	I-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
incubated	NN	O	O
with	NN	O	O
nonstimulated	NN	O	O
or	NN	O	O
ADP-activated	NN	O	B-cell_type
platelets	NN	O	I-cell_type
for	NN	O	O
6	NN	O	O
hours	NN	O	O
,	NN	O	O
and	NN	O	O
secretion	NN	O	O
of	NN	O	O
MCP-1	NN	O	B-protein
and	NN	O	O
surface	NN	O	O
expression	NN	O	O
of	NN	O	O
ICAM-1	NN	O	B-protein
were	NN	O	O
determined	NN	O	O
by	NN	O	O
ELISA	NN	O	O
and	NN	O	O
flow	NN	O	O
cytometry	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
while	NN	O	O
ligand-activated	NN	O	O
c-erbA/TR	NN	O	B-protein
accelerated	NN	O	O
differentiation	NN	O	O
,	NN	O	O
unliganded	NN	O	O
c-erbA/TR	NN	O	B-protein
effectively	NN	O	O
blocked	NN	O	O
differentiation	NN	O	O
and	NN	O	O
supported	NN	O	O
sustained	NN	O	O
progenitor	NN	O	O
growth	NN	O	O
in	NN	O	O
culture	NN	O	O
.	NN	O	O

-DOCSTART-	O

Expression	NN	O	O
of	NN	O	O
gamma-IFN	NN	O	B-DNA
responsive	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
scavenger	NN	O	O
receptor	NN	O	O
over-expressing	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
is	NN	O	O
associated	NN	O	O
with	NN	O	O
xanthomatosis	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
gamma-interferon	NN	O	B-protein
inducible	NN	O	I-protein
protein	NN	O	I-protein
10	NN	O	I-protein
(	NN	O	O
IP-10	NN	O	B-protein
)	NN	O	O
,	NN	O	O
a	NN	O	O
STAT1alpha-responsive	NN	O	B-DNA
gene	NN	O	I-DNA
and	NN	O	O
mediator	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
response	NN	O	O
,	NN	O	O
was	NN	O	O
also	NN	O	O
abnormally	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
monocytes	NN	O	B-cell_type
from	NN	O	O
II-2	NN	O	B-cell_line
.	NN	O	O

Electrophoretic	NN	O	O
mobility-shift	NN	O	O
assays	NN	O	O
revealed	NN	O	O
that	NN	O	O
recombinant	NN	O	O
IL-2	NN	O	B-protein
increased	NN	O	O
NF-kappaB	NN	O	B-protein
binding	NN	O	O
activity	NN	O	O
in	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
of	NN	O	O
the	NN	O	O
leukemia	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
Northern	NN	O	O
blot	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
IL-2	NN	O	B-protein
increased	NN	O	O
the	NN	O	O
abundance	NN	O	O
of	NN	O	O
mRNAs	NN	O	O
encoding	NN	O	O
the	NN	O	O
NF-kappaB	NN	O	B-protein
components	NN	O	O
c-Rel	NN	O	B-protein
and	NN	O	O
KBF1	NN	O	B-protein
in	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	O
levels	NN	O	O
of	NN	O	O
c-Rel	NN	O	B-protein
and	NN	O	O
Rel	NN	O	B-protein
A	NN	O	I-protein
were	NN	O	O
normal	NN	O	O
in	NN	O	O
freshly	NN	O	O
isolated	NN	O	O
tumor-draining	NN	O	O
LN	NN	O	O
,	NN	O	O
as	NN	O	O
was	NN	O	O
nuclear	NN	O	O
kappaB	NN	O	B-protein
DNA-binding	NN	O	O
activity	NN	O	O
induced	NN	O	O
by	NN	O	O
anti-CD3	NN	O	B-protein
mAb	NN	O	I-protein
or	NN	O	O
phorbol	NN	O	O
myristate	NN	O	O
acetate	NN	O	O
.	NN	O	O

The	NN	O	O
mutated	NN	O	B-DNA
human	NN	O	I-DNA
CIITA	NN	O	I-DNA
constructs	NN	O	I-DNA
were	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
tested	NN	O	O
in	NN	O	O
the	NN	O	O
pig	NN	O	O
.	NN	O	O

Macrophages	NN	O	B-cell_type
in	NN	O	O
human	NN	O	O
atheroma	NN	O	O
contain	NN	O	O
PPARgamma	NN	O	B-protein
:	NN	O	O
differentiation-dependent	NN	O	B-protein
peroxisomal	NN	O	I-protein
proliferator-activated	NN	O	I-protein
receptor	NN	O	I-protein
gamma	NN	O	I-protein
(	NN	O	O
PPARgamma	NN	O	B-protein
)	NN	O	O
expression	NN	O	O
and	NN	O	O
reduction	NN	O	O
of	NN	O	O
MMP-9	NN	O	B-protein
activity	NN	O	O
through	NN	O	O
PPARgamma	NN	O	B-protein
activation	NN	O	O
in	NN	O	O
mononuclear	NN	O	O
phagocytes	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

This	NN	O	O
inhibition	NN	O	O
correlates	NN	O	O
with	NN	O	O
decreased	NN	O	O
MMP-9	NN	O	B-protein
secretion	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
Western	NN	O	O
blotting	NN	O	O
.	NN	O	O

Purified	NN	O	B-cell_type
quiescent	NN	O	I-cell_type
human	NN	O	I-cell_type
blood	NN	O	I-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
:	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
acute	NN	O	O
exposure	NN	O	O
to	NN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
chronic	NN	O	O
exposure	NN	O	O
to	NN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
;	NN	O	O
and	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
acute	NN	O	O
exposure	NN	O	O
to	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
.	NN	O	O

Rearrangement	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
genes	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
all	NN	O	O
cases	NN	O	O
with	NN	O	O
balanced	NN	O	O
t	NN	O	B-DNA
(	NN	O	I-DNA
10	NN	O	I-DNA
;	NN	O	I-DNA
11	NN	O	I-DNA
)	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Role	NN	O	O
of	NN	O	O
GATA-1	NN	O	B-protein
in	NN	O	O
proliferation	NN	O	O
and	NN	O	O
differentiation	NN	O	O
of	NN	O	O
definitive	NN	O	O
erythroid	NN	O	B-cell_type
and	NN	O	I-cell_type
megakaryocytic	NN	O	I-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

This	NN	O	O
translocation	NN	O	O
is	NN	O	O
characteristic	NN	O	O
of	NN	O	O
a	NN	O	O
small	NN	O	O
subset	NN	O	O
of	NN	O	O
non-Hodgkin	NN	O	O
lymphomas	NN	O	O
exhibiting	NN	O	O
plasmacytoid	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Expression	NN	O	O
cloning	NN	O	O
with	NN	O	O
this	NN	O	O
region	NN	O	O
of	NN	O	O
DNA	NN	O	O
now	NN	O	O
shows	NN	O	O
that	NN	O	O
tegument	NN	O	B-protein
protein	NN	O	I-protein
VP22	NN	O	B-protein
and	NN	O	O
the	NN	O	O
viral	NN	O	B-protein
dUTPase	NN	O	I-protein
,	NN	O	O
encoded	NN	O	O
by	NN	O	O
genes	NN	O	B-DNA
UL49	NN	O	I-DNA
and	NN	O	I-DNA
UL50	NN	O	I-DNA
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
are	NN	O	O
T-cell	NN	O	B-protein
antigens	NN	O	I-protein
.	NN	O	O

Blocking	NN	O	O
mAbs	NN	O	B-protein
against	NN	O	O
CD18	NN	O	B-protein
and	NN	O	O
CD11b	NN	O	B-protein
abrogated	NN	O	O
fibrinogen	NN	O	B-protein
-induced	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
and	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
prepared	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
SLE	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
and	NN	O	O
healthy	NN	O	O
donors	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

Some	NN	O	O
monocytes	NN	O	B-cell_type
and	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
were	NN	O	O
stimulated	NN	O	O
with	NN	O	O
estradiol	NN	O	O
,	NN	O	O
PMA	NN	O	O
,	NN	O	O
and	NN	O	O
ionomycin	NN	O	O
.	NN	O	O

These	NN	O	O
stimuli	NN	O	O
also	NN	O	O
induced	NN	O	O
the	NN	O	O
stress-activated	NN	O	O
kinase	NN	O	O
pathway	NN	O	O
(	NN	O	O
SAPK	NN	O	B-protein
/JNK	NN	O	B-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
maximal	NN	O	O
induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

Using	NN	O	O
the	NN	O	O
1G5	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
harbouring	NN	O	O
the	NN	O	O
luciferase	NN	O	B-DNA
reporter	NN	O	I-DNA
gene	NN	O	I-DNA
under	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
HIV-1	NN	O	B-DNA
LTR	NN	O	I-DNA
,	NN	O	O
it	NN	O	O
was	NN	O	O
first	NN	O	O
found	NN	O	O
that	NN	O	O
culture	NN	O	O
protein	NN	O	O
filtrates	NN	O	O
(	NN	O	O
CFP	NN	O	O
)	NN	O	O
from	NN	O	O
M.	NN	O	O
tuberculosis	NN	O	O
or	NN	O	O
purified	NN	O	O
ManLAM	NN	O	O
could	NN	O	O
activate	NN	O	O
HIV-1	NN	O	B-DNA
LTR-dependent	NN	O	I-DNA
gene	NN	O	I-DNA
expression	NN	O	O
unlike	NN	O	O
similarly	NN	O	O
prepared	NN	O	O
CFP	NN	O	O
extracts	NN	O	O
devoid	NN	O	O
of	NN	O	O
ManLAM	NN	O	O
.	NN	O	O

In	NN	O	O
lymphocyte	NN	O	B-cell_type
differentiation	NN	O	O
,	NN	O	O
several	NN	O	O
HMG	NN	O	B-protein
box	NN	O	I-protein
proteins	NN	O	I-protein
play	NN	O	O
a	NN	O	O
decisive	NN	O	O
role	NN	O	O
.	NN	O	O

Sequence	NN	O	O
analysis	NN	O	O
of	NN	O	O
nine	NN	O	O
different	NN	O	O
2.3-kb	NN	O	O
cDNA	NN	O	O
clones	NN	O	O
obtained	NN	O	O
from	NN	O	O
NK-derived	NN	O	O
polyA+	NN	O	O
RNA	NN	O	O
confirmed	NN	O	O
that	NN	O	O
they	NN	O	O
corresponded	NN	O	O
to	NN	O	O
an	NN	O	O
unrearranged	NN	O	O
TcR	NN	O	B-DNA
delta	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

Fos	NN	O	O
proteins	NN	O	O
are	NN	O	O
not	NN	O	O
needed	NN	O	O
for	NN	O	O
this	NN	O	O
reconstitution	NN	O	O
,	NN	O	O
and	NN	O	O
although	NN	O	O
JunB	NN	O	B-protein
is	NN	O	O
not	NN	O	O
functional	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
NF-AT	NN	O	B-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
complex	NN	O	I-protein
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
partially	NN	O	O
purified	NN	O	O
the	NN	O	O
cytoplasmic	NN	O	O
component	NN	O	O
of	NN	O	O
NF-AT	NN	O	O
and	NN	O	O
show	NN	O	O
by	NN	O	O
elution	NN	O	O
and	NN	O	O
renaturation	NN	O	O
from	NN	O	O
SDS-polyacrylamide	NN	O	O
gel	NN	O	O
electrophoresis	NN	O	O
gels	NN	O	O
that	NN	O	O
it	NN	O	O
has	NN	O	O
a	NN	O	O
molecular	NN	O	O
mass	NN	O	O
between	NN	O	O
94	NN	O	O
and	NN	O	O
116	NN	O	O
kDa	NN	O	O
and	NN	O	O
may	NN	O	O
have	NN	O	O
multiple	NN	O	O
differentially	NN	O	O
modified	NN	O	O
forms	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
'	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
concentrations	NN	O	O
were	NN	O	O
normal	NN	O	O
or	NN	O	O
slightly	NN	O	O
elevated	NN	O	O
.	NN	O	O

Despite	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
GR	NN	O	B-protein
count	NN	O	O
and	NN	O	O
affinity	NN	O	O
in	NN	O	O
MNC	NN	O	B-cell_type
from	NN	O	O
septic	NN	O	O
patients	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
those	NN	O	O
in	NN	O	O
normal	NN	O	O
controls	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
glucocorticoids	NN	O	O
could	NN	O	O
still	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
hemodynamic	NN	O	O
compensatory	NN	O	O
phase	NN	O	O
of	NN	O	O
sepsis	NN	O	O
.	NN	O	O

The	NN	O	O
impaired	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
AP-1	NN	O	I-protein
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
derived	NN	O	O
from	NN	O	O
subjects	NN	O	O
with	NN	O	O
some	NN	O	O
symptoms	NN	O	O
of	NN	O	O
premature	NN	O	O
aging	NN	O	O
.	NN	O	O

-DOCSTART-	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
IL-2	NN	O	B-protein
induces	NN	O	O
gene	NN	O	O
expression	NN	O	O
of	NN	O	O
M-CSF	NN	O	B-protein
in	NN	O	O
human	NN	O	B-cell_type
blood-derived	NN	O	I-cell_type
Mo	NN	O	I-cell_type
and	NN	O	O
provide	NN	O	O
evidence	NN	O	O
for	NN	O	O
involvement	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
in	NN	O	O
transcriptional	NN	O	O
regulation	NN	O	O
of	NN	O	O
this	NN	O	O
gene	NN	O	O
.	NN	O	O

Within	NN	O	O
this	NN	O	O
DNA	NN	O	O
fragment	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
two	NN	O	O
novel	NN	O	O
9-bp	NN	O	O
motifs	NN	O	O
(	NN	O	O
-90/-82	NN	O	O
and	NN	O	O
-40/-32	NN	O	O
)	NN	O	O
with	NN	O	O
high	NN	O	O
homology	NN	O	O
to	NN	O	O
the	NN	O	O
nuclear	NN	O	B-DNA
factor-IL6	NN	O	I-DNA
(	NN	O	I-DNA
NF-IL6	NN	O	I-DNA
)	NN	O	I-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Mitogen-mediated	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
CAT	NN	O	B-DNA
gene	NN	O	I-DNA
in	NN	O	O
this	NN	O	O
construct	NN	O	O
was	NN	O	O
inhibited	NN	O	O
in	NN	O	O
Nef-expressing	NN	O	B-cell_line
cells	NN	O	I-cell_line
but	NN	O	O
not	NN	O	O
in	NN	O	O
control	NN	O	O
cells	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
tissue	NN	O	O
specificity	NN	O	O
of	NN	O	O
this	NN	O	O
promoter	NN	O	B-DNA
is	NN	O	O
only	NN	O	O
partial	NN	O	O
because	NN	O	O
it	NN	O	O
is	NN	O	O
active	NN	O	O
in	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
hematopoietic	NN	O	B-cell_type
cells	NN	O	I-cell_type
tested	NN	O	O
here	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
whether	NN	O	O
they	NN	O	O
constitutively	NN	O	O
express	NN	O	O
Fc	NN	O	O
epsilon	NN	O	O
RI-	NN	O	O
gamma	NN	O	B-protein
chain	NN	O	I-protein
transcripts	NN	O	O
.	NN	O	O

The	NN	O	O
hypothesis	NN	O	O
to	NN	O	O
be	NN	O	O
tested	NN	O	O
was	NN	O	O
whether	NN	O	O
or	NN	O	O
not	NN	O	O
humans	NN	O	O
exhibit	NN	O	O
a	NN	O	O
similar	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
PCDDs/PCDFs	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
surface	NN	O	B-protein
receptors	NN	O	I-protein
found	NN	O	O
previously	NN	O	O
to	NN	O	O
respond	NN	O	O
to	NN	O	O
small	NN	O	O
doses	NN	O	O
of	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
8-tetrachlorodibenzo-p-dioxin	NN	O	O
(	NN	O	O
TCDD	NN	O	O
)	NN	O	O
in	NN	O	O
Callithrix	NN	O	O
jacchus	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
interleukin-2	NN	O	B-DNA
(	NN	O	I-DNA
IL-2	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
activation	NN	O	O
shows	NN	O	O
that	NN	O	O
naive	NN	O	B-cell_type
human	NN	O	I-cell_type
helper	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
cord	NN	O	B-cell_type
blood	NN	O	I-cell_type
CD4+	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
adult	NN	O	B-cell_type
CD4+CD45RO-	NN	O	I-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
)	NN	O	O
regulate	NN	O	O
IL-2	NN	O	B-protein
transcription	NN	O	O
by	NN	O	O
a	NN	O	O
mechanism	NN	O	O
involving	NN	O	O
both	NN	O	O
a	NN	O	O
silencer	NN	O	B-DNA
and	NN	O	O
an	NN	O	O
activator	NN	O	B-DNA
acting	NN	O	O
on	NN	O	O
the	NN	O	O
purine-rich	NN	O	B-DNA
IL-2	NN	O	I-DNA
promoter	NN	O	I-DNA
elements	NN	O	I-DNA
(	NN	O	O
NF-AT	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
)	NN	O	O
.	NN	O	O

Exploration	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
induction	NN	O	O
of	NN	O	O
DNA-binding	NN	O	B-protein
proteins	NN	O	I-protein
and	NN	O	O
characterization	NN	O	O
of	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
activity	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
viral	NN	O	O
proteins	NN	O	O
involved	NN	O	O
in	NN	O	O
this	NN	O	O
process	NN	O	O
might	NN	O	O
be	NN	O	O
the	NN	O	O
Tat	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

Other	NN	O	O
studies	NN	O	O
further	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
jun-B	NN	O	B-DNA
and	NN	O	O
fra-1	NN	O	B-DNA
genes	NN	O	B-DNA
are	NN	O	O
induced	NN	O	O
by	NN	O	O
TPA	NN	O	O
in	NN	O	O
both	NN	O	O
HL-60/vinc	NN	O	B-cell_line
and	NN	O	O
HL-60/vinc/R	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
whereas	NN	O	O
c-fos	NN	O	B-DNA
expression	NN	O	O
is	NN	O	O
attenuated	NN	O	O
in	NN	O	O
the	NN	O	O
HL-60/vinc	NN	O	O
line	NN	O	O
.	NN	O	O

-DOCSTART-	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
an	NN	O	O
abnormality	NN	O	O
of/or	NN	O	O
influencing	NN	O	O
NF-AT	NN	O	B-protein
may	NN	O	O
underlie	NN	O	O
the	NN	O	O
multiple	NN	O	O
lymphokine	NN	O	B-protein
deficiency	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
two	NN	O	O
structurally	NN	O	O
distinct	NN	O	O
immunophilin-drug	NN	O	B-protein
complexes	NN	O	I-protein
bind	NN	O	O
to	NN	O	O
,	NN	O	O
and	NN	O	O
inhibit	NN	O	O
,	NN	O	O
the	NN	O	O
phosphatase	NN	O	B-protein
activity	NN	O	O
of	NN	O	O
calcineurin	NN	O	B-protein
.	NN	O	O

The	NN	O	O
Rel/NF-kappa	NN	O	B-protein
B	NN	O	I-protein
family	NN	O	I-protein
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
is	NN	O	O
composed	NN	O	O
of	NN	O	O
two	NN	O	O
distinct	NN	O	O
subgroups	NN	O	O
,	NN	O	O
proteins	NN	O	O
that	NN	O	O
undergo	NN	O	O
proteolytic	NN	O	O
processing	NN	O	O
and	NN	O	O
contain	NN	O	O
SWI6/ankyrin	NN	O	B-protein
repeats	NN	O	I-protein
in	NN	O	O
their	NN	O	O
carboxyl	NN	O	B-protein
termini	NN	O	I-protein
(	NN	O	O
p105	NN	O	B-protein
,	NN	O	O
p98	NN	O	B-protein
)	NN	O	O
,	NN	O	O
and	NN	O	O
those	NN	O	O
without	NN	O	O
such	NN	O	O
repeats	NN	O	O
that	NN	O	O
do	NN	O	O
not	NN	O	O
require	NN	O	O
processing	NN	O	O
(	NN	O	O
p65	NN	O	B-protein
,	NN	O	O
c-Rel	NN	O	B-protein
,	NN	O	O
RelB	NN	O	B-protein
,	NN	O	O
and	NN	O	O
Dorsal	NN	O	B-protein
)	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
adenovirus	NN	O	O
may	NN	O	O
be	NN	O	O
one	NN	O	O
cause	NN	O	O
of	NN	O	O
persistent	NN	O	O
or	NN	O	O
recurrent	NN	O	O
inflammatory	NN	O	O
arthritis	NN	O	O
.	NN	O	O

-DOCSTART-	O

Nuclear	NN	O	O
localization	NN	O	O
of	NN	O	O
these	NN	O	O
proteins	NN	O	O
occurred	NN	O	O
concomitantly	NN	O	O
with	NN	O	O
a	NN	O	O
rapid	NN	O	O
decrease	NN	O	O
in	NN	O	O
their	NN	O	O
cytosolic	NN	O	O
levels	NN	O	O
and	NN	O	O
was	NN	O	O
independent	NN	O	O
of	NN	O	O
phorbol	NN	O	B-protein
ester-sensitive	NN	O	I-protein
protein	NN	O	I-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
.	NN	O	O

The	NN	O	O
type	NN	O	B-protein
I	NN	O	I-protein
interleukin-1	NN	O	I-protein
receptor	NN	O	I-protein
(	NN	O	O
IL-1R	NN	O	B-protein
)	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
transducing	NN	O	O
a	NN	O	O
signal	NN	O	O
resulting	NN	O	O
in	NN	O	O
promoter	NN	O	O
activation	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Role	NN	O	O
of	NN	O	O
AP-1-	NN	O	B-protein
and	NN	O	I-protein
octamer-binding	NN	O	I-protein
proteins	NN	O	I-protein
in	NN	O	O
control	NN	O	O
of	NN	O	O
IL3	NN	O	B-protein
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Using	NN	O	O
transfection	NN	O	O
and	NN	O	O
reporter	NN	O	O
gene	NN	O	O
assays	NN	O	O
specifically	NN	O	O
designed	NN	O	O
for	NN	O	O
primary	NN	O	B-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
gel	NN	O	O
retardation	NN	O	O
assays	NN	O	O
,	NN	O	O
Western	NN	O	O
blot	NN	O	O
analyses	NN	O	O
and	NN	O	O
UV	NN	O	O
cross-linking	NN	O	O
studies	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
c-Jun	NN	O	B-protein
,	NN	O	O
c-Fos	NN	O	B-protein
,	NN	O	O
and	NN	O	O
octamer-binding	NN	O	B-protein
proteins	NN	O	I-protein
play	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
IL3	NN	O	B-DNA
gene	NN	O	I-DNA
via	NN	O	O
their	NN	O	O
interaction	NN	O	O
with	NN	O	O
two	NN	O	O
specific	NN	O	O
regions	NN	O	O
contained	NN	O	O
within	NN	O	O
the	NN	O	O
IL3	NN	O	B-DNA
5'-flanking	NN	O	I-DNA
sequence	NN	O	I-DNA
.	NN	O	O

Using	NN	O	O
Scatchard	NN	O	O
analysis	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
determined	NN	O	O
the	NN	O	O
dissociation	NN	O	O
constants	NN	O	O
of	NN	O	O
homodimeric	NN	O	B-protein
p49	NN	O	I-protein
and	NN	O	O
heterodimeric	NN	O	B-protein
p49/p65	NN	O	I-protein
for	NN	O	O
binding	NN	O	O
to	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
kappa	NN	O	I-DNA
B	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assays	NN	O	O
(	NN	O	O
EMSA	NN	O	O
)	NN	O	O
showed	NN	O	O
that	NN	O	O
specific	NN	O	O
NFAT	NN	O	B-protein
binding	NN	O	O
activity	NN	O	O
could	NN	O	O
also	NN	O	O
be	NN	O	O
induced	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
interpretation	NN	O	O
that	NN	O	O
glucocorticoid-mediated	NN	O	O
autoregulation	NN	O	O
of	NN	O	O
GR	NN	O	O
expression	NN	O	O
is	NN	O	O
a	NN	O	O
tissue-specific	NN	O	O
primary	NN	O	O
transcriptional	NN	O	O
response	NN	O	O
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
CD8	NN	O	B-protein
antigen	NN	O	I-protein
and	NN	O	O
suppressor	NN	O	O
activity	NN	O	O
by	NN	O	O
glucocorticoids	NN	O	O
in	NN	O	O
a	NN	O	O
CEM	NN	O	B-cell_line
human	NN	O	I-cell_line
leukemic	NN	O	I-cell_line
cell	NN	O	I-cell_line
clone	NN	O	I-cell_line
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
no	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
suppressor	NN	O	O
function	NN	O	O
in	NN	O	O
CEM	NN	O	B-cell_line
C1	NN	O	I-cell_line
cells	NN	O	I-cell_line
by	NN	O	O
dexamethasone	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

IFN	NN	O	B-protein
-MCP	NN	O	O
was	NN	O	O
not	NN	O	O
inhibited	NN	O	O
by	NN	O	O
infection	NN	O	O
with	NN	O	O
dl343	NN	O	O
,	NN	O	O
despite	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
large	NN	O	O
amounts	NN	O	O
of	NN	O	O
both	NN	O	O
early	NN	O	O
(	NN	O	O
E1B	NN	O	B-protein
,	NN	O	O
p55	NN	O	B-protein
)	NN	O	O
and	NN	O	O
late	NN	O	O
(	NN	O	O
hexon	NN	O	B-protein
)	NN	O	O
Ad	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

Replication	NN	O	O
of	NN	O	O
type	NN	O	O
1	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
viruses	NN	O	O
containing	NN	O	O
linker	NN	O	O
substitution	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
-201	NN	O	B-DNA
to	NN	O	I-DNA
-130	NN	O	I-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
previous	NN	O	O
transfection	NN	O	O
analyses	NN	O	O
using	NN	O	O
the	NN	O	O
chloramphenicol	NN	O	B-protein
acetyltransferase	NN	O	I-protein
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
system	NN	O	O
,	NN	O	O
we	NN	O	O
determined	NN	O	O
that	NN	O	O
linker	NN	O	O
substitution	NN	O	O
(	NN	O	O
LS	NN	O	O
)	NN	O	O
mutations	NN	O	O
between	NN	O	O
-201	NN	O	B-DNA
and	NN	O	I-DNA
-130	NN	O	I-DNA
(	NN	O	O
relative	NN	O	O
to	NN	O	O
the	NN	O	O
transcription	NN	O	O
start	NN	O	O
site	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
(	NN	O	O
LTR	NN	O	B-DNA
)	NN	O	O
caused	NN	O	O
moderate	NN	O	O
decreases	NN	O	O
in	NN	O	O
LTR	NN	O	B-DNA
transcriptional	NN	O	O
activity	NN	O	O
in	NN	O	O
a	NN	O	O
T-cell	NN	O	B-cell_line
line	NN	O	I-cell_line
(	NN	O	O
S.L.Zeichner	NN	O	O
,	NN	O	O
J.Y.H.	NN	O	O
Kim	NN	O	O
,	NN	O	O
and	NN	O	O
J.C.Alwine	NN	O	O
,	NN	O	O
J.Virol.65	NN	O	O
:	NN	O	O
2436-2444	NN	O	O
,	NN	O	O
1991	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
we	NN	O	O
derived	NN	O	O
an	NN	O	O
experimental	NN	O	O
system	NN	O	O
that	NN	O	O
allows	NN	O	O
us	NN	O	O
to	NN	O	O
dissect	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
GATA-1	NN	O	B-protein
in	NN	O	O
red	NN	O	B-cell_type
cell	NN	O	I-cell_type
development	NN	O	O
at	NN	O	O
a	NN	O	O
genetic	NN	O	O
level	NN	O	O
.	NN	O	O

It	NN	O	O
may	NN	O	O
be	NN	O	O
possible	NN	O	O
to	NN	O	O
produce	NN	O	O
such	NN	O	O
cells	NN	O	O
by	NN	O	O
first	NN	O	O
expressing	NN	O	O
the	NN	O	O
Epo	NN	O	B-protein
receptor	NN	O	I-protein
under	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
a	NN	O	O
constitutive	NN	O	O
promoter	NN	O	O
and	NN	O	O
then	NN	O	O
targeting	NN	O	O
the	NN	O	O
GATA-1	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Although	NN	O	O
sequences	NN	O	O
located	NN	O	O
between	NN	O	O
-559	NN	O	O
and	NN	O	O
-88	NN	O	O
of	NN	O	O
the	NN	O	O
zeta	NN	O	B-DNA
2	NN	O	I-DNA
globin	NN	O	I-DNA
gene	NN	O	I-DNA
were	NN	O	O
dispensable	NN	O	O
for	NN	O	O
its	NN	O	O
expression	NN	O	O
on	NN	O	O
enhancerless	NN	O	B-DNA
plasmids	NN	O	I-DNA
,	NN	O	O
they	NN	O	O
were	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
HS-40	NN	O	B-DNA
enhancer	NN	O	I-DNA
-mediated	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
zeta	NN	O	B-DNA
2	NN	O	I-DNA
globin	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
only	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
apparently	NN	O	O
nonfunctional	NN	O	B-DNA
sequence	NN	O	I-DNA
motifs	NN	O	I-DNA
was	NN	O	O
bound	NN	O	O
with	NN	O	O
factors	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
substitution	NN	O	O
of	NN	O	O
this	NN	O	O
GATA	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
by	NN	O	O
a	NN	O	O
canonical	NN	O	O
TFIID	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
suppresses	NN	O	O
the	NN	O	O
promoter	NN	O	O
activity	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
wild-type	NN	O	B-cell_line
B	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
neither	NN	O	O
of	NN	O	O
the	NN	O	O
class	NN	O	B-cell_line
II	NN	O	I-cell_line
mutant	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
could	NN	O	O
use	NN	O	O
the	NN	O	O
X	NN	O	B-DNA
box	NN	O	I-DNA
region	NN	O	I-DNA
to	NN	O	O
direct	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
transiently	NN	O	O
transfected	NN	O	O
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
X	NN	O	O
box-dependent	NN	O	O
transcriptional	NN	O	O
pathway	NN	O	O
is	NN	O	O
defective	NN	O	O
in	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

Human	NN	O	O
immunodeficiency	NN	O	O
viruses	NN	O	O
containing	NN	O	O
heterologous	NN	O	B-DNA
enhancer/promoters	NN	O	I-DNA
are	NN	O	O
replication	NN	O	O
competent	NN	O	O
and	NN	O	O
exhibit	NN	O	O
different	NN	O	O
lymphocyte	NN	O	O
tropisms	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
heterologous	NN	O	B-DNA
enhancer	NN	O	I-DNA
elements	NN	O	I-DNA
are	NN	O	O
capable	NN	O	O
of	NN	O	O
restoring	NN	O	O
Tat	NN	O	B-protein
responsiveness	NN	O	O
to	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
LTR	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
directing	NN	O	O
reporter	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
infectious	NN	O	O
progeny	NN	O	O
virions	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
in	NN	O	O
B-lymphocyte	NN	O	B-cell_type
precursors	NN	O	I-cell_type
,	NN	O	O
irradiation	NN	O	O
with	NN	O	O
gamma-rays	NN	O	O
leads	NN	O	O
to	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
stimulation	NN	O	O
of	NN	O	O
phosphatidylinositol	NN	O	O
turnover	NN	O	O
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
downstream	NN	O	O
activation	NN	O	O
by	NN	O	O
covalent	NN	O	O
modification	NN	O	O
of	NN	O	O
multiple	NN	O	O
serine-specific	NN	O	B-protein
protein	NN	O	I-protein
kinases	NN	O	I-protein
,	NN	O	O
including	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
;	NN	O	O
and	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
activation	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
.	NN	O	O

We	NN	O	O
have	NN	O	O
used	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
to	NN	O	O
define	NN	O	O
these	NN	O	O
rearrangements	NN	O	O
at	NN	O	O
the	NN	O	O
molecular	NN	O	O
level	NN	O	O
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
which	NN	O	O
expressed	NN	O	O
beta-	NN	O	B-DNA
and	NN	O	I-DNA
gamma-	NN	O	I-DNA
globin	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
two	NN	O	O
cell	NN	O	O
populations	NN	O	O
was	NN	O	O
measured	NN	O	O
by	NN	O	O
immunofluorescence	NN	O	O
with	NN	O	O
beta-	NN	O	B-protein
and	NN	O	I-protein
gamma-specific	NN	O	I-protein
antibodies	NN	O	I-protein
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
protein	NN	O	O
phosphatase	NN	O	O
1	NN	O	O
and	NN	O	O
2A	NN	O	O
inhibitors	NN	O	O
exert	NN	O	O
multiple	NN	O	O
effects	NN	O	O
on	NN	O	O
cytokine	NN	O	O
production	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
these	NN	O	O
two	NN	O	O
phosphatases	NN	O	B-protein
play	NN	O	O
important	NN	O	O
roles	NN	O	O
in	NN	O	O
regulating	NN	O	O
interleukin-1	NN	O	B-protein
production	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
tal-1	NN	O	B-protein
and	NN	O	O
GATA-binding	NN	O	B-protein
proteins	NN	O	I-protein
during	NN	O	O
human	NN	O	O
hematopoiesis	NN	O	O
.	NN	O	O

Tal-1	NN	O	B-protein
rearrangements	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
nearly	NN	O	O
30	NN	O	O
%	NN	O	O
of	NN	O	O
human	NN	O	O
T	NN	O	O
acute	NN	O	O
lymphoblastic	NN	O	O
leukemia	NN	O	O
.	NN	O	O

Latency	NN	O	O
breaking	NN	O	O
activity	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
was	NN	O	O
transferred	NN	O	O
from	NN	O	O
activator	NN	O	B-cell_line
to	NN	O	O
reporter	NN	O	B-cell_line
cells	NN	O	I-cell_line
when	NN	O	O
active	NN	O	O
,	NN	O	O
exogenous	NN	O	O
virus	NN	O	O
was	NN	O	O
added	NN	O	O
.	NN	O	O

We	NN	O	O
detected	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
reduced	NN	O	O
mitogenic	NN	O	O
response	NN	O	O
and	NN	O	O
low	NN	O	O
expression	NN	O	O
of	NN	O	O
both	NN	O	O
interleukin-2	NN	O	B-protein
(	NN	O	O
IL-2	NN	O	B-protein
)	NN	O	O
and	NN	O	O
the	NN	O	O
alpha	NN	O	B-protein
chain	NN	O	I-protein
(	NN	O	O
CD25	NN	O	B-protein
)	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
IL-2R	NN	O	B-protein
)	NN	O	O
.	NN	O	O

A	NN	O	O
concatenated	NN	O	O
form	NN	O	O
of	NN	O	O
Epstein-Barr	NN	O	B-DNA
viral	NN	O	I-DNA
DNA	NN	O	I-DNA
in	NN	O	O
lymphoblastoid	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
induced	NN	O	O
by	NN	O	O
transfection	NN	O	O
with	NN	O	O
BZLF1	NN	O	B-protein
.	NN	O	O

The	NN	O	O
CD20	NN	O	B-DNA
(	NN	O	I-DNA
B1	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
encodes	NN	O	O
a	NN	O	O
B	NN	O	B-protein
cell-specific	NN	O	I-protein
protein	NN	O	I-protein
involved	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
human	NN	O	O
B	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Studies	NN	O	O
with	NN	O	O
5	NN	O	B-DNA
'	NN	O	I-DNA
deletion	NN	O	I-DNA
CD20	NN	O	I-DNA
promoter-CAT	NN	O	I-DNA
constructs	NN	O	I-DNA
have	NN	O	O
previously	NN	O	O
revealed	NN	O	O
two	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
between	NN	O	O
bases	NN	O	O
-186	NN	O	O
and	NN	O	O
-280	NN	O	O
and	NN	O	O
between	NN	O	O
bases	NN	O	O
-280	NN	O	O
and	NN	O	O
-454	NN	O	O
which	NN	O	O
contained	NN	O	O
positive	NN	O	B-DNA
regulatory	NN	O	I-DNA
elements	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
affinity	NN	O	O
of	NN	O	O
the	NN	O	O
BAT	NN	O	B-protein
box	NN	O	I-protein
binding	NN	O	I-protein
proteins	NN	O	I-protein
for	NN	O	O
the	NN	O	O
BAT	NN	O	B-DNA
box	NN	O	I-DNA
was	NN	O	O
approximately	NN	O	O
25-fold	NN	O	O
less	NN	O	O
than	NN	O	O
for	NN	O	O
the	NN	O	O
octamer	NN	O	B-DNA
sequence	NN	O	I-DNA
and	NN	O	O
the	NN	O	O
BAT	NN	O	B-protein
box	NN	O	I-protein
binding	NN	O	I-protein
proteins	NN	O	I-protein
dissociated	NN	O	O
from	NN	O	O
the	NN	O	O
BAT	NN	O	B-DNA
box	NN	O	I-DNA
10-fold	NN	O	O
more	NN	O	O
rapidly	NN	O	O
than	NN	O	O
from	NN	O	O
the	NN	O	O
octamer	NN	O	B-DNA
sequence	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
tested	NN	O	O
whether	NN	O	O
a	NN	O	O
peptide	NN	O	O
(	NN	O	O
BCR1/25	NN	O	O
)	NN	O	O
encompassing	NN	O	O
the	NN	O	O
fusion	NN	O	B-protein
region	NN	O	I-protein
of	NN	O	O
the	NN	O	O
hybrid	NN	O	O
molecule	NN	O	O
pml/RAR	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
selectively	NN	O	O
expressed	NN	O	O
by	NN	O	O
acute	NN	O	B-cell_type
promyelocytic	NN	O	I-cell_type
leukemia	NN	O	I-cell_type
(	NN	O	I-cell_type
APL	NN	O	I-cell_type
)	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
can	NN	O	O
be	NN	O	O
recognized	NN	O	O
by	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
these	NN	O	O
experiments	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
EBNA2	NN	O	B-protein
interacts	NN	O	O
with	NN	O	O
an	NN	O	O
EBNA2	NN	O	B-DNA
responsive	NN	O	I-DNA
cis-element	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
TP1	NN	O	B-DNA
promoter	NN	O	I-DNA

In	NN	O	O
the	NN	O	O
present	NN	O	O
studies	NN	O	O
we	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
by	NN	O	O
which	NN	O	O
this	NN	O	O
monocyte-specific	NN	O	O
response	NN	O	O
is	NN	O	O
induced	NN	O	O
.	NN	O	O

A	NN	O	O
number	NN	O	O
of	NN	O	O
our	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
cAMP	NN	O	O
is	NN	O	O
the	NN	O	O
second	NN	O	O
messenger	NN	O	O
for	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
MM-LDL	NN	O	B-protein
cited	NN	O	O
above	NN	O	O
.	NN	O	O

Infection	NN	O	O
with	NN	O	O
the	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
(	NN	O	O
HIV	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
induce	NN	O	O
production	NN	O	O
of	NN	O	O
several	NN	O	O
cytokines	NN	O	B-protein
both	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Cloning	NN	O	O
and	NN	O	O
functional	NN	O	O
characterization	NN	O	O
of	NN	O	O
early	NN	O	B-protein
B-cell	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
a	NN	O	O
regulator	NN	O	O
of	NN	O	O
lymphocyte-specific	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
first	NN	O	O
results	NN	O	O
of	NN	O	O
continuous	NN	O	O
blood	NN	O	O
pressure	NN	O	O
measurements	NN	O	O
with	NN	O	O
a	NN	O	O
noninvasive	NN	O	O
,	NN	O	O
real-time	NN	O	O
blood	NN	O	O
pressure	NN	O	O
monitor	NN	O	O
(	NN	O	O
Finapres	NN	O	O
)	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
hypertension	NN	O	O
in	NN	O	O
preeclamptic	NN	O	O
women	NN	O	O
can	NN	O	O
be	NN	O	O
treated	NN	O	O
by	NN	O	O
Urapidil	NN	O	O
without	NN	O	O
side	NN	O	O
effects	NN	O	O
or	NN	O	O
reflex-tachycardia	NN	O	O
.	NN	O	O

Such	NN	O	O
changes	NN	O	O
clearly	NN	O	O
can	NN	O	O
not	NN	O	O
be	NN	O	O
explained	NN	O	O
by	NN	O	O
genomic	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
responsible	NN	O	O
for	NN	O	O
later	NN	O	O
effects	NN	O	O
than	NN	O	O
the	NN	O	O
membrane	NN	O	O
related	NN	O	O
rapid	NN	O	O
responses	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
c-fos	NN	O	B-DNA
,	NN	O	O
c-jun	NN	O	B-DNA
and	NN	O	O
jun	NN	O	B-DNA
B	NN	O	I-DNA
in	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
lymphocytes	NN	O	O
from	NN	O	O
young	NN	O	O
and	NN	O	O
elderly	NN	O	O
adults	NN	O	O
.	NN	O	O

Both	NN	O	O
c-fos	NN	O	B-RNA
and	NN	O	I-RNA
jun	NN	O	I-RNA
B	NN	O	I-RNA
mRNAs	NN	O	I-RNA
decreased	NN	O	O
to	NN	O	O
pre-activation	NN	O	O
levels	NN	O	O
within	NN	O	O
6	NN	O	O
h	NN	O	O
,	NN	O	O
while	NN	O	O
c-jun	NN	O	B-RNA
mRNA	NN	O	I-RNA
remained	NN	O	O
elevated	NN	O	O
.	NN	O	O

Because	NN	O	O
previous	NN	O	O
work	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
from	NN	O	O
elderly	NN	O	O
individuals	NN	O	O
may	NN	O	O
display	NN	O	O
normal	NN	O	O
proliferative	NN	O	O
responses	NN	O	O
when	NN	O	O
activated	NN	O	O
via	NN	O	O
the	NN	O	O
anti-CD2	NN	O	B-protein
pathway	NN	O	O
,	NN	O	O
c-jun	NN	O	O
and	NN	O	O
jun	NN	O	O
B	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
was	NN	O	O
also	NN	O	O
studied	NN	O	O
in	NN	O	O
anti-CD2-activated	NN	O	B-cell_line
purified	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
decreased	NN	O	O
IL-2	NN	O	B-protein
production	NN	O	O
and	NN	O	O
proliferative	NN	O	O
response	NN	O	O
displayed	NN	O	O
by	NN	O	O
PHA-activated	NN	O	B-cell_line
PBL	NN	O	I-cell_line
from	NN	O	O
elderly	NN	O	O
adults	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
age-related	NN	O	O
changes	NN	O	O
in	NN	O	O
c-jun	NN	O	B-RNA
mRNA	NN	O	I-RNA
expression	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
ratio	NN	O	O
of	NN	O	O
c-fos	NN	O	O
to	NN	O	O
c-jun	NN	O	B-RNA
mRNA	NN	O	I-RNA
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
eicosanoid	NN	O	O
synthesis	NN	O	O
in	NN	O	O
material	NN	O	O
from	NN	O	O
mammary	NN	O	O
cancer	NN	O	O
patients	NN	O	O
is	NN	O	O
different	NN	O	O
from	NN	O	O
that	NN	O	O
in	NN	O	O
benign	NN	O	O
mammary	NN	O	O
tissue	NN	O	O
.	NN	O	O

MR	NN	O	B-protein
count	NN	O	O
was	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.0005	NN	O	O
)	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
PIH	NN	O	O
group	NN	O	O
(	NN	O	O
148	NN	O	O
+/-	NN	O	O
9	NN	O	O
binding	NN	O	O
sites/cell	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
300	NN	O	O
+/-	NN	O	O
17	NN	O	O
binding	NN	O	O
sites/cell	NN	O	O
;	NN	O	O
mean	NN	O	O
+/-	NN	O	O
SEM	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
are	NN	O	O
the	NN	O	O
first	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
membrane	NN	O	O
binding	NN	O	O
sites	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
affinity	NN	O	O
for	NN	O	O
aldosterone	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
for	NN	O	O
cortisol	NN	O	O
.	NN	O	O

-DOCSTART-	O

Mineralocorticoid	NN	O	O
effector	NN	O	O
mechanism	NN	O	O
in	NN	O	O
preeclampsia	NN	O	O
.	NN	O	O

Aldosterone	NN	O	O
levels	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
nonpregnant	NN	O	O
values	NN	O	O
after	NN	O	O
delivery	NN	O	O
.	NN	O	O

E2-stimulated	NN	O	B-cell_line
ER+	NN	O	I-cell_line
cells	NN	O	I-cell_line
were	NN	O	O
more	NN	O	O
susceptible	NN	O	O
to	NN	O	O
lysis	NN	O	O
by	NN	O	O
LAK	NN	O	B-cell_type
cells	NN	O	I-cell_type
than	NN	O	O
corresponding	NN	O	O
TAM-treated	NN	O	B-cell_line
or	NN	O	O
control	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
while	NN	O	O
treatment	NN	O	O
of	NN	O	O
ER-	NN	O	B-cell_line
cells	NN	O	I-cell_line
with	NN	O	O
either	NN	O	O
E2	NN	O	O
or	NN	O	O
TAM	NN	O	O
alone	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
from	NN	O	O
control	NN	O	O
their	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
this	NN	O	O
immune-mediated	NN	O	O
lysis	NN	O	O
.	NN	O	O

These	NN	O	O
in	NN	O	O
vitro	NN	O	O
results	NN	O	O
provide	NN	O	O
a	NN	O	O
preclinical	NN	O	O
rationale	NN	O	O
for	NN	O	O
in	NN	O	O
vivo	NN	O	O
testing	NN	O	O
of	NN	O	O
TAM	NN	O	O
,	NN	O	O
interleukin-2	NN	O	B-protein
(	NN	O	O
IL-2	NN	O	B-protein
)	NN	O	O
,	NN	O	O
and	NN	O	O
breast	NN	O	O
cancer	NN	O	O
reactive	NN	O	O
antibody-dependent	NN	O	O
cellular	NN	O	O
cytotoxicity	NN	O	O
facilitating	NN	O	O
antibody	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
refractory	NN	O	O
or	NN	O	O
high	NN	O	O
risk	NN	O	O
breast	NN	O	O
cancer	NN	O	O
.	NN	O	O

The	NN	O	O
cellular	NN	O	B-DNA
oncogene	NN	O	I-DNA
c-myb	NN	O	B-DNA
can	NN	O	O
interact	NN	O	O
synergistically	NN	O	O
with	NN	O	O
the	NN	O	O
Epstein-Barr	NN	O	B-protein
virus	NN	O	I-protein
BZLF1	NN	O	I-protein
transactivator	NN	O	I-protein
in	NN	O	O
lymphoid	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Recent	NN	O	O
findings	NN	O	O
suggest	NN	O	O
an	NN	O	O
involvement	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
in	NN	O	O
signal	NN	O	O
transduction	NN	O	O
pathways	NN	O	O
leading	NN	O	O
to	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
.	NN	O	O

The	NN	O	O
latent	NN	O	O
phases	NN	O	O
of	NN	O	O
both	NN	O	O
HIV-1	NN	O	O
and	NN	O	O
HIV-2	NN	O	O
infection	NN	O	O
have	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
disrupted	NN	O	O
by	NN	O	O
T-cell	NN	O	O
activation	NN	O	O
,	NN	O	O
a	NN	O	O
process	NN	O	O
that	NN	O	O
requires	NN	O	O
host	NN	O	O
cell	NN	O	O
transcription	NN	O	O
factors	NN	O	O
.	NN	O	O

Mutagenesis	NN	O	O
experiments	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
these	NN	O	O
Elf-1	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
are	NN	O	O
required	NN	O	O
for	NN	O	O
induction	NN	O	O
of	NN	O	O
HIV-2	NN	O	O
transcription	NN	O	O
following	NN	O	O
T-cell-receptor-mediated	NN	O	O
T-cell	NN	O	O
activation	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
effect	NN	O	O
appeared	NN	O	O
within	NN	O	O
30	NN	O	O
min	NN	O	O
and	NN	O	O
returned	NN	O	O
to	NN	O	O
basal	NN	O	O
levels	NN	O	O
after	NN	O	O
2	NN	O	O
h	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
in	NN	O	O
transfection	NN	O	O
experiments	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
selective	NN	O	B-DNA
kappa	NN	O	I-DNA
B	NN	O	I-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
were	NN	O	O
used	NN	O	O
to	NN	O	O
drive	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
chloramphenicol	NN	O	B-DNA
acetyltransferase	NN	O	I-DNA
reporter	NN	O	I-DNA
construct	NN	O	I-DNA
,	NN	O	O
the	NN	O	O
p65	NN	O	B-DNA
-and	NN	O	I-DNA
p50-selected	NN	O	I-DNA
motifs	NN	O	I-DNA
were	NN	O	O
activated	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
p65	NN	O	B-protein
and	NN	O	O
p50/65	NN	O	B-protein
(	NN	O	O
a	NN	O	O
chimeric	NN	O	B-protein
protein	NN	O	I-protein
with	NN	O	O
the	NN	O	O
p50	NN	O	B-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
and	NN	O	O
p65	NN	O	B-protein
activation	NN	O	I-protein
domain	NN	O	I-protein
)	NN	O	O
expression	NN	O	O
vectors	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
neither	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
significant	NN	O	O
response	NN	O	O
to	NN	O	O
stimuli	NN	O	O
that	NN	O	O
induce	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activity	NN	O	O
.	NN	O	O

Enhanced	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
binding	NN	O	O
activity	NN	O	O
is	NN	O	O
followed	NN	O	O
by	NN	O	O
functional	NN	O	O
activation	NN	O	O
in	NN	O	O
that	NN	O	O
inducibility	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-protein
receptor	NN	O	I-protein
alpha	NN	O	I-protein
chain	NN	O	I-protein
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
enhanced	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
binding	NN	O	O
and	NN	O	O
that	NN	O	O
a	NN	O	O
heterologous	NN	O	O
promoter	NN	O	O
containing	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-DNA
B	NN	O	I-DNA
consensus	NN	O	I-DNA
sequence	NN	O	I-DNA
(	NN	O	O
-291	NN	O	B-DNA
to	NN	O	I-DNA
-245	NN	O	I-DNA
)	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
receptor	NN	O	I-DNA
alpha	NN	O	I-DNA
chain	NN	O	I-DNA
gene	NN	O	I-DNA
is	NN	O	O
activated	NN	O	O
.	NN	O	O

Mobility	NN	O	O
shift	NN	O	O
assays	NN	O	O
showed	NN	O	O
that	NN	O	O
addition	NN	O	O
of	NN	O	O
anti-AIM	NN	O	B-protein
mAb	NN	O	I-protein
to	NN	O	O
PMA-treated	NN	O	B-cell_type
T	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
markedly	NN	O	O
enhanced	NN	O	O
the	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
to	NN	O	O
its	NN	O	O
cognate	NN	O	O
sequence	NN	O	O
,	NN	O	O
the	NN	O	O
phorbol	NN	O	B-DNA
ester	NN	O	I-DNA
response	NN	O	I-DNA
element	NN	O	I-DNA
.	NN	O	O

Most	NN	O	O
of	NN	O	O
the	NN	O	O
AP-1	NN	O	B-protein
activity	NN	O	O
could	NN	O	O
be	NN	O	O
eliminated	NN	O	O
when	NN	O	O
the	NN	O	O
anti-AIM	NN	O	B-protein
mAb	NN	O	I-protein
was	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
culture	NN	O	O
medium	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
cycloheximide	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
de	NN	O	O
novo	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
is	NN	O	O
crucial	NN	O	O
for	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
AP-1	NN	O	B-protein
-binding	NN	O	O
activity	NN	O	O
.	NN	O	O

Transient-transfection	NN	O	O
experiments	NN	O	O
in	NN	O	O
embryonal	NN	O	B-cell_line
carcinoma	NN	O	I-cell_line
cells	NN	O	I-cell_line
demonstrate	NN	O	O
a	NN	O	O
functional	NN	O	O
cooperation	NN	O	O
between	NN	O	O
p50B	NN	O	B-protein
and	NN	O	O
RelB	NN	O	B-protein
or	NN	O	O
p65	NN	O	B-protein
in	NN	O	O
transactivation	NN	O	O
of	NN	O	O
a	NN	O	O
reporter	NN	O	B-DNA
plasmid	NN	O	I-DNA
dependent	NN	O	O
on	NN	O	O
a	NN	O	O
kappa	NN	O	B-DNA
B	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

We	NN	O	O
have	NN	O	O
investigated	NN	O	O
whether	NN	O	O
a	NN	O	O
palmitate	NN	O	B-protein
conjugate	NN	O	I-protein
of	NN	O	O
a	NN	O	O
human	NN	O	B-protein
monoclonal	NN	O	I-protein
antibody	NN	O	I-protein
specific	NN	O	O
for	NN	O	O
thyroglobulin	NN	O	B-protein
(	NN	O	O
TG	NN	O	B-protein
)	NN	O	O
could	NN	O	O
function	NN	O	O
as	NN	O	O
a	NN	O	O
surrogate	NN	O	B-protein
TG	NN	O	I-protein
receptor	NN	O	I-protein
on	NN	O	O
blood	NN	O	B-cell_type
mononuclear	NN	O	I-cell_type
cells	NN	O	I-cell_type
separated	NN	O	O
into	NN	O	O
fractions	NN	O	O
enriched	NN	O	O
for	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
or	NN	O	O
depleted	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
(	NN	O	O
non-T	NN	O	B-cell_type
cells	NN	O	I-cell_type
)	NN	O	O
.	NN	O	O

A	NN	O	O
PMA	NN	O	B-DNA
responsive	NN	O	I-DNA
element	NN	O	I-DNA
was	NN	O	O
localized	NN	O	O
to	NN	O	O
a	NN	O	O
region	NN	O	O
between	NN	O	O
-95	NN	O	B-DNA
and	NN	O	I-DNA
-36	NN	O	I-DNA
bp	NN	O	I-DNA
relative	NN	O	O
to	NN	O	O
the	NN	O	O
transcription	NN	O	B-DNA
start	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
human	NN	O	B-DNA
IL-4	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
of	NN	O	O
10	NN	O	O
kilobases	NN	O	O
,	NN	O	O
is	NN	O	O
composed	NN	O	O
of	NN	O	O
four	NN	O	O
exons	NN	O	B-DNA
and	NN	O	O
three	NN	O	O
introns	NN	O	B-DNA
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
trans-activation	NN	O	O
domain	NN	O	O
of	NN	O	O
E2	NN	O	B-protein
and	NN	O	O
Tax	NN	O	B-protein
is	NN	O	O
interchangeable	NN	O	O
although	NN	O	O
they	NN	O	O
have	NN	O	O
no	NN	O	O
obvious	NN	O	O
sequence	NN	O	O
homology	NN	O	O
between	NN	O	O
them	NN	O	O
.	NN	O	O

This	NN	O	O
result	NN	O	O
fits	NN	O	O
well	NN	O	O
into	NN	O	O
the	NN	O	O
general	NN	O	O
observation	NN	O	O
of	NN	O	O
stress-induced	NN	O	O
down-regulation	NN	O	O
of	NN	O	O
immune	NN	O	O
responses	NN	O	O
.	NN	O	O

The	NN	O	O
AP-1	NN	O	B-DNA
site	NN	O	I-DNA
at	NN	O	O
-150	NN	O	B-DNA
bp	NN	O	I-DNA
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-DNA
B	NN	O	I-DNA
site	NN	O	I-DNA
,	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
represent	NN	O	O
the	NN	O	O
major	NN	O	O
target	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
in	NN	O	O
the	NN	O	O
interleukin	NN	O	B-DNA
2	NN	O	I-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
cotransfections	NN	O	O
with	NN	O	O
c-fos	NN	O	O
and	NN	O	O
c-jun	NN	O	O
expression	NN	O	O
plasmids	NN	O	O
markedly	NN	O	O
enhance	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
minimally	NN	O	B-cell_line
stimulated	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
LTB4	NN	O	O
mediated	NN	O	O
transactivation	NN	O	O
of	NN	O	O
a	NN	O	O
heterologous	NN	O	B-DNA
promoter	NN	O	I-DNA
construct	NN	O	I-DNA
containing	NN	O	O
the	NN	O	O
NF-chi	NN	O	B-DNA
B	NN	O	I-DNA
or	NN	O	O
the	NN	O	O
NF-IL6	NN	O	B-DNA
enhancer	NN	O	I-DNA
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
AP-1	NN	O	B-DNA
enhancer	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
functionally	NN	O	O
responsive	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
estrogens	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
practically	NN	O	O
all	NN	O	O
the	NN	O	O
reproductive	NN	O	O
and	NN	O	O
sexual	NN	O	O
events	NN	O	O
of	NN	O	O
the	NN	O	O
female	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
intracellular	NN	O	O
actions	NN	O	O
by	NN	O	O
which	NN	O	O
they	NN	O	O
take	NN	O	O
place	NN	O	O
are	NN	O	O
not	NN	O	O
well	NN	O	O
known	NN	O	O
and	NN	O	O
the	NN	O	O
proposed	NN	O	O
models	NN	O	O
do	NN	O	O
not	NN	O	O
adequately	NN	O	O
satisfy	NN	O	O
the	NN	O	O
questions	NN	O	O
.	NN	O	O

Reduced	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
HIV-1	NN	O	O
infection	NN	O	O
of	NN	O	O
ethyl-methanesulfonate-treated	NN	O	B-cell_line
CEM	NN	O	I-cell_line
subclones	NN	O	I-cell_line
correlates	NN	O	O
with	NN	O	O
a	NN	O	O
blockade	NN	O	O
in	NN	O	O
their	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
signaling	NN	O	O
pathway	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
activation	NN	O	O
of	NN	O	O
c-raf	NN	O	B-protein
kinase	NN	O	I-protein
was	NN	O	O
normal	NN	O	O
.	NN	O	O

A	NN	O	O
similar	NN	O	O
result	NN	O	O
was	NN	O	O
obtained	NN	O	O
with	NN	O	O
the	NN	O	O
mature	NN	O	B-cell_line
monocytic	NN	O	I-cell_line
leukemia	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
THP-1	NN	O	B-cell_line
.	NN	O	O

Dexamethasone	NN	O	O
markedly	NN	O	O
inhibited	NN	O	O
LPS-stimulated	NN	O	O
accumulation	NN	O	O
of	NN	O	O
mRNA	NN	O	O
for	NN	O	O
ELAM-1	NN	O	B-protein
and	NN	O	O
expression	NN	O	O
of	NN	O	O
ELAM-1	NN	O	B-protein
and	NN	O	O
ICAM-1	NN	O	B-protein
(	NN	O	O
IC50	NN	O	O
<	NN	O	O
10	NN	O	O
nM	NN	O	O
,	NN	O	O
both	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
4-9	NN	O	O
)	NN	O	O
;	NN	O	O
inhibition	NN	O	O
of	NN	O	O
expression	NN	O	O
by	NN	O	O
dexamethasone	NN	O	O
was	NN	O	O
reversed	NN	O	O
by	NN	O	O
RU-486	NN	O	O
(	NN	O	O
both	NN	O	O
P	NN	O	O
<	NN	O	O
0.005	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
4-6	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
embryogenesis	NN	O	O
,	NN	O	O
the	NN	O	O
BSAP	NN	O	B-DNA
gene	NN	O	I-DNA
is	NN	O	O
transiently	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
mesencephalon	NN	O	O
and	NN	O	O
spinal	NN	O	O
cord	NN	O	O
with	NN	O	O
a	NN	O	O
spatial	NN	O	O
and	NN	O	O
temporal	NN	O	O
expression	NN	O	O
pattern	NN	O	O
that	NN	O	O
is	NN	O	O
distinct	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
other	NN	O	O
Pax	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
developing	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
recent	NN	O	O
definition	NN	O	O
of	NN	O	O
a	NN	O	O
consensus	NN	O	O
DNA	NN	O	B-DNA
binding	NN	O	I-DNA
sequence	NN	O	I-DNA
for	NN	O	O
the	NN	O	O
Ets	NN	O	B-protein
family	NN	O	I-protein
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
has	NN	O	O
allowed	NN	O	O
the	NN	O	O
identification	NN	O	O
of	NN	O	O
potential	NN	O	O
Ets	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
promoters	NN	O	B-DNA
and	NN	O	O
enhancers	NN	O	B-DNA
of	NN	O	O
many	NN	O	O
inducible	NN	O	B-DNA
T-cell	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
the	NN	O	O
studies	NN	O	O
described	NN	O	O
in	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
identified	NN	O	O
two	NN	O	O
potential	NN	O	O
Ets	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
,	NN	O	O
EBS1	NN	O	O
and	NN	O	O
EBS2	NN	O	B-DNA
,	NN	O	O
which	NN	O	O
are	NN	O	O
conserved	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
and	NN	O	I-DNA
murine	NN	O	I-DNA
interleukin-2	NN	O	I-DNA
enhancers	NN	O	I-DNA
.	NN	O	O

Elf-1	NN	O	B-protein
contains	NN	O	O
a	NN	O	O
DNA	NN	O	B-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
that	NN	O	O
is	NN	O	O
nearly	NN	O	O
identical	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
E74	NN	O	B-protein
,	NN	O	O
the	NN	O	O
ecdysone-inducible	NN	O	B-protein
Drosophila	NN	O	I-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
required	NN	O	O
for	NN	O	O
metamorphosis	NN	O	O
(	NN	O	O
hence	NN	O	O
the	NN	O	O
name	NN	O	O
Elf-1	NN	O	B-protein
,	NN	O	O
for	NN	O	O
E74-like	NN	O	B-protein
factor	NN	O	I-protein
1	NN	O	I-protein
)	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
showed	NN	O	O
that	NN	O	O
this	NN	O	O
silencer	NN	O	B-DNA
has	NN	O	O
stronger	NN	O	O
inhibitory	NN	O	O
activity	NN	O	O
in	NN	O	O
HeLa	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
K562	NN	O	B-cell_line
human	NN	O	I-cell_line
erythroleukemia	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Transcription	NN	O	O
of	NN	O	O
the	NN	O	O
hypersensitive	NN	O	B-DNA
site	NN	O	I-DNA
HS2	NN	O	I-DNA
enhancer	NN	O	I-DNA
in	NN	O	O
erythroid	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

Binding	NN	O	O
of	NN	O	O
AP-2	NN	O	B-protein
prevented	NN	O	O
the	NN	O	O
subsequent	NN	O	O
binding	NN	O	O
of	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
CREB/ATF	NN	O	B-protein
family	NN	O	I-protein
to	NN	O	O
an	NN	O	O
adjacent	NN	O	B-DNA
regulatory	NN	O	I-DNA
motif	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
21	NN	O	B-DNA
bp	NN	O	I-DNA
repeat	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

Recombinant	NN	O	B-protein
OTF-2	NN	O	I-protein
protein	NN	O	I-protein
produced	NN	O	O
by	NN	O	O
in	NN	O	O
vitro	NN	O	O
transcription/translation	NN	O	O
could	NN	O	O
also	NN	O	O
enhance	NN	O	O
DRA	NN	O	B-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

This	NN	O	O
factor	NN	O	O
is	NN	O	O
composed	NN	O	O
of	NN	O	O
a	NN	O	O
DNA-binding	NN	O	B-protein
protein	NN	O	I-protein
(	NN	O	O
ISGF3	NN	O	B-protein
gamma	NN	O	I-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
normally	NN	O	O
is	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasm	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
IFN-alpha-activated	NN	O	B-protein
proteins	NN	O	I-protein
which	NN	O	O
preexist	NN	O	O
as	NN	O	O
latent	NN	O	B-protein
cytoplasmic	NN	O	I-protein
precursors	NN	O	I-protein
(	NN	O	O
ISGF3	NN	O	B-protein
alpha	NN	O	I-protein
)	NN	O	O
.	NN	O	O

The	NN	O	O
translated	NN	O	O
protein	NN	O	O
showed	NN	O	O
weak	NN	O	O
DNA	NN	O	O
binding	NN	O	O
with	NN	O	O
a	NN	O	O
specificity	NN	O	O
for	NN	O	O
the	NN	O	O
kappa	NN	O	O
B	NN	O	O
binding	NN	O	O
motif	NN	O	O
.	NN	O	O

Regulation	NN	O	O
of	NN	O	O
M-CSF	NN	O	B-protein
expression	NN	O	O
by	NN	O	O
M-CSF	NN	O	B-protein
:	NN	O	O
role	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
and	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
NF	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
.	NN	O	O

NAC	NN	O	O
and	NN	O	O
other	NN	O	O
thiol	NN	O	O
compounds	NN	O	O
also	NN	O	O
blocked	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
by	NN	O	O
cycloheximide	NN	O	O
,	NN	O	O
double-stranded	NN	O	B-RNA
RNA	NN	O	I-RNA
,	NN	O	O
calcium	NN	O	O
ionophore	NN	O	O
,	NN	O	O
TNF-alpha	NN	O	B-protein
,	NN	O	O
active	NN	O	O
phorbol	NN	O	O
ester	NN	O	O
,	NN	O	O
interleukin-1	NN	O	B-protein
,	NN	O	O
lipopolysaccharide	NN	O	O
and	NN	O	O
lectin	NN	O	B-protein
.	NN	O	O

Recent	NN	O	O
development	NN	O	O
of	NN	O	O
primary	NN	O	B-cell_line
cultures	NN	O	I-cell_line
of	NN	O	O
human	NN	O	B-cell_line
megakaryocytes	NN	O	I-cell_line
and	NN	O	O
the	NN	O	O
molecular	NN	O	O
cloning	NN	O	O
of	NN	O	O
genes	NN	O	O
that	NN	O	O
are	NN	O	O
specific	NN	O	O
to	NN	O	O
this	NN	O	O
lineage	NN	O	O
offer	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
getting	NN	O	O
some	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
genetic	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
control	NN	O	O
megakaryocytopoiesis	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
number	NN	O	O
or	NN	O	O
affinity	NN	O	O
between	NN	O	O
depressed	NN	O	O
patients	NN	O	O
and	NN	O	O
recovered	NN	O	O
or	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Circadian	NN	O	O
rhythm	NN	O	O
in	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
GR	NN	O	B-protein
)	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	B-cell_type
liver	NN	O	I-cell_type
and	NN	O	O
human	NN	O	B-cell_type
peripheral	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
.	NN	O	O

For	NN	O	O
rats	NN	O	O
exposed	NN	O	O
to	NN	O	O
a	NN	O	O
natural	NN	O	O
environmental	NN	O	O
photic	NN	O	O
cycle	NN	O	O
or	NN	O	O
a	NN	O	O
12L	NN	O	O
:	NN	O	O
12D	NN	O	O
artificial	NN	O	O
light	NN	O	O
regime	NN	O	O
,	NN	O	O
peak	NN	O	O
values	NN	O	O
of	NN	O	O
hepatic	NN	O	B-protein
GR	NN	O	I-protein
were	NN	O	O
detected	NN	O	O
between	NN	O	O
23	NN	O	O
:	NN	O	O
00	NN	O	O
and	NN	O	O
02	NN	O	O
:	NN	O	O
00	NN	O	O
h	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
did	NN	O	O
not	NN	O	O
observed	NN	O	O
either	NN	O	O
up-regulation	NN	O	O
or	NN	O	O
antagonism	NN	O	O
of	NN	O	O
GcR	NN	O	B-protein
by	NN	O	O
ketoconazole	NN	O	O
treatment	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
that	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
Cushing	NN	O	O
's	NN	O	O
disease	NN	O	O
were	NN	O	O
reduced	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
Tax1	NN	O	B-protein
activated	NN	O	O
expression	NN	O	O
of	NN	O	O
two	NN	O	O
other	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
having	NN	O	O
zinc	NN	O	B-protein
finger	NN	O	I-protein
motifs	NN	O	I-protein
,	NN	O	O
Egr-1	NN	O	B-protein
and	NN	O	O
Egr-2	NN	O	B-protein
,	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
cells	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
1	NN	O	B-protein
,	NN	O	I-protein
25-	NN	O	I-protein
(	NN	O	I-protein
OH	NN	O	I-protein
)	NN	O	I-protein
2D3	NN	O	I-protein
receptor	NN	O	I-protein
in	NN	O	O
lymphocytes	NN	O	B-cell_type
is	NN	O	O
triggered	NN	O	O
by	NN	O	O
distinct	NN	O	O
and	NN	O	O
contingent	NN	O	O
signals	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
protein	NN	O	O
and	NN	O	O
the	NN	O	O
mRNA	NN	O	B-RNA
encoding	NN	O	O
it	NN	O	O
are	NN	O	O
identical	NN	O	O
to	NN	O	O
the	NN	O	O
classical	NN	O	B-protein
vitamin	NN	O	I-protein
D	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

The	NN	O	O
formation	NN	O	O
of	NN	O	O
a	NN	O	O
stable	NN	O	O
tetrameric	NN	O	B-protein
DCoH-HNF-1	NN	O	I-protein
alpha	NN	O	I-protein
complex	NN	O	I-protein
,	NN	O	O
which	NN	O	O
required	NN	O	O
the	NN	O	O
dimerization	NN	O	B-protein
domain	NN	O	I-protein
of	NN	O	O
HNF-1	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
the	NN	O	O
DNA	NN	O	O
binding	NN	O	O
characteristics	NN	O	O
of	NN	O	O
HNF-1	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	O
but	NN	O	O
enhanced	NN	O	O
its	NN	O	O
transcriptional	NN	O	O
activity	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
DCoH	NN	O	B-protein
did	NN	O	O
not	NN	O	O
confer	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
to	NN	O	O
the	NN	O	O
GAL4	NN	O	B-protein
DNA	NN	O	I-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
.	NN	O	O

Glucocorticoid	NN	O	O
resistance	NN	O	O
in	NN	O	O
chronic	NN	O	O
asthma	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
treatment	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
myeloid	NN	O	I-cell_type
leukemia	NN	O	I-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
12-O-tetradecanoylphorbol-13-acetate	NN	O	O
(	NN	O	O
TPA	NN	O	O
)	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
induction	NN	O	O
of	NN	O	O
monocytic	NN	O	O
differentiation	NN	O	O
and	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
c-jun	NN	O	B-DNA
and	NN	O	I-DNA
c-fos	NN	O	I-DNA
early	NN	O	I-DNA
response	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
transcriptional	NN	O	B-protein
factor	NN	O	I-protein
AP-1	NN	O	I-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
B	NN	O	B-cell_type
cell	NN	O	I-cell_type
Ig	NN	O	B-protein
production	NN	O	O
,	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
TGF-beta	NN	O	B-protein
.	NN	O	O

Processing	NN	O	O
of	NN	O	O
the	NN	O	O
precursor	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
by	NN	O	O
the	NN	O	O
HIV-1	NN	O	B-protein
protease	NN	O	I-protein
during	NN	O	O
acute	NN	O	O
infection	NN	O	O
.	NN	O	O

This	NN	O	O
factor	NN	O	O
consists	NN	O	O
of	NN	O	O
two	NN	O	O
DNA-binding	NN	O	B-protein
subunits	NN	O	I-protein
of	NN	O	O
relative	NN	O	O
molecular	NN	O	O
mass	NN	O	O
50	NN	O	O
,	NN	O	O
000	NN	O	O
(	NN	O	O
50K	NN	O	O
)	NN	O	O
associated	NN	O	O
with	NN	O	O
two	NN	O	O
65K	NN	O	B-protein
subunits	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
negative-acting	NN	O	B-DNA
sequences	NN	O	I-DNA
repress	NN	O	O
enhancer	NN	O	O
activity	NN	O	O
in	NN	O	O
a	NN	O	O
position-	NN	O	O
and	NN	O	O
orientation-independent	NN	O	O
manner	NN	O	O
at	NN	O	O
the	NN	O	O
pre-B-cell	NN	O	O
stage	NN	O	O
.	NN	O	O

The	NN	O	O
gene	NN	O	O
contains	NN	O	O
a	NN	O	O
CpG-rich	NN	O	B-protein
island	NN	O	I-protein
suggesting	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
germ	NN	O	O
line	NN	O	O
.	NN	O	O

The	NN	O	O
disruption	NN	O	O
of	NN	O	O
HIV-TF1-binding	NN	O	B-DNA
site	NN	O	I-DNA
induced	NN	O	O
a	NN	O	O
60	NN	O	O
%	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

-DOCSTART-	O

Cysteine	NN	O	O
and	NN	O	O
NAC	NN	O	O
also	NN	O	O
inhibit	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activity	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assays	NN	O	O
and	NN	O	O
chloramphenicol	NN	O	B-protein
acetyl-transferase	NN	O	I-protein
(	NN	O	O
CAT	NN	O	B-protein
)	NN	O	O
gene	NN	O	O
expression	NN	O	O
under	NN	O	O
control	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
binding	NN	O	B-DNA
sites	NN	O	I-DNA
in	NN	O	O
uninfected	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
phenotypic	NN	O	O
differences	NN	O	O
observed	NN	O	O
were	NN	O	O
attributable	NN	O	O
,	NN	O	O
in	NN	O	O
large	NN	O	O
part	NN	O	O
,	NN	O	O
to	NN	O	O
changes	NN	O	O
affecting	NN	O	O
the	NN	O	O
viral	NN	O	B-DNA
LTR	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
interaction	NN	O	O
of	NN	O	O
the	NN	O	O
Oct2	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
with	NN	O	O
the	NN	O	O
cognate	NN	O	B-DNA
octamer	NN	O	I-DNA
motif	NN	O	I-DNA
ATGCAAAT	NN	O	O
is	NN	O	O
a	NN	O	O
critical	NN	O	O
determinant	NN	O	O
of	NN	O	O
the	NN	O	O
lymphoid-specific	NN	O	O
expression	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	B-DNA
genes	NN	O	I-DNA
.	NN	O	O

All	NN	O	O
the	NN	O	O
isoforms	NN	O	B-protein
retain	NN	O	O
the	NN	O	O
previously	NN	O	O
characterized	NN	O	O
POU-domain	NN	O	O
and	NN	O	O
are	NN	O	O
therefore	NN	O	O
able	NN	O	O
to	NN	O	O
bind	NN	O	O
to	NN	O	O
the	NN	O	O
octamer	NN	O	B-DNA
motif	NN	O	I-DNA
.	NN	O	O

[	NN	O	O
Regulation	NN	O	O
of	NN	O	O
intracellular	NN	O	O
cholesterol	NN	O	O
synthesis	NN	O	O
in	NN	O	O
hypercholesterolemia	NN	O	O
by	NN	O	O
glucocorticoids	NN	O	O
]	NN	O	O

In	NN	O	O
fibroblasts	NN	O	B-cell_type
from	NN	O	O
patients	NN	O	O
with	NN	O	O
hereditary	NN	O	O
hypercholesteremia	NN	O	O
of	NN	O	O
homozygous	NN	O	O
type	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
did	NN	O	O
not	NN	O	O
exceed	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
their	NN	O	O
content	NN	O	O
in	NN	O	O
normal	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
They	NN	O	O
measured	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
lymphocyte	NN	O	B-protein
cytosolic	NN	O	I-protein
glucocorticoid	NN	O	I-protein
receptors	NN	O	I-protein
and	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
concentrations	NN	O	O
in	NN	O	O
15	NN	O	O
consecutively	NN	O	O
admitted	NN	O	O
male	NN	O	O
combat	NN	O	O
Vietnam	NN	O	O
veterans	NN	O	O
with	NN	O	O
PTSD	NN	O	O
and	NN	O	O
in	NN	O	O
a	NN	O	O
normal	NN	O	O
comparison	NN	O	O
group	NN	O	O
of	NN	O	O
11	NN	O	O
subjects	NN	O	O
.	NN	O	O

Pleural	NN	O	O
effusions	NN	O	O
from	NN	O	O
20	NN	O	O
patients	NN	O	O
with	NN	O	O
breast	NN	O	O
cancer	NN	O	O
were	NN	O	O
tested	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
mitogens	NN	O	O
(	NN	O	O
phorbol	NN	O	O
esters	NN	O	O
)	NN	O	O
or	NN	O	O
cytokines	NN	O	B-protein
(	NN	O	O
TNF	NN	O	B-protein
alpha	NN	O	I-protein
)	NN	O	O
induces	NN	O	O
NF-kB	NN	O	B-protein
nuclear	NN	O	O
translocation	NN	O	O
and	NN	O	O
the	NN	O	O
subsequent	NN	O	O
expression	NN	O	O
of	NN	O	O
NF-kB	NN	O	B-DNA
dependent	NN	O	I-DNA
T	NN	O	I-DNA
cell	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

We	NN	O	O
report	NN	O	O
differences	NN	O	O
in	NN	O	O
(	NN	O	O
Ca2+	NN	O	O
)	NN	O	O
i	NN	O	O
requirement	NN	O	O
for	NN	O	O
NF-kB	NN	O	B-protein
activation	NN	O	O
in	NN	O	O
thymocytes	NN	O	B-cell_type
as	NN	O	O
compared	NN	O	O
to	NN	O	O
mature	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

An	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
immediate	NN	O	B-DNA
promoter	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
erythroid	NN	O	I-DNA
ALAS	NN	O	I-DNA
gene	NN	O	I-DNA
revealed	NN	O	O
several	NN	O	O
putative	NN	O	O
erythroid-specific	NN	O	B-DNA
cis-acting	NN	O	I-DNA
elements	NN	O	I-DNA
including	NN	O	O
both	NN	O	O
a	NN	O	O
GATA-1	NN	O	B-DNA
and	NN	O	O
an	NN	O	O
NF-E2	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
these	NN	O	O
cells	NN	O	O
with	NN	O	O
10	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
units/ml	NN	O	O
human	NN	O	B-protein
recombinant	NN	O	I-protein
M-CSF	NN	O	I-protein
was	NN	O	O
associated	NN	O	O
with	NN	O	O
rapid	NN	O	O
and	NN	O	O
transient	NN	O	O
increases	NN	O	O
in	NN	O	O
c-jun	NN	O	B-RNA
mRNA	NN	O	I-RNA
levels	NN	O	O
.	NN	O	O

Maximal	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
c-fos	NN	O	B-DNA
gene	NN	O	I-DNA
was	NN	O	O
followed	NN	O	O
by	NN	O	O
that	NN	O	O
for	NN	O	O
the	NN	O	O
fos-B	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

Glucocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
in	NN	O	O
systemic	NN	O	O
lupus	NN	O	O
erythematosus	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
other	NN	O	O
factor	NN	O	O
bound	NN	O	O
to	NN	O	O
a	NN	O	O
putative	NN	O	B-DNA
AP-1	NN	O	I-DNA
recognition	NN	O	I-DNA
sequence	NN	O	I-DNA
predicted	NN	O	O
for	NN	O	O
the	NN	O	O
HIV-1	NN	O	O
NRE	NN	O	B-DNA
.	NN	O	O

DNA-protein	NN	O	O
crosslinking	NN	O	O
studies	NN	O	O
have	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
more	NN	O	O
rapidly	NN	O	O
migrating	NN	O	O
B2	NN	O	B-protein
complex	NN	O	I-protein
contains	NN	O	O
both	NN	O	O
p50	NN	O	B-protein
and	NN	O	O
p55	NN	O	B-protein
while	NN	O	O
the	NN	O	O
more	NN	O	O
slowly	NN	O	O
migrating	NN	O	O
B1	NN	O	B-protein
complex	NN	O	I-protein
is	NN	O	O
composed	NN	O	O
of	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
p55	NN	O	B-protein
,	NN	O	O
p75	NN	O	B-protein
,	NN	O	O
and	NN	O	O
p85	NN	O	B-protein
.	NN	O	O

Oligonucleotides	NN	O	O
containing	NN	O	O
the	NN	O	O
consensus	NN	O	B-DNA
GRE	NN	O	I-DNA
were	NN	O	O
the	NN	O	O
most	NN	O	O
efficient	NN	O	O
competitors	NN	O	O
,	NN	O	O
and	NN	O	O
fragments	NN	O	O
containing	NN	O	O
regulatory	NN	O	B-DNA
sequences	NN	O	I-DNA
from	NN	O	O
glucocorticoid-repressible	NN	O	B-DNA
genes	NN	O	I-DNA
were	NN	O	O
somewhat	NN	O	O
competitive	NN	O	O
,	NN	O	O
whereas	NN	O	O
single	NN	O	O
stranded	NN	O	O
oligonucleotides	NN	O	O
were	NN	O	O
unable	NN	O	O
to	NN	O	O
compete	NN	O	O
for	NN	O	O
mouse	NN	O	B-DNA
mammary	NN	O	I-DNA
tumor	NN	O	I-DNA
virus-long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
DNA	NN	O	O
binding	NN	O	O
,	NN	O	O
except	NN	O	O
when	NN	O	O
competitor	NN	O	O
was	NN	O	O
present	NN	O	O
at	NN	O	O
extremely	NN	O	O
high	NN	O	O
concentrations	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
1	NN	O	B-protein
,	NN	O	I-protein
25	NN	O	I-protein
(	NN	O	I-protein
OH	NN	O	I-protein
)	NN	O	I-protein
2D3	NN	O	I-protein
receptors	NN	O	I-protein
on	NN	O	O
alveolar	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
from	NN	O	O
patients	NN	O	O
with	NN	O	O
pulmonary	NN	O	O
granulomatous	NN	O	O
diseases	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
blood	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
from	NN	O	O
patients	NN	O	O
with	NN	O	O
granulomatous	NN	O	O
diseases	NN	O	O
did	NN	O	O
not	NN	O	O
express	NN	O	O
detectable	NN	O	O
1	NN	O	B-protein
,	NN	O	I-protein
25	NN	O	I-protein
(	NN	O	I-protein
OH	NN	O	I-protein
)	NN	O	I-protein
2D3	NN	O	I-protein
receptors	NN	O	I-protein
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
jun	NN	O	B-DNA
and	NN	O	I-DNA
fos	NN	O	I-DNA
gene	NN	O	I-DNA
family	NN	O	I-DNA
members	NN	O	I-DNA
in	NN	O	O
12-O-tetradecanoylphorbol-13-acetate	NN	O	O
induced	NN	O	O
hemopoietic	NN	O	O
differentiation	NN	O	O
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
have	NN	O	O
recently	NN	O	O
identified	NN	O	O
and	NN	O	O
cloned	NN	O	O
a	NN	O	O
human	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
TCF-1	NN	O	B-protein
,	NN	O	O
that	NN	O	O
binds	NN	O	O
to	NN	O	O
a	NN	O	O
functional	NN	O	O
element	NN	O	O
in	NN	O	O
the	NN	O	O
T	NN	O	O
lymphocyte-specific	NN	O	O
enhancer	NN	O	O
of	NN	O	O
CD3-epsilon	NN	O	O
.	NN	O	O

T-helper-cell	NN	O	B-protein
determinants	NN	O	I-protein
in	NN	O	O
protein	NN	O	B-protein
antigens	NN	O	I-protein
are	NN	O	O
preferentially	NN	O	O
located	NN	O	O
in	NN	O	O
cysteine-rich	NN	O	B-protein
antigen	NN	O	I-protein
segments	NN	O	I-protein
resistant	NN	O	O
to	NN	O	O
proteolytic	NN	O	O
cleavage	NN	O	O
by	NN	O	O
cathepsin	NN	O	B-protein
B	NN	O	I-protein
,	NN	O	I-protein
L	NN	O	I-protein
,	NN	O	I-protein
and	NN	O	I-protein
D	NN	O	I-protein
.	NN	O	O

Virus	NN	O	O
stocks	NN	O	O
obtained	NN	O	O
from	NN	O	O
these	NN	O	O
experiments	NN	O	O
exhibited	NN	O	O
a	NN	O	O
continuum	NN	O	O
of	NN	O	O
replicative	NN	O	O
capacities	NN	O	O
in	NN	O	O
different	NN	O	O
human	NN	O	B-cell_type
T-cell	NN	O	I-cell_type
types	NN	O	I-cell_type
depending	NN	O	O
on	NN	O	O
which	NN	O	O
element	NN	O	B-DNA
(	NN	O	O
s	NN	O	O
)	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
LTR	NN	O	B-DNA
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
1	NN	O	I-DNA
LTR	NN	O	I-DNA
possesses	NN	O	O
functional	NN	O	O
redundancy	NN	O	O
which	NN	O	O
ensures	NN	O	O
virus	NN	O	O
replication	NN	O	O
in	NN	O	O
different	NN	O	O
T-cell	NN	O	B-cell_type
types	NN	O	I-cell_type
and	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
changing	NN	O	O
depending	NN	O	O
on	NN	O	O
the	NN	O	O
particular	NN	O	O
combination	NN	O	O
of	NN	O	O
transcriptional	NN	O	B-protein
factors	NN	O	I-protein
present	NN	O	O
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
interferon	NN	O	B-DNA
beta	NN	O	I-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
in	NN	O	O
vitro	NN	O	O
by	NN	O	O
purified	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
a	NN	O	O
novel	NN	O	O
TH	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

One	NN	O	O
of	NN	O	O
these	NN	O	O
,	NN	O	O
designated	NN	O	O
Rhom-2	NN	O	B-DNA
,	NN	O	O
is	NN	O	O
located	NN	O	O
on	NN	O	O
human	NN	O	B-DNA
chromosome	NN	O	I-DNA
11	NN	O	I-DNA
at	NN	O	O
band	NN	O	B-DNA
11p13	NN	O	I-DNA
,	NN	O	O
where	NN	O	O
a	NN	O	O
cluster	NN	O	O
of	NN	O	O
T-cell	NN	O	B-DNA
leukemia-specific	NN	O	I-DNA
translocations	NN	O	I-DNA
occur	NN	O	O
;	NN	O	O
all	NN	O	O
translocation	NN	O	O
breakpoints	NN	O	O
at	NN	O	O
11p13	NN	O	B-DNA
are	NN	O	O
upstream	NN	O	O
of	NN	O	O
the	NN	O	O
Rhom-2	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
cAMP	NN	O	O
activators	NN	O	O
did	NN	O	O
not	NN	O	O
activate	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
in	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

PMA	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
not	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
acts	NN	O	O
in	NN	O	O
inducing	NN	O	O
NF-KB	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
the	NN	O	O
nuclei	NN	O	O
.	NN	O	O

